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The Physical and Chemical Characterisation of 3,4-Methylenedioxymethamphetamine / 
Ecstasy Tablets: Implications for Users 
 
Aim: The physical and chemical characterisation of batches of 3,4–
methylenedioxymethamphetamine (MDMA) / ‘ecstasy’ tablets seized in Malta were investigated 
to derive new information to be used for forensic intelligence purposes.    
  
Methods: Thirty seizures containing 45 batches of ‘ecstasy’ tablets were investigated for their 
physical (logo, breakline, colour, shape, mass, diameter, thickness, hardness, friability and 
disintegration rate) and chemical characteristics over a 5 year period. Impurity profiling was 
carried out by GC-MS with additional chemical characterization by colour tests, TLC, FT-IR and 
SEM-EDX.  MDMA enantiomer ratio was determined by TFAA derivatisation followed by GC-
MS analysis on a chiral column. The effect of UV and fluorescent light, temperature (5, 15, 25, 
35 and 40°C) and humidity (33 and 75% RH) on the physical features was assessed. ‘Ecstasy’ 
tablets from seizures (N = 172) at EDM parties by the police were analysed to determine the 
psychoactive substance content per tablet.  Partygoers at an EDM party were interviewed to 
determine their drug-use, including ‘ecstasy’ tablets and party behaviour.   
 
Results: Of the 45 batches examined 66.7% contained MDMA only as the main active 
ingredient, 6.7% contained mCPP, 4.4% BZP, 2.2% (1 batch) DPIA, 2.2% methanostenolone 
and 13% caffeine only.  The majority of seized tablets were round in shape (91%) with logo 
(88.9%). The mean of means for mass of 237.2 mg (RSD 28.9%), diameter  8.09 mm (RSD 
12.0%) and  thickness  3.86 mm (RSD 19.1%). Of the 4 batches of tablets subjected to 
photostability testing (white, blue, green and orange colour), only the orange-coloured tablets 
showed a significant change in colour (p < 0.05, one-way ANOVA).  The diameter of tablets 
stored at 15°C and 75% RH increased by 1.22 mm (p < 0.05, one-way ANOVA) and the 
thickness of tablets stored at 40 and 15°C respectively and 75% RH increased by 0.14 and 0.12 
mm respectively (p < 0.05, one-way ANOVA). Chemical profiling determined that the Leuckart 
and reductive amination reactions were most probably used to synthesize the racemic MDMA 
and all tablets had a 50:50 ratio of R and S enantiomers.  Lactose was the excipient mostly 
detected in tablets (40%). ‘Ecstasy’ tablets were the second most commonly confiscated drug at 
EDM parties (27.9%, n = 48 / 172) (cannabis being the most common), however our interviewed 
clubbers mostly (98.3%, n = 57) used alcohol.    
 
Conclusion: Physical and chemical characterisation can help link or discriminate between 
batches of ‘ecstasy’ tablets. For intelligence purposes tablets should be stored away from 
sunlight (visible and UV light) and at low RH (≈ 25%) and temperature (≈ 25°C).  
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The drug 3,4-methylenedioxymethamphetamine (MDMA), as described in this study, is 
used recreationally.  Millions of people have taken MDMA tablets with the hope that 
they will feel love, empathy with others, and euphoria.  Although some will take these 
tablets in small social gatherings [1], the majority of people try these tablets currently at 
Electronic Dance Music (EDM) events [2].   
 
1.1. MDMA History and Recent Trends 
 
1.1.1 MDMA: Production by Merck and subsequent research 
 
MDMA was first synthesised in 1912 by a German chemist, Dr. Anton Köllisch [3]. 
Köllisch discovered the compound as an intermediate, during synthesis for haemostatics 
(compounds to stop the flow of blood) at the pharmaceutical company Merck [4, 5].      
The compound MDMA, which was synthesised by the bromosafrole method, was 
patented in 1914 [3].   
 
It was not until the late 1960s that MDMA was used recreationally when the free-
thinking pop aficionados (New Age Seekers) started using this compound to achieve 
feeling of well-being and as an adjunct to spiritual pursuit [6].  MDMA appeared on the 
street in Chicago in the early 1970s where it was first detected in tablets [7].   
 
By 1977 Shulgin introduced the drug to a retired psychologist Leo Zeff [5].  It was Zeff 
who in 1977 became the first psychotherapist to use MDMA as an adjunct to psychiatric 
treatment [8].  The apparent ability of MDMA to foster communication and increase 
empathy surprised Shulgin, Zeff, and other psychologists and psychiatrists [9]. By 1978 
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Shulgin together with Dr. Dave Nichols published the first human study on MDMA [4] 
concluding that the drug induced an easily controlled distorted state of awareness, with 
emotional and physical association [10].  During the 1978 and the mid 1980s, in the US, 
MDMA was introduced to psychotherapists to assist in psychotherapy, a process which 
was never sanctioned by the American Psychological Association or the Food and Drug 
Administration [11].  The media’s reporting on the use of MDMA by psychotherapists as 
a psychocurative adjunct, a treatment to alter distress into eustress, increased the 
reputation of the drug [12].   
 
At this time MDMA began to enjoy a slow expansion in recreational use [12].  In 1984 in 
California MDMA was given the street name “ecstasy” [3] and by 1986 underground 
laboratories were reported throughout the US [7].  An overview of the history of MDMA 
/ ecstasy is given in Table 1.1 below. 
 
1.1.2 Recognition of recreational use of MDMA 
 
The recreational use of MDMA, which appears to have first occurred in the early 1970s 
[13], was moderate until the end of the decade [14].  By the early 1980s, the use of 
MDMA, being still legal, was promoted in some parts of the US as a “fun drug” and 
“good to dance to” because it was claimed that the drug could increase communication, 
emotional expression, empathy and prosocial feeling [8, 15]. When the drug reached 
recreational markets it was distributed and sold in US nightclubs [15].  During the mid-
1980s the drug was exported, originally smuggled [15], from US discotheques to their 
counterparts in Europe [16, 17].  MDMA, soon gained popularity and started to be used 
at all-night electronic dance parties [15, 17] in clubs on the Spanish holiday island of 
Ibiza in the Mediterranean.  
 
During the second half of the 1980s MDMA was fused with a distinct type of music and 
dancing called “acid house” on Ibiza [8].  This developed into the rave scene and other 
drugs such as lysergic acid diethylamide (LSD) and cannabis were popularised at all-
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night dance parties [17].  Rave events and MDMA use also spread across the continent 
and  tended  to  be  secretive  [18]  all-night  dance  parties, that were held in underground 
 
Table 1.1 History timeline of MDMA / ecstasy 
 
Year Event Literature 
1912 MDMA first synthesised and patent filed by Merch. [3, 19] 
1914 MDMA patented. [3, 19] 
1953/4 
First animal study using MDMA (chemical warfare code EA-1475) 
and other seven other psychotropic drugs at the University of 
Michigan under classified contract with US Army. Research was 
published in 1973. 
[8, 13, 19, 
20] 
1959 
Merck Chemist, Dr Wolfgang Fruhstorfer, who was interested in 




Biniecki and Krajewski, published a paper describing the synthesis 
of MDMA by the conversion of safrole to the beta-bromopropane 
with HBr, and its subsequent conversion with alcoholic 
methylamine to MDMA 
[21] 
1965 
Theodore Shulgin synthesised MDMA from MDA via N-formyl-
MDA (Leuckart reaction) and from 3,4-MDP2P using aluminium 
amalgam 
[3, 22] 
1970 First detection of MDMA in tablets in Chicago [3] 
1970s -
1980s Mid 1970s and 1980s legal use of MDMA in psychotherapy. [20] 
1980s Popular use of MDMA starts at the early part of the decade in the US [20] 
1978 First MDMA studies in humans by Shulgin and coworkers [3, 8] 
1984 MDMA street name ‘ecstasy’ was coined in California [3] 
1984 First reference to MDMA in an article published in “The Face” in the UK [23] 
1984-85 Start of MDMA tablets in US 24 
1986 Underground laboratories were reported all through the US [7] 
late 1980s ‘Ecstasy’ drugs first appeared in the UK as capsules [25] 
1988 Britain’s “Summer of Love” – increased MDMA consumption [20] 
1987-91 Rave scene started together with use of ‘ecstasy’ in the UK  [23, 26] 
 
locations or in clubs with a number of attendees taking MDMA.  All this created a sub-
culture and an explosion in the recreational use of MDMA [27].   
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In the UK in the early 1980s MDMA was a relatively new recreational drug [28].  By 
1987 rave parties in London had acquired such popularity among youths and adolescents 
that they had outgrown most dance clubs [18].  Many thousands started to attend rave 
festivals [4].  By 1990s in the UK MDMA started to feature prominently in surveys as a 
recreational drug [28].  However, the recreational use of ‘ecstasy’ is not well documented 
in the UK [28].  Although non-human research was conducted on the effects of MDMA 
this provided very little information on the drug consumption by users at dance parties in 
the UK [28].  By the late 1980s and early 1990s the phenomenon of rave parties with the 
use of MDMA was exported back to the US and spread globally [26].  The increase in the 
use of MDMA was so dramatic that by the end of the 1990s global seizures of MDMA 
were still increasing (global seizures 1999 about 22 from 5.6 million in 1998) [15, 29].   
 
1.1.3 MDMA / ecstasy tablets production in Europe 
 
In the Netherlands during the end of the 1980s most MDMA tablets and powder were 
imported from Spain and the US [15, 30].  Spain, which had rudimentary laboratories, 
also supplied Ibiza.  The MDMA powder that was imported to the Netherlands from the 
US was locally tabletted [15, 30]. When MDMA arrived in the Netherlands, at the end of 
the 1980s, users were frequently “home users” but by the end of the decade the 
“mainstream” use of MDMA was at parties and raves [31]. 
 
In the UK in the late 1980s the use of MDMA was minimal because the process for 
producing the drug was relatively expensive [32].  However, by the early 1990s the 
‘ecstasy’ laboratories in the UK were highly commercial, thus the price of MDMA tablets 
fell sharply from £ 15-20 in 1987 to £ 7 in 1996 [32]. 
 
The initial small ‘ecstasy’ laboratories in the Netherlands were set up by people taking 
the drug at parties and raves, while the ‘ecstasy’ business was started from the long-
established Dutch leading role in manufacture and trafficking of amphetamines [31].  
However, by the spring of 1990 the first professionally manufactured ecstasy tablets 
appeared on the Amsterdam market [30].   
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Most of the MDMA production in Europe during the 1990s occurred in the Benelux 
countries of Belgium, the Netherlands, and Luxembourg [33].  This was mainly due to 
the well established precursor chemical routes and to the ease by which these chemicals 
were accessed.  The transportation of MDMA to consumer countries was not a problem, 
owing to the ease of access to international air and rail transportation routes [12, 33].  By 
the mid 1990s ecstasy (MDMA) tablets that were supplied to rave parties all over Europe 
came from the Netherlands [30].  This made Europe a major source of global ecstasy 
(MDMA) supply [15] when the use of ecstasy was rising globally [33].  Moreover, by the 
late 1990s some ecstasy tablets supposed to contain MDMA were found to contain other 
psychoactive phenethylamines, such as 4-bromo-2,5-dimethoxyphenethylamine [34].  
However, while most of the ‘ecstasy’ tablets still continued to contain MDMA, 
manufacture of these tablets remained primarily in Europe [15].   
 
During the period 1999 - 2001, 75% of all seized clandestine laboratories producing 
‘ecstasy’ tablets were from the Netherlands and 14% from Belgium and more than half of 
all ‘ecstasy’ end-products and almost 90% of all ‘ecstasy’ precursors were seized in 
Europe [35].  The Netherlands was considered by most law enforcement and international 
drug control agencies as the world’s major production and trafficking centre for synthetic 
drugs [31].  For the ‘ecstasy’ and amphetamine market, the Netherlands was similar to 
Colombia as the foremost cocaine manufacture [31].  
 
1.1.4   Lower  MDMA  content  in  tablets  and  the emergence of designer drugs and 
‘legal highs’ 
 
Change in the contents of ‘ecstasy’ tablets sold on the European market had occurred 
during the last decade [15].  In 2005 most (70% or more) of the ‘ecstasy’ tablets 
contained MDMA or its analogues, 3,4-methylenedioxyethylamphetamine (MDEA) and 
MDA, as the only active substance.  However, during the same year other psychoactive 
substances, not under international control, such as benzylpiperazine (BZP) and 1-(3-
chlorophenyl)piperazine (mCPP) [36] were also detected in ‘ecstasy’ tablets [15].  
Although by 2007 most of the European countries reported that their seized ‘ecstasy’ was 
sourced from within Europe [36], the ‘ecstasy’ market in Europe had already started to 
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undergo a significant transformation in the contents of ‘ecstasy’ tablets.  This was mainly 
caused by reduced availability in the primary precursor for MDMA production, 3,4-
(methylenedioxyphenyl)-2-propanone (3,4-MDP2P), because of  control measures in 
production, trade and export [37]. 
 
In the UK similar developments were happening with regard to ‘ecstasy’ tablet scenario 
in Europe.  Going back to 2002 till 2005 the number of ‘ecstasy’ seizures in the UK had 
stabilised before increasing again in 2006/07 (Table 1.2) [38].  Between 2002 and 
2006/07 an average of about 5.1 million ‘ecstasy’ tablets were seized annually [38].  By 
2008 in the UK only 51% of ‘ecstasy’ tablets were found to contain MDMA, a fall from 
73% in 2007.  The mean MDMA content in the tablets was almost half (33.1%) of what 
was detected in 2003 (64.5%) [39].  From 2008 until  2012 in the UK both the number  of   
 
Table 1.2 The UK number of seizures of ‘ecstasy’ tablets and number of tablets 
seized from 2002 till 2011 [38]. 
 
Year 2002 2003 2004 2005 2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 
Ecstasy 
Seizures 6,960 6,401 6,190 6,634 8,141 7,148 5,197 3,712 2,524 3,168 
Tablets 
(000s) 4,132 6,899 4,740 3,019 6,685 965 547 171 371 656 
 
‘ecstasy’ seizures and tablets had drastically decreased, with the year 2009/10 registering 
the lowest-ever level for both ecstasy seizures and tablets (Table 1.2) [38].  The drastic 
decrease in number of ‘ecstasy’ tablets seized in the UK during 2008 - 2011 (average 440 
thousand annually, Table 1.2 [38]) seemed to have been counterbalanced by an increasing 
trend towards new substances termed ‘legal highs’ (unregulated new psychoactive 
substances [40]) as an alternative to ‘ecstasy’ [39].  
 
The  same trend happening in the UK with regards to the decrease in ‘ecstasy’ tablets and  
the increase in legal highs was happening in other European counties [15].  As this was 
happening, the availability of’ ‘ecstasy’ tablets containing MDMA continued to decrease 
[15].  The ‘ecstasy’ tablets were substituted by synthetic cannabinoids, different 
amphetamines (e.g. fluoroamphetamine), cathinone derivatives (e.g. mephedrone, 
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methylone), and others, in tablets and powder forms [37].  A large number of ecstasy 
production sites were found to be tabletting mephedrone [41].  However, by the end of 
the last decade there seemed to be resurgence in ‘ecstasy’ market (Table 1.2).  This 
partial resurgence may have been caused by a new pre-precursor chemical 3-
[3′4′(methylenedioxy)phenyl]-2-methyl glycidate to the precursor 3,4-MDP2P, which 
was found in underground laboratories at a production site in the Netherlands to produce 
MDMA [15, 42]. 
 
1.2 The Malta Drug Situation 
 
The Maltese archipelago (Figure 1.1) is located in the Mediterranean Sea and lies just 
south of Sicily and the northern most point of Africa.  Malta consists of three main, 
inhabited islands:  Malta, Gozo and Comino.  The three islands cover together an area of 
316 km2 [45], have territorial waters that extend to 9.65 km from the coast, comprising an 






                                                                                                                                                       
 





                                                                                       
Figure 1.1 The Maltese archipelago [43, 44]. 
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most densely populated countries, having a population of about 414,000 [45].  The largest 
island of the group, Malta, is made up of small towns and villages, with the capital, 
Valletta, on the north east part of the island.  The Island has two official languages, 
Maltese and English, with Maltese being the national language [45]. Malta became a 
member of the European Union (EU) in 2004, and a full member of the Schengen area in 
2008.  It has numerous connections to Europe and Africa due to daily flights and ships 
which call at its large commercial port.  Flights from the Netherlands and Spain are 
considered high risk flights for the importation of ‘ecstasy’ tablets (N. Harrison, 2012, 
personal communication, Assistant Commissioner, Malta Police, interview, 12 June).   
 
1.2.1 Importation of illegal drugs 
 
The illicit drug problem in Malta, which was estimated to be the eighth-highest for 
problem drug use in the EU according to the 2010 World Drug Report [36], is normally 
limited to the sale and use of imported drugs.  No evidence has ever been found to 
indicate that the production or processing of MDMA has taken place on the Island.  
Although there are a number of generic pharmaceutical firms operating on the Island 
there is no evidence that precursors or chemicals used in these firms have been diverted 
for illegal production of drugs.  All illegal drugs, with the exception of few hundred 
cannabis plants, are imported to the Island from Europe and North Africa for local 
consumption (N. Harrison, 2012, personal communication, Assistant Commissioner, 
Malta Police, interview, 12 June).  Cannabis was, and still remains, the most popular drug 
of abuse in Malta [47] and, while some cannabis plants are grown on the Island due to the 
good climatic conditions, cannabis resin (hashish) and herbal cannabis (also referred to as 
marijuana, grass or weed) is mainly imported from Morocco (N. Harrison, 2012, personal 
communication, Assistant Commissioner, Malta Police, interview, 12 June).  Heroin, 
cocaine and ‘ecstasy’ are also commonly imported to Malta.   
 
The ‘ecstasy’ tablets that were seized in Malta from 1995 till 1999 were small in number, 
less than 500, but from 2000 onward the number of ‘ecstasy’ tablets seized sharply 





















number of ‘ecstasy’ tablets seizures was high until 2011 when it drastically declined 
(Table 1.3). 
 
Table 1.3 The number of ‘ecstasy’ tablets seized in Malta between 1995-2012 (N. 
Harrison, 2013, personal communication, Assistant Commissioner, Malta Police, 
email, 23 January).   
 
Year 1995 1996 1997 1998 1999 2000 2001 2002 2003 
Tablets 513 687 247 153 459 5,192 2,458 11,012 8,695 
Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 















Figure 1.2 Illegal drug seizures of cannabis (resin and grass); cocaine, ‘ecstasy’ and 
heroin in Malta between 2006 – 2012 (N. Harrison, 2013, personal communication, 
Assistant Commissioner, Malta Police, email, 23 January), (Note: cannabis grass 
weight for 2009 and cocaine weight for 2012 were divided by 10). 
 
Between 2007 - 2009 and 2011, when ‘ecstasy’ tablets seizures declined heroin and 
cocaine were the second most commonly seized drugs (after cannabis) on the Island.  In 
2012 in Malta when ‘ecstasy’ tablets seizures were very low, cocaine was the most seized 
drug (142.9 Kg)  on the Island (Figure 1.2) (N. Harrison, 2013, personal communication, 
Assistant Commissioner, Malta Police, email, 23 January).  Heroin is mainly imported 
from Eastern Mediterranean Countries and North Africa.  However, during the last five 
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years there were cases where cocaine and heroin were imported from the African 
Western Hemisphere, Eastern European countries and South America.  Ecstasy tablets 
and small amounts of amphetamine were, and still are, mainly imported from Europe, 
mainly from the Netherlands [47].  Most recently from 2009 - 2012 new legal highs (e.g. 
mephedrone) and herbal highs (synthetic cannabinoids) have also been identified in 
Malta (N. Harrison, 2013, personal communication, Assistant Commissioner, Malta 
Police, interview, 8 February).    
 
1.2.2 MDMA / ecstasy use within party settings in Malta  
 
The rave / dance party culture began in Malta in the early 1990’s when a small group of 
people, who had close ties with the London rave scene, started organizing rave parties on 
the Island [48].  By 1992 rave parties in Malta were opened to the public. These parties 
were called S.I.N., Sex Is Natural, parties by the promoters of these events but stopped 
due competition within a year.  It is claimed that by 1994 the popularity of rave parties in 
Malta was very high [49].  These were the authentic rave parties which were normally 
held outdoors in illegal locations, outside the legitimate entertainment establishment [52].  
There is no published data about the number of rave parties and attendees that attended 
these events during those years in Malta.  When authentic raves declined these parties 
moved to legally operated venues. With the decline in raves parties, which was mainly 
caused by law enforcement, commercial forces and generational schism, where aging 
ravers were not replaced by younger generation [50], the commercial EDM events took 
over.   
 
Today large parties are organized in summer; the peak holiday season and disc jockeys 
(DJ’s) such as David Guetta, Paul Oakenfold, Carl Cox, and Tiësto, are invited to play.  
However, there is little data of the number and nationality of attendees and the type of 
illicit drugs, if any, that are consumed at these venues.   
 
A study which was conducted in Malta in 2002 showed party goers who used ‘ecstasy’ 
took the drug between the ages 16-19 years [48]. The European School Survey Project on 
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Alcohol and other Drugs studies conducted in 1999 and 2003 respectively in Malta on 
about 5,000 students aged between 15-16 years, showed that in 1999 and 2003, 2% and 
1.2% respectively of those surveyed have taken ‘ecstasy’ [51, 52].  By 2007 the annual 
prevalence of ‘ecstasy’ use in Malta for students in the 15-16 age groups had risen to 4% 
[53].    
 
According to the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA, 2010) the prevalence of ‘ecstasy use’ in the Maltese general population 
between 2004 and 2007 for those aged  15-64 years was 0.7% (EU range 0.3-8.3%) for 
life time use and 0.2% (EU range 0.1-1.6%) for last year use [54].  This was considered 
low by EMCDDA.  Furthermore, the prevalence for lifetime ‘ecstasy’ use for Maltese 
aged 15-34 years between 2004 and 2007 was 1.4% (EU range 0.6-12.7%) [54]. 
Although, the 2007 ‘ecstasy’ use for the Maltese population (15-64 years) was well 
towards the bottom of the EU range that for students in the 15-16 age group was 
relatively high (4.0%) when compared to 0.2% for the general population.  In 2009, a 
study was conducted at the University of Malta on 494 undergraduate students (mean age 
17.2 years, range about 16-27 years) revealed that 6% of the students had used ecstasy 
[47].  In 2009 the Maltese Parliamentary Social Affairs Committee issued a statement 
showing its concern about the use of illicit drugs at parties and that ‘ecstasy’ users were 
not seeking treatment for ‘ecstasy’ related induced psychiatric syndromes [55].  
 
There is a lack of research on drug use at EDM events that are held in Malta [48].  
Research by others in Europe and the US has shown widespread drug use by attendees at 
dance events [19, 56, 57].  This information is not currently available for the country of 
Malta.  To this end two studies were taken up to try and investigated the licit and illicit 
substances use and the behaviour of attendees at EDM parties in Malta.  Previous studies 
focused on the general population, secondary school and university students to determine 
the prevalence both licit and illicit substance use.  The studies conducted in this research 
were different from what had gone before because these concentrated on partygoers at 




1.3 MDMA: Chemistry and Structure-Activity Relationship  
 
Illicit tablets containing MDMA hydrochloride are usually taken orally in a tablet form 
having a characteristic logo, and less commonly as white powder or capsules [58].  This 
substance belongs to a family of drugs that has the basic phenethylamine structure which 
is found in other sympathomimetic agents, such as amphetamine, methamphetamine 
(MA) and catecholamines.  The phenethylamines, which possesses a broad range of 
central nervous system actions, unlike other class of drugs can produce a wide spectrum 
of central nervous system effects by a small change in their structure [59].  MDMA, 
being a ring substituted derivative of phenethylamine, is a psychoactive drug which is a 
completely synthetic substance that does not exist in nature.  It has been classified in the 
therapeutic class of compounds, the entactogens, because of its pharmacological 
properties and mechanism of action. MDMA is structurally related to the hallucinogenic 
MDA, being its N-methyl analog, and to the stimulant MA, being its 3,4-
methylenedioxy-analog [60].  Several structure-activity relationships clearly differentiate 




The International Union of Pure and Applied Chemistry (IUPAC) systemic name for 
MDMA is 1-(1,3-benzodioxl-5yl)-N-methylpropan-2-amine [61] but in the literature it is 
more generally referred to by the older chemical name 3,4-
MethyleneDioxyMethAmphetamine, from which the acronym MDMA (C11H15NO2 – 
CAS – 42542-10.09) is derived.  Other chemical names include methylenedioxy-
methylamphetamine and N, α-dimethyl-3,4-methylenedioxy-phenylamine. Since MDMA 
is structurally related to MA, it is also known by names related to MA, such as N-methyl-
3,4-methylenedioxyphenylisopropylamine and N-methyl-3,4-
methylenedioxyamphetamine [62].  MDMA, a secondary amine compound having a 
molecular weight of 193.25 a.m.u., has a chiral centre giving rise to two enantiomers, 
each having different degrees of central nervous system activity and also different 
affinities to the enzyme responsible for its breakdown [62].  The base compound, which 
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at room temperature is colourless oil with a boiling point of 100 - 110oC, is insoluble in 
water [62, 58]. Similarity exists between the aromatic methylenedioxy substituent of 
MDMA and the substance found in the oils of the natural products safrole and myristicin 
[63].  The most common salt of MDMA is the hydrochloride (C11H16NClO2 – CAS-
64057-70-1), which is a white or off-white powder or crystals.  The salt, which is soluble 
in water, has a melting point of 148 – 149oC [58, 62].   
 
1.3.2 Structure-activity relationship (SAR) 
 
The SAR of MDMA, which is the relationship between the chemical and its biological 
activity, is dependent on its two optical isomers, which belong to a family of drugs that 
has the basic phenethylamine structure.  MDMA as a biologically active phenethylamine 
compound is typical and has one isomer more active than the other [64].  The 
phenethylamines (Figure 1.3) consist of a group of compounds with a stimulant effect 
(e.g. amphetamine) whereas the S-(+)- enantiomer is more active, a group of compounds 
with action similar to hallucinogens (e.g. 2,5-dimethoxy-4-methyl-amphetamine) having 
a predominant R-(-)- enantiomer [65], and in between a whole spectrum of biologically 
active compounds [65].  Within all this MDA stands alone because its two biologically 
active optical isomers have different effects at nearly the same dose.  The R-(-)-MDA has 
a hallucinogenic effect, while the S-(+)-MDA has more like an amphetamine effect [64].  
The addition of a methyl group to the nitrogen atom (N-methylation) of MDA, producing 
MDMA, makes the molecule too large to fit the serotonin 5HT2A receptor of the brain 
[4], thus reducing or eliminating the hallucinogenic activity of MDA [64, 65].  It appears 
that these effects made MDMA more desirable than MDA [66].  Furthermore, if the α-
methyl of a hallucinogenic compound is extended to an α-ethyl all hallucinogenic activity 
is abolished.  Hence the ethyl homologue of MDMA, N-methyl-1-(1,3-benzodioxol-5-
yl)-2-butanamine (MBDB), which combines the N-methylation and α-ethylation show no 
hallucinogenic  effects   [64].    In   terms   of   the   biological   effects   of   MDMA   the  
N-methylation of MDA enhances the lipohilicity of the new molecule MDMA thus 
facilitating the rapid entry into the brain and producing a faster in onset of effects but 















































effect on the reuptake pump that transports MDMA into neurons that make use of 
serotonin and dopamine (DA).   
 
In the literature it is sometimes claimed that MDMA is a sort of a mix between 
amphetamine and mescaline [66, 67], a mixture of central stimulant and psychedelic [57, 
59, 68-70] and that the compound is related to hallucinogen S- type substances [27, 71].  
While MDMA and MA have a similar backbone, the S-(+)- MA enantiomer is more 
potent than S-(+)-MDMA enantiomer and able to release the stored neurotransmitter DA 
from DA-containing neurons.  The feeling of euphoria and wellbeing produced by 
MDMA could also be related to its actions on DA systems which in such a case acts 
similar to MA [4].  Both compounds can bring about the release of other 
neurotransmitters such as noradrenaline and serotonin but the release of serotonin by 
MDMA is much more pronounced than that of MA.  Whereas the only relationship 
between MDMA and mescaline is that they are both phenethylamines.  The oxygen 
atoms on the mescaline ring do not have the same biological effect as the methylenedioxy 
(O-CH2-O-) group on the phenyl ring of MDMA, which is largely responsible for the 
release of serotonin [6].  Moreover, the lack of hallucinogenic activity of MDMA, except 
at very high doses [12], continues to make these compounds pharmacologically different.  
 
The stimulant effect of both MDA and MDMA, although MDMA is less potent than 
MDA, is achieved by the ability of their S-(+)- isomers to block the reuptake of DA [64, 
72].  Both the hallucinogen 2,5-Dimethoxy-4-bromoamphetamine and the entactogen 
MBDB have no such ability, thus indicating that the entactogenic effect is not mediated 
through the dopaminergic pathway [64].  However, the compounds MDA, MDMA and 
MBDB which are all able to release serotonin (unlike the hallucinogen 2,5-dimethoxy-4-
methylamphetamine), are also potent serotonin reuptake inhibitors.  This indicates that 
the primary mode of action of entactogenic compounds is the ability of their S-(+)- 
isomers, which is the most active, to release serotonin and block its reuptake into the 





1.4 MDMA: Pharmacology and Toxicology 
 
To better understand the desired and undesired effects of MDMA on the user a brief 
review of the pharmacology of the drug is given.  The effects of MDMA are dependent 
on the dose, the frequency and duration of use.  Serious or fatal toxicity that might occur 
if the drug is used at higher doses by sensitive individuals that could suffer from adverse 
effects such as psychoactive, cardiovascular, and hepatic among others, or if used with 
other illicit drugs, is described separately [73-75].   
 
1.4.1 Pharmacology of MDMA 
 
MDMA is metabolized by two main pathways [76]. The first pathway involves N-
dealkylation, and O-demethylenation, while the second pathway involves O-methylation. 
MDMA also causes the release of serotonin (5-HT), DA and noradrenaline (NA) in the 
central nervous system [73]. 
 
 1.4.1.1 Pharmacokinetics 
 
MDMA is usually taken by ingestion and is absorbed from the small intestinal tract rather 
than the stomach.  It reaches its peak concentration in plasma about 2 hours after oral 
administration [73, 77].  The metabolism of MDMA involves the N-demethylation by 
CYP3A4 to its main active metabolite MDA (Figure 1.4) [76, 78, 79].  Since MDA is 
pharmacologically active the duration of action of MDMA may be somewhat longer [73]. 
Both MDMA and MDA are O-demethylenated to 4-hydroxy-3-
methoxymethamphetamine (HHMA) and, 4-dihydroxyamphetamine (HHA) respectively, 
which are regulated by the enzymes in the liver (CYP2D6) [76, 78, 79].  Individuals with 
genetic variations of the CYP2D6 enzyme (slow or rapid metabolisers) may have variable 
concentrations of the parent compound MDMA and its metabolites [74].  Furthermore, 
HHMA and HHA are both O-methylated by catechol-O-methyltransfarase mainly to 4-
hydroxy-3-methoxymethamphetamine (HMMA) and 4-hydroxy-3- methoxyamphetamine 
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(HMA) respectively [76, 78, 79].  The conjugated glucuronide and sulphate of the four 




















Figure 1.4 Metabolism of MDMA [76]. 
 
 
Potent 2D6 inhibitors, such as fluoxetine, paroxetine (both antidepressants of 
the selective 5-HT reuptake inhibitor class), and cocaine, may block the main metabolic 
pathway and therefore increase the concentration of MDMA [64].  MDMA has non-
linear pharmacokinetics, when regular users take several doses at one time large increases 
in blood and brain concentration of the drug occur [73, 76], thus small increases in 
dosage may increase the risk of toxicity [73].  Since the half-life of MDMA is in the 
order of 8 hours and it takes about 5 half-lives to remove the drug from the body it is 
estimated that it may take about 40 hours for over 95% of the drug to be cleared from the 
40 
 
body [73].  This could be the reason for the after-effects of the drug, after one to two days 
of its use, because some of its metabolites, such as MDA could still be pharmacologically 
active [73].   
 
It is reported that the clandestine synthetic procedures usually employed in the 
preparation of MDMA are not stereoselective and the hydrochloride salt, employed in the 
clandestine manufacture of tablets, is a racemic mixture, of the S-(+)- and R-(-)- 
enantiomers [80]. However, in this study MDMA from seized ecstasy tablets were 
investigated to determine if illegal chemists were producing a racemic or chiral specific 
MDMA tablets.   
 
The activities of the different MDMA stereoisomers were reported by Anderson et al. 
[81] and confirmed by different studies later on [82–85].  All studies confirmed the 
higher amphetamine-like activity (toxicity – mydriasis and jaw clenching) of the S-(+)- 
enantiomer [82–86] compared to the R-(-)- enantiomer where some studies suggest to 
have the mescaline or LSD-like hallucinogenic properties [73].  Differences in the 
pharmacokinetics of the stereoisomers of MDMA were demonstrated after rats were 
dosed with racemic MDMA given intravenously or subcutaneously [87].  All dose groups 
showed a greater area under the blood curve for R-(-)-MDMA than that of the S-(+)-
MDMA, an enantioselective metabolism, where the S-(+)- enantiomer is metabolized 
faster than the R-(-)- enantiomer [62, 88].  Studies have also been done in humans and 
have demonstrated similar stereospecific differences in the biotransformation of MDMA, 
even though studies were limited to a few individuals [89–92]. 
 
 1.4.1.2 Pharmacodynamics 
 
The  action  of  MDMA  in  the  central  nervous  system  is   complex   affecting   several  
molecular sites.  The major effects are on the 5-HT pathways but it also affects two other  
major transmitter systems in the brain, which are the DA and NA.  MDMA increases the 
release of the monoamine neurotransmitters 5-HT, noradrenalin and to a lesser extent DA 
from the respective axon terminals [73].  The 5-HT receptors mediate the effects of 
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serotonin, as an endogenous ligand, and also of a number of pharmaceutical and 
psychoactive drugs, such as MDMA.    
 
MDMA, does not directly release 5-HT but it enters the serotonergic neurones via the 
serotonin transporter (SERT) and reverses the normal direction of monamine travel thus 
inducing the release of 5-HT (Figure 1.5) by binding and blocking the reuptake of 5-HT 



















Figure 1.5 Schematic diagram showing the serotonergic synapse and the target for 
MDMA. Symbol: stimulatory effect (+); inhibition or blockade (-) (adopted from 
Ayala, 2009 [101]. 
 
release  and  the  stimulant  effects  produced  by  MDMA  are  the indirect stimulation of 
5-HT1B (it induces presynaptic inhibition and behavioural effects) and 5-HT2A (the main 
excitatory receptor subtype among the G protein-coupled receptor 5-HT) receptors [94, 
95].  The emotional closeness, euphoria and sensory delight attributed to the use of 
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MDMA are caused by this 5-HT boost [74].  Some acute adverse effects caused by 
MDMA by decreasing the 5-HT reuptake (SERT) binding include increased heart rate 
and blood pressure, tremor, sweating and hyperthermia [74]. 
 
A similar, but weaker, action is also exerted on the reuptake of DA but the concentrations 
of MDMA required to induce DA release is 10 times higher than that needed to induce 5-
HT release [96].  MDMA produces DA release and uptake inhibition by the DA 
transporter, and by noradrenergic neurons via the NA uptake   pump   [97–100].   MDMA 
inhibition of monoamine oxidase B prevents metabolism of DA [102].  It is also reported 
that MDMA displaces NA from adrenergic nerve terminal endings and may also be 
involved in the competitive blockade of NA transporter [103].  The characteristic MDMA 
effects, such as euphoria, altered perception, relaxation, and decrease in negative affect 
and defensiveness [104], of MDMA are attributed to the net release of 5-HT and possibly 
DA, while the physical effects (such as increase in wakefulness, sense of energy, 
decrease in fatigue and sleepiness [73]) are credited to the increased release of NA [73].  
The S-(+)- enantiomer of MDMA is more potent  than  R-(-)- enantiomer  in  producing  
the  prosocial  characteristic effects that are credited to the drug [73].   
 
1.4.2 Toxicity of MDMA  
 
Although rare, MDMA use has been linked to serious toxicities and death [105]. The 
most profound adverse reaction to MDMA is hyperthermia and hyperpyrexia, with body 
temperature reaching as high as 44oC usually followed by multiple organ failure.  The 
majority of these adverse reactions occur at raves or nightclubs [106].  Other adverse 
reactions, which are caused by MDMA induced excess intrasynaptic 5-HT, can be 
grouped together under the heading of ‘serotonin syndrome’ which include behavioural 
hyperactivity, mental confusion, agitation, hyperreflexia, hyperpyrexia, tachycardia, 
shivering, clonus, myoclonus, ocular oscillation and tremor [107] and syndrome of 
inappropriate antidiuretic hormone secretion (SIADH) [108].   
 
The  severity  of  symptoms  caused  by  the  ingestion  of ‘ecstasy’ tablets shows marked  
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variability in response suggesting individual pattern  of  metabolism, possibly genetically  
determined due to the highly polymorphic CYP2D6  gene  [75],  where  ‘slow 
metabolisers’  are genetically predisposed to more severe MDMA toxicity [109].  In 
cases of death, involving MDMA, it was typically found that the deceased took several 
different drugs (prescribed and non-prescribed) with ecstasy, however death also 
occurred when ecstasy tablets containing MDMA were taken [110]. Severe Depression 
that could cause suicide could also be induced by MDMA [73].  Moreover, motor vehicle 
accidents were reported where drivers and pedestrians were affected by MDMA [73].   
 
The toxicity could be further exacerbated with the use of other legal and / or illegal drugs 
that may interact with this substance. Some ecstasy users may concurrently take drugs in 
order to enhance and prolong the pharmacological effects (e.g. cocaine, known as 
‘bumping up’, other amphetamine derivatives, caffeine) or to counteract undesired side 
effects (e.g. moclobemide - a reversible monoamine oxidase inhibitor drug, cannabis), 
such as insomnia, depression and anxiety [111, 112].  If MDMA is taken with cocaine 
and / or amphetamine it may increase the likelihood and severity of the serotonin effect 
[74], while with caffeine it promotes hyperthermia and serotonergic loss [113], and with 
moclobemide fatal serotonin toxicity could be caused [111].  Furthermore, if MDMA is 
taken with cannabis various psychological problems, such as impulsiveness, anxiety, 
somatic complaints, obsessive compulsive patterns, and psychotic behaviour, together 
with interpersonal sensitivity, depression, and paranoid ideation, could be caused [112].  
What is clear is that the recreational use of ‘ecstasy’ is not always safe especially when 
taken with other drugs. 
 
1.5 Synthesis of MDMA 
 
The clandestine manufacture of MDMA requires chemical synthesis.  Laboratories where  
the drug is synthesised range from improvised operations, where simple processes and 
makeshift apparatus are utilised, to sophisticated operations where advanced equipment 




















1.5.1 Precursor chemicals used in MDMA synthesis 
 
Precursor chemicals that are used for MDMA synthesis include safrole (3,4-
methylenedioxyallybenzene), (some times in the form of safrole-rich oils – (SROs)), 
isosafrole (3,4-methylenedioxypropenylbenzene), piperonal (3,4-
methylenedioxybenzaldehyde), and 3,4-MDP2P, which is the key precursor for MDMA 
synthesis.  These compounds, which are all under international control, have also 
legitimate uses e.g. in perfumery and the food industry.   
 
The SROs are the main raw materials for the manufacture of safrole for commercial 
purposes.  Safrole-rich oil tree species that are found in North and South America and in 
East and South-East Asia grow naturally and / or are cultivated for commercial purposes 
[115].  SROs are distilled from the timber, root and stump and yields range between 1% 
and 3.5% [115].   
 
The most common synthetic route for the production of MDMA is from the precursor 
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Figure 1.6  3,4-MDP2P synthesis by isosafrole oxidation (Note: (1) isosafrole,  (2) 
isosafrole epoxide,  (3) isosafrole monoformyl glycol, (4) isosafrole glycol and (5) 3,4-
MDP2P) [118]. 
 
To get 3,4-MDP2P a natural source of safrole is required, which needs to be isomerised 
to isosafrole by heating with sodium hydroxide (NaOH) or potassium hydroxide (KOH) 

















The two most probable routes of synthesis of 3,4-MDP2P in clandestine production are 
by oxidizing isosafrole in an acid medium (Figure 1.6) or by reduction of 1-(3,4-
methylenedioxyphenyl)-2-nitropropene, which is prepared by condensation of piperonal.  
The common citation of the synthesis of piperonal is by oxidation from isosafrole with 






                            (1)                                                             (2)                                       (3) 
 
Figure 1.7 3,4-MDP2P synthesis by 3,4-MDP-2-nitropropene (Note: (1) piperonal, 
(2) 3,4-MDP-2-nitropropene and (3) 3,4-MDP2P) [118]. 
 
 
Another route used to produce 3,4-MDP2P was the Wacker oxidation of safrole using p-
benzoquinone, palladium chloride and methanol [120].  More, recently 3-
[3′4′(methylenedioxy)phenyl]-2-methyl glycidate, a non-controlled chemical which is 
made from piperonal, has been used as a precursor to produce 3,4-MDP2P [37, 115]. 
 
Unlike other illegal drugs, such as cocaine and heroin, whose production is limited by 
geography and climate, MDMA can be produced almost anywhere [36].  Production is 
dependent upon chemical and technological knowledge; the availability of chemicals and 
equipment; and easy access to literature on the subject, especially from the internet [121]. 
The choice of synthetic route is largely determined by the availability of precursors and 
other reagents.  The efficiency with which a given amount of precursor can be converted 
into MDMA is dependent on the different manufacturing methods; an example is the 
reductive amination method which gives the highest yield for MDMA.  
   
The most popular method of synthesis of MDMA is reductive amination of 3,4-MDP2P 













the Leuckart method via 3,4-MDP2P and the direct bromination of safrole where 3,4-
MDP2P is not an intermediate. 
 
1.5.2 Methods of synthesis of MDMA  
 
1.5.2.1 Reductive amination 
 
A  diversity  of  the  reductive  amination method exists because different reducing agents  
can be used.  However, the two most commonly used methods are the catalytic metal 
reduction and the so called ‘cold method’ [122].  The catalytic reduction involves the 
reductive amination of 3,4-MDP2P with methylamine with hydrogen gas over a platinum 
oxide (PtO2) catalyst [123].  In the ‘cold method’ the sodium borohydride (NaBH4) reacts 
with 3,4-MDP2P and methylamine at low temperature (-20°C – use of freezers).  The 
process is called ‘cold method’ because the reaction is exothermic and hence the vessel is 
cooled in order to control the temperature.  In the clandestine laboratories were the ‘cold 
method’ is used freezers are always present [118] (Figure 1.8).   
 
Other alternative methods of reduction are the dissolving metal reduction, also known as 
the low pressure reductive amination, using aluminum amalgam (Al/Hg, aluminum foil 
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Figure 1.8 Reductive amination methods for MDMA synthesis (Note: (1) is 3,4-
MDP2P and (2) is MDMA) [118]. 
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at room temperature (Figure 1. 8) [12 5].  Substituting methylamine with ethylamine  
produces MDEA, the use of ammonia gas produces MDA, while dimethylamine 
produces 3,4-methylenedioxydimethylamphetamine (MDDMA) [12 3], which is a 
structural isomer of MDEA, a psychoactive substance. 
 
 
1.5.2.2 Leuckart method 
 
The illicit manufacture of MDMA by the commonly used Leuckart method is analogous 
to the manufacture of amphetamine by the same method.  For MDMA, 3,4-MDP2P and 
N-methylformamide are reduced using formic acid, producing the intermediate N-formyl-
MDMA which is then hydrolised by refluxing with strong acid or base to produce 
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Figure 1.9 Leuckart method for MDMA synthesis (Note: (1) 3,4-MDP2P, (2) N-
Formyl-MDMA  and (3) MDMA) [118]. 
 
1.5.2.3 Safrole bromination method 
 





                         (1)                                                   (2)                                                     (3) 
 
Figure 1.10 MDMA synthesis by safrole bromination followed by methylamine 




bromosafrole  by  the  addition  of  hydrobromic  acid  at  low  temperature,  followed  by 
treatment with methylamine to form the final product (Figure 1.10) [118, 126].  The yield 
will depend on the water content of the reaction mixture [123].  Other different MDMA-
type products such as MDA, MDEA or MDDMA could be produced by the substitution 
of methylamine [123]. 
 
1.5.3 Seizures of precursor chemicals  
 
Between 2006 - 2009 differences were observed in the amount of precursor chemicals 
seized that could have been used in synthesis of MDMA (Table 1.4).  Various factors 
could have caused the difference in the amount of seized precursor chemicals such as 
changes in enforcement and changes in manufacture and trafficking [127].   However, the 
low amount of the precursor chemicals seized considering the amount of ‘ecstasy’ tablets 
on the market suggest that much of the precursors used for MDMA synthesis are not 
detected [36].   
 









1 kg of MDMA 
2006 2007 2008 2009 ~ Amount of Precursor Needed 
Safrole 39 L 45,986 L 1,904 L 1,048 L 1.5 L 
Isosafrole / 225 L 1L 5 L 1.7L 
Piperonal 107 g 2 mt 1.4 mt 4.3 mt 2.1 kg 
3,4-MDP2P 8,816 L 2,297 L 2,823 L 40 L 1.25 L 
 
 
In Europe in 2004, there was a decline in the amount (about 17 mt) of reported seizures 
of 3,4-MDP2P, with the last seizures reported in 2007. The decrease in 3,4-MDP2P 
seizures could have been caused by tighter controls on the manufacture of this chemical 
in China (traditionally the source of this chemical), after an agreement between China 
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and the EU in 2009 to improve precursor controls [36].  However, it was also suggested 
by the UNODC in 2010 that the decrease in 3,4-MDP2P in Europe could have been 
caused by an increased demand of this precursor in other parts of the world where 
MDMA manufactured had increased, such as North America, South-East Asia and 
Oceania [36].   
 
Those manufacturing MDMA resorted to alternative methods of production and in 2008, 
1,900 L of uncontrolled SRO [54], which is typically sourced from South-East Asia, were 
seized in Europe.  Safrole bromination or the production of the precursor chemical 3,4-
MDP2P by safrole oxidation are used in the synthesis of MDMA.  In 2009 the 
Government of Cambodia disposed of 15 mt of SRO and seized another 5.2 mt (Table 
1.1) [36].  In 2007 45 mt of safrole was seized in Thailand, [36].  Furthermore, in 2010 
the first clandestine laboratory for the domestic extraction and processing of SRO for the 
manufacture of ‘ecstasy’ was uncovered in Australia [130].  
 
1.5.4 MDMA production 
 
The average yield for MDMA production shows large variation due to a variety of 
influences including difficulty in obtaining precursor chemicals, differing methods, and 
levels of expertise of clandestine operators [115, 131].  The manufacture of MDMA, 
which is slightly more complicated when compared to amphetamine or MA, requires 
some level of chemical expertise [132] which varies according to the route of synthesis 
used.  MDMA can be produced clandestinely by safrole bromination using safrole oil.  
However production of the drug is easiest if the starting chemical precursor is 3,4-
MDP2P, because MDMA can be made via a simple conversion process using Leuckart 
method or the reductive amination as described above [133].  However, irrespective of 
variables some methods will be more efficient at converting the precursor to the end-
product, MDMA, than others.  Information about the manufacturing methods are 
commonly encountered in clandestine laboratories and from the limited information 




Clandestinely produced MDMA would normally contain impurities which are caused by 
the manufacturing process.  Impurities from carry over precursors chemicals used in the 
synthesis of MDMA could be detected in the final product such as 3,4-MDP2P, which is 
the most used precursor chemical in clandestine laboratories in Western Europe [118, 
134].  Other impurities emanating from precursor chemicals could include safrole and 
isosafrole,  which  both  could  be  used  as starting materials to synthesise MDMA [134].  
 
Table 1.5 Average practical yield of MDMA by safrole bromination, Leuckart and 











During the synthesis of MDMA in clandestine laboratories the impurities which could be 
produced could give information on the synthetic routes used.  Impurities such as 3,4-
methylenedioxphenyl-2-propanol and N-formyl-MDMA which could be indicative of 
reductive amination and Leuckart reaction respectively [134, 135].  Impurities could also 
originate from contact of the finished tablets with materials such a plastic or substances 
both licit and illicit [135].   
 
In this work MDMA from tablets seized in Malta were analysed for their organic 
impurities and plausible routes of synthesis of MDMA were determined.  Moreover, the 
total ion chromatogram (TIC) of the organic impurities profiles of the MDMA tablets 
were used to link or differentiate between the tablets from different batches.  As far as is 
known this is the first study where MDMA-only tablets seized in Malta were analysed for 
their organic impurities to determine the routes of synthesis of MDMA. 
MDMA Synthesis 
Precursor  
(1 Kg or 1 L) Synthesis Method 
Average 
Practical Yield 
Sassafras oil Safrole bromination 48% 
3,4-MDP2P Leuckart method (with formic acid) 66% 
3.4-MDP2P Reductive amination  (Al/Hg) 95% 
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1.6 Production of Compressed Tablets 
 
Once synthesised MDMA is mainly converted to tablets with logo impression, however 
MDMA could also come in powder (know as “molly” by users) which could me mixed 
with excipients and adulterants [136].   
 
It is reasonable to assume that producers of ‘ecstasy’ tablets would resort to similar 
methods used for licit tablet production.  This has been corroborated by the discovery of 
many illicit laboratories in many countries around the world [121, 130] where ‘ecstasy’ 
tablets were produced and the publication of a catalogue–book by Europol in 2010 of the 
equipment used at illicit laboratories for ‘ecstasy’ tablet production [137].  However, as 
far as it is known no research has been done on methods for illicit production of ‘ecstasy’ 
tablets. 
 
1.6.1 Criteria for licitly produced tablets 
 
The ‘quality’ of tablets can be assessed by five different criteria: 
 
a) Uniformity in the dose of the active ingredient(s) – In the case of legally 
produced tablets the amount of medicament is stated and the variation of the 
active ingredient(s) should vary within accepted limits.  This will depend on the 
mixing of the powders and the uniformity in the mass of the final tablets which 
will be dependent on the uniformity in the fill of dies; 
 
b) Release of the active ingredient(s) – When the tablet is taken it should readily 
undergo disintegration so that the prescribed active material is readily available 
for dissolution, and the release of the active ingredient(s) from the tablets should 
be controlled and reproducible;  
 
c) Friability  and hardness (mechanical strength)  – The friability and the 
mechanical strength, which are closely related, should be enough to withstand 
abrasion in packing, transportation and handling;  
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d) Appearance, weight and size – The tablet should have an elegant appearance and 
the appearance, weight and size should be consistent; 
 
e) Packaging – The tablet should be packaged in a safe manner to protect from 
mechanical shock and from moisture [138]. 
 
There is very minimal information in the literature on the manufacture and the quality of 
‘ecstasy’ tablets.  This had led part of this study to focus on the above mentioned areas to 
determine the ‘quality’ of the illicit tablets.  Most of the examined ‘ecstasy’ tablets were 
from batches of tablets seized by the Malta Police Drug Squad from traffickers and / or 
‘ecstasy’ tablets sellers.  Different batches were normally received at the Malta Forensic 
Laboratory packed in plastic bags unprotected from moisture.   
 
‘Ecstasy’ tablets are manufactured in clandestine laboratories by tabletting machines used 
to manufacture pharmaceutical tablets [139].  Thus it is expected that similar excipients 
used in the manufacture of licit tablets are used in the manufacture of ‘ecstasy’ tablets.  
Hence the plausible identification of the excipient used in the examined ‘ecstasy’ tablets 
was also undertaken in this study.  The data obtained from the characterisation of the 
tablets, both physical and chemical, was used to differentiate between or link batches of 
tablets. 
  
1.6.2 Formulation of tablets  
 
The formulation of tablets, which can be very complex, can vary considerably in 
ingredients from one manufacturer to another.  The powder or granules that are used in 
tablets are a mixture of the active ingredient(s) and a combination of excipients.   The 
quality of the tablet is dependent on the chemical and the physical properties of active 
ingredient(s), and on the accurate individual selection and proportions of the suitable 
excipients.  It is usual practice for excipients, which are physiologically inert substances, 
to be intentionally incorporated into tablets, apart from the active ingredient(s), to play 
specific functional roles.  Almost all tablets contain excipients in amounts normally 
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greater than the present active ingredient(s) [140].  Excipients which could be organic or 
inorganic substances are obtained from natural sources, or produced semisynthetically or 
synthetically [140].  Depending on their functionality in the resultant formulation 
excipients can be sub-divided into the following classifications: 
 
Diluents These are inert substances, which are known as bulking agents or 
fillers that are added to active ingredient in sufficient amounts to 
make a reasonably sized tablet.  The size of the tablets is normally 
kept above 2-3 mm and the mass above 50 mg and so tablets 
containing low doses of active ingredient(s) would contain a 
diluent.  This agent may not be necessary if the dose of the active 
ingredient(s) in the tablet is high, thus the range of diluent in the 
tablets may vary between 5-80%.  Diluents when added to tablet 
formulation enhance the flow, improve cohesion, allow direct 
compression, and adjust the weight of the tablet according to the 
die capacity.  Lactose, sucrose, sorbitol, starch, powdered cellulose 
and calcium phosphate are some examples of diluents [126, 141, 
142].  Diluents are also expected to be used in ‘ecstasy’ tablets 
such as lactose, sorbitol, starch, sodium, and calcium and barium 
sulphate and phosphate salts [143, 144].  
 
Binders  These substances, which are added to tablet formulations, provide 
the necessary bonding between the powders which when 
compressed form the tablet.  Substances that could be used as 
binders include gelatine, acacia, polyvinylpyrrolidone, hydroxyl 
propyl cellulose, pregelatinized starch and hydroxypropyl methyl 
cellulose among others [126, 141].  Binders are also found in 
‘ecstasy’ tablets such as cellulose [143]. 
 
Lubricants    These substances, which are normally added in the final mixing 
step, avoid adhesion between the tablet material, the dies and 
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punches during tablet compression.  Also, these agents make easy 
the ejection of tablets from the die. Some common lubricants 
include magnesium and calcium stearates, stearic acid and talc 
[141]. Lubricants, such as magnesium, zinc, aluminium and 
lithium stearates and boric acid, have also been found in ‘ecstasy’ 
tablets [144].  
 
Glidants These are substances which are added in the dry state before 
compression to improve the flow characteristics of the powder 
mixture.  Common glidants, which are uses in a concentration of 
less than 1%, include silicone dioxide and talc, which may also 
serve as lubricant [141]. 
 
Disintegrators  Substances, insoluble in water at low temperatures, which are 
added to a tablet to help with its disintegration by swelling. The 
most popular disintegrants are corn and potato starch. Others 
include polyvinylpyrrolidone, sodium carboxymethylcellulose, 
agar and bentonite are also used [126, 141].  
 
Colouring agents Colours are used in compressed tablets to improve the appearance 
of the dosage form.  Most commonly used colourants are synthetic 
dyes or lakes. Lakes are choice for sugar or film coating as they 
give reproducible results [141]. The colouring agents found in 
‘ecstasy’ tablets included E 127 (Erythrosine, red dye), E172 (iron 
oxides and iron hydroxides, yellow dye) and E 141 (copper 
complexes of chlorophyll, green dye) [144].  In this study colour 
was used to differentiate between batches of tablets and reflectance 
spectroscopy was employed to measure the colour of some 
samples of ‘ecstasy’ tablets.  Moreover, to investigate the possible 
use of colour of ‘ecstasy’ tablets as a discriminatory physical 
feature a photostability study was conducted on samples of tablets 
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to determine how UV-visible (VIS) radiation may alter the colour 
of the tablets. 
 
1.6.3 Tablets manufacturing methods   
 
To produce tablets formulators can choose from a range of manufacturing methods 
including wet granulation, direct compression and dry granulation. 
 
1.6.3.1 Wet granulation 
 
The wet granulation of powders is done to ameliorate the flow and compressibility of the 
tablet mix [145]. It is a process that uses a liquid binder or adhesive to the powder mix.  
The binder used would increase the particle strength, and the particle size is optimized for 
flow.  Furthermore, due to improved handling dustiness is decreased, the tablet can be 
dried to low final moisture content and segregation of fines can be prevented [146].  In 
general this method produces spherical uniform–sized particles with hydrophobic 
surfaces with a uniform distribution of the active ingredient. This process exposes liable 
drugs to moisture and heat conditions, such as acetylsalicylic acid [147], and there is also 
some material loss during this process [146].  However, stabilizing agents, such as pH 
modifiers, to stabilize the drug could be used during this process [148]. Though this 
method is popular because any drug can be wet granulated successfully [145], it has the 
disadvantage of using a large number of steps making the process more expensive and 
more complex than other methods [146].  This method, which involves nine steps, 
includes the blending of the dry powder, drying moist granulation and granule sizing, 
mixing screened granules with lubricant and tablet compression [145, 146]. 
 
1.6.3.2 Direct compression 
 
By  contrast  with  wet  granulation,  direct  compression,  which  consists  of  three  steps  
involving the milling of drugs and excipients, the mixing of ingredients and tablet 
compression, is rather simple and cheap [146, 149].  In direct compression the active 
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ingredient is mixed with the excipient and lubricant followed by compression in a press 
to make a tablet without any of the ingredients having to be changed [146, 150].  The 
method, which makes it easy for the tablet to be processed, would save labour, time, 
equipment and space [145, 149].  This process, which is ideal for simple formulations, 
improves the stability of the tablet because neither heat nor moisture is required [146].  
However, high-dose (> 50 mg dose [151]) drugs that have poor compression and flow 
properties, such as certain polymorphic forms of the analgesic and antipyretic 
acetaminophen [152], and low-dose (≥ 10 mg dose [151]) drugs due to the non-
homogenous distribution in the final tablet would not be suitable for this type of 
manufacturing method [146].  Also drugs with extremely low bulk density, such as the 
anticonvulsant rufinamide [153], would be difficult to directly compress due to air 
entrapment, using this method [145]. 
 
1.6.3.3 Dry granulation 
 
Dry granulation, which is considered to be a pre-compression process, is used when the 
tablet ingredients are labile to moisture and heat [146, 154].  Compared to wet 
granulation this process, which provides added flexibility of dwell time and compression 
force, provides better stability and thus it could also be used when direct compression is 
not possible [146].  This method, that is suitable for medium and high doses, improves 
the flow property of particles by increasing their size and also increases the density of 
low-density drugs [145, 155].  The elastic recovery of some compounds is decreased by 
this method thus increasing the final compactability [146].  Dry granulation, which is a 
six step process, includes the milling of drugs and excipients, mixing, slugging (which 
are large tablets), dry screening, lubrication and tablet compression [146, 154].   
 
1.6.3.4 The compression of granules or powders 
 
When the mixture is prepared the tablets are formed by feeding the granules or powder in  
the tablet press and compressing the material between two punches in a die (Figure 1.11). 
There is no mention in the literature of the favoured clandestine tabletting process used to 
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produce ‘ecstasy’ tablets.  However, Palhol et al [134] suggested that the presence of both 















Figure 1.11 Schematic diagram of tablet production [156]. 
 
1.6.4 Tablets compressing machines 
 
Compressing machines, also called tabletting machines, range from small inexpensive 
models that make one tablet at a time, the so called single punch tablet press, with only 
around a half-ton pressure, to large computerized industrial models, the rotary multiple 
punch tablet press, that can make hundreds of thousands to millions of tablets an hour 
with much greater pressure.  Both these type of compressing machines have been used 
for tabletting ‘ecstasy’ tablets [137]. 
 
The single punch tablet press, which normally operates at a speed from 1 to 60 tablets per 
minute, has one station of tooling.  These machines normally generate considerable 
vibrations which could cause segregation of granules and powders in the hopper [157].  
Earlier machines had an output between 500 and 1000 tablets per minute with today 
58 
 
presses having output orders of magnitude greater than this [157].  The high-speed 
machines consist of “double-rotary” presses where the cycle of operation is repeated 
twice in one revolution of the turret carrying the tooling producing about 11,000 tablets 
per minute.  Most of the above mentioned types of tabletting machines were seized from 
illegal laboratories producing ‘ecstasy’ tablets [137].    
 
The synthesis and tabletting of MDMA was previously centralized in one laboratory, 
however nowadays it is less likely that the two processes happens in one laboratory, but 
tabletting is normally done in other laboratories specializing in production of ecstasy 
tablets [122].    
 
1.6.5 Defects on tablets 
 
It has been suggested by some that ‘ecstasy’ tablets produced in illicit laboratories will 
have some form of defects caused by the die [144].  Defects detected in pharmaceutical 
tablets were also caused by the low quality of raw materials used, the tablet formulation, 
the poor flow of the powdered mixture, lack of compressibility of the mixture and the 
tabletting machines [158].  Moreover, other detected defects in pharmaceutical tablets 
were caused by the milling process (produces fine and constant particle size) which could 
produce fines causing capping, black spots, laminations and hardness variations [158].  
While, as far as we know, there has never been any report or study concerning ‘ecstasy’ 
tablets manufacture with relation to their physical defects, there have been some mention 
of ‘ecstasy’ tablets defects, such as weight variation, hardness problems, sticking, 
capping, chipping and mottling [126, 159, 160], when describing the illicit tablets or 
writing about ‘ecstasy’ tablet manufacture. 
   
Weight variation of tablets could be caused by a number of factors, such as inadequate 
lubricant, unsuitable glidant, irregular mixing of lubricants and incorrect tool setting 
[161, 162], among others.  Uneven lengths of the lower punches will result in variations 
of powder / granular fill in the die which will affect the weight, while variations in the 
upper punch will effect the compression [161].  According to Tousey [158] controlling 
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the tablet weight, which is dependent on the space between lower and upper punch, is 
always the key for hardness control [158].  Hardness variation and insufficiency could be 
caused by excessive lubricating agents; overly dry mixture and low pressure during tablet 
manufacture [126].   
 
Another tablet defect that has been described is sticking, which is when the powder sticks 
to the punches faces [158], which is normally caused by excessive moisture, lack of 
lubricating agents [163], low melting point substances [162], or worn punches and dies 
[158]. An additional defect similar to sticking is ‘picking’, which is caused when the 
tablet material from the surface of the tablet sticks within the engraving, or debossing on 
the punch [114, 158].  This is normally caused by insufficient lubricant [163], improper 
mixing of the total powder or by unpolished dies [163], causing print defects, which are 
normally seen in ‘ecstasy’ tablet logos.   
 
Capping of tablets, which is a very common defect, is the complete or partial breaking 
away of the tablet upper or lower surface as it is ejected [114].  It could be caused by 
poor blending, the introduction of air, break granules or over blend powder, [163] speedy 
machines and the strength of the compression [162].  In addition, tablets having sharp 
edges tend to chip, mostly by rough handling, around the tablet surface where small 
pieces are broken [114, 162]. Also mottling which is the unequal distribution of colour on 
the tablet surface, caused by the variation in the colour ingredients, the drug and 
excipients [114].   
 
On internet website ‘Pharmainfo’ it is noted that pharmaceutical tablet defects, which 
could also be observed on ‘ecstasy’ tablets, could include lamination (similar to capping 
except that the tablet is separated into layers [114]), which could be caused by small 
amount of binding agent used [162].  However, this defect, which is often blamed on over 
compressing [158], is caused by air trapping between the layers of the tablet and this 
could occur quickly after the compress or during storage [126, 162]. Black spots, which 
could sometimes be seen on colored ‘ecstasy’ tablets, could be caused by the 
inappropriate method of cleaning of the punches and / or the incompatibility between the 
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excipients and / or active ingredient/s used [162]. Some other defects would include the 
production of soft tablets, which could be caused by the lack of drying of the mixture 
used, the low compaction pressure, and the inadequate storage [162], the double 
impression caused by the uncontrolled movement of the punches with engraving (logos) 
on them [114] and the unsuitable disintegrating time, caused by the hydrophobic 
excipients and / or unsuitable disintegrators used [126].  In this research study the defects 
on the examined ‘ecstasy’ tablets were noted.  
 
1.7 Legislative Controls  
 
In the UK the potential for abuse of ring-substituted phenethylamines, such as MDMA, 
had been well anticipated.  The generic controls of 1977, in the Misuse of Drugs Act, 
1971, in Part 1 of Schedule 2, paragraph (c) define phenethylamines as “any compound 
(not being methoxyphenamine or a compound for the time being specified in sub-
paragraph (a) above) structurally derived from phenethylamine, an N-
alkylphenethylamine, α-methylphenethylamine, an N-alkyl- α-ethylphenethylamine by 
substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide 
substitutes, whether or not further substituted in the ring by one or more other univalent 
substituents” (Figure 1.12), [164].  Thus, these controls made all compounds that could 
be derived structurally from phenethylamines Class A drugs under the 1971 Misuse of 
Drugs Act.  This made MDMA then virtually unknown, and not yet scheduled in any UN 
Convention, illegal in the UK under the Misuse of Drugs Act [164]. 
 
In 1986 the World Health Organization (WHO) and the UN Commission on Narcotic 
Drugs placed MDMA in Schedule 1 of the 1971 Convention on Psychotropic Substances 
[20].  At that time in 1986 MDMA, which was already under national control in Canada 
and the UK, was controlled in the US [165].  Although in the US in January of 1988 
MDMA was removed from the schedule for controlled drugs it was again scheduled in 
March of that year [20].   
 





international treaty obligation to implement and control the drug MDMA.  In Malta the 
substance,  which was considered a restricted drug, was first scheduled in 1988 [166].  By 
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Figure 1.12 (a) The UK Misuse of Drugs Act, 1971, defines phenethylamines as any 
compound structurally derived from phenethylamine by substitutions on the 
molecule – R’ = H or alkyl; R” = Rα1 = Rβ2 =H; Rβ2 = H, methyl or ethyl; Rx = 
alkyl, alkoxy, alkylenedioxy or halogen (either singly or in any combination) with or 
without any other substituents in the ring [164], (b) MDMA chemical structure. 
1990 in Malta it had become a criminal offence if one was caught trafficking, dealing or 
using MDMA [167] and by 1998 the laws for trafficking in psychotropic drugs (under 
which MDMA is classified) were made harsher, to life imprisonment [168].  Today, 
under a UN agreement, MDMA is controlled in most countries in the world, and its 
possession, manufacture, or sale may result in criminal prosecution [169].  
Chemicals or substances that are used in the manufacture of other substances are called 
precursors. Many legitimate industrial chemicals are used in the manufacture of illicit 
drugs.  Since MDMA is a synthetic drug, it is manufactured from chemicals that often get 
diverted from legitimate businesses.  Because precursor chemicals are normally needed to 
synthesise MDMA governments have adopted legal control as part of their overall drug 
control and enforcement plans.  These controls offer a means of attacking illicit drug 
production and disrupting the process before the drugs have entered the market. 
 
The 1988 UN Convention “Against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances”  has established control measures on the diversion of the precursor chemicals  
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which could be used in the production of illegal drugs, including the synthesis of MDMA 
[170].  The four chemicals, safrole, isosafrole, piperonal and 3,4-MDP2P, used in the 
synthesis of  MDMA were  included in the Convention [170].  Over the years most 
member states have introduced trade controls on these chemicals.  These precursor 
chemicals were controlled in the US in 1989 [171] in the UK during 1990 [172] and in 
Malta it was 1998 [173].   
 
Governments also tried to eliminate rave parties by means of enforcement and 
legislations.  This agenda was a response to perceptions that the rave scene became 
corrupted due to drug use, mainly ecstasy.  By 1990 in the UK the Government tried to 
control the rave culture by legislative control [19].  It is believed that this altered the UK 
rave scene and managed to push raves parties and the use of ecstasy into the legitimate 
clubs [19, 174] to avoid prosecution.  This was not unique to the UK, the same was 
happening in the US where many communities and US legislators attempted to reduce the 
number of rave parties which were considered as    locations of ecstasy use [175].  The 
same happened in Malta when in 1999 the Government tried to control rave parties by 
legislative control [176].  Nevertheless Townsend, from the Guardian [177] confirmed 
the continuation of these events in London.  Thus raves and the use of illegal drugs 
during these parties will probably thrive during the coming years. 
 
1.8 Characterisation of MDMA / Ecstasy Tablets 
 
A recurring theme in illicit drug intelligence is to determine the sources of supply and 
manufacture of MDMA by means of indicative chemical or physical properties.  With 
this aim in mind, the Commission on Narcotics Drugs, in its resolution 1 (xxxix) of the 
24 April 1996, requested the Executive Director of the United Nations International Drug 
Control Programme (UNDCP) to develop standard methods for the profiling / signature 
analysis of key narcotic drugs and psychotropic substances.  Since then, activities 
initiated by the Scientific Section of UNDCP have been aimed at developing methods for 
the characterisation and impurity profiling of such substances [178].  A similar project, 
the “Collaborative Harmonisation Methods for Profiling of Amphetamine Type 
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Stimulants” (CHAMP), which focused on MA and MDMA, was launched in 2004 and 
funded by the European Commission [179].   
 
The CHAMP project has shown that data from batch specific organic impurities, such as 
3,4-MDP2P and N-formyl-MDMA [179], recorded by a harmonised gas 
chromatography-mass spectrometry (GC-MS) method and the physical features diameter, 
thickness, weight and score were found to be reliable and relevant features for forensic 
drug intelligence perspective.  This study also demonstrated the possibility to 
discriminate / link MDMA samples and batches of tablets, manufactured by a tabletting 
machine with given settings, using the data from both the organic impurities and the 
physical features by statistical methods [179].  Thus, physical and chemical 
characterisation of ‘ecstasy’ tablets, that could provide information on links between 
users and suppliers, drug supply patterns and source, could be defined as the profiling of 
visual (e.g. shape and colour), physical (e.g. mass, diameter and thickness) and chemical 
features (e.g. chemical impurities arising from precursors and reaction by-products) to 
provide information for both evidential and drug forensic intelligence purposes [180]. 
These characteristics occur at different stages during the clandestine production of tablets 
[181]. The three main steps in the production of ecstasy tablets are: 
 
i. The synthesis of MDMA; 
 
ii. Mixing of MDMA with excipients / cutting agents produce the tablets 
chemical characteristics; 
 
iii. The manufacture of the tablets by the tabletting machine with given 
settings which produce the tablets physical characteristics [181]. 
 
Generally, the procedure followed by forensic scientists and researchers to characterise 
‘ecstasy’ tablets is to start with examination of the physical features which would include 
the visual inspection of the features of the seized tablets, such as colour, size, shape and 
logo if present, and the measurable characteristics, such as mass, diameter and thickness, 
which could provide important information on the source of the illicit tablets [144].   
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 Nevertheless, similarities between the physical features of different tablets only suggest a 
relationship at the tableting level, and that the powders used for the tablets could be from 
different sources [180].  Conversely tablets with different physical features could have 
been manufactured from the same powder [180].  Thus physical characterisation will be 
followed by determination of the chemical features, which would normally include the 
identification of the psychoactive substance/s, adulterants (e.g. ephedrine, caffeine and 
ketamine [122]) and excipients (e.g. the diluents lactose and sorbitol [122, 144] used to 
fill up the volume of tablets), which are used in the tablet manufacture and characteristic 
impurities, such as starting materials, intermediates and by products [144, 182].  In these 
circumstances a random sample of tablets, normally based on visual similarities would be 
taken for characterisation.  It is generally assumed that batches of ‘ecstasy’ tablets having 
similar physical and chemical features come from the same production batch, while 
tablets with different features are from different batches [139].  
 
1.8.1 Visual and physical characterisation of MDMA / ecstasy tablets 
 
The simplest way of investigating ecstasy tablets is by visually inspecting the physical 
features of the tablets where the differences and similarities in, for example, the colour 
and shape of the tablets can be observed and recorded.  In the medical field, online visual 
description of prescription tablets is used to identify a particular tablet, such as the 
“Pharmer.org” [183] and “Drugs.com” [184] which are websites that help in tablet 
identification. Another is TICTAC, a UK commercial visual drug database for healthcare 
and law and order authorities, which contain information on legal and illegal drugs [185].   
 
In forensic science, only a few publications have described results of a detailed physical 
comparison of tablets and the use of such characterisation from a drug intelligence 
perspective.  However, there have been some attempts to collect visual data of ‘ecstasy’ 
tablets, such as the logo project of Europol [186], where a large number of ’ecstasy’ 
tablets logos were collected, and websites such as “ecstasydata.org” [187], where various 
information on ‘ecstasy’ tablets, such as logo, active ingredients and percentage 
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pharmacological content, date when found and country of seizure, were collected.  There 
is little information available in the literature about the use of ‘ecstasy’ tablet colour, 
mass, diameter and thickness for intelligence purposes.  Some research has focused on 
the use of microscopes and comparative microscopes to determine tablet shape; to 
measure the physical features such as tablet width, thickness and angle of breaklines 
when present; and to compare the damage marks transferred by the punches to illicit 
tablets [126].  Other researchers such as Zingg [126] and Marquis et al. [181] have 
focused on similar physical parameters such as logo, breakline, colour, shape, mass, 
diameter and thickness to establish the physical characteristics of ‘ecstasy’ tablets.  These 
physical properties were found to be useful for drug intelligence purposes and to be 
applied to make links or differentiate between tablets of ‘ecstasy’ tablets [181].   
  
For legally manufactured pharmaceutical tablets, there are pharmacopeial and 
pharmaceutical criteria for quality control of parameters such as mass, diameter, 
thickness, hardness, friability and disintegration time of a tablet in water.  As far as can 
be ascertained hardness, friability and disintegration time have not been used to 
characterise ‘ecstasy’ tablets.  These physical features were investigated in this research 
study to determine the ‘quality’ of the ‘ecstasy’ tablets seized in Malta.  These 
measurable features were also used to differentiate or link batches of tablets.     
 
Drug synthesis and tabletting does not necessary take place in the same location [122].  
Differences in the physical features of tablets does not rule out the possibility that the 
chemical characteristics could be related, because the same manufactured powder may be 
tabletted by different moulds, different machines and at different tabletting laboratories 
[180].  Hence a link between samples based on physical features, would only be 
indicative of the tabletting machine used with a particular settings.  Thus, physical 
characterisation of tablets should be complemented by chemical profiling to get 
information on the active ingredient/s and excipients used and to possibly determine the 





1.8.2 Chemical characterisation of MDMA / ecstasy tablets 
 
The chemical characterisation, both organic and inorganic, of ‘ecstasy’ tablets can be 
divided in two parts: (1) the general profiling where the major and minor substances, 
such as active substance/s present, the excipients and adulterants (psychoactive 
substances other than the named substance), are identified and (2) impurity profiling 
where trace chemicals found in / on the tablet are detected and, where possible, 
identified.  Impurities in tablets can arise from precursors, reaction by-products, synthetic 
intermediates, impurities from contaminated reagents, all of which can accumulate during 
the manufacturing process because of inadequate purification methods.  Impurities may 
also arise from packaging, handling and storage [188-190]. 
 
Many techniques have been used to determine the chemical composition of ‘ecstasy’ 
tablets ranging among others from methods to identify the psychoactive substance/s in 
‘ecstasy’ tablets such as presumptive tests, the most common Marquis test, used to 
identify drug classes [126], thin-layer chromatography (TLC), a separating technique 
used for identifying psychoactive substances [126].    Liquid-liquid extraction and solid 
phase extraction-TLC were also evaluated in a study involving impurities found in an 
intermediate 1-(3,4-methylenedioxyphenyl)-2-nitropropene in the synthesis of MDMA 
[191]. In this study liquid-liquid extraction was found to be more effective than solid 
phase extraction in isolating characteristic impurities from drug matrix [191]. However, 
in another study the solid phase extraction of impurities in ‘ecstasy’ tablets was found to 
be more effective than liquid-liquid extraction when used with GC analyses [188].   
 
The instrumental methods used for chemical characterisation of ‘ecstasy’ tablets included 
among others infrared (IR) surface Raman spectroscopy [192, 193] and near IR (NIR) 
spectroscopy [143].   The Raman spectroscopy was used to differentiate between tablets 
from different seizures using compositional differences [192].  Studies on ‘ecstasy’ 
tablets had shown that distinction between tablets was possible using the difference in 
excipients, the active drug:excipient ratio and the hydration of the active drug in ‘ecstasy’ 
tablets [192, 194].   In another study principal component analysis was applied to the first 
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derivative of Raman spectra [195].  This method, which was conducted on mixtures of 
illicit substances with maltose, lactose and flour among others, categorised mixtures of 
cocaine, heroin and MDMA [195].   
 
Dyes present in illicit tablets were also investigated using a combination of solid-phase 
extraction, thin layer chromatography (TLC) and capillary zone electrophoresis with 
diode array detection [196].  The most detected dyes were the hydrosoluble, acidic, 
synthetic food dyes found in EU countries [196].  It was claimed that the added dye 
information provided by this method could be useful for comparative purposes and to 
determine common production sites [190].  In addition NIR spectroscopy, operated in 
transmittance and diffuse reflectance modes, was developed as calibration model to 
quantify MDMA and MDEA, in ‘ecstasy’ tablets [197] and also to study excipients in 
‘ecstasy’ tablets [198].  In another study applying NIR spectroscopy in reflectance mode 
and high performance liquid chromatography (HPLC), the most common detected 
‘ecstasy’ tablets excipients were lactose, starch, cellulose and sorbitol [143].  The NIR 
spectra of seized ‘ecstasy’ tablets containing more than one excipient were more complex 
and excipient identification was not always possible for some tablets [190]. 
 
Other instrumental methods used included X-Ray diffraction; isotopic characterisation 
[199]; 1H and 13C-nuclear magnetic resonance (NMR) [200]; solid state-NMR (SSNMR) 
[201]; and chromatographic separation methods such as: HPLC [202]; GC-MS [117, 203-
209]; HPLC-MS [210]; and capillary zone electrophoresis.  These methods were very 
effective in providing evidence for the presence of MDMA (or related compounds) 
within a tablet formulation and as a means to characterise either bulk excipients or 
manufacturing impurities.   
 
Another research study investigated the identity and percentage composition of the active 
ingredient(s) in ‘ecstasy’ tablets confiscated in Taiwan over a three year period [207]. 
Most (66–71%) of the analysed tablets were found to contain MDMA, as the only active 
ingredient,  which  varied  from  89  to  133 mg / tablet  [207].   While MDMA content in 
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‘ecstasy’ tablets in Taiwan decreased over time other compounds were also detected 
which included caffeine, MA and MDEA among others [207].   
 
Other techniques which are not routinely used and rarely reported include inductively 
coupled plasma-mass spectrometry, and inductively coupled plasma-atomic emission 
spectroscopy [144].  These techniques were used to determine trace metal in ‘ecstasy’ 
tablets [144, 211].  In a study where inductively coupled plasma-mass spectrometry and 
inductively coupled plasma-atomic emission spectroscopy techniques were used the 
stearates of Mg, Zn, Al, and Li were detected [144].  These stearates are used as 
lubricants in ‘ecstasy’ tablets manufacture [144].  However, the true potential of the 
inductively coupled plasma-mass spectrometry and inductively coupled plasma-atomic 
emission spectroscopy techniques for ‘ecstasy’ tablets characterisation needs to be further 
evaluated.  Very few studies have been conducted using these techniques possibly 
because of the lack of quantitative information and variation in the analyte signals due to 
the poor homogeneity of some illicitly produced tablets [190].  In part of this research 
study somewhat similar analyses using scanning electron microscopy with energy 
dispersive X-ray analyser (SEM/EDX) were conducted to determine the elemental ions 
and their percentage concentration on the surface of ‘ecstasy’ tablets.  Further, the 
inorganic profiles of the tablets were evaluated for their use to link or differentiate 
between the tablets.   
 
Considerable research has been carried out on impurity profiling of ‘ecstasy’ tablets 
containing MDMA.  These tablets are not normally produced in clean rooms as are 
pharmaceutical products and the chemicals used to synthesise the illicit drug (depending 
on the route of synthesis used) are not of pharmaceutical quality [122].   
 
When carrying out analyses for intelligence purposes, impurities, which are normally 
present at low concentrations, need to be isolated from the total tablet content by an 
extraction process prior to analyses by instrumental methods [188].  The examination of 
the impurity profiles, including the possible identification of the compounds present, 
results in an “impurity profile” of the tablet.  This can be used to differentiate between, or 
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to link, different seizures of ‘ecstasy’ tablets.  It would be expected that a “profile” from 
the same manufacturing batch would have the same impurities in the same relative 
amounts [134].   
 
Research on impurities found in MDMA synthesised by different methods showed that 
different synthetic routes and variations to the same synthetic route produced different 
impurity profiles [190].  When MDMA was synthesised by three different routes: two 
involving the Leuckart reaction and another described in the Merck patent (safrole 
bromination) [200] a number of impurities, which were analysed by a combination of: 
TLC, IR, UV, 1H NMR 13C NMR, XRD, GC and GC-MS, were detected.  Identified 
compounds included precursors safrole and isosafrole; and intermediates isosafrole 
glycol, 3,4-MDP2P, N-formyl-3,4-methylenedioxymethylamphetamine, N-formyl-3,4-
methylenedioxyamphetamine (for Leuckart Synthesis) and 1-(3,4-
methylenedioxyphenyl)-2-bromopropane (MBPBP) ( for safrole bromination) [200].  
Also, the reaction by-products N,N-dimethyl-3,4-methylenedioxyamphetamine 
(DMMDA), a tertiary amine found in illicit MDMA produced by low pressure reductive 
amination, the methylenedioxy substituted pyrimidines and pyridines analogues were also 
determined by the same techniques [200].   
 
Impurity profiling was also used to identify the precursors used to produce MDMA [190].  
By using GC with flame ionization detection (GC-FID), and corroborating the results by 
GC-MS, it was possible to confirm that 3,4-MDP2P was the precursor of choice for 
clandestine MDMA synthesis [190].  GC-FID and GC-MS were also used to identify 
impurities such as N-formyl-MDMA and 3,4-Methylenedioxyphenyl-2-propanol from 
Leuckart and reductive amination synthesis respectively [134].  Other impurity profiling 
analysis, conducted on ‘ecstasy’ tablets containing MDMA seized in Hong Kong between 
2000 - 2001, identified the common precursors 3,4-MDP2P, 3,4-methylenedioxyphenyl-
2-propanol, 3,4-methylenedioxy-N-methylbenzylamine (MDB), piperonal, and N-formyl-
3,4-methylenedioxymethylamphetamine [212].  The detection of 3,4-MDP2P as a 
precursor was attributed to the popular Leuckart and reductive amination syntheses, and 
MDP to the direct reduction of 3,4-MDP2P [212].  In another research by a different 
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group, the detection of two major impurities, MDA- and MDMA-dimers, and three 
substituted pyridines by-products during analysis carried out on MDMA tablets seized in 
Hong Kong between 2002 - 2004, indicated the use of Leuckart synthesis [209].   
 
Route specific impurities produced during the synthesis of 3,4-MDP2P via isosafrole 
oxidation and the nitrostyrene route were also identified by GC-MS analysis [135].  In 
addition, basic and neutral impurities, such as N-methyl-2-methyl-1-(3,4-
methylenedioxyphenyl)-ehaneamine and 3,4-methylenedioyphenyl-2-bromopropanme 
produced during the synthesis of MDMA via Leuckart, bromosafrole and reductive 
amination routes were also examined [206].  Analyses by TLC, GC and GC-MS carried 
out on precursors, intermediates, reaction by-products and MDMA, obtained from 
MDMA synthesis in the laboratory, were used to establish the route of synthesis of the 
illicit compound by the study of trace impurities [181].  Undoubtedly the above organic 
impurity profiling methods had helped researchers to identify most of the precursors, 
intermediates, by products produced during the synthesis of MDMA, thereby generating 
a “chemical fingerprints” of the differently synthesised MDMA found in different 
batches of ecstasy tablets.   
 
Over the years legislative controls have been put in place to control MDMA tablets and 
its precursor chemicals as well as other psychoactive substances used in the production of 
‘ecstasy’ tablets. Thus it was thought that this research study would focus on the physical 
characterisation and chemical profiling of MDMA / ecstasy tablets to provide 
information to law enforcement agencies.  This study was carried out on ‘ecstasy’ tablets 
that were seized in Malta over a five year period from 2006 - 2011. 
 
‘Ecstasy’ tablets which are illicitly produced are not strictly controlled.  Thus the physical 
features and physical stability of ‘ecstasy’ tablets were examined using adopted methods 
from European and British Pharmacopoeia and the International Conference on 
Harmonisation (ICH).  Chemical analyses of ‘ecstasy’ tablets and chemical profiling of 
MDMA tablets were carried out using various analytical methods.  The data obtained 
from the physical features together with the chemical profiling was used to try to 
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discriminate or link batches of ‘ecstasy’ tablets from same or different seizures.  It is 
hoped that the scientific information gathered during this research study together with the 
methods used could be of benefit to scientists involved in law enforcement, intelligence 
gathering that try to determine distribution networks, traffickers of ‘ecstasy’ tablets and 
also linking dealer with user of these tablets. 
 
In Malta, where the drug problem is usually limited to the sale and the use of consumer 
quantities [213], MDMA / ecstasy tablets have also found their place and compared to the 
use of other illegal drugs these tablets are still popular [47].  However, the research on 
drug use in recreational settings in Malta is scant.  For this reason a field study was 
carried out to examine the behaviour of party attendees and also to investigate if the 
substances used, especially ‘ecstasy’ tablets, were related to the drugs seized by the 
authorities. 
 
1.9 Rationale for the Thesis 
 
‘Ecstasy’ tablets could be characterised in terms of a set of selected physical and 
chemical properties, giving in the process information (i.e. profile) on the particular batch 
of clandestinely produced tablets.  The physical and chemical characterisation of 
‘ecstasy’ tablets was labelled as a “promising methodology” by Swist et al [206] that 
could provide information on links between users and suppliers, drug supply patterns and 
source.  In this research a set of selected physical (visual and measurable) and chemical 
features were studied to investigate their use in linking or differentiating between batches 
of ‘ecstasy’ tablets seized in Malta over a 5 year period from 2006 – 2011 and the utility 
of these characteristics for intelligence purposes. 
 
The physical features of ‘ecstasy’ tablets might have a bearing on whether a scientist 
feels able to link tablets obtained from different seizures.  It is generally assumed that 
tablets with similar physical features are from the same production batch and were 
manufactured with the same tabletting machine and punches, while tablets with different 
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characteristics are from different batches [139].   Unfortunately the physical features of 
‘ecstasy’ tablets for profiling purposes have been neglected in the literature [181].   
 
In this research study to establish the physical characteristics of the tablets in the batches 
10 parameters were chosen which included the visual features (logo, breakline, colour, 
shape), the measurable features (mass diameter, thickness), and the tablet handling 
characteristics (hardness, friability and disintegration rate).  The examinations of the 
tablets in the batches always started with the description of the visual features.  This was 
always followed by the determination of the measurable features and the tablet handling 
characteristics of the seized ‘ecstasy’ tablets, using in the process, for the first time, 
adopted methods from the European and British pharmacopeia and pharmaceutical 
criteria.     
 
A gap noted in the scientific literature is the lack of information on the stability of 
physical features of ‘ecstasy’ tablets during storage, if the physical characteristics are to 
be used for drug intelligence purposes.  Thus, to address this lack of information three 
tests were conducted which included a photostability test to investigate possible changes 
that might occur in the colour, and two tests on the measurable features (mass, diameter 
and thickness), and tablet handling characteristics (hardness, friability and disintegration 
rate)  of ‘ecstasy’ tablets at different storage conditions (an accelerated storage 
experiment - 40°C and 75% relative humidity (RH) for 6 months and a stability 
experiment - 5, 15, 25, 35 and 40°C and 33 and 75% RH for 16 weeks).  Storage 
conditions were also recommended based on the results obtained. 
 
Some researchers are of the opinion that the physical features of tablets are not 
considered sufficient enough to provide evidence of a link or to discriminate between 
seizures of batches of ‘ecstasy’ tablets [214].  To investigate this issue and to further 
enhance the discriminative potential of the physical features, chemical profiling, both 
organic and inorganic, of ‘ecstasy’ tablets was undertaken.  Organic and inorganic 
profiling was conducted on ‘ecstasy’ tablets to determine major and minor substances, 
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such as psychoactive substances and tablet excipients.  Impurity profiling of MDMA 
tablets was also carried out to try and determine the route of synthesis.    
 
In an overview of MDMA-related literature for 2003 on the Multidisciplinary 
Association for Psychedelic Studies website, it is stated that MDMA used in ‘ecstasy’ is 
assumed to be a racemic mixture, and to date, the racemate has been employed in all 
human trials [215]. While an EMCDDA report on MDMA states that almost all illicit 
MDMA exist as a racemic mixture [58].  The latest and only study that carried out to 
determine the enantiomer ratio of MDMA was concluded by the CHAMP Group in 2006 
[179].  So it was felt that MDMA tablets seized during the period of this study should be 
analysed to determine the S-(+)- and R-(-)- steroisomer ratio.  The properties of MDMA 
enantiomers are different the S-(+)- enantiomer being more potent than the R-(-)- 
enantiomer [73, 80-84, 216, 217].  MDMA has an enantioselective metabolism where the 
S-(+)- enantiomer is metabolized faster than the R-(-)- enantiomer [65, 88].   
 
Over the period of this study commercial EDM parties in Malta have grown.  Scientific 
literature shows a high level of drug use behaviour by attendees at dance music events 
[218, 219].  It is also accepted that some illicit drug use would occur amongst the Maltese 
partygoers who attend EDM parties.  However, there is a lack of research on these types 
of parties that are held in Malta and no information is currently available.  To this effect 
two studies were undertaken to try and investigated the licit and illicit substance use and 
the pre, during and post party behaviour of partygoers at EDM events in Malta.   
 
1.10 Aims and Hypotheses  
 
The contribution of this project to the scientific literature is three-pronged, involving (a) 
the physical characterisation and chemical profiling, including the psychoactive 
substances and enantiomeric ratio of MDMA / ecstasy tablets, (b) using the data obtained 
to link and discriminate between batches of ‘ecstasy’ tablets and (c) investigating the licit 
and illicit substances used at EDM parties in Malta over a six year period and the 
behaviour of attendees at these events. 
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1.10.1 Main hypotheses 
 
For this research study five basic hypotheses have been considered which were: 
 
Hypothesis 1:  The physical state of different batches of ‘ecstasy’ 
tablets seized on different occasions in Malta during 
2006 – 2011 will be significantly different from each 
other. 
Hypothesis 2:  Seized ‘ecstasy’ tablets will contain MDMA as the 
predominant psychoactive substance. 
 
Hypothesis 3:  The enantiomers ratio of MDMA tablets will be 50:50 in 
illicit tablets. 
 
Hypothesis 4: The chemical composition of different batches of 
‘ecstasy’ tablets seized on different occasions in Malta 
during 2006 – 2011 will be significantly different from 
each other. 
 
Hypothesis 5:  Those ‘ecstasy’ tablets seized by the police at EDM 
events in Malta will match batches seized on different 






























2.1.1 Solvents and reagents 
 
All  solvents  and  reagents  used  were  of  analytical  reagent  AR grade  (Rathburn, 
Walker-burn and BDH, both UK).  The tablets excipients lactose, sorbitol, and starch 
were purchased from BDH, UK and dibasic calcium phosphate (DCP) from Sigma – 
Aldrich, Germany.  The reference standards MDMA, MDA, amphetamine, BZP, mCPP, 
caffeine, methandrostenolone, heroin and cocaine, all at a concentration of 1 mg mL-1, 
tetrahydrocannabinol (THC) at a concentration of 100 μg mL-1 and LSD at a 
concentration of 25 μg mL-1, were purchased from Alltech, USA.  The S(+)- and R(-)-
MDMA reference standards were generously donated by Dr. Andrew T. Kicman, Drug 
Control Centre, Department of Forensic Science and Drug Monitoring, King’s College 
London. 
 
2.1.2 Tablets   
 
The examined batches of ‘ecstasy’ tablets were mostly confiscated at entry points into the 
country, hidden in false bottoms of suitcases, or found on premises in Malta by the Police 
Drug.  Polythene bags, which are known to be permeable to water vapour, were typically 
used by traffickers to pack their batches of tablets such that, especially during the 
summer months, the tablets might have also been subjected to sunlight.  
 
In Malta a police drug case, which could be part of a larger police operation, would 
normally involve drug seizure(s), which by court order would be handed to the Forensic 
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Laboratory for analyses. During particular drug cases where ‘ecstasy’ tablets were 
involved there have been a number of tablet seizures.  In some cases police searches of 
premises resulted in the finding of ‘ecstasy’ tablets at different locations.  When tablets 
were found in bags in different locations these were “bagged up” separately and 
registered as separate seizures even if the tablets in the seizures were visually 
indistinguishable.  Seizures containing visually indistinguishable tablets were 
characterised by the time and place of the seizure and the total number of ‘ecstasy’ tablets 
 
 
 CASE  
 


































 Sample / 
Tablet 
 
Figure 2.1 Seizures handling of ‘ecstasy’ tablets for physical and chemical 
characterisation. 
 
found.  Although uncommon, two to four different types of tablets were sometimes found  
77 
 
mixed together in a bag during a seizure.  In such cases the analyst at the Forensic 
Laboratory would sort the tablets according to their visual characteristics.  The sorted 
tablets from the same seizure or the bagged indistinguishable tablets constituted the 
batch.  Random samples of visually similar tablets were used for characterisation and 
each tablet, being the lowest possible unit of the sample, was visually, physically and 




Ecstasy tablets from 30 cases of large seizures of tablets (100 or more ‘ecstasy’ tablets - 
(EUROPOL criteria for large seizures (E. Mangion, 2006, personal communication 
Superintendent, Malta Police, Malta’s representative at Europol, telephone conversion, 
20th November) and 51 small seizures (ranging from 1 to 4 tablets), were investigated 
over a five and six year period respectively, from 2006 - 2011. 
 
The characterisation of ‘ecstasy’ tablets is defined in this study as the use of methods to 
determine the physical features, visual and measurable, and chemical characteristics 
which included the main active ingredient, enantiomer ratio and impurity profiles of 
MDMA, major excipients and elemental profiles. 
 
The methods used for physical and chemical characterisation of MDMA / ecstasy tablets 
are shown in Table 2.1. 
 
The general procedure followed in examining the batches of tablets was first to note the 
visual features which included the logo, shape, breakline (if present) and colour and then 
measuring the measurable features.  It was expected that tablets manufactured with same 
tableting machine and punches would have very similar measurable features.  Thus the 
mass, diameter, thickness, hardness, friability and disintegration were measured. 
 
The stability of the physical features of ‘ecstasy’ tablets, which included colour, mass, 
diameter,  thickness,  hardness,  friability  and  disintegration  rate were also investigated.   
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Table 2.1 The investigated characteristics and stability of ecstasy / MDMA tablets. 
 
 
Visual Physical Stability of Physical 
Characteristics   
Chemical 
 






















• Temperature  
    and humidity 
 
 
• Psychoactive substances 
and quantity 
 
• Percentage isomeric content 
of MDMA-only tablets  
 
• Major excipients 
 
• Organic impurity profiles 
of MDMA-only tablets 
 
• Elemenatal profiles   
 
 
The stability of the physical characteristics was studied to determine any changes that 
might occur due to different environmental conditions, such as light, temperature and 
RH, if these features were used for intelligence purposes.  In these experiments the colour 
of tablets was determined by a portable spectrophotometer. 
 
The presumptive colour tests, TLC and GC-MS analyses were used with the scope to 
help separate tablets in two groups those having MDMA as the main active ingredient 
and those without MDMA but having other psychoactive substances.  All psychoactive 
substances were confirmed by the use of standard reference samples of different drug 
compounds, comparing their retention times and mass spectrum obtained from sample 
analyses.  
 
If tablets were found to contain MDMA their percentage isomeric content was 
determined.  To this end extracts from such tablets had to be derivatised by trifluoroacetic 
anhydride (TFAA) and analysed by GC-MS using a chiral column.  
 
Tablets found to contain MDMA were further analysed to determine their organic 
impurity profile to further link or discriminate between the batches.  In such cases liquid-
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liquid extraction and GC-MS analyses was used.  The organic impurity profiles obtained 
from the tablets was also examined to establish if the synthetic routes used to synthesise 
MDMA could be determined.   
 
When tablets were found to contain only one psychoactive substance a UV 
spectrophotometric method for drug quantification was used.  The UV method was 
preferred because it was simple, less time consuming, economical and did not require any 
elaborate pre-treatment of the drug and tedious extraction procedures usually associated 
with chromatographic method [220].  
 
To further chemically characterise the batches, tablets were analysed for the presence of 
major excipients using Fourier transform infrared transmittance spectroscopy (FTIR).  It 
was thought possible that a rapid indication of the major excipient by FTIR directly from 
powdered tablet was possible.  
 
In final analyses the elemental profiling of ‘ecstasy’ tablets was conducted using 
SEM/EDX.  The SEM/EDX was chosen because of its low detection limit, 1000 ppm, 
when compared to both inductively coupled plasma atomic emission spectrometry or 
inductively coupled plasma mass spectrometry, with a detection limit ranging from 2 to 
0.005 ppm and 0.038 to 0.0002 ppm respectively [144].  Thus the idea of using the 
SEM/EDX for the inorganic analyses of ‘ecstasy’ tablets was that of detecting elements 
from the tablets and not elements from external contamination, such as Pb, Ni, Co, which 
are at very low ppm concentration (0.2 – 0.003 ppm [144]). 
 
The physical and chemical characterisation of ‘ecstasy’ tablets was done because it was 
expected that both the physical state and the chemical composition of the batches seized 
on different occasions would be significantly different (hypothesis 1 and 4 respectively).  
Also, it was predicted that MDMA would be the predominant psychoactive substance 





2.2.1 Physical characterisation 
 
The visual and physical characterisations of ‘ecstasy’ tablets have been investigated to 
determine the potential of such information for forensic drug intelligence purposes.  The 
data from the physical characterisation was used to try to differentiate or link batches of 
‘ecstasy’ tablets from the same or different seizures.  The minimal characterisation 
needed to differentiate or link batches with a reasonable degree of certainty was also 
determined. The data from the physical characterisation of ‘ecstasy’ tablets was also 
examined to determine the information this provided on the illicit tablets seized in Malta.  
An overview of the investigated physical characteristics of ‘ecstasy’ tablets and their 
stability are listed in Table 2.1.  The data obtained from the physical characterisation was 
also used to determine the physical qualities of the ‘ecstasy’ tablets.  Pharmaceutical and 
pharmacopeial criteria were used as benchmarks to evaluate the qualities of the seized 
illicit tablets. 
 
2.2.1.1 Visual characteristics of MDMA / ecstasy tablets 
 
Tablets seized as ‘ecstasy’ tablets (i.e. assumed from their visual appearance to contain 
MDMA) have the advantage of providing visual information such as logo and breakline, 
if present, colours and shape. 
 
 Logos, breaklines, colours and shapes 
 
For the identification and naming of logos, if present, on tablets the Europol Ecstasy 
Logo System catalogue, produced by the Drugs Unit of Europol was used [186].  
 
Breaklines on tablets were recorded using the characterisation, (a) no, breakline, (b) yes, 
breakline and (c) other, type of breakline.  The colours and shapes of tablets were also 
noted. 
 
After  the  visual  characterisation  representative  samples  of  the  tablets  were  taken  to  
81 
 
N                     
n 
determine the measurable physical characteristics, which included the mass, diameter and 
thickness, and the tablet handling characteristics, which included the hardness, friability, 
and disintegration.  The parameters measured were compared, with limits of tolerance 
given for pharmaceutical tablets as listed in the European Pharmacopoeia [221].   
 
2.2.1.2 Sampling of tablets  
 
In seizures were a large number of tablets were involved, the number of tablets in the 
seizure was estimated from the mass of 100 tablets and then working proportionally from 
the total mass of tablets.  A frequentist approach, which assumes that a fixed but 
unknown proportion of the tablets contained drugs, was used to statistically determine the 
sample size to be taken for analysis.  The hypergeometric sampling method, which is 
sampling without replacement, was used to take samples from batches of ‘ecstasy’ tablets 
having similar visual features [222].   
 
Hypergeometric sampling method 
 
The used hypergeometric sampling method is a statistically-based model involving a 
defined confidence level with an associated probability of finding failures in a population 
[222].  The probability that a sample of size n of tablets contains x positives (tablets 
containing the same active ingredient), given that the population of size N contains N1 
tablets containing the same main active ingredient, can be calculated by: 
 
 
                                                  N1        N – N1  
                                                                             x           n – x 
                                   
                                   P(X = x|N1, N, n) =       _______________ 
                   





This  hypergeometric  distribution  was  used  to  calculate  the sample  size n of ‘ecstasy’  
82 
 
tablets that had to be analysed such that at least K(= kN) tablets contained the same active 
ingredient with (1 - α) 100% confidence.  For this research work α was taken as 0.05 and 
k as 0.9 (implying that the required sample size had to guarantee with 95% of confidence 
that the seizure contained at least a proportion of 0.9 of ecstasy tablets having the same 
active ingredient).  If an assumption is made about the number of tablets expected to 
contain MDMA, as their main active ingredient, in the sample (usually x), the sample 
size n can be solved by the above formula.  For the cumulative probability P(X ≥ x) = (1 -
α) and N1 = K.  The sample size of ‘ecstasy’ tablets for analyses was calculated by means 
of the hypergeometric software provided by ENFSI [223].  If a proportion of 0.9 of the 
analysed ecstasy tablets, having the same visual features, were found to contain the same 
active ingredient(s) another sample, using the hypergeometric method, was taken to carry 
out measurements of the physical features (mass, diameter and thickness).   
 
The “black-box” sampling method was used where the respective batches were put in a 
black plastic bag and the samples of tablets were taken at random from the plastic bag.  In 
this case this “black-box” sampling method was applied to eliminate (or at least reduce to 
a minimum) any bias that may be introduced by the person selecting the samples of 
‘ecstasy’ tablets. 
 
2.2.1.3 Physical characteristics of MDMA / ecstasy tablets 
 
  Procedures for determining the mass, diameter and thickness 
 
The measurements for the mass, diameter and thickness were done on randomised 
samples of tablets that were taken from seized different batches of tablets.  The tablets 
were weighed individually using an electronic balance (Sartorius – CP 225D – readability 
0.01 mg, linearity 0.03/0.2 mg; precision of measurements + 0.01 mg) to determine the 
individual and the mean mass. The diameter and thickness of the individual tablets were 





  Hardness (mechanical strength) 
 
The test was conducted to determine the force needed to disrupt ecstasy tablets by 
crushing.  This property is controlled in a pharmaceutical environment to ensure that the 
tablets are firm enough to withstand handling without breaking or crumbling but not so 
hard that the disintegration time is unduly prolonged.  
 
A sample of 10 tablets was taken at random and subjected to hardness testing using 
Pharma test – PTB 311E hardness tester.  The results were expressed as the minimum, 
maximum and the mean values of the forces measured, all expressed in N [221]. 
 
Friability testing  
 
Friability is a measure of the tendency of a tablet to chip, crack or crumble due to friction 
and abrasion resulting from movement such as shipping and handling.  A friabilator was 
used (Pharma test – PTF 1DR) to measure friability, by tumbling tablets in a drum.  For 
‘ecstasy’ tablets with a unit mass < 650 mg a sample of whole tablets corresponding as 
near as possible to 6.5 g was taken.  The tablets were dedusted prior to testing, weighed 
and placed in the drum.  The drum was rotated 100 times and the tablets were then 
removed [221], dedusted and weighed again.  If the mass loss > 1% the test was repeated 
twice more on the same tablets and the mean of the three tests determined.  A maximum 
loss of mass (obtained from a single test or from the mean of three tests) of ≤ 1% is 
considered acceptable for most tablets manufactured to industry standards [221].   
 
  Disintegration rate  
 
The purpose of testing the rate of disintegration for ‘ecstasy’ tablets was to determine if 
these tablets would disintegrate and if so the time taken for this to occur.  The 
disintegration test was carried out using the disintegration apparatus (Pharma test PTZ – 
Auto 2EZ) which consisted of a basket rack that held 6 plastic tubes, open at the top and 
bottom.  The bottom of each tube was covered by a 10 – mesh sieve.  For the 
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disintegration test six ‘ecstasy’ tablets were selected at random from a batch of tablets 
and were placed one in each of the tubes of the basket rack. The basket rack was 
immersed in distilled water, contained in a 1L glass beaker, maintained at 37 + 2°C [221, 
224].  The time taken by the tablets to disintegrate was recorded. Disintegration was 
considered to be achieved when no residue, except fragments of undissolved tablet, 
remained on the screen of the test apparatus. In cases where residue remained on the 
screen, the residue was checked to confirm that it consisted of a soft mass having no 
palpably firm, unmoistened core [225]. 
 
2.2.2 Stability tests of ‘ecstasy’ tablets 
 
Stability test experiments to determine the effect of environmental conditions, light, 
temperature and humidity, were conducted on two seizures of ‘ecstasy’ tablets.  Two 
types of stability tests were carried out: accelerated and stress testing.  Both were 
designed to investigate possible physical changes in ‘ecstasy’ tablets.  During accelerated 
test studies pharmaceutical tablets are exposed to stress storage conditions to increase the 
rate of any possible physical changes [226].  These tests were adopted for use on 
‘ecstasy’ tablets in this study.  
 
Photostability of the colours of ‘ecstasy’ tablets was also examined to investigate any 
potential change in the colour of tablets when these were exposed to visible and UV light.  
The objective of these experiments was to establish the ideal storage conditions for 
‘ecstasy’ tablets so as to minimize changes in the colour characteristic if this feature was 
to be used for intelligence purposes.    
 
2.2.2.1 Photostability of the colour of ‘ecstasy’ tablets using stress testing 
 
The photostability was adopted from the ICH) method [227].  An actinometer system that 
was based on quinine monohydrochloride to monitor the light exposure from the near UV 




 Photostability experiment of ‘ecstasy’ tablets 
 
Photostability testing was carried out on 4 different batches of ‘ecstasy’ tablets: batches 5  
and 8 (blue and green tablets with omega logo), batch 11 (white tablets with euro logo), 
and batch 14 (orange tablets with pisces logo).  Forty tablets were taken randomly from 
each batch and divided in two sub-samples.  Each sub-sample was placed in glass petri 
dish and then one sub-sample covered with aluminium foil.  Tablets in the non-covered 
sub-sample for each batch (exposed sample) were spread in a single layer in petri dishes 
(Figure 2.2) and positioned so as to provide the maximum area of exposure to the light 
source which was positioned 20 cm from the tablets.  This gave a total of four batches of 
‘exposed’ tablets and four covered. 
 
The samples of ‘exposed’ and ‘covered’ tablets were placed together with two 
actinometric solutions in a quartz spectrophotometer cell (2% aqueous solutions of 
quinine monohydrochloride dihydrate, with one of the solutions wrapped in aluminum 
foil, the control solution) in the light chamber (Figure 2.2). The light chamber was 
illuminated by a cool fluorescent lamp (Sylvania 18 W, 57 V, 1350 lm) for 38 days and 


















Figure 2.2 Photostability experiment - showing the 8 samples of tablets, 4 exposed 
samples to light and 4 covered with foil (control samples) in the light chamber. 
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fluorescent lamp (Sylvania 18 W, 57 V, UVA at 315 – 400 nm – peak at 352 nm and 368 
nm) for  a  total  of  11 hours and 7 minutes exposure, to provide a total of 200 Wh m-2 of 
ultraviolet light, according to the ICH adopted method.  The chamber was kept at a 
temperature  of  34 + 1°C and RH of 29 + 1% during the whole experiment. At the end of 
the exposure period both the exposed and covered samples of tablets were examined for 
any change in colour. 
 
At the end of the exposure period the colour of both the ‘exposed’ and ‘covered’ samples 
of tablets were measured and the CIELAB coordinates were measured by a portable 
spectrophotometer (model Micromatch Plus, Sheen Instruments, UK), which was 
calibrated using three colour standards (Sheen Instruments, UK).  The colour standards 
were the black standard (serial number 188094/6732), the white standard (serial number 
188094/6733, D65, L* 94.56, a* -13.80, b* 0.13, ± 0.3) and the green standard (serial 
number 188094/6734, D65, L* 79.55, a* -13.80, b* 11.54, ± 0.3) respectively.  
 
The measurement principle was based on the measurement of spectral reflectance within 
the visible spectrum of wavelength from 400-700 nm.  The Commission International de 
l’ Èclairage (CIE) L*a*b* colour scale system [228] was used.  Any change in the colour 
of the ‘exposed’ tablets was determined from the difference in the colour measurements 
between the ‘covered’ (control) and the ‘exposed’ samples of tablets from the same 
batch.  
 
After the exposure period the absorbance of both the exposed (AT) and non-exposed (Ao) 
quinine monohydrochloride dihydrate solutions was determined at 400 nm, by means of a  
UV spectrophotometer (model – EvolutionTM 500).  The change in absorbance, Δ A = AT 
– Ao was calculated.  The length of exposure had to be sufficient to ensure a change in 
absorbance of at least 0.5 [227].  
 
 Calculation of the colour difference 
 
The   colour   difference  (ΔE)  between  the  tablets   (control   and   exposed)   after   the  
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photostability stress testing (total 39 days) was calculated using the Euclidean distance 




   ΔE = [ (ΔL*)2 + (Δa*)2 + (Δb*)2]1/2                     
 
The term ΔE was used to describe the colour difference in the CIELAB colour scale 
system.  A change or difference in colour corresponding to a value of ΔE > 1.5 can be 
perceived by the human eye.  The changes in colour, ΔE, of the tablets were compared to 
published data as shown in Table 2.2 below. 







The standard deviation (SD) of ΔE was calculated as the square root of the VΔE [230].  
 
Table 2.2 The change in colour, ΔE, of the tablets were evaluated according to 













ΔE  Colour difference 
up to 0.2 not visible 
0.2 – 0.5 very slight 
0.5 – 1.5 slight 
1.5 – 3.0 obvious 
3.0 – 6.0 very obvious 
6.0 – 12.00 large 
more than 12.0  
 
   VΔE = [((ΔL*)2 / M)VΔL* + ((Δa*)2 / M)VΔa* +((Δb*)2 / M)VΔb*] 
 




  CIELAB method precision and intra-batch variation 
 
The precision was determined by repeatability (intra-day) and intermediate precision 
(inter-day) on one orange ‘ecstasy’ tablets with pisces logo (batch 14).  Repeatability was 
evaluated by 6 determinations of the CIELAB coordinates (1 determination was the mean 
of 3 readings) during the same day, under the same experimental conditions.  
Intermediate precision was evaluated by 3 determinations during 5 different days.  The 
intra-day and inter-day RSD values obtained by the proposed method were found to be 
lower than 1%. 
 
The variation (represented by the RSD) for the three coordinates of CIELAB (L*, a*, b*) 
for the tablets was determined by examining six tablets, taken at random, from a single 
batch of  orange coloured ‘ecstasy’ tablets with pisces logo (batch 14). The intra-batch 
variation by the proposed method was found to be lower than 2%.  Results are given in 
Tables 2.3 and 2.4 respectively. 
 
Table 2.3 Intra-day and inter-day precision data for the portable spectrophotometer 
method for one orange coloured ‘ecstasy’ tablet (batch 14) for the three coordinates 
of CIELAB (L*, a*, b*). 
 
     
        
 a Numbers in parenthesis are the RSDs. 
 
 
Precision L* a* b* 
Intra-day (n = 6)  83.08 (0.04)a 9.81 (0.51) 36.55 (0.25) 
Inter-day - day 1 (n = 3) 83.06  9.81  36.62  
Inter-day -  day 2 (n = 3) 83.13  9.75  36.51  
Inter-day - day 3  (n = 3) 83.11 9.82 36.56 
Inter-day - day 4 (n = 3) 83.16 9.67 36.51 
Inter-day - day 5 (n = 3) 83.10 9.66 36.53 
Inter-day  (n = 15) mean 83.11 (0.05) 9.74 (0.82) 36.55 (0.14) 
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Table 2.4 Intra-batch variation data for the portable spectrophotometer method for 
6 orange coloured ‘ecstasy’ tablets (batch 14) for the three coordinates of CIELAB 
(L*, a*, b*). 
 
Tablet No. L* a* b* 
1 83.03 9.85 36.64 
2 83.14 9.74 38.18 
3 83.04 9.92 37.22 
4 83.63 9.83 36.61 
5 83.19 9.76 37.51 
6 83.46 9.89 37.44 
mean  83.25 (0.29)a 9.83 (0.71) 37.22 (1.59) 
        
      a Nnumbers in parenthesis are the RSDs. 
 
2.2.2.2 Accelerated storage conditions - temperature and humidity 
 
The purpose of accelerated storage conditions testing was to provide evidence on how the 
physical characteristics of the tablets of ‘ecstasy’ tablets would vary with time under the 
influence of temperature and humidity.  The accelerated testing, which was adapted from 
the ICH accelerated storage testing method [231], was carried out on 4 randomly selected 
samples of 80 ‘ecstasy’ tablets each, from 4 different batches of tablets used for the 
photostability testing (batches 5, 8, 11 and 14).  Eighty bumetanide tablets (Remedica 
Limited, Cyprus) were used as a control.  The bumetanide tablets were chosen because of 
their similarity in their measurable physical features, mass, diameter and thickness, to 
‘ecstasy’ tablets.  The bumetanide control tablets used were not in blister packs but were 
dispensed from large container packages. 
 
The mass, thickness and diameter of the tablets were measured before the experiment was 
started.  The four samples of ‘ecstasy’ tablets plus the control bumetanide tablets were 
stored in a chamber at 40oC + 2°C and a RH ≈ 75 % + 5%.  After 3 months about 30 
tablets (corresponding as near as possible to 6.5 g) were taken from each of the 4 samples 
90 
 
and from the bumetanide control tablets and the mass, diameter, thickness, friability, 
hardness and disintegration measured (as described in Section 2.2.1.3).  The same 
procedure was repeated on all the samples and control tablets after 6 months of exposure 
[231].  
 
2.2.2.3 Effect of temperature and humidity on physical characteristics 
 
A further experiment was conducted to investigate the effect of temperature and humidity 
on the physical characteristics of ‘ecstasy’ tablets.  The tablets for this experiment were 
taken from batch 33 (white with versace) which contained 837 tablets.   
 
The method that was used, to create RHs of 33 + 1% and 75 + 1% respectively, was 
based on the use of 2 saturated salt solutions (approximately 5% undissolved salt in 
solution) of magnesium and sodium chloride (MgCl2 and NaCl), respectively.  Both salts 
were of AnalaR grade and deionized water was used for dilution of the salts to create the 
saturated solution.  Each of the saturated salt solutions was put into four separate glass 
containers, with rubber sealable tops, 10 cm high and 8 cm diameter.  About 3 cm of 
saturated salt solution was placed in each container, leaving 7 cm above the solution to 
contain air at a fixed humidity.  Prior to the start of the experiment the glass containers 
containing the saturated salt solutions were left for 24 hr to stabilise to the temperature 
and RH indicated below.   
 
A total of 80 ecstasy tablets, which were taken at random from batch 33, were divided 
into 8 groups of 10 tablets each for each test condition.  The 8 groups of tablets were each 
put in a plastic net pocket and were suspended above the saturated solution, in each 
container and kept for a total of 16 weeks under the following conditions:  
 
RH of 33 + 1% (MgCl2) - 4 groups - °C RH 75 + 1% (NaCl) - 4 groups - °C 
05 15 25 35 05 15 25 40 
 
During  this  period  the  temperature and RH, which is the amount of water vapour in the  
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air at a particular temperature, were checked periodically with a calibrated 
thermohygrometer (Cooper-Atkins, Model SRH77A).  The thermohygrometer deviated 
by no more than + 1°C for the five different temperatures 5, 15, 25, 35 and 40°C and +  
3% for the RH 33 and 75%.  Prior to the experiment the tablets has been stored in an air 
conditioned room at RH of 25% and a temperature of 25 + 2°C.   
 
a) Baseline measurements:  The mass, diameter and thickness of all the 80 tablets 
contained in the 8 samples were measured at the start of the experiment together 
with hardness.  Extra samples were taken to measure the hardness of the tablets; 
 
b) Tests carried out during the experiment:  The mass, diameter and thickness of 
all the tablets in the 8 samples were measured every week till week 5, and then 
every 2 weeks from week 8 to week 16.  On week 16 the hardness of all the 80 
tablets was determined. 
 
2.2.3 Chemical characterisation 
 
To chemically characterise the batches of ‘ecstasy’ tablet seized over a five year period 
(2006 – 2011) several different experiments were conducted. The psychoactive 
substances (if any) in the tablets were detected using routine colour, TLC and GC-MS.  
The quantification of tablets containing one active ingredient was done by UV 
spectrophotometry.  Moreover, the percentage isomeric content and the organic impurity 
profiles of MDMA-only tablets were also determined. The major excipients and the 
elemental profiles of the tablets were also investigated using FTIR transmittance 
spectroscopy and SEM/EDX analyses (2.1 Table).  
 
2.2.3.1 Experiment A:  Detection and quantification of psychoactive substances 
in batches of ‘ecstasy’ tablets 
 
 Colour tests 
 
Colour  tests  were  used  as  a  first  screening  procedure  to  provide an indication of the  
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presence or absence of drugs in ‘ecstasy’ tablets.  A sample of tablets from each seizure 
(hypergeometric sampling) was individually crushed to a fine powder using an agate and 
mortar.  Independent colour tests were then conducted on each powdered sample using 
Marquis, Simons’s, Chen’s and Scott’s reagents [232].  A small amount (1 – 2 mg) of the 
crushed tablet was placed in a depression on a spot plate and 1 drop of reagent was 
added.  The mixture was mixed by means  of  a  capillary  tube  and  any  colour  change  
was  noted.   Negative and positive controls of amphetamine, MDMA, MDA, BZP, 
mCPP, caffeine, methandrostenolone and cocaine were also tested with the reagents and 
any colour change obtained with the tablets was compared with the control mixtures.  
The colour test reagents were prepared as follows: 
 
 Marquis reagent [232]:  
 
A 1% solution of formaldehyde (40%, v/v) in concentrated sulphuric 
acid was prepared. 
 
 Simon’s reagent [232]: 
 
 Solution 1 was prepared by dissolving 1g of sodium nitroprusside in 100 
mL of water and then 2 mL of acetaldehyde was added to the solution 
with thorough mixing.  Solution 2 was freshly prepared by dissolving 2g 
of sodium carbonate in 100 mL of water.   
 
 Chen’s reagent [232]: 
 
 Solution 1 was prepared by adding 1 mL of glacial acetic acid to 100 mL 
of water (=1% (v/v) aqueous acetic acid solution).  Solution 2 was 
prepared by dissolving 1 g of copper (II) sulphate in 100 mL of water 
(=1% (w/v) aqueous copper sulphate (CuSO4) solution).  Solution 3 was 
prepared by dissolving 8 g of sodium hydroxide in 100 mL of water (= 
2M aqueous sodium hydroxide solution).   
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 Scott’s reagent [232] 
 
 Solution 1 was prepared by dissolving 2g of cobalt thiocynate in 100 mL 
of water and then the solution was diluted 1:1 with glycerine.  Solution 2 
was concentrated hydrochloric acid, while solution 3 was chloroform.   
 
Thin layer chromatography (TLC) of ‘ecstasy’ tablets  
 
TLC was used as a second test for the presumptive identification of the drug(s) found in 
the tablets.  A known mass of each powdered samples was dissolved in 
dichloromethane:methanol (1:1; v/v) (≈ 5 mg of sample per mL of solvent).  This 
concentration was based on the premise that ecstasy tablets contained between 30 to 82 
mg of MDMA [233] in a matrix of excipients, giving a solution of MDMA 
approximately 0.3 - 1.0 mg mL-1.  Test solutions, positive and negative controls (negative 
control: dichloromethane:methanol (1:1, v/v); positive control: MDMA at 1 mg mL-1) 
were developed on a silica gel 60 F254, 0.25 mm pre coated TLC plate (Whatman Ltd. 
Maidstone, UK) using a mobile phase of methanol:strong (35%) ammonia solution 
(100:1.5 v/v).  A volume of about 5 – 10 μL of sample solution and ≈ 4 μL of positive 
control were spotted on the TLC plates.  Prior to TLC the plate was sprayed with 0.1M 
potassium hydroxide in methanol and left to dry.  Detection was achieved by spraying 
with acidified iodoplatinate solution (0.25 g of platinic chloride and 5 g of potassium 
iodide dissolved in 100 mL of water and then 5 mL of  hydrochloric acid added to the 
solution [232]) and and Fast Black K salt (solution A: a 1% solution of Fast Black K salt 
in water (2,5-Dimethoxy-4-((4-nitrophenyl)azo)benzene diazonium tetrachlorozincate  
(2:1)) and solution B: a 1 M NaOH [123]).   
 
Confirmation of active substances in tablets by GC-MS 
 
A portion of powdered tablet (20 mg) was shaken with distilled water (2 mL) and to this 
a solution of 1 M NaOH was added drop-wise to pH 10.  The alkaline aqueous solution 
was extracted with 2 x 5 mL of chloroform then ransferred to the GC-MS for analysis.  
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Chromatographic and mass spectral data were obtained on a Hewlett Packard 6890 gas 
chromatograph coupled with a Hewlett Packard 5973 mass selective detector.  The GC 
was fitted with an HP-5 (5% phenyl / 95% methylpolysiloxane) capillary column 30 m x 
0.25 mm i.d., 0.25 μm film thickness and helium was used as a carrier gas at a flow rate 
of 1.0 min-1.  The injection (≈ 2 μL) was made in split mode (20:1) with the injection port 
at 250°C. The GC oven temperature was programmed as follows: 60°C for 2 min, 20°C 
min-1 to 250°C and 15°C min-1 to 300°C, with a 6 min final hold time.  The mass 
spectrometer was operated in electron impact ionization mode (EI) and the electron 
energy was 70 eV.  The temperature of the MS source was 230°C, MS quadrupole 150°C 
and transfer line 280°C.  A full scan mass spectrum 40-500 amu was obtained at a scan 
rate of 0.3 scan s-1. 
 
Analyses for the presence of amphetamine in ‘ecstasy’ tablets  
 
In order to test for the presence of amphetamine in tablets derivatisation was undertaken 
using carbon disulphide (CS2).  Powdered tablets (20 mg) were dissolved in 1 mL of 
ammonical methanol (100 mL of methanol containing 200 μL of 0.880 ammonia)  and  
combined  with  2 mL of CS2 [234].  The mixture was then thoroughly shaken and 
allowed to stand, at room temperature, for 30 min before being evaporated to dryness 
under nitrogen and re-suspended in 1 mL of methanol for analysis using GC-MS (EI) as 
described above.  
 
Determination of mCPP by 1H NMR 
 
The isomers of chlorophenylpiperazine (CPP) identified in ‘ecstasy’ tablets were 
determined using 1H NMR because GC-MS could not distinguish the different isomers.  
A portion of approximately 2 mg of crushed tablet was shaken with 1 mL of deuterated 
methanol (MeOD).  After centrifugation for 1 min at 1000 rpm, 0.6 mL of the supernatant 
was transferred to a 5 mm NMR tube. 1H NMR spectrum was acquired with a Varian 
UnityINOVA 500 MHz spectrometer. 1H chemical shifts were referenced relative to 
external 4,4-dimethyl-4-silapentane-1-sulfonic acid, the proton calibration standard. 
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Quantifying drug content in tablets by UV spectrophotometry  
 
A UV spectrophotometer (model EvolutionTM 500) was used to determine the quantity of 
drug content in tablets.  A sample of ten tablets was taken from each batch.  Tablets were 
crushed, prepared in solution in methanol at a concentration of 1 mg mL-1, sonicated (10 
min) and then centrifuged for 3 min at 2,000 rpm to remove solid material.  The tablets 
solutions were diluted about 10 times by methanol.  The maximum absorbance (methanol 
maxima used: MDMA - λ 285 nm, BZP - λ 258 nm, mCPP – λ 249, caffeine – λ273 nm, 
methandienone – λ 245 nm and bumetanide – λ 270 nm)  values for each tablet solution 
were recorded within the wavelengths of 200 - 400 nm and the amount of the active 
ingredient in each tablet was determined against standard solutions.  The UV spectra of 
the psychoactive substances from the tablets were verified by comparing the ratio of peak 
height to trough depth (peak / trough ratio = θ trough – θ peak / θ trough) of the 
maximum absorbance peak with that of the respective reference standard. 
 
UV spectrophotometric method validation for the MDMA assay 
 
Specificity 
Specificity  was  evaluated  by  analysing  methanol  extracts  from  mixture  of   possible  









Figure 2.3 UV spectra of (A) in house mixture of excipients (magnesium stearate 
and lactose) and (B) reference standard of MDMA solution in methanol.  
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each, all containing magnesium stearate (ratio of 1.5:100, of magnesium stearate) with (a) 
lactose, (b) sorbitol and (c) starch.  The system response was examined for the presence 
of interference or overlap with MDMA responses at 285 nm.  Absorption spectra did not 




The analytical curve as obtained with 5 concentrations of reference solution of MDMA 
diluted in methanol in the range of 15 - 40 μg mL-1 (15, 20, 25, 30, 35 and 40 μg mL-1).  
Each solution was prepared in triplicate.  The linearity was evaluated by linear regression 
analysis which was used to calculate the correlation coefficient, y-intercept and slope of 
the regression line. 
 
A linear relationship was found between the absorbance and the concentration of MDMA 
in the range of 10 to 40 μg mL-1 in methanol.  The correlation coefficient was 0.9765 
indicating excellent linearity.  The representative linear equation was y = 0.0236x + 


















Figure 2.4 The linear relationship between the absorbance and concentration of 
MDMA in the range of 15 to 40 μg mL-1 in methanol.  
 

























The precision was determined by repeatability (intra-day) and intermediate precision 
(inter-day).  Repeatability was evaluated by assaying 6 determinations of the same 
concentration (30 μg mL-1) of MDMA reference solution diluted in methanol, during the 
same day, under the same experimental conditions.  Intermediate precision was analysed 
comparing the assays in 3 determinations at the same concentration (30 μg mL-1) during   
3 different days.  Precision (repeatability and intermediate precision) was expressed as 
RSD).  The intra-day and inter-day RSD values obtained by the proposed method were 
found to be lower than 1.5 (Table 2.5). 
 
Table 2.5 Intra-day and inter-day precision data of UV spectrophotometric method 












Limit of detection (LoD) and limit of quantification (LoQ) 
 
The LoD, is the minimum concentration of MDMA which could still be detected by the 
analysis method at a specified level of confidence and the LoQ is the minimum 
concentration of MDMA that could still be quantitatively detected with accuracy and 
acceptable precision by the analysis method. The LoD and LoQ were determined in the 
residual standard deviation and regression line and slope.  A plot of absorption versus 
concentration (μg mL-1) was drawn and LoD and LoQ values were predicted by STEYX 
Precision Mean Absorbance RSD 
Intra-day (n =6) 0.807 0.10 
Inter-day 
Day 1 (n = 3) 0.809 0.37 
Day 2 (n = 3) 0.800 1.00 
Day 3 (n = 3) 0.799 1.13 
Mean (n = 9) 0.803 0.75 
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(SD) and slope (S) method using the formula 3.3 x SD / S for LoD and 10 x SD / S for 




Robustness of the proposed method was determined by the analyses of 3 determinations 
at  the same concentration (30 μg mL-1) of MDMA reference solutions diluted in 
methanol at  stored at 3 different  temperatures (4, 25 and 35°C).  The robustness RSD 
values were found to be lower than 1.5% (Table 2.6). 
 
Table 2.6 The robustness data of UV spectrophotometric method for MDMA diluted 









2.2.3.2 Experiment B:  Specific identification and percentage isomeric content 
of MDMA-only tablets 
 
It is normally assumed that MDMA is formulated in tablets using a racemic mixture (1:1) 
of its enantiomers.  MDMA has an enantioselective metabolism, the (S)-enantiomer 
being metabolised faster than the (R)-enantiomer.  To separate the two enantiomers, 
MDMA was derivatised using TFAA and the resultant mixture was analysed by GC-MS 
using an Rt-βDEXcst-TM capillary column.  The column had a stationary phase coating 
of a β-cyclodextrin which was diluted in polysiloxane polymer (Thames Restek UK). 
 
A portion (10 mg) of crushed MDMA tablet was dissolved in 2 mL of absolute ethanol. 
The mixture was shaken for 10 min on an orbital shaker (Lab-Line, model 3520) and then 
Robustness Mean Absorbance RSD 
Temperature °C 
4  (n = 3) 0.799 0.63 
25 (n = 3) 0.804 0.50 
35 (n = 3) 0.798 1.38 
Mean (n = 9) 0.800 0.38 
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filtered using an ‘Anotop’ 10 (0.2 μm) filter (Whatman) to remove the tablet excipients. 
To 100 µl of each filtrate, which was dried by a stream of air at 50°C, were added 20 µl 
of ethyl acetate followed by the addition of 100 µl of TFAA.  The derivitisation mixtures 
were incubated in capped bottles at 70°C for 20 min.  Following the incubation samples 
were evaporated to dryness under a stream of air at 55°C and reconstituted with 100 µl of 
ethyl acetate.  The same method was used for the MDMA standard (1mg mL-1), where a 
sample of 100 µl of the standard was used and after derivatisation with TFAA was 
reconstituted with 100 µl of ethyl acetate. 
 
GC-MS analyses was carried out on a Hewlett Packard 6890 GC coupled with a Hewlett 
Packard 5973 mass selective detector.  The GC was   fitted   with   an   Rt-βDEXcst-TM 
capillary column 30m x 0.25 mm i.d., 0.25 μm film thickness (cyclodextrin material 
added to 14% cyanopropylphenyl – 86% dimethyl polysiloxane).  Helium was used as a 
carrier gas at a flow rate of 1.0 mL min-1 (analysis was also carried out at flow rates of 2 
and 5 mL min-1).  The injection (≈ 1 μL) was made in split mode (35:1) with GC with 
injection port 200°C and a GC oven temperature isothermal at 160°C.  The mass 
spectrometer was operated in electron ionization mode (EI) with electron energy 70 eV.  
The temperature of the MS source was 230°C, MS quadrupole 150°C and transfer line 
160°C.  The MS was operated in full scan mode, scanning 40-500 amu at a scan rate of 
0.3 scan s-1.  The isomeric content ratios of 22 MDMA tablets were measured using 
software integration (Agilent Chemstation) [179] (Figures 2.2 and 2.3). Since the peaks 
were merged the process used by the integrator was that of the dropping perpendicular.  
The area of the first peak was calculated from the start of the peak till the valley and that 
of the second peak from the valley until the end of the peak.  Then the peak areas were 
ratioed.    
 
Method validation for derivatised single enantiomer and racemic 
MDMA 
 
Single MDMA enantiomers (S(+)- and R(-)-) were derivatised using TFAA and analysed 
by GC-MS on an  Rt-βDEXcst-TM  capillary  column.  The two single peaks had 
retention  times  of  37.6  min  for  the  S(+)-MDMA  and 39.9 min for R(-)-MDMA. The  
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Figure 2.5 The TIC (Rt 37.6 min) of the TFAA derivatised S(+)-MDMA control 
(concentration 1 μg μL-1).  The EI mass spectrum of the S(+)-MDMA with base peak 
































Figure 2.6 The TIC (Rt 39.9 min) of the TFAA derivatised R(-)-MDMA control 
(concentration 1 μg μL-1).  The EI mass spectrum of the TFAA - R(-)-MDMA with 






Figure 2.7 (A) The TIC of the TFAA derivatised MDMA control (1mg mL-1). The 
peaks occurred at Rts of 38.5 and 39.4 min respectively.  The EI mass spectra of (B) 
TFAA - S(+)-MDMA and (C) TFAA - R(-)-MDMA, both spectra having the same  
fragmentation pattern with base peak at m/z 154, ions at m/z 162, 135, 110 and 42 
and molecular ion at m/z 289. 
 
S(+)-MDMA  enantiomer  eluted  slightly  earlier then the R(-)-MDMA enantiomer.  The  
mass spectrum of the two peaks, which were similar, had a base peak of m/z 154 with 
ions at m/z 162, 135, 110, 77 and 42 and a molecular ion at m/z 289 (Figures 2.5 and 2.6 
respectively).  The TFAA derivatised MDMA standard (Alltech, 1 mg mL-1) had two 
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peaks with retention times of 38.5 (S(+)-MDMA) and 39.4 (R(-)-MDMA) min 
respectively.  The EI mass spectra of the S(+)- and R(-)-MDMA from the tablet had both 
a base peak of m/z 154 with ions at m/z 162, 135, 110, 77 and 42 and a molecular ion at 
m/z 289 (Figure 2.7). The enantioseparation of the TFAA derivitised MDMA was partial. 
   
To distinguish between an equal or non-equal ratio of enantiomers 
 
A sample of 100 µl of racemic MDMA standard (1mg mL-1, Alltech Standard) was 
derivatised and reconstituted as described above and analysed by GC-MS.  The ratio of 
the enantiomers was determined as described above.  This procedure was repeated for 
both single enantiomer samples S(+)- and R(-)-MDMA (concentration 1 μg μL-1).   
 
To 80 μL (80 μg) of the racemic MDMA standard were added 20 μL (i.e. 20 μg) of single 
enantiomer (S(+)- or R(-)-MDMA).  The solution was derivatised by TFAA, using the 
method described above and then analysed by GC-MS.  The difference in the isomeric 
content ratio when compared with the isomeric content ratio of the racemic MDMA 
sample was due to the added single enantiomer sample.  The difference in the isomeric 
content ratios was due to the added single enantiomer control (Table 2.7, Figure 2.8).  
 
Table 2.7 MDMA control and MDMA tablet after ‘spiking’ with the respective 










peak area % 
R(-)-MDMA 
peak area % 
Ratio 
S(+)-/R(-)- 
80 µg of MDMA 
control 
S(+)-MDMA 59.69 40.31 ~ 1.5 : 1 
R(-)-MDMA 40.63 59.37 ~ 1 : 1.5 
~72 µg of MDMA 
tablet – batch 19 
 
S(+)-MDMA 60.78 39.22 1.55 : 1 
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Figure 2.8 The TIC of (A) TFAA derivatised MDMA from tablet spiked with S(+)-
MDMA control. Peaks at Rt 29.6, 38.4 and 39.0 min are attributed to internal 
standard (C19), TFAA - S(+)-MDMA from tablet (≈ 72μg) spiked with TFAA - S(+)-
MDMA control (20 μg) and TFAA - R(-)-MDMA from tablet respectively; (B) 
TFAA derivatised MDMA from tablet spiked with R(-)-MDMA control (20 μg).  
Peaks at Rt 29.6, 38.3 and 39.0 min are attributed to internal standard (C19), S(+)-
MDMA from tablet (≈ 72 μg) and  R(-)-MDMA from tablet spiked with R(-)-






To 80 μL (72 µg, from 0.9 mg mL-1) of a racemic MDMA sample, from an ‘ecstasy’ 
tablet (batch 19, white coloured with heart logo), were added 20 μL of a 1 μg μL-1  
solution of the single enantiomer (S(+)- or R(-)-MDMA) and the resultant solution 
derivatised and analysed by GC-MS.  The difference in the isomeric content ratios was 
due to the added single enantiomer control (Table 2.7, Figure 2.8).  
 







Where tR2 is the retention time of the first peak, tR2 is the retention peak of the second 
peak, wh1 is the peak width at half height (units of time) of the first peak and wh2 is the 
peak width at half height (units in time) of the second peak [235].  The resolution of the 
enantiomers peaks was ~ 0.79 (resolution 53%). 
 
Robustness and stability 
 
TFAA derivatised MDMA enantiomers controls were analysed with the GC oven at 150, 
160 or 170°C and flow rates of 1, 2 and 5 mL min-1.  Robustness and stability of the GC 
analysis was checked by verifying if there was any change in the order of elution of 
enantiomers on the chiral stationary phase when the column temperature and carrier gas 
flow rate were varied at 5°C intervals between 150-165°C and flow rates of 0.5, 1 and 2 
mL min-1.  No change was detected in the retention times of the derivatised single 
enantiomers.  There was no separation of the enantiomers when the temperature of 165°C 




Precision  of  analysis  was  determined  as   repeatability   (intra-day)   and   intermediate  
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precision (inter-day).  Repeatability was evaluated by assaying 6 determinations of TFAA 
derivatised MDMA standards at the same concentration (1µg µL-1), during the same day, 
under the same experimental conditions.  Intermediate precision was analysed by 
comparing the assay in 3 determinations at the same concentration (1µg µL-1) on 3 
separate days.  Table 2.8 shows the intra-day and inter-day precision data of GC-MS 
method (TFAA derivatised MDMA standard, 1 μg μL-1) for the percentage enantiomeric 
composition of S(+)- and R(-)-MDMA using software integration (Agilent Chemstation). 
 
Table 2.8 Intra-day and inter-day precision data of GC-MS method for S(+)- and 
R(-)-MDMA enantiomers (RSD = relative standard deviation). 
 
Precision S(+)-MDMA % R(-)-MDMA %  RSD 
Intra-day - mean (n = 6) 49.93  50.07  0.34 
Inter-day – day 1 - mean (n = 3) 49.93  50.07 0.22 
Inter-day – day 2 - mean (n = 3) 50.02  49.98  0.14 
Inter-day – day 3 - mean (n = 3) 49.99  50.01  0.24 
Inter-day – mean (n = 9) 49.98  50.02  0.20 
Intra and Inter-day – mean (n =15) 49.96  50.04  0.26 
  
LoD and LOQ   
 
LoD is the minimum concentration of (±) MDMA enantiomers which could still be 
detected by the analysis method and LoQ is the minimum concentration of (±) MDMA 
enantiomers that could still be quantitatively detected with accuracy and acceptable 
precision by the analysis method.  These parameters were not a requirement for the (±) 
MDMA enantiomers determination percentage content; however, it is always useful to 
demonstrate that the analyses were being conducted in a region which was above the LoQ 
value.  LoD and LoQ for each enantiomer were calculated from the calibration curve of 0, 
25, 50, 100, 200 and 400 μL of (±) TFAA derivatised standard solution (1mg mL-1), 
which contained 0 – 200 μg of both enantiomers.  An internal standard C 19 was in each 
standard solution at a concentration of 25 μg mL-1.   
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The LoD and LoQ were determined in the residual standard deviation and regression line 
(y = 0.0078x + 0.0057, R2 = 0.9981 for both enantiomers) and slope.  A plot of ratio peak 
area (Ax / As – peak are of analyte, Ax, is divided by the peak area of the internal 
standard, As) versus concentration (μg mL-1) was drawn and LoD and LoQ values were 
predicted by STEYX (SD = 0.029) and slope (S = 0.0078) method using the formula 3.3 
x SD / S for LoD and 10 x SD / S for LoQ [236].  The calculated values for LoD and LoQ 
were 12.27 and 37.18 μg mL-1 respectively.   
 
2.2.3.3 Experiment C: Organic impurity profiling of MDMA-only tablets  
 
The impurity profiling analyses were conducted to determine the possible synthetic 
routes of MDMA tablets.  Moreover, the generated GC-MS impurity profiles were treated 
like fingerprints to link / discriminate the tablets taken from the different batches. The 
profiling method used was adapted from Gimeno et al. [121, 205].  A known mass of 
about 20 mg of crushed tablet was dissolved in 2 mL of water in a glass stoppered test-
tube.  The solution was made basic (pH 11.0) with the addition of 200 μL of 1 M NaOH 
and shaken for 10 min on an orbital shaker (Lab-Line, model 3520).  Diethylether (3 mL) 
was added and the mixture shaken for another 10 minutes.  The organic layer was then 
transferred to another test-tube by a Pasteur pipette. 
 
The solvent was evaporated to dryness under nitrogen at room temperature and 
reconstituted in 500 μL of diethylether and then transferred to a micro-vial for profile 
analysis.  In order to avoid the possibility of impurity degradation, 2 μL of the extracts 
were analysed by GC-MS on the same day they were prepared. Each sample was 
extracted and analysed in duplicate.   
 
The GC-MS profiling analyses were carried on a Hewlett Packard 6890 GC coupled to a 
Hewlett Packard 5973 mass selective detector.  The GC was fitted with an HP-5 (5% 
phenyl / 95% methylpolysiloxane) capillary column 30 m x 0.25 mm i.d., 0.25 μm film 
thickness  and  helium  was used as a carrier gas at a flow rate of 1.0 min-1.  The injection 
(≈ 2μL) was made in splitless mode with GC injection port at 250°C.  The GC oven 
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temperature was programmed as follows: 80°C for 2 min, 8°C min-1 to 210°C and 15°C 
min-1 to 300°C, with a 6 min final hold time.  The mass spectrometer was operated in 
electron ionization mode (EI) electron energy 70 eV.  The temperature of the MS source 
was 230°C, MS quadrupole 150°C and transfer line 280°C.  A full scan mass spectrum 
40-500 amu was obtained at a scan rate of 0.3 scan s-1. 
 
The EI mass spectra of the compounds were identified by either using spectra published 
in the literature or by the use of the National Institute of Standards and Technology 
library PMW_TOXR.L.  
 
2.2.3.4 Experiment D:  Determination  of  major  excipients  in  ‘ecstasy’ tablets  
by  Fourier  transform  infrared  (FTIR)   transmittance                
                                    spectroscopy 
 
Major excipients in these set of experiments refers to diluents which are added to increase 
the bulk volume when the amount of the active ingredient is insufficient to form a tablet 
of acceptable size.  In order to investigate the major excipients in ‘ecstasy’ tablets a 
single tablet from each of the 34 batches (34 not 45 batches were used as tablets from the 
other batches were all used) was used and an FTIR spectrum of the powdered tablet was 
obtained using an Interspec 2020 FTIR spectrometer.  The tablet sample was prepared by 
grinding and thoroughly mixing about 1 mg of the sample with about 300 mg of spectral 
grade potassium bromide (KBr).  The background was spectral grade KBr.  Both the 
crushed tablets and the KBr were kept in an oven at 40oC overnight before preparing the 
KBr.  KBr disk spectra were recorded between 4000 and 500 cm-1, by averaging 32 scans 
for each spectrum at a resolution of 4 cm-1.  The spectrum of the excipient lactose is 
produced.                  
                                                              
2.2.3.5 Experiment E:  Elemental profiling  of   ‘ecstasy’   tablets   by  scanning  
                                 electron    microscopy    with   energy   dispersive   X-ray 
analyser (SEM/EDX) 
 
Analyses  were  conducted on 37 tablets taken from batches (37 not 45 batches were used  
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as tablets from the other batches were all used).  The tablets were each mounted on a 
SEM sample stub using double-sided carbon adhesive tape.  The tablets, which were 
coated with a thin carbon layer in a sputter coater (Emiscope, UK), were subjected to 
elemental analysis using a SEM (Zeiss Evo 50, Oberkochen Germany) and EDX detector 
(Oxford Inca 200, Oxford Instruments, Wiesbaden Germany).  The EDX was equipped 
with a liquid nitrogen cooled x-ray detector (Si(Li) having 10 mm2 crystal.  A fixed 
working distance of 16 + 1 mm for the EDX detector and electron energy (acceleration 
voltage) of 25 kV were used.  A fixed magnification of 25 times and a live time of 50 
seconds were used during EDX analyses.  The spatially resolved semi-quantitative 
(sample was not polished) EDX analysis of the tablet area (≈ 7 mm2) was obtained by the 
detection of characteristic X-rays that were emitted by the tablet following excitation by a 
high energy electron beam.  The X-ray spectra were optimized by a cobalt optimization 
standard.   
 
SEM/EDX method precision 
 
The precision was determined by repeatability (intra-day) and intermediate precision 
(inter-day).  Repeatability was evaluated by assaying an ‘ecstasy’ tablet at 8 different 
positions in the SEM chamber, using the rotating specimen stage, during the same day, 
under the same experimental conditions.  An area of ≈ 7 mm2 of the tablet was analysed 
each time with the exception of the intra-day analyses of 10 random spots on the surface 
of the tablet. Intermediate precision was analysed by comparing the same ‘ecstasy’ tablet 
during 10 different days at the same position on the rotating specimen stage in the SEM 
chamber, using the same experimental conditions.  Precision (repeatability and 
intermediate precision) was expressed as relative standard deviation (RSD) of the mean 
(SD/mean*100%). 
 
The precision for the SEM/EDX method was conducted on a white tablet with euro logo 
(batch 11).  Table 2.9 shows the mean weight % for the elemental ions, Mg, Si and Cl 
detected by SEM/EDX analyses for the tablet from batch 11.  The mean weight % for the 
individual elemental ions was quite high with the quantification method used.  
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Table 2.9 Intra-day and inter-day precision data of the weight % of elemental ions 
Mg, Si and Cl detected on a tablet, containing MDMA, from batch 11 (white tablet 
with euro logo) by SEM/EDX analyses.  
 
a n = 15 is the total number of positions after 5 days (3 positions analysed each day). 
b The numbers are the means of the weight % and the numbers in parentheses are the RSDs. 
 
The variation, represented by the RSD, for the detected elemental ions was higher for the 
method analyzing 10 spots at eight different positions of the tablet, than for the method 
analysing an area of ≈ 7 mm2 at eight different positions (Table 2.9).  Hence, the second 
method, where an area of ≈ 7 mm2 of the tablet was analysed, was used for the elemental 
profiling of the tablets.  However, the RSD for the second method was still high and 
therefore it was considered as semi-quantitative.   
 
Variation within batch 
 
The weight % variation (represented by the RSD) of the detected individual elemental 
ions  for a batch of tablets was determined by analysing six tablets, taken at random, from  
Elemental ions – W eight % 
Precision (Tablet no. 2  
MDMA with euro logo) Mg  Si  Cl  
Intra-day (n = 8 positions) 
(analysed area ≈ 7 mm2)  17.57 (14.00) 22.31 (16.74) 60.12 (9.78) 
Intra-day (n = 8 positions) 
(analysed 10 random spots)  18.46 (17.93) 21.74 (19.55) 59.80 (10.99) 
Inter-day - (n = 3 positions) 
(analysed area ≈ 7 mm2) - day 1  18.21 24.19 57.60 
Inter-day -  (n = 3 positions) 
(analysed area ≈ 7 mm2) - day 2  15.23 19.45 65.32 
Inter-day - (n = 3 positions) 
(analysed area ≈ 7 mm2) – day 3  17.45 21.44 61.11 
Inter-day - (n = 3 positions) 
(analysed area ≈ 7 mm2) – day 4  20.56 20.73 58.71 
Inter-day - (n = 3 positions) 
(analysed area ≈ 7 mm2) – day 5  18.78 26.63 54.59 
Inter-day (n = 15) a  18.05 (10.80) b 22.49 (12.85) 59.46 (6.78) 
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Table 2.10 SEM/EDX analyses of an area of ≈ 7 mm2 of 6 white tablets, containing 
MDMA, from batch 29 (D&G logo).  The data shows the weight % of elemental ions 
Mg, Al, Si and Cl detected on the tablets (numbers in brackets are the relative 




Table 2.11 SEM/EDX analyses of an area of ≈ 7 mm2 of 6 white tablets, containing 
mCPP, from batch 32 (mercedes logo).  The data shows the weight % of elemental 
ions Mg, P, Cl and Ca detected on the tablets (numbers in brackets are the relative 





Mg Al Si Cl 
Tablet 1 21.01 6.95 21.06 50.98 
Tablet 2 19.65 8.67 23.41 48.27 
Tablet 3 22.85 5.97 17.79 53.39 
Tablet 4 20.06 8.30 20.53 51.11 
Tablet 5 17.34 7.94 23.91 50.81 












Elemental ions  
Weight % 
Mg  P  Cl  Ca 
Tablet 01 2.89 34.64 21.24 41.23 
Tablet 02 2.61 38.76 19.24 39.39 
Tablet 03 3.34 37.63 20.58 38.45 
Tablet 04 3.56 36.51 21.92 38.01 
Tablet 05 3.82 44.43 16.66 35.09 













two batches of ‘ecstasy’ tablets, batch 29 (containing MDMA tablets), Table 2.10  and 
batch 32 (containing mCPP tablets), Table 2.11.  These two batches (batches 29 and 32), 
containing different psychoactive substances, were also chosen to compare any difference 
in their intra-batch variation.  However, not much difference was noted when the results 
for the intra-batch variation for detected elemental ions for the respective batches were 
compared.  
 
SEM/EDX – weight percentage calculation of detected elements 
 
The  Oxford  INCA  software  in  the EDX was used to calculate the weight percentage of  
the detected elements (software suppresses the background).  Data of the default standard 
and detected peak intensity of selected sample element were used to calculate the 








Where  IAspl,  IAstd  and  wt%Astd  are the detected intensity of element A in the tablet and  
the default intensity of element A in the standard respectively.  The apparent 
concentration was then subjected to intensity correction to give the weight percentage of 
each element.  Finally, the total percentage of these selected elements was adjusted to 
100% to give a normalized result.   
 
2.2.4 Analyses of substances seized during EDM parties 
 
Qualitative analyses were conducted on the powders, plants and cannabis-like material.  
Pharmaceutical tablets, which were identified visually and compared to an in-house 




Apparent concentration of A = (IAspl ÷ IAstd) x wt%Astd 
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2.2.4.1 Colour tests 
 
The powders and liquids seized during EDM parties were first screened by means of 
colour tests as described in Section 2.2.3.1 to determine the presence or absence of active 
ingredients.  The plant like material was screened by the Duequenois-Levine reagent for 
the presence of THC.  The Duequenois-Leivine reagent was prepared as follows: 
    
 Duequenois-Leivine reagent [232]:  
 
 Solution 1 was prepared by dissolving 0.4g of vanillin in 20 mL of 95% 
ethanol and then adding 5 drops of acetaldehyde.  Solution 2 was 
concentrated hydrochloric acid and solution 3 chloroform.  
 
2.2.4.2 Thin layer chromatography (TLC)  
 
TLC was also used to determine the presence or absence of heroin, cocaine and THC.  
The following TLC systems were used: 
 
 Heroin and cocaine 
 
Powders (≈ 5 mg mL-1) from samples were dissolved in chloroform.  Test solutions, 
positive and negative controls (negative control: chloroform; positive controls: heroin and 
cocaine at 1mg mL-1) were developed on a silica gel 60 F254, 0.25 mm pre coated TLC 
plate (Whatman Ltd. Maidstone, UK) using a mobile phase of chloroform : methanol 
solution (90:10 v/v). Detection was achieved by spraying with acidified iodoplatinate 




The material (herbal - ≈ 1g or resin - ≈ 0.25 g) was pulverized and extracted using 
chloroform  to  produce  a  sample concentration of 50 mg mL-1 for the herbal and ≈ 5 mg  
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mL-1 for the resinous material.  Test solutions, positive and negative controls (negative 
control: chloroform; positive control: THC at 100 μg mL-1) were developed on a silica 
gel 60 F254, 0.25 mm precoated TLC plate (Whatman Ltd. Maidstone, UK) using a 
mobile phase of petroleum spirit 60/90 : diethyl ether (80:20 v/v) for separation.  
Detection was achieved by fast blue B spray (50 mg of fast blue B dissolved in 1 mL of 
water and 20 mL of methanol) [237].  
 
2.2.4.3 Confirmation of active ingredients by GC-MS 
 
Methanoic extracts were prepared for the powders, plants and cannabis-like material with 
a final concentration of ≈ 1 mg mL-1.  The powders were assumed to be ≈ 50% pure 
(usually cocaine), while the plants and cannabis-like material was assumed to be ≈ 10% 
pure.  For the liquid, suspected to be gamma-butyrolactone (GBL), a 0.1% solution in 
chloroform was prepared.  The same GC-MS method described in Section 2.2.3.1 was 
used to determine the active ingredients in the seized material. 
 
2.3 Court Permission  
 
In Malta the appointment of a forensic drug analyst by the magistrate falls under the 
provisions of article 650 (1) of  Chapter 9 of the Criminal Code, which states that “in all 
cases where for the examination of any person or thing special knowledge or skill is 
required, a reference to experts shall be ordered” [238].  All drug analyses on the Island 
are carried out at the Forensic Laboratory Services which makes part of the Malta 
National Laboratory (MNL).  The appointed court forensic analyst would do the analysis 
and would then report his findings to the Courts in viva voce in front of the accused.  
  
All the ‘ecstasy’ tablets that were physically and chemically profiled in this research 
study were obtained from court cases where tablets were seized from traffickers or users 
by the Police Drug Squad.  In all cases the researcher has obtained the necessary 
permissions from the inquiring magistrates to use a sample of the seized tablets for the 
research study.  In the study to monitor illegal substances for personal use (Chapter 6A), 
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samples were confiscated by the police from partygoers at major EDM parties and those 
where the researcher was the appointed court expert were included in the analyses. 
 
2.4 Statistical Methods  
 
All calculations were performed on the Statistical Package for Social Science (SPSS) 
version 16.   
 
2.4.1 Physical features of tablets and stability studies 
 
Descriptive statistics were used in these studies.  The examined tablets in the physical 
characterisation study were selected at random from the batches using the 
hypergeometric method.  One-way analyses of variance (ANOVA), using a p value of 
0.05 as a cut-off for statistical significance, was used in the physical characterisation and 
stability studies.  In the physical characterisation study one-way ANOVA was used to 
compare the means for each measurable feature (mass, diameter, thickness, hardness and 
disintegration rate) in order to discriminate or link batches of ‘ecstasy’ tablets.  In the 
stability studies one-way ANOVA was used to test the difference in the physical features 
of tablets after a photostability experiment and two other experiments were tablets were 
subjected to various temperatures and humidity  
 
2.4.2 Drugs seized at EDM parties and the Malta party study 
 
Descriptive statistics were used in these studies.  For the drugs seized at EDM parties and 
the Malta party study the data was statistically tested using the one-way ANOVA. When 
the normality and homogeneity of variance assumption was not satisfied the equivalent 
non-parametric Kruskall-Wallis test was applied.  Post hoc tests for ANOVA were Tukey 
HSD and Games-Howell.  The Games-Howell procedure was used when the variances 
were unequal when tested with Levene’s test for equality of variances. Significance was 





PHYSICAL CHARACTERISTICS OF 
‘ECSTASY’ TABLETS  
 
‘Ecstasy’ tablets normally provide visual and physical characteristics that are usually 
produced during the tabletting process [144].  While the increase in the misuse of 
‘ecstasy’ had prompted scientists to use these features to compare illegal tablets, in the 




The presence of physical features of ‘ecstasy’ tablets could provide valuable information 
that potentially can link tablets from different seizures [239]. Some researchers claim that 
tablets with similar physical features are from the same production batch, while tablets 
with different characteristics were from different batches but that these physical features 
were not considered sufficient to provide evidence of a link between seizures in court 
[214].  However, others argue that tablets with the same physical characteristics do not 
necessarily mean that these have the same chemical compositions [240]. A further view is 
that some clandestine laboratories use different metal taps and dies to produce ‘ecstasy’ 
tablets having the same active ingredient but with different visual characteristics [212].  
 
One of the determinants by which illegal drugs are used is their perceived quality and 
price [241, 242].  It is claimed that illicit drug users are willing to pay more money to 
acquire better quality controlled drugs and they would only pay for drugs when they think 
that the quality is acceptable [242].  Hence, the visual and the physical features of 
‘ecstasy’ tablets could be of importance to users if tablets give the perception of ‘good’ 
quality drugs, thus making the user decide to buy the tablets.  However, while some 
hypothesised that the decrease in the perceived quality of ‘ecstasy’ would have a 
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significant impact on the number of users who purchase these tablets and the amount 
purchased, others claimed the opposite stating that the decrease in quality would have no 
such effect [242, 243].  
 
The aim of this part of the research study was to investigate the distinguishing features 
(visual and measurable features) of seizures collected by the police authorities over a 
five-year period, from 2006 - 2011, to determine if these features could be used to 
discriminate or link batches for drug intelligence purposes. Within this study 
discrimination and linking is defined as the ability to differentiate or connect batches of 
‘ecstasy’ tablets by their visual (logo, shape, breakline and colour) and / or measurable 
(mass, diameter, thickness, hardness, friability and disintegration rate) features.   In 
addition, the data obtained from the measurable features was also compared against 
standards set for pharmaceutically produced tablets to determine how “well-made” the 
‘ecstasy’ tablets seized in Malta during a five year period.  The study also sought to test 
the following hypothesis (1), that: 
 
The physical state of different batches of ‘ecstasy’ tablets seized on 
different occasions in Malta during 2006 – 2011 will be significantly 




In this study, a total of 30 seizures that comprised of 45 batches of ‘ecstasy’ tablets were 
examined for their visual and measurable physical characteristics.  Table 3.1 records the number 
of tablets in each batch and the date of the seizure.  The visual features of the ecstasy’ tablets, 
which included the logo, tablet shape, breakline (if any) and colour, described in the 
methodology in Section 2.2.1.1, were identified. 
 
All the measurable physical characteristics of the samples of tablets, which were taken at 
random from each batch, were evaluated together against the pharmacopoeial or 
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pharmaceutical criteria listed below (mass, diameter, thickness, hardness, friability and 
disintegration rate).   
 
3.2.1 Mass, diameter and thickness 
 
The measurements for the mass, diameter and thickness were made on randomised 
samples of tablets from each batch as described in the methodology Section 2.2.1.3.  The 
following criteria were applied: 
 
a) Uniformity of mass: that not more than 2 of the individual masses of tablets 
should deviate from the average mass by more than 7.5% for tablets with average 
mass of more than 80 mg and less than 250 mg, and by not more than 5% for 
tablets with average mass of more than 250 mg [221]; 
 
b) Diameter: British Pharmacopoeia criteria that the diameter of tablets with 
diameter up to 12.5 mm can deviate by up to 5% [225]; 
 
c) Thickness: the 5% tolerance as for normal manufacturing practices [244]; 
 
3.2.2 Hardness (mechanical strength), friability and disintegration 
 
The physical tests with limits of acceptance, relating to the tablet performance of 
handling, hardness and friability, and disintegration were carried according to the 
methods as described in the methodology Section 2.2.1.3. The applied criteria were: 
 
a) Hardness:  applied for pharmaceutical tablets - 39.22 to 78.45 N [245]; 
 
b) Friability:  loss in mass of less than 1% [221];  
 




Table 3.1 The 45 batches of ‘ecstasy’ tablets from 30 cases, seized by the Malta Police Drug 
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1,021 20  
2007 
8 1,990 35  1,947 
6 1,018 21  
2007 
9 2,876 36  2010 
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`7 1,154 22 
 
2007 
10 4,989 37  1,261 
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1,029 23  
2008 
11 172 38  2010 
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365 
9 1,142 24  
2008 
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10 1,032 25  
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1,069 26  
2008 
14 154 41  
2011 
26 369 
12 1,020 27  
2008 
15 103 42  
2011 
27 281 
13 1,031 28  
2008 





1.114 29  
2008 
17 133 44  
2011 
29 113 
15 1,344 30  
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In this study one-way ANOVA was used in order to discriminate or link batches of 






The visual and measurable physical characteristics of the 30 seizures made up of 45 batches of 
‘ecstasy’ tablets (98,640 tablets) are shown in Table 3.2, which displays the logo and tablet 
shape, breakline (if any) and colour.  While most of the seizures consisted of 1 batch of 
tablets, seizures 2, 22, 23 and 24 consisted of 2 batches each and seizure 4 consisted of 12 
batches.   
 
3.3.1 Visual characteristics of MDMA / ecstasy tablets   
 
All the examined batches of ‘ecstasy’ tablets had tablets (about 60 to 70%) with defects, 
such as mottling, chipping, sticking and capping among others.  Some of the batches of 
tablets had more defects than others such as batches 11-13, the white euro logo tablets, 
which were chipped, and tended to cap, while batches 27, the blue with question mark 
logo tablets, 42, the blue with euro logo tablets and 43, the blue with armani logo tablets 
were very mottled.    
 
The visual characterisation of the 45 batches of ‘ecstasy’ tablets are given in Table 3.2., 
including those for the control bumetanide tablets.  
 
3.3.1.1 Logos and shape                
 
From the 45 batches of tablets from the 30 seizures it was found that most of the batches 
had round shaped tablets with logos (91%, n = 41 respectively).  Four of the batches had 
non-round-shaped tablets; two batches with heart shaped tablets, one batch with diamond 
shaped tablets and another batch with triangular shaped tablets.  The most common logos 
were the omega and euro 6 batches each (batches 5-10 and 11-13, 17, 24 and 42), heart 4 
batches (batches 19, 28, 36 and 37), followed by the lacoste, pisces and question mark 3 
batches each (batches 4, 44 and 45 for lacoste, 14-16 for pisces and 27, 34 and 35 for 





Table 3.2 Visual characteristics of 45 batches of ‘ecstasy’ tablets from 30 cases. 
 
 Batch 
No. Tablets Logo Colour Breakline 
Batch 




control white yes 23  
/ pink no 
1 
 
thumbs-up blue no 24 
 
Euro blue no 
2  / white no 25  
Star white yes 
3 
 
/ white no 26 
 
Smiley pink no 
4 
 
lacoste white yes 27 
 
question  
mark blue yes 
5 
 
omega blue yes 28 
 
Heart white yes 
6 omega blue yes 29 
 
D&G white no 
7 omega blue yes 30 
 
/ blue yes 
8 
 
omega green yes 31 
 
Tulip white no 
9 omega green yes 32 
 
Mercedes white no 
10 omega green yes 33 
 
Versace white yes 
11 
 
euro white no 34  
question  
mark blue no 
12 euro white no 35 
 
question  
mark green no 
13 euro white no 36 
 
Heart blue  no 
14 
 
pisces orange yes 37 
 
Heart blue no 
15 pisces orange yes 38 
 
rolex crown blue no 
16 pisces orange yes 39 
 
rolex crown green no 
17 
 
euro white yes 40 
 
E=mc2 white no 
18 
 
D&G white no 41 
 
route 66 white cross 
19 
 
heart white no 42 
 
Euro blue no 
20 
 
shark white yes 43 
 
Armani blue no 
21 
 
kangaroo pink no 44 
 
Lacoste pink cross 
22 
 
letter X white no 45 
 








































Figure 3.1  Breaklines on ‘ecstasy’ tablets for all years (2006 - 2011). 
 
breakline.  A breakline aligned along the diameter of the tablet was found in 17 batches 
(37.7%), while the other remaining batches had a cross breakline (Figure 3.1). 
 
3.3.1.3 Tablet colour 
 
In an attempt to minimize the problems that occur when trying to classify tablets by 
colour, shades of colour were not recorded.  Thus tablets which appeared light blue were 
classified only as ‘blue’.  Figure 3.2 shows the percentage frequency of colours within the 


























Most (44%, n = 20 batches) of the tablets were white followed by blue (29%, n = 13) 
which together these made up 73% of tablets examined.  During the period 2009 - 2011 
more batches of coloured tablets (76.9%, n = 10 out of 13 batches) were seized. 
 
The physical characteristics of the tablets including, mass, diameter and thickness of the 
45 batches of ‘ecstasy’ tablets are given in Table 3.3. The bumetanide tablets were 
control tablets.                   
 




The means of the mass of tablets in each of the 45 batches ranged between 135 mg to 448 
mg and the RSD values of the majority (93.3%, n = 42) of the batches were under 5% .  
While the mean of means of the mass of the batches was 237.2 mg, the median was 236 
mg (RSD 28.9% and RQD 22.7%, Table 3.3, Figure 3.3).  However, over the five year 
period the mean mass of most batches ranged between 200 mg to 300 mg (71%, n = 32). 
The bumetanide control tablets (n = 29) had a mean mass of 177 mg and the RSD was 
0.91%.   
 
From the uniformity of mass test it transpired that most (73%, n = 33) of the batches of 
‘ecstasy’ tablets had no more than 2 tablets that deviated from the mean mass by more 
than 5% (tablets with mean mass > 250 mg) or 7.5% (tablets with mean mass > than 
80mg but < 250 mg).  The rest of the batches of tablets had more than 2 tablets that 
deviated from the mean by more than 5% or 7.5%.  
 
Difference was also noted in the intra-batch variation in tablet mass for the respective 
batches, such as the 27 blue tablets with the rolex crown logo (batch 38, mean mass of 
338 mg, RSD 1.31%), with low intra-batch variability, the 29 pink tablets with the 
kangaroo logo (batch 21, mean mass of 241 mg, RSD 3.39%),  with  median  intra-batch  
variability  and  the  28 white tablets with E = mc2  logo (batch 40, mean mass of 237 mg,  
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Table 3.3 Physical characteristics, mass, diameter and thickness of 45 batches of 
















































































































































































































































































































352 (5.68) / 
4.43 (3.61) 








Note:  Mass, diameter and thickness – 1st line: mean, and relative standard deviation (RSD), 2nd line: median 





Figure 3.3 Mean mass (mg) of each batch of ‘ecstasy’ tablets over a 5 year period 
from 2006 - 2011 (● is the mean of random sample from control batch 
(bumetanide), ● is the mean of random sample from a batch, n = 45 batches, the 
error bars, SD, do not show because SD of the batches was < 10%). 
 
RSD 10.89%) with high intra-batch variability.  The intra-batch variability (RSD 1.31%) 
of the blue tablets with the rolex crown logo (batch 38) compared favourably with the 
intra-batch variability in the mass for the bumetanide control tablets (RSD 0.91%).  
However, the white tablets with the E = mc2 logo (batch 40) had considerably high intra-




The means of the diameter of round tablets in each of the 41 batches ranged between 7.02 
mm to 9.32 mm and the RSD values of the majority (97.6%, n = 40) of the batches of 
round tablets were under 1%.  While the mean of means of diameter of the batches was 
8.09 mm, the median was 8.09 mm (RSD 12.0% and RQD 25.83%, Table 3.3, Figure 
3.4).  The bumetanide control tablets (n = 29) had a mean diameter of 8.12 mm and the 






Figure 3.4 Mean diameter (mm) of each batch of round ‘ecstasy’ tablets over a 5 
year period from 2006 - 2011 (● is the mean of random sample from control batch 
(bumetanide), ● is the mean of random sample from a batch, n = 41 batches, the 
error bar shown indicate SD, batch 20, SD = 0.47, the rest of the error bars do not 
show because SD ≤ 0.07).  
 
The diameter of nearly all the examined batches of tablets (97.6%, n = 40 out of 41) and 
the bumetanide control tablets had satisfied the criterion that tablets with diameter of 12.5 
mm can deviate by up to 5% [225].  Only one batch of white tablets with shark logo had 




Thickness is another important physical attribute and any variation of this feature on the 
tablet press may mean a variation in mass or hardness or both.  The means of the 
thickness of tablets in the 45 batches ranged between 3.04 to 6.30 mm and the RSD 
values of the majority (88.9%, n = 40) of the batches were under 5% (Table 3.3).  The 
mean of means of the thickness of the batches was 3.88 mm and the median was 3.86 mm 
(RSD 19.1% and RQD 23.1%, Table 3.3.  However, the mean thickness of most of the 
tablets (91.1%, n = 41) was found to vary between 3 and 4.5 mm. For the bumetanide 
control tablets (n = 29) the mean thickness was 2.73 mm and the RSD was 1.1%.   
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The thickness of tablets in 33.3% (n = 15) of the batches, did not deviate by more than 
5% from the mean.  However, more batches (n = 18, 40%) were found to have more than 
2 tablets that deviated by more than 5% from the mean thickness.   
 
 3.3.2.4 2-D scatter plots of the means of mass, diameter and thickness 
 
The possibility of differentiating or linking batches of ‘ecstasy’ tablets by the measurable 
features, mass, diameter and thickness was evaluated by the use of 2-D scatter plots 
(Figure 3.5 and see Figures 1.1 and 1.2, Appendix 1).  Three 2-D scatter plots were used, 
where the data from 41 batches with round tablets was used for the plots of mass versus 
diameter and diameter versus thickness, and the data from 45 batches was used for the 
plot of mass versus thickness.  
 
The batches of tablets were considered linked when the spots, representing the batches on 
the 2-D scatter plots, were superimposed or touching. The results obtained from the three 
2-D scatter plots to discriminate or link batches of tablets were fairly good.  Moreover, 
from the 2-D scatter plots it transpired that 18 batches (in 5 groups of batches: group1 - 
[5-10], group 2 - [11-13], group 3 - [14-16], group 4 - [29, 36, 42, 43], and group 5 - [44, 
45] batch number as in Table 3.2 above) had very similar means for mass, diameter and 
thickness (Table 3.4).  
 
 3.3.2.5 3-D scatter plots of the means of mass, diameter and thickness 
 
The differentiation or linking of the batches of tablets was further evaluated by 3-D 
scatter plots where the measurable features, mass, diameter and thickness were again 
used (Figure 3.6 and see Figure 1.3, Appendix 1).  Two 3-D scatter plots were used, 
where data from 41 batches with round tablets was used for the plot of thickness, 
diameter and mass. To further  investigate  the possible linkage of the 28 batches of 
tablets (batches 5-16, 18, 19, 24, 29, 31, 34-38, 40-45)  shown in Figure 3.6 as 
superposed or touching, another 3-D scatter plot  of the thickness, diameter and mass was 





Figure 3.5 2-D scatter plot of the means of mass versus diameter of 41 batches of round ‘ecstasy’ tablets (the numbers near the 
coloured spots indicate the batch number as in Table 3.2, batch 0 is the control batch, bumetanide). 
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Table 3.4 2-D scatter plots results for the batches of tablets (the numbers refer to 
batch number as given in Table 3.2 above). 
 
2-D Scatter plots Linked batches Unlinked batches 
Mass vs Diameter 
(41 batches, Figure 3.5) 
[5-10, 44, 45], [11-13, 18, 19, 
24, 29, 31, 36, 42, 43], [14-16], 
[34, 35], [37, 38], [40, 41],  
1, 3, 4, 17, 20, 21, 25-28, 32, 
33, 39 
Mass vs Thickness 
(45 batches, see Figure 
1.1, Appendix 1) 
[5-10, 40], [11-13, 18], [14-
16], [17,19], [23, 30], [26, 31, 
32], [29, 36, 42, 43], [44, 45]  
1-4, 20-22, 24, 25, 27, 28, 33-
35, 37-39, 41 
Diameter vs Thickness 
(41 batches, see Figure 
1.2, Appendix 1) 
[5-10], [11-13], [14, 16], [15, 
29, 36, 42, 43], [24, 34], [31, 
32, 35], [44, 45] 
1, 3, 4, 17-21, 25-28, 33, 37-40 
Results from the 3  
2-D scatter plots 
(45 batches) 
[5-10], [11-13], [14-16], [29, 
36, 42, 43], [44, 45] 1-4, 17-28, 30-35, 37-41 
 
The batches of tablets were considered linked when the spots, representing the batches on 
the 3-D scatter plots, were superimposed or touching.  The results obtained from the two 
3-D scatter plots to discriminate or link batches of tablets were considered to be fairly 
good.  Moreover, from the 3-D scatter plots it transpired that 20 batches (divided in 4 
groups of batches according to similarity in the mean mass, diameter and thickness were: 
group 1 - [5-10, 40], group 2 - [11-13, 18, 29, 36, 42, 43], group 3 - [14-16], and group 4 - [44, 
45], batch number as in Table 3.2 above) had very similar means for mass, diameter and 
thickness (Table 3.5).  The linked batches in the 2-D scatter plots were confirmed by the 3-D 
scatter plots.   
 
The linkage between the batches was further examined statistically using one-way 
ANOVA.  There was significant similarity in the mass, diameter and thickness of the 
tablets in batches 5-10, batches 11-13, batches 14-16 (except the diameter) and batches 
44 and 45 (p > 0.05, one-way ANOVA for nearly all the features).  However there was 




Figure 3.6 3-D scatter plot of the means of thickness, diameter and mass of 41 batches of round ‘ecstasy’ tablets (the numbers 
near the coloured spots indicate the batch number as in Table 3.2, batch 0 is the control batch, bumetanide). 
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and tablets in batches 5-10 and significant difference in tablets in batches 18, 29, 36, 42, 
43 and tablets in batches 11-13 (p < 0.05, one-way ANOVA). 
 
Table 3.5 3-D scatter plots results for the batches of tablets (the numbers refer to 
batch number as given in Table 3.2 above)  
 
 
3-D Scatter plots 
 
Linked batches Unlinked batches 
 
Thickness, Diameter and 
Mass (41 batches, Figure 
3.6) 
 
[5-10, 40, 41, 44, 45], [11-13, 
18, 19, 24, 31, 42, 43], [14-
16], [29, 34-36], [37, 38]  
1, 3, 4, 17, 20, 21, 25- 28, 32, 
33, 39 
 
Mass, Diameter and 
Thickness (28 batches, see 
Figure 1.3, Appendix1) 
 
[5-10, 40], [11-13, 18, 29, 36, 
42, 43], [14-16], [44, 45]  19, 24, 31, 34, 35, 37, 38, 41 
 
Results from the 2  
3-D scatter plots 
 
[5-10, 40], [11-13, 18, 29, 36, 
42, 43], [14-16], [44, 45] 
1, 3, 4, 17, 19, 20, 21, 24-28, 
31-35, 37-39, 41 
 
3.3.3 Other physical characteristics: hardness, friability and disintegration 
 
The results obtained from other physical characterisation which included hardness, 
friability and disintegration of the 45 batches of ‘ecstasy’ tablets are given in Table 3.6.  
These parameters of the ‘ecstasy’ tablets were compared with the control (bumetanide) 
tablets, to assess against a known standard.                  
 
3.3.3.1 Hardness (mechanical strength) 
 
Although there are no official pharmacopoeial limits for hardness, this feature must be 
controlled to ensure that the tablet is firm enough to withstand handling without breaking 
or crumbling and not so hard that the disintegration time is unduly prolonged. 
 
The means of the hardness of the tablets in each of the 45 batches ranged between 37.52 
N to 135.29 N and the RSD values of the majority (75.6%,  n = 34)  of  the  batches  were  
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Table 3.6 Other measurable physical characteristics, hardness, friability and 





















73.67 (5.96) 0.1 
2 + 1 
(50.0) 23  
48.33, 53.22 
50.79 (3.21) 0.4 





54.87 (9.00) 0.6 
39 + 11 
(28.2) 24  
47.13, 55.19 
50.48 (5.47) 0.5 




45.96 (10.49) 0.5 
7 + 2 
(28.6) 25  
48.33, 53.22 
50.79 (7.11) 0.4 





50.88 (10.34) 0.6 
7 + 2 
(28.6) 26  
33.48, 40.46 
37.52 (5.73) 2.0 





53.29 (14.52) 0.6 
11 + 3 
(27.3) 27  
72.69, 164.52 
104.03 (30.48) 0.4 





97.16 (5.03) 0.2 
6 + 3 
(50.0) 28  
36.20, 52.82 
42.17 (11.45) 1.6 
3 + 1 
(33.3) 
6 70.17, 88.40 80.38 (6.83) 0.2 
9 + 5 
(55.6) 29  
80.56, 123.53 
105.71 (14.75) 0.2 
558 + 26 
(4.66) 
7 71.43, 96.68 85.22 (9.61) 0.2 
4 + 7 
(175.0) 30  
82.35, 106.33 
93.27 (8.29) 0.1 





67.17 (10.45) 0.2 
10 + 6 
(60.0) 31  
72.70, 94.11 
84.13 (7.96) 0.5 
96 + 24 
(25.0) 
9 53.00, 66.24 58.98 (6.75) 0.3 
6 + 4 
(66.7) 32  
50.85, 67.86 
59.34 (9.27) 0.1 
13 + 4 
(30.8) 
10 51.02, 61.77 56.89 (6.24) 0.2 
11 + 4 
(36.4) 33  
44.76, 50.49 
47.00 (4.06) 0.9 





63.16 (13.27) 3.8 
743 + 478 
(64.3) 34  
60.15, 101.51 
79.45 (15.21) 0.2 
87 + 14 
(16.1) 
12 53. 71, 83.06 68.78 (13.41) 4.4 
784 + 434 
(55.4) 35  
52.82, 79.49 
66.19 (13.92) 0.2 
77 + 34 
(44.2) 
13 48.88, 80.02 58.01 (14.86) 4.0 
663 + 406 
(61.2) 36  
41.17, 63.92 
51.70 (16.00) 0.4 





53.42 (13.96) 0.8 
5 + 4 
(80.0) 37  
85.40, 106.16 
98.34 (6.11) 0.1 
147 + 108 
(73.5) 
15 41.01, 54.61 47.50 (13.01) 0.6 
5 + 3 
(60.0) 38  
88.44, 123.34 
106.09 (9.11) 0.1 
258 + 108 
(41.9) 
16 41.54, 61.77 48.77 (13.27) 0.3 
7 + 3 
(42.9) 39  
94.16, 124.06 
113.07 (7.87) 0.1 





64.79 (12.58) 0.6 
11 + 6 
(54.5) 40  
80.93, 132.48 
100.85 (17.58) 0.2 





57.34 (4.69) 0.5 
13 + 2 
(15.4) 41  
55.68, 131.04 
89.57 (24.53) 0.4 





61.53 (8.96) 0.7 
12 + 3 
(25.0) 42  
85.40, 162.74 
135.29 (19.14) 0.5 





49.52 (7.90) 0.5 
8 + 6 
(75.0) 43  
81.64, 129.62 
103.85 (13.61) 0.5 





47.66 (7.41) 0.7 
47 + 2 
(4.26) 44  
51.38, 116.00 
81.76 (21.39) 0.3 





77.64 (10.11) 0.3 
4 + 2 
(50.0) 45  
62.23, 96.45 
82.89 (12.30) 0.2 
224 + 48 
(21.4) 
 
Note: Hardness N – 1st line: the minimum and maximum values of force measured, 2nd line: the mean force 




over 7%.  While the mean of means of the hardness of the batches was 70.74 N, the 





Figure 3.7 Mean hardness (N) of each batch of ‘ecstasy’ tablets over a 5 year period 
2006 - 2011 (● is mean of random sample from control batch (bumetanide), ● is the 
mean of random sample from a batch, n = 45 batches, the error bars indicate SD). 
 
bumetanide control tablets (n = 29) had a mean hardness of of 73.67 N and RSD of 96%.  
More than half of the batches (60%, n = 27) had their means within the range for 
hardness for pharmaceutical tablets (39.22N to 78.45 N).  However, it transpired that 
only 19 batches (42.2%) had all their examined tablets within the hardness range for 
pharmaceutical  tablets,  while  51.1%  (n  =  23)  of  the  batches  had 1 tablet or more 
above the recommended values and 6.7% (n = 3) of the batches had 2 tablets or more 
below the recommended values.  Moreover, batches 27, 29, 39, 41 to 44 had a greater 




The  friabilities of  the 45 batches of ‘ecstasy’ tablets ranged between 0.1% to 4.4%.  The  
 134 
mean of the friabilities of the batches was 0.7% and the median was 0.4%.  The 
friabilities of the tablets in the batches were very varied resulting in a very large RSD and 
RQD (≥ 100%, Table 3.6).   
 
The friability of the bumetanide tablets (0.1%) and the friability of the majority of the 
batches of ‘ecstasy’ tablets (89%, n = 40) was found to be less than 1% (Table 3.6).  
During the friability test the maximum loss in the total mass of the batches tested was not 





During disintegration tests, which were carried out on all batches of ‘ecstasy’ tablets, the 
time required for 6 tablets to disintegrate was measured.  The disintegration rate means of 
the  45 batches of ‘ecstasy’ tablets ranged between 3 s to 836 s and the RSD values of the  
 
 
Figure 3.8 Mean disintegration (s) of each batch of ‘ecstasy’ tablets over a 5 year 
period 2006 - 2011 (● is mean of random sample from control batch (bumetanide), 
● is the mean of random sample from a batch, n = 45 batches, the error bars 
indicate SD). 
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majority (91.1%, n = 41) of the batches were over 15%.  The mean of the means of 
disintegrations of the batches was 159 s and the median was 13 s. The disintegration rates 
of the batches was very varied resulting in a very large RSD and RQD (> 100%) (Table 
3.6, Figure 3.8).   
 
More than half (60%, n = 27) of the batches of ‘ecstasy’ tablets were found to have 
disintegration rates of less than 60 s (1 min) (bumetanide control tablets – mean 
disintegration rate was 2 s + 1 s, RSD 50%).  However, 11.1% (n = 5) of the batches were 
found to have 2 or more tablets that took more than 900 s (15 min) to disintegrate. 
 
    3.3.3.4 2-D scatter plots of friability and means of hardness, disintegration 
rates and mass 
 
The possibility of differentiating or linking batches of ‘ecstasy’ tablets by the measurable 
features, hardness, friability, disintegration rate and mass was evaluated by the use of 2-D 
scatter plot (Figure 3.9 and see Figures 1.4 to 1.6 in Appendix).  Four 2-D scatter plots 
were done, where the data from 45  batches  of  ‘ecstasy’  tablets  was  used  for  all  the  
plots.   It   was   noted   that   the discrimination and linkage of the batches was not as 
good as the 2-D scatter plots for the mass, diameter and thickness.  This was mainly 
caused by the high RSD values of the batches for the means of hardness and 
disintegration rates.  However, using these plots the linkage between the batches 5-10, 
11-13, 14-16 and 44-45 were confirmed (batch number as in Table 3.6 above). 
 
    3.3.3.5 3-D scatter plots of the friability and the means of hardness, 
disintegration rates, mass and diameter 
 
The possibility of differentiating or linking batches of ‘ecstasy’ tablets by the measurable 
features, hardness, friability, disintegration rate, mass and diameter was evaluated by the 
use of 3-D scatter plots (see Figures 1.7 to 1.9, Appendix 1).  Three 3-D scatter plots 
were used, where data from 45 batches of ‘ecstasy’ tablets were used for the plot of 
disintegration, hardness and friability and 41 batches with round tablets were used for the 
plot of diameter, mass and hardness and the plot of friability, diameter and mass.  The 






Figure 3.9 2-D scatter plot of the friability versus mean disintegration of 45 batches of ‘ecstasy’ tablets (the numbers near the 
spots in the scatter plot indicate the batch number as in Table 3.2, batch 0 is the control batch, bumetanide).  
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friability and the plot of diameter, mass and hardness was not as good as the 3-D scatter 
plots for the mass, diameter and thickness.  This was mainly caused by the high RSD 
values of the batches for the means of hardness and disintegration rates.  However, using 
these two plots the linkage between the batches 5-10, 11-13, 14-16 and 44-45 was 
confirmed and batches 1, 21, 33 and 27 were discriminated (batch number as in Table 3.2 
above).  Additionally, the plot of friability, diameter and mass was a much better plot 
than the earlier two 3-D plots to link or discriminate between batches of tablets.  Using 
this plot the linkage between the batches 5-10, 11-13, 14-16 and 44-45 was again 
confirmed and the batches 1, 20, 21, 26-28, 33 and 39 were discriminated (batch number 
as in Table 3.2 above). The linkage and differentiation between the batches of tablets 
were further confirmed statistically using one-way ANOVA.   
 
3.3.4 Quality and linkage 
 
Only four batches of ‘ecstasy’ tablets satisfied all the six pharmacopoeial and 
pharmaceutical physical characteristic criteria (mass, diameter, thickness, hardness, 
friability and disintegration).  These batches, which had reached a standard with regards 
to the studied criteria that would be accepted in pharmaceutics, were batch 18, white 
tablets (n = 2195) with D&G logo, batch 24, blue tablets (n = 153) with euro logo, batch 
32, white tablets (n = 538) with mercedes logo and batch 33, white tablets (n = 837) with 
Versace logo (total n = 3723).  The most poorly made batches of tablets are shown in 
Table 3.7 and it transpired that batch 40, white tablets (n = 1000) with E = mc2 logo, was 
the most poorly made batch. 
 
From this study it transpired that there was linkage between fourteen batches of ‘ecstasy’ 
tablets from three seizures (p > 0.05, one-way ANOVA).  The batches of tablets, which 
had  high  similarity  in  their visual and measurable physical features, including RSD and 
relative quartile deviation (RQD), are shown in Table 3.8.  There was even a linkage 
between the six batches of the blue and green tablets with omega logo (batches 5 to 10).  
The other thirty one batches of tablets had different physical characteristics (p < 0.05, 
one-way ANOVA).  
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 Table 3.7 Poorly made tablets according to pharmaceutical criteria 
 
Defects of poorly made tablets Batches 
High intra-variation in mass, RSD ranged between 8.27% to 10.89% 40, 44, 45 
High intra-variation in thickness, RSD ranged between 6.61% to 9.44%  5, 40, 44, 45 
High hardness which ranged between 100.85 N and 135.29 N 27, 38-40, 42, 43 
High friability which ranged between 1.6% to 4.4% 11-13, 26, 28 
 
3.3.5 Summary of key findings 
 
 Common features of the 45 batches 
 
• The table shape was round (91.1%, n = 41) and with a logo (88.9%, n = 40); 
 
• More than half of the batches of tablets were coloured (57.8%, n = 26); 
 
• The tablets had a mean mass which ranged between 150-250 mg (71.1%, n = 
32), a mean diameter which ranged between 7-9 mm (63.4%, n = 26) and a 
mean thickness which ranged between 3-4 mm (66.7%, n = 30); 
 
• Some of the batches of tablets had a mean mass > 300 mg (n = 6), a mean 
diameter > 9 mm (n = 16) and a thickness > 5 mm (n = 4); 
 
• The mean hardness was 70.74 N and about one third of the batches of tablets 
was ≥ 80 N (35.6%, n = 16); 
 
• The friability of most of the tablets was ≤ 0.5% (68.9%, n = 31); 
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Table 3.8 Batches of ‘ecstasy’ tablets with similar visual and physical measurable characteristics indicative of a possible 
linkage between the respective batches. 
 
 
Note: Mass, diameter and thickness – 1st line: mean, and RSD, 2nd line: median and RQD, Hardness – 1st line:  minimum and maximum values of 




























1,021 240 (4.65) 245 (7.16)  
9.22 (0.55) 
9.20 (0.78)  
3.14 (6.66) 
3.15 (6.61)  
89.70, 105.81 
97.16 (5.03) 0.2 
6 + 3 
(50.0) 
6 omega 1,018 239 (3.32) 241 (6.33)  
9.21 (0.47) 
9.20 (0.47)  
3.09 (3.46) 
3.11 (5.76)  
70.17, 88.40  
80.38 (6.83)  0.2 
9 + 5 
(55.6) 
7 omega 1.154 240 (3.66) 243 (2.98)  
9.21 (0.56) 
9.21 (0.68)  
3.12 (3.65) 
3.14 (3.08)  
71.43, 96.68 
 85.22 (9.61) 0.2 









1,029 239 (4.02) 240 (4.70) 
9.20 (0.53) 
9.19 (0.47) 
3.07 (4.76)  
3.09 (3.91) 
58.00, 78.60  
 67.17 (10.45)  0.2 
10 + 6 
(60.0) 





53.00, 66.24  
58.98 (6.75) 0.3 
6 + 4 
(66.7) 





51.02, 61.77  
56.89 (6.24)  0.2 







1,069 201 (3.22) 200 (3.63) 
7.13 (0.10)  
7.12 (0.13) 
4.11 (3.31) 
4.15 (2.13)  
52.64, 74.60  
 63.16 (13.27)  3.8 
743 + 478 
(64.3) 
12 euro 1,020 202 (4.59) 204 (5.39)  
7.13 (0.10) 
7.13 (0.08)  
4.15 (3.25) 
4.17 (3.15)  
53. 71, 83.06  
 68.78 (13.41) 4.4 
784 + 434 
(55.4) 
13 euro 1,031 200 (4.19) 203 (5.17)  
7.13 (0.17) 
7.13 (0.18)  
4.15 (3.25) 
4.17 (2.59)  
 48.88, 80.02  
 58.01 (14.86) 4.0 












44.58, 64.27  
 53.42 (13.96)  0.8 
5 + 4 
(80.0) 





41.01, 54.61  
 47.50 (13.01) 0.6 
5 + 3 
(60.0) 





 41.54,  61.77  
 48.77 (13.27) 0.3 












81.76 (21.39) 0.3 
242 + 54 
(22.3) 








82.89 (12.30) 0.2 
224 + 48 
(21.4) 
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• The mean disintegration rate of the batches of tablets was < 900 s (5 min) 
(84.4%, n = 38). 
 
Discriminating or linking characterising features 
 
• For the visual characteristics the logo (when Europol catalogue was used), 
shape and breakline were all reliable features to differentiate or link batches of 
‘ecstasy’ tablets.  The logo was the most discriminating feature; 
 
• The colour was found to be a very subjective feature and thus fairly reliable 
when used as a discriminating feature; 
 
• The measurable features mass, diameter and thickness were all reliable 
features (RSD normally < 5%) and also very good discriminating features; 
 
• The friability and the hardness (RSD normally ≥ 7%) were fairly reliable 
features but the disintegration rate was a poorly reliable feature (RSD 




This study focused on the use of the physical characteristics of ‘ecstasy’ tablets to 
investigate their possible use for intelligence purposes.  A total of 45 batches of tablets   (≥ 
100 tablets per batch) were seized in Malta over a five year period and the physical 
characteristics, including the visual features, logo, tablet shape, breakline and colour and 
the measurable features, mass, diameter, thickness, hardness, friability and disintegration 
rate were examined.  It was shown that the use of some of these physical features could 
help link or discriminate between batches of tablets.  The physical characterisation 
process of the batches of tablets was carried out in two stages.  In the first stage the 
tablets in the batches were examined for their visual features (logo, shape, breakline and 
colour). In the second stage the mass, diameter, thickness, hardness, friability and 
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disintegration rate of the tablets from the batches were measured.  The use of the 
measurable features hardness, friability and the disintegration rate used in this study to 
differentiate between batches of illicit tablets, as far as is known, is a novel approach and 
has never been used for forensic intelligence purpose. The data obtained from the 
physical characterisation of the batches was used to discriminate or link the batches.  The 
linkage of batches by the measurable features mass, diameter, thickness, hardness and 
disintegration rate was verified by one-way ANOVA.   Furthermore, two (2D) and three-
dimensional (3D) scatter plots of the measurable features were used to visualize the 
discrimination or linkage between the different batches.  The batches of ‘ecstasy’ tablets 
were compared to a test batch of pharmaceutically produced bumetanide tablets. 
   
The possible linking or discrimination of batches of ‘ecstasy’ tablets normally starts with 
the examinations of the visual features to assess similarity or not between the batches.  
The logo, tablet shape and breakline of ‘ecstasy’ tablets depend on the die and the 
punches used in the tabletting machine.  While the colour of tablets is dependent on the 
addition of the dye together with other excipients prior to tablet manufacture [196]   
Using the visual features together (logo, shape, breakline and colour, significant 
difference between the groups Welch’s F(3,83.30 = 40.40, p < 0.001)) more than half 
(68.9%, n = 31) of the examined batches of ‘ecstasy’ tablets in this study were 
differentiated from each other.  While the majority of tablets had a logo (88.9%, n = 40) 
and a round shape (91.1%, n = 41), more than half were coloured (55.6%, n = 25).  
During 2006 - 2009 the trend with regards to breakline on ‘ecstasy’ tablets was 
approximately divided between batches with tablets without a breakline and batches with 
tablets with a breakline on one side running diagonally along the diameter.  In 2010 all 
the examined batches of tablets (n = 7, 4 seizures) had no breakline and in 2011 a new 
breakline in the form of a cross was noted on one side of three batches of tablets (3 out of 
5 seizures).  However, some of the batches could not be distinguished from each other 
because of similar visual features, thus indicating possible linkage. These were batches 5-
7, blue tablets and batches 8-10, green tablets both with omega logo, batches 11-13 and 
17, white tablets with euro logo, batches 14-16, orange tablets with pisces logo, batches 
18 and 29, white tablets with D&G logo, batches 19 and 28, white tablets with heart logo, 
 142 
batches 24 and 42, blue tablets with euro logo, batches 27 and 34, blue tablets with 
question mark logo  and batches 44-45, pink tablets with lacoste logo.   
 
The mass, diameter and thickness were also used to link or discriminate between batches 
of ‘ecstasy’ tablets. These three characteristics are a reflection of the three stage 
manufacturing process: filling of the die with powder, compression of the powder and 
ejection of the tablet from the die.  The uniformity of mass of tablets in a batch is 
dependent on the flow properties of the material being tabletted [246].  If the material 
being tabletted does not flow freely at the required rate then improper filling of the die is 
possible.  Variations in the quantity of powder in each die would result in tablets having 
different mass and densities [247] such as batches in increasing variation 41, 44, 45 and 
40.  Hence, large variation in mass of ‘ecstasy’ tablets does not necessarily mean that 
tablets were from a different batch.  The inadequate quality control during illicit tablet 
production could cause these variations.   
 
The diameter is the most important physical feature from a forensic point of view because 
it is produced by the fixed dimensions of the hole of the metallic part in the die of the 
tabletting machine.  This part of the die is never changed by the operator of the tabletting 
machine. It is also possible to have different diameters within a batch of visually similar 
tablets, such as batch 20 which consisted of white tablets with shark logo.  The high 
variability in the diameters of illegal tablets could happen when the operator uses more 
than one punch, for example when using rotary machines.  The thickness like the mass of 
a tablet is determined by the quantity of powder per tablet and the position of the punches 
in relation to each other during compression.   
 
This study indicated that the values of the mass, diameter and thickness of the tablets 
sampled from the 45 batches were grouped in three classes: with the mean mass of the 
batches which ranged between 150 - 300 mg (82.2%, n = 37), the mean diameter of the 
batches which ranged between 6.5 – 9.5 mm (91.1%, n = 41) and the mean thickness of 
batches which ranged between 3 – 5 mm (88.9%, n = 40).   
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The trends in the measurable features, mass diameter and thickness, for the examined 
batches of ‘ecstasy’ tablets seized in Malta were compared with trends for the same 
features for tablets seized in other countries. A study which was conducted in Israel by 
Levy et al. [139] on ‘ecstasy’ tablets from 2925 seizure had diameters which ranged 
between 6.07 – 9.17 mm.  Another study by Marquis et al. [181] carried out on 560 
samples of ‘ecstasy’ tablets, which were seized in Finland, Netherlands, Czech Republic, 
France, Germany, Switzerland and USA, were found to have features which ranged 
between 150 - 345 mg for mass, 7 – 9 mm for diameter and 3 – 5.4 mm for the thickness.  
A further study which was conducted in Switzerland by Milliet et al. [214] on ‘ecstasy’ 
tablets from 120 seizures had features which ranged between 190 – 308 mg for the mass, 
7.1 – 9.5 mm for most of the diameters and 3.2 – 5.8 mm for the thickness.  This 
indicated that the measurable features mass, diameter and thickness of the ‘ecstasy’ 
tablets that were seized in Malta were not dissimilar to tablets seized elsewhere in 
Europe.   
 
The batches of ‘ecstasy’ tablets that were discriminated by their visual features were 
further discriminated using two (2D) and three-dimensional (3D) scatter plots. Using the 
scatter plots  for the means of mass, diameter and thickness of the 41 batches of tablets 
(only round tablets used) 21 batches (51.2%) could be differentiated (batches 1, 3, 4, 17, 
19-21, 24-28, 31-35, 37-39 and 41), while 4 groups composed from the remaining 20 
batches were linked (group 1 - batches 5-10, 40, group 2 – batches 11-13, 18, 29, 36, 42, 
43, group 3 – batches 14-16 and group 4 – batches 44 and 45).  The linkage between the 
batches was further examined statistically using one-way ANOVA.  There was 
significant linkage between batches 5-10, batches 11-13, batches 14-16 (except the 
diameter) and batches 44 and 45 (p > 0.05, one-way ANOVA for nearly all the features).  
Moreover, batch 40 was differentiated from batches 5-10 and batches 18, 29, 36, 42, 43 
were differentiated from each other and from batches 11-13 (p < 0.05, one-way ANOVA) 
 
It is sometimes claimed that a link between samples of tablets based on physical 
characteristics, such as mass, diameter and thickness, does not necessarily mean that the 
same press was used because it could have been another press with the same settings 
 144 
[181].  For this reason three other physical features, the hardness and disintegration rates, 
which are both destructive methods and friability were used to further try to link or 
discriminate between batches of ‘ecstasy’ tablets.   
 
It would be difficult to produce tablets having the same hardness, friability and 
disintegration rates using different tabletting machines because these features depend on 
the tablet formulation [245] and on the compression force. The hardness of tablets, which 
is directly related to the compression force used during manufacture, tends to increase 
with increasing compression force [248].  In normal tablets the friability tends to decrease 
with increasing compression [248].  With respect to disintegration time this tends to 
increase linearly with the range of the compression force used.  However, it is also 
claimed that the lubricant used in the tablet production may affect the hardness and the 
disintegration rate of the tablets [249].  It has been reported that an increase in the mixing 
time for the lubricant magnesium stearate tended to decrease the hardness but increased 
the disintegration time of the tablet [249, 250].  
 
The use of the measurable characteristics, the hardness, friability and the disintegration 
rate to provide data to further link or discriminate batches of illicit tablets as far as is 
known has never been used for forensic intelligence.  This could be because a large 
number of tablets (n ≈ 50) would be required to measure these features and also because 
the measurements of hardness and disintegration rates are destructive. 
 
There was high intra – variation observed within most samples of tablets taken from the 
batches for the hardness (variation RSD ≥ 7%, 77.8%, n = 35) and for the disintegration 
(variation RSD ≥ 20%, 84.4% n =38).  The discrimination potential for the friability was 
low when compared with the other five measurable features (mass, diameter, thickness, 
hardness, disintegration rate).  However, although the measurement of these features 
might not be considered as first priority it was still possible to discriminate between the 
batches of ‘ecstasy’ tablets, such as the white tablets with the D&G logo (batches 18 and 
29) and the tablets with the heart logo (batches 19 and 28) using these physical features.   
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The 2-D and 3-D scatter plots of hardness, disintegration rates, friability, mass and 
diameter helped to confirm the linkage between the batches of ‘ecstasy’ tablets with 
similar visual characteristics, the batches 5-7, blue tablets with omega logo, batches 8-10, 
green tablets with euro logo, batches 11-13, white tablets with euro logos, batches 14-16, 
orange tablets with pisces logo and batches 44 and 45, pink tablets with lacoste logo. (p > 
0.5, both one–way ANOVA, for hardness for most of the samples and for all samples for 
disintegration rates).  The linkage between the batches of ‘ecstasy’ tablets with similar 
visual characteristics and similar measurable characteristics could be an indication that 
the tablets were produced with the same tabletting machines.  
    
The tablets in the forty five batches were assessed for their ‘quality’ by examining the 
tablets for defects and their measurable features (mass, diameter, thickness, hardness, 
friability and disintegration rate) against pharmacopeial and pharmaceutical criteria.  
Most of the ‘ecstasy’ tablets in the batches were found to have some form of defect such 
as sticking, capping, chipping and mottling among others.  The defects found on ‘ecstasy’ 
tablets were expected because of the illicit manner in which they are produced.   When 
the batches of ‘ecstasy’ tablets were evaluated for their mass nearly three quarters (73%, 
n = 33) did comply with the pharmacopeial specification [221], and nearly all batches 
complied with the diameter criterion [225] (97.6%, n = 40).  For thickness only about 
one-third of the batches complied with the 5% tolerance for pharmaceutically   
manufactured tablets [225] (33.3%, n = 15).  One possibility for the lack of conformity to 
the criterion for thickness could have been the different pressures of the dies that had 
been set during the tabletting process [247].   
 
The hardness of tablets is dependent on the mass of the materials and the space between 
the upper and lower tablet punch at the moment of compression.  More than half of the 
batches (60%, n = 27) had a mean hardness which was within the pharmaceutical tablets 
criteria values for hardness (39.22 – 78.45 N) [245].  However, there was variability and 
nearly half of the batches (51.1%, n = 28) had 1 or more of the examined tablets above 
the recommended pharmaceutical maximum value, while 3 batches had 2 or more tablets 
below the hardness minimum value for pharmaceutical tablets.     
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The friability of the majority of batches of tablets (88.9%, n = 40) was found to be in line 
with pharmaceutically produced tablets (below the 1% cut-off).  This indicated that most 
of the seized batches of tablets were able to withstand handling and transportation during 
the illicit drug trafficking process.  
    
The absorption of a drug from a solid dosage form, after oral administration, depends on 
the break-up of the tablet, known as disintegration. The primary role of tablet 
disintegration is to expose rapidly a large surface area of the drug and thereby facilitate 
speedy dissolution. More than half (60%, n = 27) of the examined batches of ‘ecstasy’ 
tablets were found to have a disintegration rate of less than 60 s (1 min), with the 
majority (88.9%, n = 40) having a disintegration rate of less than 900 s (15 min).  Thus 
the disintegration rates of most of the examined ‘ecstasy’ tablets were within the desired 
time range of 900 s (15 min) for pharmaceutical tablets [225].  The batches of ‘ecstasy’ 
tablets which were within the disintegration time range of 900 s (15 min) had mean 
disintegration rates which ranged between 0.06 seconds to 733 s (12.22 min), while that 
for the bumetanide tablets was 0.06 seconds.  
 
The good compliance obtained for the pharmacopeial and pharmaceutical criteria for the 
individual measurable physical features described earlier for the examined batches of 
‘ecstasy’ tablets was not expected (70.3%, n = 187 measurable features from the 45 
batches complied to pharmacopeial and pharmaceutical criteria, out of a total of 266).  It 
is clear that there is good expertise available to those producing illicit ‘ecstasy’ tablets.  
However, only four batches of tablets were found to satisfy all the criteria laid down by 
the pharmaceutical industry.  These were the white round tablets with D&G logo (batch 
18, 2195 tablets, seized in 2007), the blue round tablets with euro logo (batch 24, n = 153 
tablets, seized in 2008), the white round tablets with mercedes logo (batch 32, n = 538 
tablets, seized in 2008) and the white round tablets with versace logo (batch 33, n = 837 
tablets, seized in 2009), which were found not to be linked and hence were manufactured 
differently by the clandestine tabletting chemist.   
 
It  transpired  from  this  part  of  the  study  that  the  small  ‘ecstasy’  market  in Malta is  
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normally characterized by a gradual penetration of tablets with new logos.  Nevertheless, 
this study has also shown that the turnover rate with respect to changes in the physical 
characteristics, both visual and measurable, of ‘ecstasy’ tablets seized on different 
occasions was rather high, such as the colour and logos and difference in the mass, 
diameter, thickness and hardness of the tablets in the different batches.  However, during 
the period of study batches of ‘ecstasy’ tablets seized on different occasions did not 
always have different logos and / or colour, and measurable features.  So the hypothesis 
(1) that: 
 
The physical state of different batches of ‘ecstasy’ tablets seized on 
different occasions in Malta during 2006 – 2011 was significantly 
different from each other. 
 
was partially satisfied because 14 batches confiscated during 3 out of  the 30 seizures 
were found to have similar features. 
 
The results from this study have also shown that the physical properties of ‘ecstasy’ 
tablets can be used for forensic drug intelligence purposes.  The visual features logo, 
shape, breakline and the measurable features mass, diameter, thickness and friability were 
found to be very reliable features to be used for characterization to discriminate or link 
batches of ‘ecstasy’ tablets.  The mass, diameter and thickness were the most 
discriminating features.  Moreover, the two (2D) and three-dimensional (3D) scatter plots 
were able to show that batches could be linked when they had similar features and 
discriminated when coming from different batches.  A link between batches of tablets 
based on most of these physical characteristics would make it more difficult to exclude 











INVESTIGATIONS REGARDING THE 
STABILITY OF ‘ECSTASY’ TABLETS 
 
The stability of the physical characteristics (colour, mass, diameter and thickness) of 
‘ecstasy’ tablets is important if these characteristics are to be used to show links between 
samples of tablets for drug intelligence.  In order to explore the stability of the physical 
features (colour, mass, diameter, thickness, hardness, friability and disintegration) of the 
seized ‘ecstasy’ tablets photostability and stability testing were conducted on samples 
from the 45 batches of tablets to determine how environmental factors, such as UV-
visible (VIS) radiation, RH and temperature may alter these features.  In addition, the 
colour and colour difference of ‘ecstasy’ tablets were evaluated using reflectance 
spectroscopy, as an added physical discriminator.  Storage conditions for ‘ecstasy’ tablets 




In the Netherlands when the tabletting facilities were investigated it was noted that the 
produced ‘ecstasy’ tablets had very similar physical features, such as mass, diameter and 
thickness, but the logos and colours were different [182].  In cases of illegal tabletted 
drugs, production of the illicit compound and tabletting may not necessarily take place in 
the same location. Thus similarities in the physical characteristics between different tablet 
seizures may simply suggest a relationship at the tabletting laboratory [180].  ‘Ecstasy’ 
tablets once compressed cannot be changed and their physical characteristics are 
maintained following trafficking, until seized or consumed. Tablets which have specific 
characteristics such as mass, diameter and thickness, could be of forensic value if these 
features are used for intelligence purposes.  The physical characteristics of ‘ecstasy’ 
tablets could highlight links between batches of tablets with similar physical properties 
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coming from the same illegal tabletting source, thus connecting separate seizures [214], 
and discriminating between batches with different external characteristics [181].   
 
Currently in Malta or internationally the comparison of ‘ecstasy’ tablets from different 
seizures is mainly based on visual examinations [182] of the physical features such as the 
logo, colour and shape.  The features such as diameter, which is fixed, thickness and 
mass are also measured [182].  These last two features are dependent on the powder 
quantity per tablet and the pressure of the punches used during the tablet production 
[251]. Previous work evaluating the discriminatory effect of both visual and measurable 
physical features had discarded colour and colour variance of tablets, because it was 
claimed that these features were not reproducible and that they were operator subjective 
[181].  During this research study reflectance spectroscopy, was employed as developed 
by the Commission International de l’ Èclairage (CIE) to measure the colour of ‘ecstasy’ 
tablets.  As far as it is known this method has never been used to discriminate between 
different samples of ‘ecstasy’ tablets.  To further investigate the possible use of colour as 
a discriminatory physical feature tablets were subjected to photostability stress testing.   
 
As far as we know nothing has been written about the stability of the physical features of 
‘ecstasy’ tablets used for batches discrimination, and whether these measurable 
characteristics are stable to environmental changes, such as RH and temperature. Studies 
conducted on legally produced sugar tablet formulation have shown that tablets expanded 
and became more friable when stored at 71% RH and at 25oC [252].  Similar results were 
obtained for tablets prepared by direct compression using lactose and microcrystalline 
cellulose when stored at high RH (85% at 37°C) for short periods of time [253]. 
Additionally, studies have also shown deterioration in hardness and decrease in friability 
of pharmaceutical tablets when stored at 75% RH and temperatures of 25 and 40°C 
respectively [254].   
 
Thus it was hypothesized that ‘ecstasy’ tablets undergo colorific change with alteration in 
the light conditions and that measurable features of ‘ecstasy’ tablet (mass, diameter, 
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‘Ecstasy’ tablets are thought to be imported to Malta from the Netherlands (N. Harrison, 
2011, personal communication, Assistant Commissioner, Malta Police, email, 17 March).  
It could be speculated that ‘ecstasy’ tablets produced in the Netherlands may be exposed 
to a temperate maritime climate which is influenced by the North Sea and Atlantic 
Ocean.  Daytime temperatures in the Netherlands vary from 2-6°C during the moderate 
winter and 17-20°C in the summer with average daily sunshine that ranges between 2 to 4 
hours in winter and to 7 hours in summer. Since the country is small there is little 
variation in climate from region to region. Furthermore, the average daily RH ranges 
between 76 to 86% in summer and from 83 to 89% in winter [255] 
 
In Malta ‘ecstasy’ tablets are subjected to a typical Mediterranean climate which is 
strongly influenced by the sea. The Islands have a very sunny climate with a daily 
average of 5 to 6 hours sunshine in mid-winter to more than 12 hours in summer.  The 
summer temperatures ranges between 24°C in May and 32°C and more in August, which 
is the warmest month, while in winter the average temperature is 16°C.  The daily 
average RH, which is amount of water vapour in the air at a particular temperature,  
ranges between 67 to 76% in summer and 77 to 81% in winter [255]. 
 
The stability of the physical features, colour and the measurable characteristics, of 
‘ecstasy’ tablets, which are used to discriminate between batches of tablets for 
intelligence purpose, were investigated. Three separate experiments were conducted 
which included (a) colour, colour variation after photostability stress testing, (b) 
accelerated storage conditions testing and (c) stability testing at different RHs and 
temperatures.  Prior to the experiments the tablets were all kept in an air conditioned 
room at RH of 25% and a temperature of 25 + 2°C.   
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During these experiments, which are described in Section 2.2.2 of the “Materials and 
Methodology”, Chapter 2, five different batches of ‘ecstasy’ tablets (Table 4.1), with 




Five batches of tablets (batches 5, 8, 11, 14 and 33) plus control tablets (bumetanide) 
were used to carry out the experiments (Table 4.1). 
 
Table 4.1 Batches of tablets used for the experiments. 
 








• Batches 5, 8, 11 and 14 were 
used in both Exps. A and B 
 
• Exp. A: photostability stress 
testing 
 
















/  / 
• Used in Exp. B: accelerated  
storage conditions testing 
33 6 
 
versace • Exp. C:  stability testing: effect of  RH and temperature 
 
Key: Exp. = Experiment 
 
4.3.1 Experiment A: Colour and photostability stress testing 
 
As explained in Section 2.2.2.1, samples of tablets were subjected to photostability stress 
testing using an adopted ICH method.  The samples from batches 5, 8, 11 and 14 were 
split into two groups of four samples each (Table 4.1).  One group of four samples was 
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exposed to the stress conditions using a cool fluorescent lamp for about 39 days and a UV 
fluorescent lamp for about 11 hours, while another group of four samples, the control, 
was covered in foil for the entire experiment to prevent light exposure.  At the end of the 
experiment the colour change in the exposed tablets was compared with control samples. 
The colour change was evaluated by reflectance spectroscopy using the CIE colour 
system. The mean CIELAB (CIE L*a*b* - L* brightness, a* is the red-green axis, and b* 
is the blue-yellow axis) colour results, the ΔE (colour difference between the tablets, 
control and exposed), the standard deviation (SD) of ΔE. 
 
4.3.2 Experiment B: Accelerated storage conditions 
 
In this experiment, described in Section 2.2.2.2, several observations and measurements 
were undertaken in order to investigate the stability of tablets when stored for long 
periods of time up to 180 days. Four different batches of ‘ecstasy’ tablets (batches 5, 8, 
11 and 14) which had different physical features between them (mass, diameter and 
thickness) were used in this experiment (Table 4.1). 
 
The tablets in the batches and the control bumetanide tablets were kept in storage for 180 
days at a temperature of 40 + 2°C and a RH of about 75 + 5%.  The measurable features 
of the tablets, mass, diameter and thickness, hardness, friability and disintegration rates 
were measured at the start of the experiments and after 90 and 180 days respectively.  
Moreover, the mean volume of the tablets was calculated from the obtained data of 
diameter and thickness using the formula for the volume (V = π r2h, π (pi) = 3.142, r (half 
the diameter) and h (thickness of tablet). 
 
4.3.3 Experiment C: Stability testing at different RHs and temperatures 
 
In this experiment the mass, diameter, thickness, volume (from data of diameter and 
thickness), and hardness were calculated for eight different samples of white ‘ecstasy’ 
tablets with versace logo (batch 33) (Table 4.1).  The tablets were placed under specific 
conditions as described in methods Section 2.2.2.3.  Four samples of tablets (n = 10 each)  
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were stored at a RH of 33 + 1% and temperatures of 5, 15, 25 or 35°C respectively.  Four 
other samples of tablets were stored at a RH of 75 + 1% and temperature of 5, 15, 25 or 
40°C respectively.  The physical characteristics of each tablet in the eight samples were 
measured on a weekly basis up to 5 weeks, then at week 8 and subsequently at weeks 10, 




4.4.1 Colour and colour variation and photostability stress testing 
 
The colour change for the samples of exposed ‘ecstasy’ tablets from batches 5, 8 11 and 
14, that were subjected to photostability stress testing, and control tablets (covered with 
foil) are described in Table 4.2.  The change in the absorbance ≈ 0.6 between the two 
actinomeric solutions (‘exposed’ and ‘covered’) indicated that the length of light 
exposure was sufficient and in accordance with ICH recommendations for photostability 
stress testing [227].  
 
When the individual (CIE) L* (brightness), a* (red / green) and b* (yellow / blue) colour 
space values of the ‘exposed’ green tablets with omega logo (batch 8) were compared 
with the ‘control’ tablets no statistical difference in colour change was found between the 
tablets.  However, there was a significant increase (p < 0.001) in the b* values for the 
‘exposed’ white tablets with the euro logo (batch 11) when compared with ‘control’ 
tablets.  This was due to a statistically significant difference in yellowness in the exposed 
tablets (increase) for batch 11.  There was also a significant increase (p = 0.009) in the L* 
values for the ‘exposed’ blue tablets with omega logo (batch 5) when compared with 
‘control’ tablets, indicating a significant change in brightness and also a significant 
increase (p < 0.001) in the a* values indicating a decrease in greenness.  Furthermore, for 
the ‘exposed’ orange tablets with pisces logo (batch 14) when compared with ‘control’ 
tablets, there was a significant decrease in redness (p < 0.001, decrease in a* values), and 
a significant decrease in yellowness (p < 0.001, decrease in b* values) as shown in Table  
4.2.  
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Table 4.2  CIELAB colour space mean values (L* - brightness, a* - red / green and 
b* - yellow / blue) for the 8 samples of tablets (4 samples exposed and 4 samples 
covered with foil - controls) and change in colour of exposed tablets. 
 
 
Note: The numbers in bold text indicate statistical significance. 
a Colour difference is subjective. 
 
Photostability testing: key findings  
 
• Significant increase in the brightness and significant decrease in the 
greenness of the tablets in batch 5; 
• No change in batch 8; 
• Significant increase in the yellowness of the exposed tablets in batch 11; 
• Significant decrease in the redness and yellowness of the tablets in batch 
14, which was very obvious change. 
 
The tablets  with  ‘very  obvious’  colour  change  were  the  range coloured  tablets  from  
batch 14 (E* = 5.06, SD 1.98) (Table 4.2).  The colour of these tablets had faded as 






















(L*) 72.6 (0.48) (L*) 72.9 (0.4) 0.009 
0.42 0.27 very slight (a*) -3.3 (0.61) (a*) -3.0 (3.7) <0.001 





(L*) 80.7 (1.07) (L*) 80.8 (0.9) 0.685 
0.54 0.70 slight (a*) -5.6 (7.0) (a*) -5.8 (4.5) 0.966 





(L*) 86.9 (0.6) (L*) 87.1 (1.0) 0.403 
0.42 0.49 very slight (a*) 1.5 (9.9) (a*) 1.5 (11.0) 0.111 





(L*) 83.3 (0.2) (L*) 83.6 (0.8) 0.053 
5.06 1.98 very obvious (a*) 9.7 (1.3) (a*) 9.0 (8.3) <0.001 
(b*) 37.8 (1.6) (b*) 32.8 (6.2) <0.001 
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4.4.2 Accelerated storage conditions testing: effects on physical features 
 
The purpose of accelerated storage conditions testing was to investigate changes in the 
measurable physical characteristic, mass, diameter, thickness, volume, hardness, friability 
and disintegration rates of ‘ecstasy’ tablets.  Changes in these characteristics could affect 
the comparative examinations of ‘ecstasy’ tablets for intelligence purposes.  
 
4.4.2.1 Baseline measurements of tablet samples used for accelerated storage at 
day one 
 
Table 4.3 gives an overview of the measurable features of the tablets (mass, diameter and 
thickness), at day one (baseline). At day one the mean mass of the tablets in these four 
‘ecstasy’ batches varied between 154 - 240 mg, while the mean diameter and thickness of  
 
Table 4.3 Properties of the 4 samples (n = 80 tablets each) of ‘ecstasy’ tablets from 




Note: The numbers in parenthesis are the RSD 
a Hardness (mechanical strength) – (a) refers to the mean value (b) refers to the minimum value of force 
measured and (c) refers to the maximum value of force measure. 























a = 76.7 (7.96) 
b = 66.4 
c = 87.0 
 













a = 97.2 (5.03) 
b = 89.7 
c = 105.8 
 
 













a = 67.2 (10.45) 
b = 58.0 
c = 78.6 
 













a = 63.2 (13.27) 
b = 52.6 



















a = 53.4 (13.96) 
b = 44.6 
c = 64.3 
 
0.8 5 + 4 (80.0) 
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the tablets varied between 7.1 - 9.2 and 3.1 – 4.1 mm respectively.  The control tablets 
bumetanide had a mean mass of 177 (RSD 0.91%) mg, while the mean diameter and 
thickness were 8.1 (RSD 0.25%) mm and 2.7 (RSD 1.10%) mm respectively.  The mean 
hardness of all the tablet samples varied between 53.4 – 97.2 N.  The mean hardness of 
the control tablets was 76.7 N.  
 
At baseline the friability of the batches of ‘ecstasy’ tablets, with the exception of batch 11 
(white tablets with the euro logo), was below 1%.  The tablets from batch 11 were found 
to chip (breaking away of the surface of the tablet) and cap and so the friability test had to 
be excluded. At baseline, the disintegration time of the ‘ecstasy’ tablets was found to be 
less than 780 s (13 min), which was better than the standard required for licit uncoated 
tablets. The friability of the control bumetanide tablets was less than 1% and the 
disintegration time about 2 s. (Table 4.3). 
 
It was also determined that the major excipients of the tablets used for the accelerated 
storage conditions testing were sorbitol for the blue and green tablets with omega logo 
(batches 5 and 8) and orange tablets with pisces logo (batch 14) and lactose for the white 
tablets with euro logo (batch 11) (see Section 5.3.4). 
 
4.4.2.2 Effects on ‘ecstasy’ tablets and control bumetanide tablets after 90 and 




There was a significant decrease in the mean mass of the tablets from batch 14, of 6 mg 
(p = 0.004, one-way ANOVA), after 90 days.  The mass of the tablets from batch 14 
could not be measured after 180 days because the tablets had disintegrated.  The mean 
mass of control tablets and the tablets from batch 11 after 180 days respectively remained 
unchanged compared to initial measurements.  The decrease of 3.5 mg in the mean mass 
of the tablets from both batches 5 and 8 at the end of the experiment was not statistically 
significant (Table 4.4).   
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Table 4.4 Change in the mass of ‘ecstasy’ tablets after 90 and 180 days following 




Day 1 Day 90 
Change  
observed  









 (3.40) a 
241 
(3.43) 
decrease  - 1 mg   
from day 1 




decrease – 3 mg  
 from day 1  
(p > 0.05) 
decrease – 2 mg  
from day 90  









decrease -  3 mg 
from day 1 




decrease – 4 mg 
  from day 1 
(p > 0.05) 
decrease – 1 mg   
from day 90 






















decrease – 6 mg   
from day 1 














from days  
1 and 90 
(p > 0.05) 
 
 




There was a significant increase (p ≤ 0.001, one-way ANOVA) in the mean diameter of 
batch 5 and 8 and 11 after 90 days and 180 days respectively (Table 4.5 below). The 
friability of the ‘ecstasy’ tablets  from  batch  14  had  increased  so  much  after  90  days 
that their diameter could not be measured because the tablets had begun to disintegrate. 
There was no statistically significant change in the mean diameter of the control tablets. 
 158 
Table 4.5 Change in the diameter of ‘ecstasy’ tablets after 90 and 180 days following 





Day 1 Day 90 
Change  
observed  












increase - 0.29 mm 
from day 1 
(p < 0.001) 
9.58 
(0.52) 
increase - 0.35 mm 
from day 1 
(p < 0.001) 
increase - 0.06 mm 
from day 90 








increase - 0.20 mm  
from day 1 
(p < 0.001) 
9.49 
(0.95) 
increase - 0.28 mm  
from day 1 
(p < 0.001) 
increase - 0.08 mm 
from day 90 








increase - 0.06 mm   
from day 1 
(p < 0.001) 
7.23 
(0.14) 
increase - 0.10 mm 
from day 1 
 (p < 0.001) 
increase - 0.04 mm  
from day 90 














(p > 0.05) 
8.17 
(0.12) 
slight change from 
days 1 and 90 
(p > 0.05) 
 




There was significant increase in the mean thickness (p < 0.001, one-way ANOVA) of 
batch 5 and 8 respectively after 90 days.  Moreover, there was also significant increase in 
mean  thickness (p < 0.001, one-way ANOVA) of batch 5 and 8 respectively from day 90  
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to day 180 and batch 11 of (p = 0.004, one-way ANOVA) after 180 days (Table 4.6 
below).  The thickness of the tablets from batch 14 could not be measured because of the 
high increase in the friability of the tablets.  There was no statistically significant 
difference in the mean thickness of the control tablets. 
 
Table 4.6 Change in the thickness of ‘ecstasy’ tablets after 90 and 180 days following 




Day 1 Day 90 
Change  
observed  












increase - 0.40 mm  
from day 1 
(p < 0.001) 
3.68 
(3.53) 
increase - 0.54 mm  
from day 1 
 (p < 0.001) 
increase - 0.14 mm 
from day 90 








increase - 0.20 mm  
from day 1 
(p < 0.001) 
3.44 
(3.78) 
increase - 0.37 mm  
from day 1 
(p < 0.001) 
increase - 0.17 mm  
from day 90 








increase - 0.06 mm   
from day 1 
(p = 0.345) 
4.25 
(3.77) 
increase - 0.15 mm  
from day 1  
(p = 0.004) 
increase - 0.09 mm  
from day 90 












increase  - 0.01 
(p > 0.05) 
2.78 
(1.80) 
as day 90 
(p > 0.05) 
 
a Mean thickness followed by relative standard deviation (RSD) in parenthesis. 
 
  Tablets volume 
 
There was a significant increase (p ≤ 0.013, one-way ANOVA) in the mean volume, of 
batch 5 and 8 and 11 after 90 days and 180 days respectively (Table 4.7 below). There 
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was no statistically significant change in the mean volume of the control tablets. The 
friability  of  the  tablets from batch 14 had  increased  so  much  after  90  days  that  
their volume could not be measured because the tablets had begun to disintegrate. 
 
Table 4.7 Change in the volume of ‘ecstasy’ tablets after 90 and 180 days following 
accelerated storage conditions. 
 
 




After storage for 90 days there was a significant decrease (p < 0.001, one-way ANOVA), 
in the mean hardness of the tablets from batch 5 (97.16 N, RSD 5.03% to 39.28 N, RSD 
Tablets 
Volume (mm3) 
Day 1 Day 90 
Change  
observed  









 (4.98) a 
252.04 
(4.52) 
increase - 41.82 mm3  
from day 1 
(p < 0.001) 
264.93 
(3.44) 
increase - 54.71 mm3 
 from day 1 
(p < 0.001)  
increase - 12.89 mm3 
from day 90  








increase - 22.63 mm3 
from day 1 
(p < 0.001) 
243.34 
(3.80) 
increase - 38.49  mm3 
  from day 1 
(p < 0.001) 
increase - 15.86 mm3   
from day 90 








Increase - 5.46  mm3  
from day 1 
(p = 0.009) 
174.47 
(3.86) 
increase - 10.71 mm3 
from day 1 
(p < 0.001) 
increase - 5.25 mm3 
from day 90 












increase - 0.23 mm3 
from day 1 
(p > 0.05) 
145.48 
(1.91) 
increase - 0.37 mm3  
from day 1 
(p > 0.05) 
increase - 0.14 mm3 
from day 90 
(p > 0.05) 
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7.33%) and a significant decrease in the hardness of the tablets from batch 11 after 180 
days (63.16 N, RSD 8.38% to 42.85 N, 6.45%).  Only 5 out of 10 tablets, selected at 
random from batch 5, could be examined after 90 days because the rest were very friable.  
After 90 days no tests could be conducted on the tablets from batch 8 because these were 
too friable, while the tablets from batch 14 started to disintegrate (Table 4.8).   
 
Table 4.8 Change in the hardness of ‘ecstasy’ tablets after 90 and 180 days following 




Day 1 Day 90 
Change  
observed  












decrease - 57.88 
from day 1 















decrease - 13.03   
from day 1 
(p = 0.001) 
42.84 
(16.25) 
decrease - 20.32 
from day 1  
(p = 0.001) 
decrease - 7.29 
from day 90 












increase - 4.32 
from day 1 
 (p > 0.05) 
79.83 
 (9.76) 
increase - 3.17  
from day 1 
(p > 0.05) 
decrease - 1.15  
from day 90 
(p > 0.05) 
 
a Mean thickness followed by relative standard deviation (RSD) in parenthesis. 
 
Friability and disintegration of tablets 
 
The  friability  of  the  tablets  from batches 5 and 8 was found to have increased by 1.4%  
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and 10.5% respectively after 90 days and by 4.0% and 21.3% respectively after 180 days, 
whereas the friability of the control tablets remained unchanged (0.1%) at 180 days.  
Some of the tablets from batch 11 were found to chip (breaking away of the surface of 
the tablet) and cap (complete or partial separation of the upper or lower surface), hence 
the high friability at days 1 and 180.  The tablets from batch 14 did not survive the 
accelerated stress test.  After 90 days the tablets were very friable and  disintegrated  after  
 
Table 4.9 Friability and disintegration of ‘ecstasy’ tablets after 90 and 180 days 
following accelerated storage conditions. 
 
         
180 days (Table 4.9, Figures 4.1 and 4.2), hence the friability and disintegration tests 
were not done.  The mean  disintegration  rates  of the tablets from batches 5 and 8 had 
significantly decreased (p = 0.002, one-way ANOVA and Welch test respectively) after 
Tablets 
 
Friability (%) and Disintegration (s) + SD and (RSD) 
 











6 + 3 (50.0) 
 











10 + 6 (60.0) 
 




3.8 (some tablets 
chipped / capped) 0.73 
2.6 (some tablets 
chipped / capped) 
752 + 480 (63.8) 524 + 548 (104.6) 
 






0.3 100 disintegrated 
 













2 + 1 (50.0) 
 
64 + 5 (7.8) 62 + 12 (19.4) 
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90 days and thereafter there was no significant change (p > 0.05, one-way ANOVA and 
Welch test respectively) in  the  disintegration  in  both  batches  till  day 180 (Table 4.9). 
The  mean  disintegration  rates  of  the tablets from batch 11 did not change significantly 
 
 
Figure 4.1  Change in the friability of ‘ecstasy’ tablets after 90 and 180 days of 
accelerated storage conditions at 75% RH and 40°C.  Batch 14 at day 90 friability 
was 100%. 
 
after 90 and 180 days respectively (p > 0.05, Welch test) (Table 4.9).  Moreover, the 
mean disintegration rates of the control tablets had significantly increased (p < 0.001, 
Welch test) after 90 days and thereafter there was no significant change in the 





                            
                         
 
                            Day 1                             Day 90                                   Day 180    
 
 
Figure 4.2 The orange tablets with pisces logo (batch 14) after 90 and 180 days of 
accelerated storage conditions, stored at 75% RH and 40°C. 
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Accelerated storage: key findings  
 
Mass 
• Significant decrease in the mean mass of tablets from batch 14 after 
storage of 90 days at 75% RH and  40°C; 
• At 180 days no change in batch 11 and non significant decrease in the 
mean mass of batches 5 and 8 and disintegration of batch 14; 
Diameter 
• Significant increase in the mean diameter of tablets from batches 5, 8 and 
11 after storage of 90 days at 75% RH and  40°C; 
Thickness 
• Significant increase in the mean thickness of tablets from batches 5, 8 and 
11 after storage of 180 days at 75% RH and 40°C; 
Volume 
• Significant increase in the mean volume of tablets from batches 5, 8 and 
11 after storage of 180 days at 75% RH and 40°C; 
Hardness 
• Significant decrease in the mean hardness of tablets from batches 5 and 11 
after 90 days storage at 75% RH and 40°C;  
• Batch 8 and 14 too friable to conduct test at day 90 and batch 5 to conduct 
test at day 180; 
Friability  
• increase in the friability of the all the batches; 
Disintegration rate 
• Significant decrease in the mean disintegration rates of tablets from 
batches 5 and 8 at day 90 at 75% RH and 40°C;  
• There was no significant change in the disintegration rates of tablets from 
batch 11 after 90 and 180 days respectively; 
• Batch 14 to friable to conduct test. 
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4.4.3 Stability testing: effect of RH and temperatures on the physical features of 
‘ecstasy’ tablets 
 
4.4.3.1 Baseline measurements of tablet samples used for stability experiment 
 
Table 4.10 shows the physical properties of the ‘ecstasy’ tablets from batch 33 (with 
versace logo) that were used for the stability experiment. At baseline, the hardness and 
the friability of the tablets were within the acceptable limits for pharmaceutical tablets.  
 
Table 4.10 Baseline properties of the 80 ‘ecstasy’ tablets which were then divided 




















Note: the numbers in parenthesis are the relative standard deviation (RSD). 
a(i) mean value (RSD), (ii) minimum value of force measured and (iii) 
maximum value of force measured. 
 
At baseline, the frequency distribution of the mass showed a strong bimodal distribution 
(Figure 4.3 below). This indicated the presence of two distinct tablet populations within 
the sample of 80 tablets which had been taken at random from one batch.  It was also 
 
White coloured ‘ecstasy’ tablets 
with Versace logo – batch 33 
Mass (mg) 
Mean = 275 (2.39) 
Range = from 263 to 286 
 
Diameter (mm) 
Mean = 8.20 (0.37) 
Range = from 8.15 to 8.30 
 
Thickness (mm) 
Mean = 4.40 (1.57) 
Range = from 4.25 to 4.57 
 
Hardness (N) a (i) 47.00 (4.06%), (ii) 44.76, (iii) 50.49, 
 








262 265 268 271 274 277 280 283 287








determined that the major excipient of the white tablets with versace logo was lactose 




















Figure 4.3 Frequency distribution of the mass of ‘ecstasy’ tablets with versace logo 
from batch 33 used during the stability study (Week 0). 
 
 
4.4.3.2 Temperature and RH effects 
 
This section gives the results on the effects of RHs (33-75%) at different temperatures (5, 
15, 25, 35 and 40°C) on the physical features (mass, diameter, thickness, volume, 
hardness and friability) of the examined ‘ecstasy’ tablets. 
 
  Tablets mass 
 
Although there was no significant statistical difference between the mean mass of the 
tablets stored at 33 and 75% RH for the separate temperatures between weeks 0 and 1, it 
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was noted that for the tablets stored at 33% RH there was a slight decrease in mean mass 
at 5, 25 and 35°C and a slight increase for all samples stored at 75% RH (Table 4.11).  
 
Table  4.11  Mean mass (mg) of ‘ecstasy’ tablets at week 0 and week 1 when exposed 
at 5, 15, 25 and 35°C and 33% RH and at 5, 15, 25 and 40°C and 75% RH (Number 
in the parenthesis is SD). 
 
 
Based on the trends shown in Figure 4.4 (A) there was no change in the mean mass of 
tablets at 15°C at 33% RH over 16 weeks.  There was a slight decrease in the mass at 
temperatures of 5 and 25°C and a decrease in the mean mass at 35°C after 16 weeks 
when stored at 33% RH. 
 
At  the  start  of  the  experiment  (week  0)  there was no difference (F(3,36) = 1.936, p =  
 33% RH 
Week Temperatures (°C) 
5 15 25 35 
0 
270.5 (6.62) 275.1 (7.16) 275.9 (7.02) 277.6 (6.79) 
1 
269.6 (6.50) 276.0 (7.45) 273.4 (6.65) 270.3 (6.48) 
p – value 
one-way ANOVA 0.763 0.786 0.424 0.920 
 
 75% RH 
Week 
Temperatures (°C)   
5 15 25 40 
0 275.2 (6.18) 274.5 (5.68) 273.5 (7.44) 274.0 (5.33) 
1 278.5 (6.50) 278.7 (5.85) 275.1 (7.78) 274.6 (5.56) 
p – value 
one- way ANOVA 
0.851 0.621 0.997 1.000 
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0.141, one-way ANOVA) between the mean mass of the tablets in the 4 separate samples 
which were then stored at 33% RH and separate temperatures (5, 15, 25 and 35°C).  
Investigating the weekly change in the mean mass of the 4 separate samples of tablets 
under the different storage conditions there was significant difference (p < 0.05, one-way 
ANOVA) between the mean mass of the tablets for weeks 2 to 4, 10 and 14.  However, 
no significant difference (p > 0.05, one-way ANOVA) existed between the mean mass of 
tablets in the 4 separate samples for the other weeks (see Table 1.1, Appendix 2).  
Moreover, there was no significant change in the mean mass (p > 0.05, one-way 
ANOVA) of 3 out of 4 separate samples of tablets that were stored at 33% RH and 5, 15, 
and 25°C respectively, after 16 weeks when compared to the mean mass of the separate 
samples at the start of the experiment (week 0).  For the samples of tablets stored at 33% 
RH and 35°C there was a significant  decrease (p = 0.06, one-way ANOVA) of 3.5%  in 
the mean mass of tablets after 16 weeks when compared with the mean mass at week 0 
(Figure 4.4, B).  
   
For the tablets stored at 75% RH and all temperatures (5, 15, 25 and 40°C) at week 0 
there was no difference (F(3,36) = 0.137, p = 0.938, one-way ANOVA) between the 
mean mass of the samples. Additionally, there was no significant difference when 
comparing the mean mass of the 4 separate samples of tablets stored at 75%  RH  and  all  
temperature for each week, from week 1 to 16 (p > 0.05, one-way ANOVA) (see Table 
1.1, Appendix 2).  For the tablets stored at 75% RH at 5 and 15°C respectively there was 
a slight increase in mass after 1 week, and thereafter there was a slight decrease till week 
16.  For the tablets stored at 25 and 40°C there was a slight continuous decrease 
throughout the 16 weeks (Figure 4.5, A).  There was no significant change in the mean 
mass of the 4 separate samples of tablets when stored at 75% RH and all temperature 
after 16 weeks when compared to the mean mass of the separate samples at week 0 (p > 
0.05, one-way ANOVA) (Figure 4.5, see Table 1.1, Appendix 2).  Additionally, there 
was no significant difference when comparing the mean mass of the 4 separate samples 
of tablets stored  at  75%  RH  at  all  temperature  (5,  15,  25 and  40°C),  for  each  
week,  starting from  week  1  to  week  16 (p > 0.05, one-way ANOVA) (see Table 1.1, 












































Week 0 Week 16
 
 
Figure  4.4  A: Mean mass (mg) of ‘ecstasy’ tablets exposed at 5, 15, 25 and 35°C 
and 33% RH between 0 and 16 weeks (Errors bars overlap). B: Comparison of 


























Week 0 Week 16  
 
Figure  4.5  A: Mean mass (mg) of ‘ecstasy’ tablets exposed at 5, 15, 25 and 40°C 
and 75% RH between 0 and 16 weeks (Errors bars overlap). B: Comparison of 





















5°C 15°C 25°C 40°C
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At week 16 there was no significant difference between the mean mass of the two 
samples of tablets stored at 33 and 75% RH at 15°C and the two samples at 25°C 
respectively (p > 0.05, one-way ANOVA) (Figure 4.6).  There was also no statistically 
significant difference in the mean mass of the two separate samples of tablets stored at 33 
and 75% RHs and at separate temperatures of 35 and 40°C (p > 0.05, one-way ANOVA).  
However, at week 16 there was a significant increase (p = 0.008, one-way ANOVA) in 
the mean mass of tablets stored at 75% RH and temperature of 5°C when compared with 
the sample of tablets stored at 33% RH and similar temperature (Figure 4.6, see Table 
























Figure 4.6  Mean mass (mg) of ‘ecstasy’ tablets exposed at 5, 15, 25 and 35°C and 
33% RH and at 5, 15, 25 and 40°C and 75% RH at week 16  (Error bars represent 
the SD of each mean). 
 
 
If only the RH is considered there was no significant difference between the mean mass 
of the total tablets (n = 40, refers to 4 samples with 10 tablets each) in the 4 samples that 





















33% RH 75% RH
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Moreover, there was no significant difference between the mean mass of the total tablets 
(n = 40) in the 4 samples that were stored at 75% RH for all weeks (F (10, 429) = 0.796, 
p = 0.632, one-way ANOVA).    
 
The tablets stored at 75% RH had a significantly greater mass (p < 0.05, one-way 
ANOVA) on week by week basis when compared to tablets stored at 33% RH, regardless 
of temperature (Figure 4.7, see Table 1.2, Appendix 2).  Moreover, while there was a non 
significant decrease (1.64%, p = 0.2 one-way ANOVA) in the mean mass of the total 
tablets (n = 40) stored at RH 33% after 16 weeks, the mean mass of the total tablets (n = 
40) stored at RH 75% remained largely unchanged as week 0 after 16 weeks (Figure 4.7, 

























Figure  4.7  Mean mass (mg) of total ‘ecstasy’ tablets (n = 40, 10 tablets in each of 
the 4 samples) exposed at 33% RH and mean mass of total ‘ecstasy’ tablets (n = 40) 






















33% RH 75% RH
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     Tablets diameter 
 
At the start of the experiment (week 0) there was no difference (F(3,36) = 0.416, p = 
0.743, one-way ANOVA) between the mean diameter of the tablets in the 4 samples 
which were then stored at 33% RH at different temperatures (5, 15, 25 and 35°C).  There 
was no significant change in the mean diameter (p > 0.05, one-way ANOVA) of 3 out of 
4 samples of tablets when stored at 33% RH and at temperatures of 15, 25 and 35°C after 
16 weeks when compared to the mean diameter of the separate samples at the start of the 
experiment (week 0) (Figure 4.8).  However, there was significant increase (p = 0.042, 
one-way ANOVA) after 16 weeks in the mean diameter at 5°C when stored at 33% RH 
when compared with week 0.  The difference between the mean diameter of the 4 
separate samples of tablets stored at 33% RH and all temperatures (5, 15, 25 and 35°C) 
for each week, were found to be significant (p < 0.05, one-way ANOVA) for weeks 1, 2, 
8 and 10 but not significant (p > 0.05, one-way ANOVA) for the other weeks (see Table 
1.3, Appendix 2).   
 
From the Figure 4.8 (A, B), it could be observed there was a slight change in the mean 
diameter of tablets at 15°C when stored at 33% RH over 16 weeks.  There was a trend to 
a slight increase in the mean diameter for tablets at 5 and 25°C after week 2.  However, 
while for the tablets at 5°C the mean diameter stabilised after week 4, for the tablets at 
25°C there was a slight decrease at the end of week 16 when stored at 33% RH.  For the 
tablets at 35°C there was a decrease in the mean diameter after week 1 and then at week 3 
the mean diameter was again similar to week 0 where it appeared to stabilise (Figure 4.8, 
A).  
 
At the start of the experiment (week 0) there was no difference (F(3,36) = 0.402, p = 
0.752, one-way ANOVA) between the mean diameter of the tablets in the 4 samples 
which were then stored at 75% RH and different temperatures (5, 15, 25 and 40°C). 
There was significant increase in the mean diameter (p < 0.05, one-way ANOVA) of the 
4 separate samples of tablets when stored at 75% RH at all temperatures (5, 15, 25 and 

















































Week 0 Week 16  
 
Figure  4.8  A: Mean diameter (mm) of ‘ecstasy’ tablets exposed to 5, 15, 25 and 
35°C and 33% RH between 0 and 16 weeks (Errors bars overlap). B: Comparison of 




















































Week 0 Week 16  
 
Figure  4.9  A: Mean diameter (mm) of ‘ecstasy’ tablets exposed to 5, 15, 25 and 
40°C and 75% RH between 0 and 16 weeks (Errors bars overlap). B: Comparison of 




the start of the experiment (week 0) (Figure 4.9, see Table 1.3, Appendix 2).  The 
increase in mean diameter was most prominent in the samples of tablets stored at 75% 
RH and separate temperatures of 15 and 40°C (increase of 1.22 mm at 15°C and 1.10 mm 
at 40°C, Figure 4.9, B).  The difference between the mean diameter of the 4 separate 
samples of tablets stored at 75% RH and all temperatures (5, 15, 25 and 40 °C) for each 
week, between 1 to 16 weeks, was found to be significant (p < 0.05, one-way ANOVA) 
(see Table 1.3, Appendix 2).   
 
When looking at Figure 4.9 (A) it could be concluded that there was a change in the mean 
diameter of tablets at all temperatures (5, 15, 25 and 40°C) when stored at 75% RH over 
16 weeks.  The increase in the mean diameter was sustained over several weeks at the 
beginning of the study, up to week 3 for many temperatures and continuing in tablets 
exposed to 25°C for 8 weeks.  For the tablets stored at 15 and 40°C at 75% RH after 
increase in the mean diameter at weeks 3 and 4 respectively, stabilised to week 16.  The 
tablets at 5°C, after the initial increase in the mean diameter stabilised till week 10 when 
it then decreased and stabilised till week 16.  The mean diameter of tablets at 25°C after 
the increase at week 8 started to decrease till week 16 (Figure 4.9, A).  The mean 
diameter of the tablets at 16 weeks at all temperatures at 75% RH had increased when 
compared with the mean diameter at the start of the exposure (Figure 4.9, A).   
 
At week 16 there was significant increase in the mean diameter of the separate samples of 
tablets stored at 75% RH and temperatures of 5, 15 and 25°C (p < 0.05, one-way 
ANOVA) when compared with the mean diameter of tablets in the separate samples 
stored at 33% RH and similar temperatures  (Figure 4.10).  There was also significant 
increase in the mean diameter of the tablets stored at 40°C at 75% RH when compared 
with  the  mean  diameter  of  the  tablets  stored  at  35°C  at 33% RH (p < 0.05, one-way 
ANOVA) (Figure 4.10).  The most increase in the mean diameter of tablets stored at 75% 
RH when compared with the tablets stored at 33% RH occurred with the tablets at 15 and 
40°C (an increase of 1.10 mm at 15°C and 0.97 mm at 40°C) (Figure 4.10, see Table 1.3, 
Appendix 2).  If only the RH is considered the mean diameter of the total tablets (n = 40) 















Figure  4.10  Mean diameter (mm) of ‘ecstasy’ tablets exposed to 5, 15, 25 and 35°C 
and 33% RH and at 5, 15, 25 and 40°C and 75% RH at week 16  (Error bars 
represent the standard deviation of each mean). 
 
after week 2 and remained rather constant thereafter.  Furthermore, if week 1 is excluded, 
no significant difference existed between the mean diameter of all the tablets in the 4 
samples stored at RH of 33% from week 0 to week 2 through to week 16.  (F (9, 390) = 
0.720, p = 0.690, one-way ANOVA) (Figure 4.11).  
 
Whereas the mean diameter of all the tablets (n = 40) in the 4 samples that were stored at 
75% RH had significantly increased from week 0 to week 3 and remained more or less 
constant to week 16 (F (10, 429) = 27.199, p < 0.001, one-way ANOVA).  There was 
also a significant increase in the mean diameter of the total tablets (n = 40) that were 
stored at 75% RH and all temperatures (5, 15, 25 and 40°C) for weeks from 3 to 16 when 
compared to week 2 (p > 0.05, one-way ANOVA) (Figure 4.11). 
     
A Tukey post-hoc test indicated that the mean diameter of all the tablets in the 4 samples 
stored at RH of 75% after 1 week were significant wider (8.25 mm SD 0.04, p < 0.001,  




































Figure 4.11  Mean diameter (mm) of total ‘ecstasy’ tablets (n = 40, 10 tablets in each 
of the 4 samples) exposed to 33% RH and mean diameter of total ‘ecstasy’ tablets (n 
= 40) exposed at 75% RH between 0 and 16 weeks  (Error bars represent the SD of 
each mean). 
 
in the width to week 16 (8.27mm SD 0.04, p < 0.001, one-way ANOVA, increase of 
0.98%).  The tolerance limit for the mean diameter of all the tablets in the 4 samples 
stored at RH of 75% using the tolerance factor k for a two-sided test, (95% CI and 99% 
coverage) changed from 8.19  mm (SD 0.10) at week 0 to 8.27 mm (SD 0.11) at week 16 
(Figure 4.11, see Table 1.4, Appendix 2).  
 
Considering only the RHs there no significant difference between the mean diameter of 
all tablets (n = 40) stored at 75% RH when compared with all tablets at 33% RH at week 
0 (p > 0.05, one-way ANOVA).  However there was significant increase (p < 0.05, one-
way ANOVA) for each week (between week 1 to 16) in the mean diameter of all the 
tablets in the 4 samples (n = 40) stored at 75% RH when compared with the mean 
diameter of all tablets (n = 40) stored at 33% RH (Figure 4.11, see Table 1.4, Appendix 
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33% RH after 16 weeks, and an increase of 0.98% in the mean diameter of the total 




At the start of the experiment (week 0) there was no significant difference (F(3,36) = 
0.847, p = 0.477, one-way ANOVA) between the mean thickness of the tablets in the 4 
samples which were stored at 33% RH and separate temperatures (5, 15, 25 and 35°C).  
However, significant difference were observed between the mean thickness of the 4 
separate  samples of tablets stored at 33% RH and all temperatures (5, 15, 25 and 35°C) 
(p < 0.05, one-way ANOVA) for each week with the exception of weeks 1 and 3 were 
there was no significant difference (p > 0.05, one-way ANOVA) (see Table 1.5, 
Appendix 2).  
 
From the Figure 4.12 (A), it could be concluded there was slight change in the mean 
thickness of tablets at 5 and 35°C when stored at 33% RH over 16 weeks.   The mean 
thickness of the samples of tablets at 25°C had slightly decreased, while those at 15°C 
had increased when stored at 33% RH during the 16 weeks.  It was also noted that the 
increase in the mean thickness for the tablets at 15°C had occurred in the first two weeks 
(Figure 4.12, A).  There was no significant change in the mean thickness (p > 0.05, one-
way ANOVA) of the 4 separate samples of tablets when stored at 33% RH and all 
temperatures (5, 15, 25 and 35°C) at the end of the study after 16 weeks when compared 
to the mean thickness of the separate samples at the start of the experiment (week 0) 
(Figure 4.12, B).   
 
At the start of the experiment (week 0) there was no difference (F(3,36) = 0.467, p = 
0.707, one-way ANOVA) between the mean thickness of the tablets in the 4 samples 
which were then stored at 75% RH and different temperatures (5, 15, 25 and 40°C). 
There was significant increase in the mean thickness (p < 0.05, one-way ANOVA) of the 
4 separate samples of tablets when stored at 75% RH and all temperatures (5, 15, 25 and 


















































Week 0 Week 16  
 
Figure  4.12  A: Mean thickness (mm) of ‘ecstasy’ tablets exposed to 5, 15, 25 and 
35°C and 33% RH between 0 and 16 weeks (Errors bars overlap). B: Comparison of 






















































Week 0 Week 16  
 
Figure  4.13  A: Mean thickness (mm) of ‘ecstasy’ tablets exposed to 5, 15, 25 and 
40°C and 75% RH between 0 and 16 weeks (Errors bars overlap). B: Comparison of 




with the mean thickness of the separate samples at the start of the experiment (week 0) 
(Figure 4.13) (see Table 1.5, Appendix 2).  The increase in the mean thickness was most 
prominent in the samples of tablets stored at 75% RH and separate temperatures of 15 
and 40°C (increase of 0.12 mm at 15°C and 0.14 mm at 40°C, Figure 4.13, B) (see Table 
1.5, Appendix 2).  The difference between the mean thickness of the 4 separate samples 
of tablets stored at 75% RH and all temperatures (5, 15, 25 and 40 °C) for each week, 
between 1 to 16 weeks, were not found to be significant (p > 0.05, one-way ANOVA) 
(see Table 1.5, Appendix 2).   
 
Figure 4.13 (A) demonstrates that there was a change in the mean thickness of tablets at 
all temperatures (5, 15, 25 and 40°C) when stored at 75% RH over 16 weeks, with the 
increase in the mean thickness occurring within the first two weeks for all temperatures.  
For the tablets stored at 5, 15 and 25°C at 75% RH after the initial increase in the mean 
thickness in the first two weeks, there appears to be a very slight decrease in the thickness 
between 2 to 16 weeks.  For the tablets stored at 40°C, the increase in thickness was most 
marked in the first two weeks and continued to week 12 were it appeared to stabilise.  
The mean thickness of the tablets at 16 weeks at all temperatures and stored at 75% RH 
had increased when compared with the mean thickness at the start of the exposure (Figure 
4.13, A).   
 
At week 16 there was significant increase in the mean thickness of the separate samples 
of tablets stored at 75% RH and 5 and 25°C (p < 0.05, one-way ANOVA) when 
compared with the mean thickness of the tablets in the separate samples stored at 33% 
RH and similar temperatures (Figure 4.14).  There  was  also  significant  increase  in  the 
mean thickness of the tablets stored at 40°C at 75% RH when compared with the mean 
thickness of the tablets stored at 35°C at 33% RH (p = 0.003, one-way ANOVA) (Figure 
4.14).  However, there was no significant difference between the mean thickness of 
tablets stored at 15°C at 33 and 75% RH (p = 0.478, one-way ANOVA).  The greatest 
increase in the mean thickness of the tablets stored at 75% RH when compared with 
tablets stored at 33% RH occurred at 5 and 40°C (an increase of 0.10 mm for both 
temperatures) (Figure 4.14, see Table 1.5, Appendix 2). 
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Figure 4.14  Mean thickness (mm) of ‘ecstasy’ tablets exposed to 5, 15, 25 and 35°C 
and 33% RH and at 5, 15, 25 and 40°C and 75% RH at week 16  (Error bars 
represent the SD of each mean). 
 
There was no significant difference between the mean thickness of the total tablets (n = 
40) stored at RH of 33% during the study period (F(10, 429) = 0.473, p = 0.908, one-way 
ANOVA) (see Table 1.6, Appendix 2).  However, there was significant increase in the 
mean thickness of the total tablets (n = 40) that were stored at 75% RH for weeks from 1 
to 16 when compared to week 0 (F (10, 429) = 9.484, p <0.001, one-way ANOVA).  
Moreover, there was no significant difference between the mean thickness of the total 
tablets (n = 40) that were stored at 75% RH and all temperatures (5, 15, 25 and 40°C) 
between 1 to 16 weeks (p > 0.05, one-way ANOVA).   
 
A Tukey post-hoc test revealed that after 1 week the mean thickness of tablets stored at 
75% RH had significantly increased (4.46 mm SD 0.08, p < 0.001, one-way ANOVA) 
and remained so even after 16 weeks (4.50 mm SD 0.07, p < 0.001, one-way ANOVA) 
when compared to the tablets thickness at week 0 (4.39 mm SD 0.07) (see Table 1.6, 
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two-sided test (95% CI and 99% coverage) changed from 4.39 mm (SD 0.21) for week 0 
to 4.50 mm (SD 0.22) at week 10 and to 4.50 mm (SD 0.21) at week 16 for the tablets 
stored at 75% RH (Figure 4.15).   
 
There was significant increase (p < 0.05, one-way ANOVA) for each week (between 
week 1 to 16) in the mean thickness of all the tablets in the 4 samples (n = 40) stored at 
75% RH when compared with the mean thickness of all tablets (n = 40) stored at 33% 
RH (Figure 4.15, see Table 1.6, Appendix 2), when RH was considered as the sole 





















Figure 4.15  Mean thickness (mm) of total ‘ecstasy’ tablets (n = 40, 10 tablets in each 
of the 4 samples) exposed to 33% RH and mean thickness of total ‘ecstasy’ tablets (n 






At the start of the experiment (week 0) there was no difference (F(3,36) = 0.389, p = 
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at 33% RH and separate temperatures (5, 15, 25 and 35°C).  There was no significant 
change in the mean volume (p > 0.05, one-way ANOVA) of the 4 separate samples of 
tablets when stored at 33% RH and at temperatures of 5, 15, 25 and 35°C after 16 weeks 
when compared to the mean volume of the separate samples at the start of the experiment 
(week 0) (Figure 4.16).  The difference between the mean volume of the 4 separate 
samples of tablets stored at 33% RH and all temperatures (5, 15, 25 and 35°C) for each 
week, was not significant (p > 0.05, one-way ANOVA and Welch test) (see Table 1.7, 
Appendix 2).   
 
From the Figure 4.16 (A), it could be concluded that at week 1 there was a slight decrease 
in the mean volume of tablets at 5°C and a decrease in the mean volume of tablets stored 
at 33% RH and 35°C.  However, at weeks 2 and 3 respectively the mean volume of 
tablets at 5 and 35°C was again similar to week 0 where it stabilised to week 16.  There 
was an initial increase in the mean volume of the tablets at 15°C and 33% RH after week 
2 and then stabilising to week 16.  For the tablets at 25°C stored at 33% RH there was 
little change in the mean volume over 16 weeks (Figure 4.16, A).  
 
At the start of the experiment (week 0) there was no difference (F(3,36) = 0.287, p = 
0.835, one-way ANOVA) between the mean volume of the tablets in the 4 samples which 
were then stored at 75% RH and separate temperatures (5, 15, 25 and 40°C). There was a 
significant increase in the mean volume (p > 0.05, one-way ANOVA) of the 4 separate 
samples of tablets when stored at 75% RH and all temperatures (5, 15, 25 and 40°C) after 
16 weeks when compared with the mean volume of the separate samples at the start of 
the experiment (week 0) (Figure 4.17, see Table 1.7, Appendix 2).  The increase in mean 
volume was most prominent in the samples of tablets stored at 75% RH and at 40 and 
15°C (increase of 13.1 mm3 at 40°C and 11.9 mm3 at 15°C, Figure 4.17, B).  The 
difference between the mean volume of the 4 separate samples of tablets stored at 75% 
RH and all temperatures (5, 15, 25 and 40 °C) for each week, between 1 to 16 weeks, was 
found to be significant (p < 0.05, one-way ANOVA) for weeks 1, 5, 12 to 16 and not 













































Week 0 Week 16  
 
Figure  4.16  A: Mean volume (mm3) of ‘ecstasy’ tablets exposed to 5, 15, 25 and 
35°C and 33% RH between 0 and 16 weeks (Errors bars overlap). B: Comparison of 



















































Week 0 Week 16  
 
Figure  4.17  A: Mean volume (mm3) of ‘ecstasy’ tablets exposed to 5, 15, 25 and 
40°C and 75% RH between 0 and 16 weeks (Errors bars overlap). B: Comparison of 




When looking at Figure 4.17 (A) it could be concluded that there was a change in the 
mean volume at all temperatures (5, 15, 25 and 40°C) when stored at 75% RH over 16 
weeks.  The increase in the mean volume for the tablets at 5, 15 and 25°C occurred at 
week 1, and for tablets at 40°C occurred at week 3 and went on until week 12 (Figure 
4.17, A).  For the tablets stored 15°C at 75% RH after the initial increase in the mean 
volume at week 1 stabilised to week 16.  The mean volume of the tablets at 16 weeks at 
all temperatures at 75% RH had significantly increased (p ≤ 0.004, one way ANOVA) 
when compared to the mean volume at the start of the exposure (Figure 4.17, A).   
 
At week 16 there was significant increase in the mean volume of the separate samples of 
tablets stored at 75% RH and 5, 15 and 25°C (p < 0.05, one-way ANOVA) when 
compared with the mean volume of tablets in the separate samples stored at 33% RH and 
















Figure  4.18  Mean volume (mm3) of ‘ecstasy’ tablets exposed to 5, 15, 25 and 35°C 
and 33% RH and at 5, 15, 25 and 40°C and 75% RH at week 16  (Error bars 
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volume of the tablets stored at 40°C at 75% RH when compared with the mean volume of 
the tablets stored at 35°C at 33% RH (p < 0.05, one-way ANOVA).  The greatest increase 
in the mean volume of tablets stored at 75% RH when compared with tablets stored at 
33% RH occurred with the tablets at 40 and 15°C (an increase of 10.4 mm3 at 40°C and 
8.3 mm3 at 15°C, Figure 4.18, see Table 1.7, Appendix 2).   
 
If only the RH is considered the mean volume of the total tablets (n = 40) stored at 33% 
RH had a relatively marked increase in the volume after week 3 and remained rather 
constant thereafter.  There was no difference in the mean volume of all tablets (n = 40) 
stored at 33% RH when compared for each week, from week 0 to 16 (F (10, 428) = 
















Figure 4.19 Mean volume (mm3) of total ‘ecstasy’ tablets (n = 40, 10 tablets in each 
of the 4 samples) exposed to 33% RH and mean volume of total ‘ecstasy’ tablets (n = 




The mean volume of all the tablets (n = 40) that were stored at 75% RH had significantly 
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429) = 14.67, p < 0.001, one-way ANOVA) when RH was considered as the sole 
parameter.  A Tukey post-hoc test indicated that the mean volume of all the tablets (n = 
40) stored at RH of 75% after 1 week had significantly swelled (238.7 mm3 SD 6.12, p < 
0.001, one-way ANOVA) when compared with week 0 (231.4 mm3 SD 0.03) and that 
there was further significant increase in the volume to week 16 (241.9 mm SD 5.32, p < 
0.001, one-way ANOVA).  (Figure 4.19, see Table 1.8, Appendix 2).   
 
There was significant increase (p < 0.05, one-way ANOVA) for each week (between 
week 1 to 16) in the mean volume of all the tablets in the 4 samples (n = 40) stored at 
75% RH when compared with the mean volume of all tablets (n = 40) stored at 33% RH 
(Figure 4.19, see Table 1.8, Appendix 2) if only the RH is considered.  Moreover, there 
was an increase of 0.34% in the mean volume of the total tablets stored at 33% RH after 
16 weeks, and an increase of 4.54% in the mean volume of the total tablets stored at RH 




There was no significant change (p > 0.05, one-way ANOVA) in the hardness of tablets 
stored at 33% RH and temperatures 5, 15 and 35°C respectively with the exception  of  
tablets  stored  at  25°C  (p = 0.04,  one-way  ANOVA) after 16 weeks when compared to 
week 0 (see Table 1.9, Appendix 2).  Also, there was significant decrease (p < 0.001, 
one-way ANOVA) in the hardness of tablets that was stored at 75% RH and temperatures 
of 5, 15, 25 and 40°C respectively after 16 weeks when compared with week 0 (mean of 
47 N at week 0 and means ranging between 37.46 N to < 20 N after 16 weeks) (see Table 




Although the friability tests for the samples of tablets at week 16 could not be calculated 
because there was not enough tablets in each sample to carry out the test, it was noted 
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that the tablets stored at 75% RH and temperatures of 5, 15, 25 and 40°C were more 













Figure 4.20 Friability of one of the tablets at 40°C and at 75% RH after 16 weeks. 
 
 
Stability testing: key findings 
 
Mass 
• Significant decrease in the mean mass of tablets stored at 33% RH and 
35°C; 
• Regardless of temperature the tablets stored at 75% RH gained 
significantly more mass on week by week bases compared to those stored 
at 33% RH; 
Diameter 
• Significant increase in the mean diameter of tablets stored at 33% RH and 
5°C over 16 weeks; 
• Significant increase in the mean diameter of tablets in all samples stored at 
75% RH between week 0 an16 regardless of temperature; 
• Mean diameter increased most in samples of tablets stored at 75% RH and 
15 and 40°C; 
• Mean diameter increased more significantly in samples of tablets stored at 
75% RH and 15 and 40°C when compared to 33% RH; 
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Thickness 
• Significant increase in the mean thickness of tablets in all samples stored 
at 75% RH between week 0 and 16 regardless of temperature; 
• Mean thickness increased most in samples of tablets stored at 75% RH and 
15 and 40°C; 
• Significant increase in the mean thickness of samples of tablets stored at 
75% RH at 5, 25 and 40°C when compared to 33% RH, not at 15°C; 
• Mean thickness increased more significantly in samples of tablets stored at 
75% RH and 5 and 40°C when compared to 33% RH; 
Volumes 
• Significant increase in the mean volume of tablets in all samples stored at 
75% RH between week 0 and 16 regardless of temperature; 
• Mean volume increased most in samples of tablets stored at 75% RH and 
15 and 40°C; 
• Regardless of temperature the tablets stored at 75% RH gained 
significantly more volume on week 16 when compared to those stored at 
33% RH; 
• Mean volume increased more significantly in samples of tablets stored at 
75% RH and 40°C when compared to 33% RH and 35°C; 
Hardness 
• Significant decrease in the mean hardness of tablets in all samples stored 
at 75% RH at week 16 when compared to week 0 regardless of 
temperature; 
• Mean hardness decreased most in samples of tablets stored at 75% RH and 
40°C. 
 
4.4.4 Comparison between the ‘accelerated storage’ study and the ‘stability’ study  
 
The changes occurring  in tablets from batches 5, 8 and 11 after 90 and 180 days were 
compared with changes occurring after 13 weeks (91 days) and 16 weeks (112 days) in 
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tablets stored at 33 and 75% RH at 35 and 40°C.  The tablets from batch 14 were 
excluded because after 90 days the tablets were very friable. 
 
 Tablets mass 
 
There was significant decrease (p = 0.013, one-way ANOVA) in the mean mass of tablets 
from batch 33 after 13 weeks when compared with week 0.  There was no further 
decrease in the mean mass of tablets from batch 33, 3 weeks later (total 16 weeks) when 
compared with week 13 (Figure 4.21, see Table 1.10, Appendix 2).  However there was 
no significant change (p > 0.05, one-way, ANOVA) in the mean mass of tablets from 
batches 5, 8, 11 and 33 and control tablets, stored at 75% RH and 40°C at the end of the 
experiments.  The decrease in the mean mass for tablets from batches 5, 8 and 33 stored 
at 75% RH and 40°C after 180 days / 6 weeks ranged between 1.67 mg for batch 8 and 




Figure 4.21 Mean mass (mg) of tablets at days 1, 90 and 180 for tablets from batches 
5, 8 and 11 stored at 75% RH at 40°C and at weeks 0, 13 and 16 for tablets from 
batch 33 stored at 33 and 75% RH at 35 and 40°C (Error bars represent the SD of 
each mean). 
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 Tablets diameter 
 
 
There was significant increase (p < 0.001, one-way ANOVA) in the mean diameter of 
tablets from batches 5, 8, 11 and 33 which were stored at 75% RH and 40°C after 90 days 
(batches 5, 8 and 11) and 13 weeks (batch 13) respectively (see Table 4.11, Appendix 2).  
The increase in the mean diameter of the tablets from batches 5, 8 and 11 was again 
significant (p ≤ 0.001, one-way ANOVA) after another 90 days (total 180 days) (Figure 
4.22, see Table 1.11, Appendix 2).  There was no change in the mean diameter of tablets 
from batch 33, stored at 75% RH and 40°C, after another 3 weeks (total 16 weeks).  The 
increase in the mean diameter of the tablets from the batches 5, 8 and 11 after 180 days 
and the tablets from batch 33 after 16 weeks, stored at 75% RH and 40°C, ranged 




Figure  4.22  Mean diameter (mm) at days 1, 90 and 180 for tablets from batches 5, 
8 and 11 stored at 75% RH at 40°C and at weeks 0, 13 and 16 for tablets from batch 




There was no significant change (p > 0.05, one-way ANOVA) in the mean diameter of 
tablets from batch 33 stored at 33% RH and 35°C after 16 weeks and the control tablets 
after 180 days (Figure 4.22, see Table 1.11, Appendix 2). 
 
 Tablets thickness 
 
There was significant increase (p ≤ 0.345, one-way ANOVA) in the mean thickness of 
tablets from batches 5, 8, 11 and 33 which were stored at 75% RH and 40°C after 90 days 
(batches 5, 8 and 11) and 13 weeks (batch 13) respectively.  The increase in the mean 
thickness of the tablets from batches 5, 8 and 11 was again significant (p ≤ 0.148, one-
way ANOVA) after another 90 days (total 180 days) (Figure 4.23, see Table 1.12, 
Appendix 2).  There was no significant change (p > 0.05, one-way, ANOVA) in the mean 




Figure 4.23  Mean thickness (mm) at days 1, 90 and 180 for tablets from batches 5, 8 
and 11 stored at 75% RH at 40°C and at weeks 0, 13 and 16 for tablets from batch 
33 stored at 33 and 75% RH at 35 and 40°C (Error bars represent the SD of each 
mean). 
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(total 16  weeks).  The increase in the mean thickness of the tablets from the batches 5, 8 
and 11 after 180 days and the tablets from batch 33 after 16 weeks, stored  at 75% RH 
and 40°C, ranged between 17.20% for the tablets from batch 5 to 3.20% for tablets from 
batch 33. There was no significant change (p > 0.05, one-way ANOVA) in the mean 
thickness of tablets from batch 33 stored at 33% RH and 35°C after 16 weeks and the 
control tablets after 180 days (Figure 4.23, see Table 1.12, Appendix 2). 
 
 Tablets volume 
 
There was significant increase (p ≤ 0.009, one-way ANOVA) in the mean volume after 
90 days for the tablets from batches 5, 8, 11 and 13 weeks for the tablets from batch 33 




Figure 4.24  Mean volume (mm3) at days 1, 90 and 180 for tablets from batches 5, 8 
and 11 stored at 75% RH at 40°C and at weeks 0, 13 and 16 for tablets from batch 
33 stored at 33 and 75% RH at 35 and 40°C (Error bars represent the SD of each 
mean). 
from batches 5, 8 and 11 was again significant (p ≤ 0.013, one-way ANOVA) after 
another 90 days (total 180 days) (Figure 4.24, see Table 4.12, Appendix 2).  There was 
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no significant change (p > 0.05, one-way ANOVA) in the mean volume of tablets from 
batch 33, stored at 75% RH and 40°C, after another 3 weeks (total 16 weeks).  The 
increase in the mean volume of the tablets from the batches 5, 8 and 11 after 180 days 
and the tablets from batch 33 after 16 weeks, stored  at 75% RH and 40°C, ranged 
between 26.12% for the  tablets  from  batch  5  to  5.67%  for tablets from batch 11.  
There was no significant change (p > 0.05, one-way ANOVA) in the mean volume of 
tablets from batch 33 stored at 33% RH and 35°C after 16 weeks and the control tablets 
after 180 days (Figure 4.24, see Table 4.12, Appendix 2). 
 
  Hardness 
 
The hardness was very low (< 20 N) for the tablets from batches 5 and 8 after 180 days 
and for the tablets from batch 33 after 16 weeks, stored at 75% RH and 40°C.  The 
hardness was greater than 40 N for the tablets from batch 11 and control tablets stored at 
75% RH and 40°C after 180 days and for the tablets from batch 33 stored at 33% RH and 




The main aim of these experiments was to establish the ideal storage conditions for 
‘ecstasy’ tablets.  The determination of the right storage conditions would help forensic 
laboratories to properly store and preserve the physical features of ‘ecstasy’ tablets for 
the eventual use of these features to link or differentiate batches for court, investigative 
and intelligence purposes. 
 
4.5.1 Experiment A: Photostability stress testing on batches 5, 8, 11 and 14 
 
The surface colours of the four samples of tablets were found to have changed at the end 
of the photostability stress testing experiment when compared to control tablets.  Colour 
testing using a spectrocolourimeter revealed a very slight discolouration (ΔE* = 0.42) of 
the white tablets with the euro logo (batch 11).  The same colour tests indicated a very 
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slight (ΔE* = 0.42) to ΔE* = 0.54) colour change in the blue and green tablets (batches 5 
and 8 respectively).  The change in the colour of the orange tablets with pisces logo 
(batch 14), which could be seen by the naked eye, was very obvious (ΔE = 5.06).  The 
human eye can perceive a colour change of ΔE > 1.5 [230].  
 
The photostability stress testing experiment have shown that the colour of ‘ecstasy’ 
tablets can change if tablets are left exposed to visible and UV light for long periods of 
time (e.g. this experiment ≈ 39 days - adopted ICH method).  If colour is used as one of 
the physical features to link batches of ‘ecstasy’ tablets a significant change in the colour 
would be necessary, as happened with the orange tablets from batch 14, in order for this 
to be observed by the naked eye.  This experiment has also shown that to preserve the 
colour the tablets should be protected from visible and UV light.  Thus if the colour of 
tablets is to be used for forensic drug intelligence the tablets should be stored in light-
resistant containers.  
 
Colour and colour variance are basic features of many ‘ecstasy’ tables that together with 
other characteristics, such as shape, mass, diameter and thickness could be used to 
differentiate or link batches of tablets for intelligence purposes.  Colour has often been 
discarded as a discriminating feature as it is claimed that it is not reliable and it is highly 
dependent on the operator [181].  The visual observation of colour is subjective and lack 
precision [230, 256].  In this study the lack in exactness and objectivity in colour 
assessment was addressed by reflectance spectroscopy using a portable 
spectrocolourimeter together with the CIELAB colour system to get an exact numerical 
specification of the human colour vision [230, 256].  Colour vision, which is 
trichromatic, is calculated by the CIEL*a* and b* (CIELAB) colour space values.  Each 
colour has a unique location in three dimensional space as defined by its Cartesian 
coordinates which are the L* (brightness axis), a* (red-green axis) and b* (yellow-blue 
axis).  Spectrophotometric techniques together with CIELAB colour values have already 
been described in the literature, and have been used during stability testing of 
pharmaceutical products [256] and in the field of food and dyes industry [256].  
However, as far as is known, there has never been any study on the application of 
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instrumental evaluation of colour of ‘ecstasy’ tablets using the CIELAB colour system 
for intelligence purposes. 
 
The photostability experiment has shown that the use of a portable spectrocolourimeter 
together with CIELAB colour system was a quick, simple and good method that could be 
used to differentiate or link batches of ‘ecstasy’ tablets by their colour, including white 
tablets.  Using this method it was possible to differentiate between the four batches (5, 8, 
11 and 14) of ‘ecstasy’ tablets used as controls and also to differentiate between the 
tablets from the same batch at the end of experiment, that is between the control and 
exposed tablets.  The results obtained from the experiment were very promising for 
differentiating between batches of ‘ecstasy’ tablets, and it would be worthwhile that 
further experiments be performed.   
 
If this method is to be used for drug forensic purposes a sample of about ten ‘ecstasy’ 
tablets would be needed.  The colour of the tablets, which should always be taken at 
random from the batch, would be measured by a portable spectrocolourimeter using the 
L*, a* and b* values.  Batches of ‘ecstasy’ tablets having similar colour could be 
differentiated or linked using one-way ANOVA for the L*, a* and b* values.   However 
the L*, a* and b* values are instrument dependent and thus the CIELAB values could 
only be compared when measurements are conducted with similar or correlated 
instruments [256].  
 
4.5.2 Accelerated and stability experiments on batches 5, 8, 11, 14 and 33 
 
When ‘ecstasy’ tablets were subjected to varying conditions of RHs and temperatures the 
main discriminative measurable features, mass, diameter and thickness were found to be 
affected. Other calculated and measured features such as the volume, hardness, friability 
and disintegration were also found to be affected. 
 
4.5.2.1 Experiment B: Accelerated storage testing on batches 5, 8, 11 and 14   
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The high RH (75%) and temperature of 40°C that were used during the accelerated 
storage experiment did not seem to have had any significant effect (p > 0.05, one-way 
ANOVA) on the mean mass of tablets from batches 5, 8 and 11, after 180 days.  
However, the mean mass of the sample of tablets from batch 14 had significantly 
decreased (p = 0.013, one-way ANOVA) after 90 days from the start of the experiment.  
The decrease in the mean mass of the tablets from batch 14 was probably caused by a 
high increase in the friability.  The physical properties of the tablets during storage at 
constant RH and temperature are dependent on the equilibrium moisture content (EMC).  
The EMC is the amount of moisture which a tablet contains when it reaches equilibrium 
with the surrounding environment [257].  When the RH is high, such as was the RH 
(75%) used in the accelerated storage experiment, the tablets would reach the critical 
moisture content (CMC), which is the moisture at which the physical features, such as the 
friability and hardness, would start to deteriorate.  Thus if the increase in friability of the 
tablets from batch 14 had occurred during the clandestine storage, the tablets would not 
have withstanded the rough handling and transportation during trafficking. 
 
The diameter and thickness, considered the most reliable features for intelligence 
purposes, of the ‘ecstasy’ tablets used in the experiment had increased significantly (p < 
0.05, one-way ANOVA) when subjected to 75% RH and 40°C after 180 days.  The 
increase in the diameter and thickness caused a significant increase in the volume (p ≤ 
0.013, one-way ANOVA) and the tablets to swell.  The other three physical features, the 
hardness, friability and disintegration, were also affected by the accelerated storage 
conditions.  After 180 days the hardness of the tablets from batches 5 and 8 could not be 
measured because the tablets were very friable, the tablets from batch 14 had 
disintegrated, and the hardness of the tablets from batch 11 had significantly decreased (p 
< 0.001, one-way ANOVA).  Moreover, with the exception for the tablets from batch 11 
the friability of the tablets from batches 5 and 8 had increased while the disintegration 
had decreased after 180 days.  This indicated that the RH and the temperature used in the 
accelerated storage testing had adversely affected the measurable features of the tablets.  
The changes noticed with the ‘ecstasy’ tablets have also been noticed with 
pharmaceutical tablets prepared in the laboratory when these were stored at high RH 
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(75%) and room temperature [258].  Moreover, similar to ‘ecstasy’ tablets extensive 
volume expansion was also observed when laboratory prepared pharmaceutical tablets 
were exposed to 75% RH [258].  The extensive changes noticed in the examined 
‘ecstasy’ tablets, also noticed with pharmaceutical tablets when stored at 75% RH, occur 
when the tablets reach the CMC deteriorating in the process the physical features such as 
friability and hardness [254].   
 
4.5.2.2. Experiment C: Stability testing: varying conditions of RHs and 
temperatures 
 
At the start of the experiment it was noted that the mass of the individual tablets, used for 
the 8 samples for the stability experiment, varied from the mean of 274 mg by - 4.40 to + 
4.00%.  The tablets prior to the experiment were kept in an air conditioned room at 25% 
RH and a temperature of 25 + 2°C.  From the individual tablet mass measurements it 
transpired that two sample populations were present within batch 33 containing tablets 
with the versace logo (Figure 4.3 above).  There are several possible explanations for this 
observation.  Studies to investigate the mass variation of pharmaceutical tablets produced 
by single punch tabletting machines, also used for ‘ecstasy’ tablets production [137], 
have attributed the variation in the mass to the non uniform filling of the dies.  Moreover, 
mass variation could also be caused by the use of old punches and dies and by the 
multiplicity of punches and dies used during tablet production by multiple-station 
tabletting machines, which are also used for ‘ecstasy’ tablet production [259].  Studies 
conducted on pharmaceutical standard tablets have shown that if one of the lower 
punches or both upper and lower punches are short by 0.05 mm the tablet will be about 
0.4 % overweight [259].  Since the RSDs of the diameter and thickness of the examined 
‘ecstasy’ tablets were very low (0.24 and 1.59% respectively) it could be postulated that 
tablets with a mean mass of 268 mg, might have been produced together with the 
overweight tablets, mean mass of 280 mg, on the same tabletting machine. 
 
There  was  no  statistical  difference  in the mean mass of each sample of tablets stored at  
33 and 75% RH and all temperatures, with the exception of the sample stored at 33% RH 
and 35°C, at the first and second week when compared with week 0. Nevertheless, it was 
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noticed that during the first week the mean mass of the tablets in three out of the four 
samples stored at 33% RH and 5, 25 and 35°C had decreased, while the mean mass of the 
tablets in the four samples stored at 75% RH regardless of temperature had increased.  
Moreover, it transpired that after 1 week the greatest decrease in the mean mass occurred 
when the tablets were stored at 33% RH and 35°C (decrease of 7.3 mg), while the 
greatest increase in the mean mass occurred when the tablets were stored at 75% RH and 
15°C (increase of 4.2 mg) .   These observed results were similar to results obtained in a 
study conducted on pharmaceutical tablets in blister packs where the mass of tablets had 
increased (≈ 2 mg at 75% RH and 21 - 22°C, Amidon and Middleton (1998)) [260].  It 
was reported that when tablets were exposed to humidities greater than 60% the mass 
tended to increase, but decreased when exposed to lower humidities (≈ 3.5 mg at 25% 
RH and 21 - 22°C; this study decrease of 2.5 mg at 33% RH and 25°C ) [260].  Amidon 
and Middleton [260] did not statistically evaluate the increase and decrease in mass of 
tablets.  However, after 16 weeks there was no statistical difference in the mean mass of 
‘ecstasy’ tablets in seven out of the eight separate samples stored at 33 and 75% RH, 
regardless of temperature, when compared to week 0.  The only exception was the sample 
of tablets stored at 33% RH at 35°C where after 16 weeks the mean mass had statistically 
decreased when compared with week 0. 
 
The mean diameter of tablets significantly increased at 33% RH and 5°C, but otherwise 
the mean diameter and thickness of the tablets remained unaffected after 16 weeks, 
regardless of temperature.  However, the mean diameter and thickness of the tablets 
stored at 75% RH were significantly increased over 16 weeks regardless of temperature 
when compared to tablets stored at 33% RH.  This finding confirmed the results of the 
accelerated storage experiment where the mean diameter and thickness of tablets stored at 
75% RH and at 40°C had increased after 90 and 180 days respectively.  Moreover, on 
week 16 there was no statistical significant difference between the mean thickness of the 
tablets in the 4 separate samples stored at 75% RH and all temperatures but there was 
statistical difference between the mean diameters of the tablets.   
Considering only the RH both the mean diameter and mean thickness of the total tablets 
in the 4 samples stored at 75% RH had increased after 16 weeks (mean diameter 
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increased from 8.19 to 8.27 mm, an increase of 0.98%, and the mean thickness increased 
from 4.39 to 4.50 mm, an increase of 2.51%).  Again considering only the RH there was 
no significant difference (p > 0.05, one-way ANOVA) at week 0 in the mean diameter of 
the total tablets in the 4 samples stored at 75% RH when compared with the mean 
diameter of the total tablets in the 4 samples stored at 33% RH.  However, there was a 
significant increase (p < 0.05, one-way ANOVA) in the mean diameter of the total tablets 
stored at 75% RH when compared with the mean diameter of the total tablets stored at 
33% RH for all weeks 1 to 16.  Moreover, when considering only the RH there was no 
significant difference (p > 0.05, one-way ANOVA) at week 0 in the mean thickness of 
the total tablets in the 4 samples stored at 75% RH when compared with the mean 
diameter of the total tablets in the 4 samples stored at 33% RH.  There was but a 
significant increase (p < 0.05, one-way ANOVA) in the mean thickness of the total 
tablets in the 4 samples stored at 75% RH when compared with the mean thickness for 
the total tablets in the 4 samples stored at 33% RH for all weeks 1 to 16.   
 
As far as it is known, this was the first study which investigated the stability of the 
measurable physical features of ‘ecstasy’ tablets at different RHs and temperatures.  
Changes in the measurable features of ‘ecstasy’ tablets caused by changes in the 
environmental conditions during storage of the tablets could affect the use of these 
features for forensic drug intelligence purposes.  The overall overview of the stability 
study was that at 75% RH there was a significant increase (p < 0.05, one-way ANOVA) 
in the mean diameter, thickness and volume of the tablets with duration of storage 
regardless of the temperature.  However, for the tablets at 75% RH the greatest increase 
in the mean diameter occurred at 15 and 40°C respectively.  The greatest increase for the 
mean thickness and volume occurred at 40 and 15°C respectively.  The effect of the 
increase in the volume of the tablets was that of swelling.  After 16 weeks the swelling of 
the tablets stored at 75% RH and all temperatures caused a statistical decrease in the 
hardness of the tablets.  The swelling of tablets observed at 75% RH was in line with 
other scientific studies on pharmaceutical tablets stored at fairly high to high RHs (65-
95%) [252, 258, 260] were the decrease in hardness was followed by increase in friability 
[261].  It has been suggested that the increased adsorption at high water vapour by tablets 
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can disturb the interparticulate bonds in the tablet thus decreasing the hardness and 
friability [258].  However, the adsorption of moisture by the tablet also depends on the 
excipients and the hardness of the tablet [261].  The harder the tablets the less moisture it 
absorbs [261].  The hardness of the ‘ecstasy’ tablets used in this study was relatively low 
(47.00 N mean hardness) at the start of the experiment, further explaining the reason for 
the significant decrease in the hardness of the tablets stored at 75% RH at all 
temperatures after 16 weeks.  
 
In stability studies in the literature the major importance is generally given to the effect of 
RH on the physical features of pharmaceutical tablets and the effect of temperature is not 
much discussed [253, 254, 258, 260, 261].  However, from the results of this stability 
experiment it transpired that the physical features of samples of ‘ecstasy’ tablets stored at 
75% RH and different temperatures were affected differently.  When comparing the 
results from the stability experiment of 4 samples of tablets stored at 75% RH but at 
different temperatures (5, 15, 25 and 40ºC) it was noted that the most significant changes 
in the physical features had occurred when the tablets were stored at a temperature of 
40ºC.  The mean hardness of the tablets stored at 75% RH and 40ºC had decreased much 
more markedly than the mean hardness for the samples stored at the same RH but lower 
temperatures (5, 15 and 25ºC) after 16 weeks.  Similar results were obtained by Ahmad 
and Shaikh (1994) where after 5 months the hardness of 5 samples of tablets, stored at 
75% RH, had decreased when the temperature of the samples was increased from 25 to 
45ºC (the decrease in hardness ranged between 0.52 to 39.13%) [254].   The significant 
changes in the physical features of tablets at 40ºC when compared to tablets stored at the 
other temperatures (5, 15 and 25ºC) and 75% RH was caused by the increased amount of 
water in the air at 40ºC [262].  The increase in the temperature at a particular RH 
increases the water in the air and as a result the tablets would take up water in a shorter 
time from the surrounding air [262] (absolute humidity at 75% RH - 40ºC is 36.0 g m-3 
compared with 14.9 g m-3 at 25ºC). 
 
4.5.3. Difference and changes in the measurable features of ‘ecstasy’ tablets 
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Tablets exposed to high RH (75%), during the accelerated storage and stability 
experiments, had a marked effect on the measurable features diameter, thickness, volume, 
hardness and friability of the tablets.  The high RH (75%) used in the two experiments 
was the main cause for the significant increase in the measurable features of the tablets 
when compared to tablets stored at 33% RH regardless of temperature.  If a hypothetical 
forensic case scenario is considered where two batches of ‘ecstasy’ tablets with similar 
visual features and stored under different environmental condition are seized, then the 
implications from the obtained results in these studies could be very important.  If these 
batches are seized on different occasions they might have different measurable features 
making it difficult to link the batches.  The batch stored at high RH (≥ 60%) might have 
reduced hardness, high friability or could even disintegrate as happened with batch 14 in 
the accelerated storage experiment.  This would make it very difficult or even impossible 
to measure the physical features of the tablets if these are needed for a court case or to be 
used for forensic drug intelligence purposes.       
 
It could be speculated that at the end of the accelerated storage and stability experiments 
the increase in diameter and thickness of the tablets stored at 75% RH corresponded to 
the EMC [262].   During the process the tablets had swelled causing a change in volume, 
a feature that was noticed with tablets from batches 5, 8, 11 and 33.  It could also be 
hypothesised that the lack of packing material for the ‘ecstasy’ tablets during the 
accelerated storage and stability experiments could have caused the tablets to reach the 
EMC more quickly thus causing the tablets to swell.  As for the tablets from batch 14, 
these had reached the CMC during the accelerated storage and disintegrated at about 170 
days   
 
Another reason for the significant change in the physical features of the tablets at high 
RH could have been due to the added excipients.   Lactose, which is the most widely used 
excipient in legal tablet formulations [205], was reported to be one of the most frequently 
used excipient in ‘ecstasy’ tablets [263].  Placebo tablets that were prepared by direct 
compression using lactose have been reported to swell considerably when stored at 85% 
RH and 37°C [253].  In this study the swelling of tablets was mostly noted when tablets 
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were stored at 75% RH regardless of temperature, where the significant increase in mean 
volume ranged between 5.67% (at 40°C) and 3.19% (at 25° C).  Moreover, there was no 
significant swelling for tablets stored at 33% RH.  The results obtained in this study for 
the increase in the mean volume of ‘ecstasy’ tablets stored at 75% RH were fairly similar 
to results reported by Sangekar et al. [253] for tablets with lactose excipient and starch 
disintegrant (0% for tablets at 25°C and 43% RH and an increase of 4.97 – 5.67% in 
volume for tablets at 25°C and 75% RH [253]).     
 
The hardness of a tablet provides a measure of the bonding potential of the materials 
concerned while the friability is a measure of the loss in mass of the tablets due to 
abrasion or when the tablets attain the CMC and starts to deteriorate.  The resistance of 
tablets to capping, abrasion or breakage under conditions of transportation and handling 
before usage depends on hardness [264], which is closely related to friability.  Also the 
moisture adsorptive capacity of a compressed tablet is generally considered to be 
dependent on the hardness, that is the harder the tablet the less moisture it absorbs [261].  
Both the friability and hardness are dependent on the RH of the environment which 
would affect both the rate and the amount of water uptake by the tablets during storage 
[265].  The interparticulate bonds in the tablets may be disrupted by the moisture [252] if 
the RH in the environment is high.  It could be speculated that the moisture absorption for 
the tablets from batches 5 and 8 after 180 days when stored at 75% RH and 40°C had 
affected the interparitculate bonds thus causing a high increase in the friability and a 
statistical significant decrease in the hardness of the tablets.  Similar changes were 
observed at 75% RH during the stability experiment where the friability had increased 
and hardness decreased for batch 33 (versace logo) regardless of temperature.   
 
The results have shown that the visible and UV light together with high RHs and 
temperatures, which could change the physical features of tablets, play an important role 
in the storage of ‘ecstasy’ tablets.  In cases of seizure of a number of similar or different 
batches of ‘ecstasy’ tablets it is normally assumed that the batches were stored under 
similar conditions of RH and temperatures.  Friability testing, which is quick and easy to 
perform, could be used to determine whether the tablets were stored under similar 
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conditions.  Friability is normally affected by the moisture content in the tablets [254].  
As the moisture increases, the interparticulate bonds start to be disrupted, thus increasing 
the porosity and decreasing the strength of the tablets causing the friability to increase 
[254].  Difference in the friability (> 0.5%) of batches of ‘ecstasy’ tablets having similar 
visual features but seized on different occasions could be an indication that the tablets 
were stored under dissimilar environmental conditions.  Different environmental 
conditions could cause changes in the measurable feature, such as mass, diameter, 
thickness, volume, hardness, friability and disintegration rates of similar batches of 
‘ecstasy’ tablets.  Thus, if the measurable features of ‘ecstasy’ tablets are to be used for 
forensic intelligence purposes to link batches seized on different occasions it would be 
helpful for officers to first measure the friability of the separate batches to make sure that 
the batches were not affected by dissimilar environmental conditions.  From the 
accelerated storage and stability experiments it was noted that the most significant 
changes in the physical features of ‘ecstasy’ tablets had occurred when the tablets were 
stored at 75% RH and 40°C when compared with samples stored at temperatures of 5, 15 
and 25°C. However, from the stability experiment it had also transpired that the least 
change in the measurable features had occurred when tablets were stored at 33% RH and 
at temperatures between 15 and 35°C.  Thus it is recommended that batches of ‘ecstasy’ 
tablets kept at different laboratories in order to ensure interlab comparability should be 
stored at low RH (≈ 25%) and temperature (≈ 25 °C) and away from sunlight if the 












OF ‘ECSTASY’ TABLETS 
 
The chemical characterisation of ‘ecstasy’ tablets can help link or differentiate between 
batches of tablets from different seizures irrespective of their physical features.  
Moreover, the impurities detected in MDMA tablets can serve to act as chemical markers 




The misuse of the amphetamine and amphetamine-type stimulants, such as MA and 
MDMA has been widely reported with these drugs being consumed worldwide.  Typical 
of the way in which the market for these substances has emerged and remained one step 
ahead of the authorities has been the manufacture of designer drugs derived from 
amphetamine. Over the years analogues of amphetamine, such as 4-
methoxyamphetamine and 4-methylthioamphetamine [266] have been identified in 
tablets used by clubbers have been linked to overdose and fatalities [267, 268].   
 
Ecstasy was the street name which was designated to MDMA, but since 2005 some of 
these tablets started to contain other new psychoactive substances [269].  In addition to 
the classic empathogens which became scheduled, to evade the law new designer drugs 
containing the piperazine moiety, such as the 1-aryl-piperazine compounds, known to be 
psychoactive in man [270] have been identified.  One such “family” of drugs, the 1-aryl-
piperazines (e.g. BZP drug), has been launched on the grey market by means of the 
internet in most European drug markets as new designer drugs [270].  
 
These  piperazine  derived  drugs were sold mainly as ‘ecstasy’ tablets but also in powder  
or liquid forms [271].  In some seizures of tablets presumed to be ecstasy no MDMA or 
psychoactive substances was detected [212].    
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However, ‘ecstasy’ production, which mainly consists of two stages (266) the synthesis 
of the psychoactive substance/s and (2) tabletting, may be carried out at different 
locations to avoid detection [269].  Thus it could be speculated that ‘ecstasy’ tablets with 
the same physical features could have different chemical characteristics.  Therefore in addition 
to physical characterisation of ‘ecstasy’ tablets, profiling of the chemical composition 
may be valuable for drug intelligence purposes to further differentiate or link batches 
from different seizures. 
 
The study to investigate the chemical characterisation of batches of ‘ecstasy’ tablet seized 
over a five year period (2006 – 2011) had several different experiments: 
 
Experiment A: The detection of psychoactive substances (if any) in ‘ecstasy’ tablets 
from 45 batches using routine colour, TLC, GC-MS and quantification 
of the active ingredients; the experiment also tested the hypothesis (2) 
that:  
 Seized ‘ecstasy’ tablets will contain MDMA as the predominant 
psychoactive substance. 
Experiment B: The specific identification and the percentage isomeric content of 
MDMA-only tablets; the experiment also tested the hypothesis (3) that:  
 The enantiomeric ratio of MDMA tablets will be 50:50 in llicit tablets. 
Experiment C: The organic impurity profiles of MDMA-only tablets; 
Experiment D: The determination of the major excipients of ‘ecstasy’ tablets using 
FTIR transmittance spectroscopy; 
Experiment E:  The elemental profiling of ‘ecstasy’ tablets using SEM/EDX analyses. 
 
These experiments also tested the hypothesis (4) that:  
 
The chemical composition of different batches of ‘ecstasy’ tablets seized on different 





In this study the same 45 batches of ‘ecstasy’ tablets used for the physical 
characterisation (Chapter 3) were used for chemical characterisation (Table 5.1).  
 
Table 5.1 The 45 batches of ‘ecstasy’ tablets that were used for the chemical 
characterisation experiments (Exp.) to determine (A) the psychoactive substances, 
(B) percentage isomeric content and (C) organic impurity profiles of MDMA-only 













A - E Tablet 
1 A  16 
A, D, 
E  31 
A, D, 
E  
2 A, E  17 A – E  32 
A, D, 
E  
3 A  18 A – E  33 A – E  
4 A, D, E  19 A – E  34 
A, D, 
E  
5 A – E 
 
20 A – E  35 
A, D, 
E  
6 A, D, E 21 A – E  36 
A, D, 
E  
7 A, D, E 22 A – E  
37 A, D, E  
8 A, E 
 
23 A – E  38 
A, D, 
E  
9 A, D, E 24 A – E  39 
A, D, 
E  
10 A, D, E 25 A – E  40 A – E  
11 A – E 
 
26 A – E  41 A – E  
12 A, D, E 27 A – E  42 
A, D, 
E  
13 A, D, E 28 A – E  43 
A, D, 
E  
14 A – E 
 
29 A – E  44 A – E  
15 A, D, E 30 
A, D, 
E  45 A – E  
5.2.1 Experiment A:  Detection and  quantification  of   psychoactive   substances   in  
                                    batches of tablets   
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5.2.1.1 Colour tests and TLC  
 
Colour tests of tablets from all batches were conducted on small amounts (~1-2 mg) of 
crushed ‘ecstasy’ tablets using Marquis, Simons’s, Chen’s and Scott’s Reagents [210], 
while TLC was done on samples taken from the remaining tablets samples as described in 
the methodology, Section 2.2.3.1, for colour tests and for TLC.  A negative control and 
positive controls of amphetamine, MDMA, MDA, BZP, mCPP, caffeine, 
methandrostenolone and cocaine were used during these analyses.  
 
Although when using the combination of colour tests and TLC it was possible to 
discriminate between MDMA and the other reference standards used (MDA, 
amphetamine, BZP, mCPP, caffeine and cocaine) due to the number of amphetamine 
type stimulants available, it was necessary to use GC-MS analyses to confirm the results. 
 
  5.2.1.2 Determination of the psychoactive substances in ‘ecstasy’ tablets 
 
The determination of the major active ingredients in ‘ecstasy’ tablets was based on the 
liquid extraction of samples of crushed tablets taken at random from the 45 batches (one 
tablet from each batch), followed by GC-MS analyses as described in the methodology 
Section 2.2.3.1.    
 
5.2.1.3 Quantification of active ingredients in ‘ecstasy’ tablets 
 
Quantification of all ‘ecstasy’ tablets containing only one active ingredient was carried 
out by UV spectrophotometry.  The wavelength of the principal peaks for each single 
active ingredient found in the tablets together with the corresponding absorptivity was 
noted.  The quantity of the drug in each tablet was calculated from a standard curve for 
the particular psychoactive substance.  
 
5.2.2  Experiment   B:   Specific  identification  and  percentage  isomeric  content  of  
                                        MDMA-only tablets  
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Samples from batches of tablets which gave positive results for MDMA (batches 5, 8, 11, 
14, 17-29, 33, 40, 41, 44 and 45) were derivatised using TFAA to confirm the presence of 
MDMA in the tablets.  The same derivatised samples were used to determine the 
enantiomeric composition of the MDMA in the tablets.  The samples were analysed by 
GC-MS using an Rt-βDEXcst-TM capillary column. The method was validated for the 
derivatised single enantiomer and racemic MDMA as described in Section 2.2.3.2.   
 
5.2.3 Experiment C:  Organic impurity profiling of MDMA-only tablets 
 
The organic impurity profiling analyses (Section 2.2.3.3), which were carried out on 
tablets from batches indicated in Section 5.2.2 (see Table 5.1 above), were conducted to 
determine the possible synthetic routes of MDMA in the tablets. The GC-MS profiles 
were treated like fingerprints to link / discriminate tablets taken from the different 
batches.  The profiling method, which was adapted from Gimeno et al. [121, 205], 
consisted of extraction of MDMA-only tablets using liquid-liquid extraction under basic 
conditions with subsequent GC-MS analyses. 
 
5.2.4 Experiment D: Determination of major excipients of ‘ecstasy’ tablets 
 
To determine the major excipients FTIR spectroscopy by transmission was used with the 
KBr disk technique (Section2.2.3.4).  The KBr disk spectra, which were also used for 
characterisation of the tablets, were recorded between 4000 and 500 cm-1, by averaging 
32 scans for each spectrum at a resolution of 4 cm-1.  The analyses were conducted on 
single tablets from batches 4-18, 21-23, 25, 26, 28, 29, 31-41, 44 and 45 (35 tablets), as 
indicated in Table 5.1 above 
 
5.2.5 Experiment E: Elemental profiling of ‘ecstasy’ tablets  
 
As described in Section 2.2.3.5 tablet samples were analysed using SEM/EDX, which is a  
‘surface’ technique with a penetration depth of about 2-5 μm, that allow the elemental 
characterisation of minor and major elements.  The SEM/EDX method was used for the 
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analyses of compounds containing elements with atomic number ≥ 11, other than carbon 
and oxygen, found on the surface of tablets at a concentration of at least 0.1% by weight.   
The signals used for capturing the image of the tablets were secondary electrons (SEI) 
and backscatter electrons – shadow.   
 
Analyses were conducted on a total of 37 individual tablets that were taken from the 
batches 2, 4-18, 21, 23, 24, 26-41, 44 and 45 (37 tablets) as described in Table 5.1 above.  
The tablets were each mounted on a SEM sample stub using double-sided carbon 
adhesive tape and coated with a thin carbon layer in a sputter coater (Emiscope, UK) in 
order to obtain a conductive surface.  The sample tablets were observed from the SEM, 
with elemental compositions being analyzed by EDX detector as described in Section 




5.3.1 Experiment A:  Detection  and  quantification  of  psychoactive   substances   in  
                                     batches of tablets   
 
5.3.1.1 Colour tests and TLC 
 
Tablets from batch 1 gave an orange → brown with Marquis reagent, indicative of 
amphetamine type substance and the tablets from batches 2 and 3 gave a blue colour with 
Simon’s reagent, indicative of secondary amines.  The tablets from batches 5-29, 33, 40, 
41, 44 and 45 gave a positive colourimetric tests results, giving a dark-blue black colour 
with Marquis reagent and a deep blue colour with Simon’s reagent. Tablets from batch 30 
gave an orange colour with Marquis reagent.   None of the tablets gave a colour change 
with the Scott’s and Chen’s reagents. Moreover the tablets from batches 4, 31, 32, 34-39, 
42 and 43 did not give any colour change with Marquis and Simon’s reagents (Table 5.2).     
 
The  TLC  tests  carried out on extracts from the tablets from batches 1, 5 - 16, 17-29, 33,  
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40, 41, 44 and 45 gave a blue spot with acidified iodoplatinate spray and an orange red 
spot with fast black K spray (tablets in batch 1 - Rf 0.87 + 0.01 and batches 5-16, 17-29, 
33,  40,  41, 44 and 45 - Rf 0.39 + 0.01) (Table 5.3).  The tablets from batches 2–4, 31, 32 
 
Table 5.2 The colour test results of ‘ecstasy’ tablets from the 45 batches and 
controls. 
 
Batches   Marquis Simon’s Scott’s Chen’s 
1 orange → brown NR NR NR 
2 and 3 NR blue NR NR 
5-29, 33, 40, 41, 44 and 45 dark blue-black deep blue NR NR 
30 orange NR NR NR 
4, 31-32, 34-39, 42 and 43 NR NR NR NR 
Controls  
Amphetamine orange → brown NR NR NR 
MDMA dark blue-black deep blue NR NR 
MDA dark blue-black NR NR NR 
BZP NR blue NR NR 
mCPP NR NR NR NR 
Caffeine NR NR NR NR 
Methandrostenolone orange NR NR NR 
Cocaine NR NR 
blue ppt., then 
pink, and  
pink over blue  
NR 
Negative NR NR NR NR 
 
Key: NR = no reaction 
 
34 - 39 gave a blue coloured spot with acidified iodoplatinate spray (tablets from batches 
2 and 3 - Rf 0.27; batches 4, 31 and 32 - Rf 0.29 and batches 34-39 - Rf 0.52 + 0.01) and 
no colour with fast black K spray.  Extracts from tablets from batches 30, 42 and 43 gave 
no colour spots with the used visualization sprays.  
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5.3.1.2 Organic profiling of ‘ecstasy’ tablets 
 
All the tablets were initially analysed by GC-MS for the compound MDMA.   Thirty 
batches (66.7%) (batches 5-29, 33, 40, 41, 44 and 45) were found to contain only MDMA 
(Figure 5.1).  The remaining batches (batches 1-4, 30- 32, 34-39, 42 and 43) were tested 
for other psychoactive substances including DPIA, BZP, mCPP and caffeine. 
 
Table 5.3 The TLC test results of ‘ecstasy’ tablets from the 45 batches and controls. 
 




iodoplatinate Fast Black K 
1 0.34 (0.01) blue orange red 
2 and 3 0.27 (0.01) blue NR 
4, 31 and 32 0.29 (0.01) blue NR 
5 - 29, 33, 40, 41, 44 and 45 0.39 (0.01) blue orange red 
34 – 39 0.52 (0.01) blue NR 
30, 42 and 43 / NR NR 
Controls 
Amphetamine 0.51 blue purple 
MDMA 0.39 blue orange red 
MDA 0.35 blue violet 
BZP 0.26 blue NR 
mCPP 0.30 blue NR 
Caffeine 0.53 blue NR 
Methandrostenolone / NR NR 
Cocaine 0.60 blue NR 
Negative / NR NR 
 
Key: SD – Standard deviation; NR - no reaction 
1Rf is the retardation factor 
 
The tablets from batch one were further analysed for the presence of amphetamine. 
Although with the GC-MS system used it was possible to obtain a molecular ion and 
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individual fragments for amphetamine, if the compound was present in very low 




























Figure 5.1 The top trace is the total ion chromatogram (TIC) of MDMA at retention 
time (Rt) of 9.05 min for a pink tablet from batch 44 (crocodile (lacoste) logo) and 
the lower trace is the EI mass spectrum of MDMA from the tablet (58 base peak 
with ions m/z 135, 77 and 136).  
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of non-derivatised amphetamine is dominated by fragment ions of low molecular weight 
which are not particularly characteristic.  Although the molecular ion is more 
characteristic, it is possible that if amphetamine was present in samples at very low 
concentration, the molecular ion would not be visible in the mass spectrum.  Hence to test 
for the presence of amphetamine, extracts from the tablets were initially derivatised using 
carbon disulphide (CS2) (Figure 5.2) and then analysed by GC-MS.  Derivatisation of 
amphetamine with CS2 not only produce a more characteristic mass spectrum but it also 













Figure 5.3 The mass spectrum of a tablet containing di(β-phenylisopropyl)amine 






increase the sensitivity of the analyses [239].  From the analyses no amphetamine was 
detected and only di-(β-phenylisopropyl)amine (DPIA) was detected  in the tablets 
(Figure 5.3).  Only batch one was found to contain tablets with the DPIA present.  
  
Batches 2 and 3 gave positive results for synthetic stimulant BZP (Figure 5.4) while 
batches 4, 31 and 32 gave all positive results to a chlorophenylpiperazine (CCP) 
compound. The identification of CPP based on mass spectrometry was unable to 
differentiate between its three isomers 1-(2-chlorophenyl)piperazine oCPP, 1-(3-
chlorophenyl)piperazine (mCPP) or 1-(4-chlorophenyl)piperazine (pCPP).  Thus the 




Figure 5.4 The mass spectrum of a tablet containing benzylpiperazine (BZP) 
showing peaks at (m/z) = 91 (base peak), 134, 56, 176, 65, 85. 
 
analyses of the tablets were carried out by  Professor Antonio Randazzo at the Faculty of 
Pharmacy, at the University “Federico II” of Naples. 
 
The 1H NMR spectra (Figure 5.5) do not show the exchangeable NH in MeOD given the 
amount of peaks in the region 3.5 – 4.0 ppm.  The NMR spectrum obtained for the 
 219 
aromatics excluded both the para-substitution, which is too characteristic, and the ortho-
substitution, which tends to give the 4 contiguous protons coupling together, while 
confirming the meta-substitution, which is characteristic and could be seen on the 
spectrum. The aromatic region (7-8 ppm) was characterized by the presence of two 
doublets at 6.89 (J = 8.1 and 1.9 Hz) and 6.93 ppm (J = 8.1 and 1.9 Hz), respectively, 
attributable to H4’ and H6’ protons.  The protons H4’ and H6’ each show the large 
coupling to proton H5’ to give doublets, that are further split by the long range coupling 
to H2’ proton.  Furthermore, the two triplets at 7.02 (J = 1.9 Hz) and 7.23 ppm (J = 8.1 
Hz), are attributed to H2’, which is essentially a singlet, and H5’ protons, which appears 

























Figure 5.5 1H NMR spectrum shows the presence of 1-(3-chlorophenyl)piperazine 
(mCPP), as the main and only active ingredient, from an extract of a portion of ≈ 2 
mg of one crushed tablet (batch 4) by 1 mL of deuterated methanol.  The mCPP is 
characterised by the presence of two doublets, attributable to H4’ and H6’ protons 
and coupling to H5’ and H2’ as indicated.  
 
protons.   Hence, the 1H NMR spectra confirmed the presence of mCPP molecule (Figure  
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5.6),  which  does  not  contain  an asymmetric carbon atom and thus has no stereoisomer.   
Moreover, the doublets at 5.08 and 4.34 ppm, along with other signals between 3 and 4 
ppm are consistent with the presence of sugars in the sample (Figure 5.5).  Hence the 
tablets from batch 4 contained only mCPP.  The presence of mCPP as the only active 




Figure 5.6 The mass spectrum of a tablet containing 1-(3-chlorophenyl)piperazine 
(mCPP) showing peaks at (m/z) = 154 (base peak), 196, 156, 138, 55, 111. 
 
 
The tablets from batch 30 were found to contain the anabolic steroid methandrostenolone 
as the only active ingredient (≈ Rt 14.83 min, the mass spectrum of this compound had a 
base peak of m/z 122 with ions at m/z 121, 91, 43, 161, 147), while tablets from batches 
34 - 39 were found to contain only caffeine (≈ Rt 10.72 min, the mass spectrum of this 
compound had a base peak of m/z 194 with ions at m/z 109, 67, 55, 82, 193).  The tablets 
from batches 42 and 43 contained no psychoactive substances. 
 
 
5.3.1.4 Content of psychoactive substance in ‘ecstasy’ tablets 
 
Table  5.4  shows  those  batches that contained only MDMA with the means for the mass  
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and content of MDMA, quantified by UV spectrophotometry. The mean content of the 
batches of the MDMA tablets was 52.6 mg (SD 14.75) and batch 22 had tablets with the 
highest content of MDMA (mean 81.3 mg of base, SD 2.96),  while batch 24 had tablets 
with the lowest content (mean 12.9 mg of base, SD 0.34). 
 
Table 5.4 Batches of ecstasy tablets containing MDMA as the only active ingredient 




















































7 240 (3.66) 
59.3 























9 236 (4.21) 
48.8 









10 236 (4.34) 
48.4 























12 202 (4.51) 
43.6 









13 200 (4.13) 
43.2 
























a MDMA is the base 
b Numbers in parentheses are the RSDs 
 
Although in Figure 5.7 it looks like the bigger the tablet the more MDMA it contains, the 
correlation between the mean “MDMA content” and mean “tablet mass” was found to be 
low (R2 = 0.2721) even when batches 26 and 24 were removed the correlation was still 




Figure 5.7 The correlation between the mean “MDMA content” and mean “tablet 
mass” for the batches of tablets which contained MDMA as their active ingredient 
(the brown spot is batch 23, the green is batch 26 and yellow batch 24). 
 
Table 5.5 ‘Ecstasy’ tablets containing psychoactive substances (P.S.) other than 




































































































a Numbers in parentheses are the RSDs. 
b No reference standard.  
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The twelve batches of ‘ecstasy’ tablets which contained the active ingredients BZP 
(batches 2 and 3), mCPP (batches 4, 31 and 32), methandrostenolone are (batch 30) and 
caffeine (batches 34-39) are presented in Table 5.5.  The mean content for the DPIA 
tablets could not be calculated because no control was available.  The two batches 





Figure 5.8 The correlation between the mean “active ingredient content” and mean 
“tablet mass” for the batches of tablets which contained BZP, mCPP and caffeine as 
their active ingredient (the black spot is the mean of control tablets bumetanide). 
 
 
Similar to Figure 5.7, it seems from Figure 5.8 that the bigger the tablet the more active 
ingredient the tablet contains, however, the correlation between the mean “active 
ingredient content” and mean “tablet mass” was found to be low (R2 = 0.4633). 
 
5.3.2 Experiment B: Specific identification and enantiomeric composition of MDMA   
                                    tablets  
  
In  order  to  investigate  the  isomeric  content  ratio  a  ingle tablet was selected from 22  
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batches known to contain MDMA.  The GC-MS method described in Section 2.2.3.2 was 
used to determine the enantiomeric ratio.  The mean for the S(+)-MDMA was 50.36%  
(SD  1.90%) and ranged between 46.96 – 52.95% and for the R(-)-MDMA the  mean was 
 
Table 5.6 MDMA tablets and control sample results listed as percentage (%) of S(+) 
and R(-)-MDMA enantiomers.  The isomeric content ratios of 22 MDMA tablets 

























omega 49.69 50.31 24  euro 51.91 48.09 
8 
 
omega 51.77 48.23 25 
 
star 50.69 49.31 
11 
 
euro 52.04 47.96 26 
 
smiley 52.22 47.78 
14 
 
pisces 49.49 50.51 27  
question 
mark 52.95 47.05 
17  euro 51.38 48.62 28  
heart 51.98 48.02 
18 
 
D&G 49.86 50.14 29 
 
D&G 50.76 49.24 
19 
 
heart 49.19 50.81 33 
 
versace 51.64 48.36 
20 
 
shark 47.76 52.24 40 
 
E=mc2 52.48 47.52 
21 
 
kangaroo 49.60 50.40 41 
 
route 66 50.31 49.69 
22 
 
letter X 46.96 53.04 44 
 




shaped 51.58 48.42 45  
lacoste 47.19 52.81 
Single MDMA enantiomers 1mg mL-1 52.09 47.91 
(+)-(R,S)-MDMA (Alltech) Control 1 mg mL-1 51.09 48.91 
 
Key: Batches 6, 7 and 9, 10 and 12, 13 and 15, 16 were from the same seizure as batches 5, 8, 11 and 14.  
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49.64% (SD 1.90%) and ranged between 47.05 - 53.49% (GC area peak %).  The 
enantiomeric ratio composition (S(+)-/R(-)-) for all the tablets was ~ 1 : 1.  The 
percentage for the S(+) and R(-) – MDMA of the analysed tablets are shown in Table 5.6.    
 
5.3.3 Experiment C: An investigation to determine  the  organic  impurity  profile  of  
                                   MDMA tablets 
  
The impurity profiles of 22 MDMA tablets, from different batches as indicated in Table 
5.1, were carried out using GC-MS (EI) analyses as described in Section 2.2.3.3. The 
chemical profiles of MDMA tablets in this study are taken to be the coextracted and 
manufacturing impurities, also known as impurity profiles.  Each MDMA tablet has a 
characteristic chemical pattern of impurities which is also known as a profile.  Typical 
total ion current chromatograms of extracted MDMA tablets are shown in Figure 5.9.   
 
The retention times and mass spectra peaks of the MDMA (only main active ingredient) 
and other compounds identified in the tablets are listed in Table 5.7 below.  The 
identification of compounds was based on the EI mass spectra published in literature or 
by National Institute of Standards and Technology (NIST) library PMW_TOXR.L.  
Thirteen different compounds that are known precursors or reaction intermediates for the 
MDMA synthesis were identified, these included piperonal, isosafrole, 3,4-MDP2P, 
DMMDA and N-formyl MDMA.  Not all the peaks could be identified because their 
corresponding mass spectra were not recorded in the literature. In this study the GC-MS 
impurity profiles were treated like fingerprints to link / discriminate the tablets from the 
different batches seized on different occasions. 
 
The most detected impurities in the analysed tablets were 3,4-MDP2P (86.4%, n = 19), 
followed by piperonal (72.7%, n = 16) and isosafrole, 3,4-MDP2-propanol and DMMDA 
which were all detected in 11 tablets (50%).  Other identified impurities were N-Formyl-
MDMA (36.4%, n = 8), MDA and 3-Methyl-6,7-methylenedioxy-3,4-dihydroisoquinolin-
1(2H)-one both detected in 6 tablets (27.3%),  N-Methyl-(1,2-methylenedioxy)-4-(1-ethyl-2-
aminopropyl)benzene (22.7%, n = 5) and safrole (18.2%, n = 4).  Three identified impurities 
not related to MDMA synthesis included palmitic and stearic acid and cocaine.  
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White tablets with heart logo – batch 28 
 
                                                              9 
 
 
                                                       7 
                                          3                                           12 
                                                    6                                   14 
 
 
Pink tablets with lacoste logo – batch 44 
 
                                                     7       9                                     16 
                                           3                                                15 
 
                                                   6              
                                                                       11 
                                                         8 
                                                                 
 
Pink tablets with lacoste logo – batch 45 
 
                                                      7       9                                    16 
                                                                                              15 
                                                    6                        
                                                                       11 
                                            3           8 
 
Figure 5.9 Three TIC of  illicitly  prepared  MDMA  and impurities. 3:  Piperonal; 
6:  3,4-MDP2P;  7: MDA (psychoactive substance);  8: 3,4-Methylenedioxy-phenyl-
2-propanol; 9: MDMA; 11: 3-Methyl-6,7-methylenedioxy-3,4-dihydroisoquinolin-
1(2H)-one; 12: N-Formyl MDMA, 14: N-Acetyl-MDMA, 15: Palmitic acid and 16: 
Stearic acid.  The operating conditions were in the EI mode as described in Chapter 




Table 5.7 The retention times (Rts) and the 5 major EI spectral data (first m/z is the 
base peak) of the impurities found in 22 MDMA tablets.  The EI mass spectra of the 
compounds were identified from the literature [121, 272, 273] (numbers in brackets 
are the EI mass spectra references).  
 
* These compounds are psychoactive substances 
No. Chemical Name ≈  Rt Mass Spectral data – principal peaks at m/z 
1 Safrole 8.39 162, 131, 104, 135, 103 [272] 
2 3,4-(Methylenedioxy)-phenylpropane 9.41 135, 164, 77, 51, 50 [121] 
3 Piperonal 10.02 149, 150, 121, 63, 65 [272] 
4 Isosafrole 10.84 162, 131, 104, 103, 161 [272] 
5 Piperonyl alcohol 11.58 152, 135, 93, 65, 123 [121] 
6 3,4-MDP2P 12.40 135, 178, 77, 136, 79 [272]  
7 MDA * 12.81 44, 135, 136, 77, 51 
8 3,4-Methylenedioxy-phenyl-2-propanol (3,4-MDP2-propanol) 12.98 135, 136, 180, 77, 106 [121] 
9 MDMA 13.41 58, 135, 77, 105 
10 DMMDA 14.22 72, 56, 44, 73, 58 [273] 
11 3-Methyl-6,7-methylenedioxy-3,4-dihydroisoquinolin-1(2H)-one  15.26 148, 190, 147, 205, 188 [272] 
12 N-Formyl-MDMA 18.42 86, 162, 58, 135, 77 [272] 
13 N-Methyl-(1,2-methylenedioxy)-4-(1-ethyl-2-aminopropyl)benzene 18.61 58, 162 , 77 135, 194 [121] 
14 N-Acetyl-MDMA 18.91 58, 162, 100, 43, 135 [273] 
15 Palmitic acid 19.08 73, 60, 57 55 129 (M+ 256) 
16 Stearic acid 21.15 73, 60, 57 55 129 (M+ 284) 
17 Cocaine * 21.56 182, 82, 83, 105, 303 
 228 
Table 5.8 Impurities from precursor chemicals and reaction by-products found in MDMA tablet batches from the analysed 




































1 2 3 4 5 6 7 8 10 11 12 13 14 
5 √  √ √     √   √  
8 √  √ √     √   √  
11    √  √   √ √ √   
14 √    √    √ √ √   
17   √   √ √ √  √    
18   √   √ √ √ √     
19      √  √ √     
20   √ √  √     √   
21    √  √   √  √   
22   √ √  √  √ √     
23   √ √  √  √ √   √  
24 √  √   √  √ √   √  
25   √ √  √     √   
26   √ √  √     √   
27   √   √ √ √  √    
28   √   √ √    √  √ 
29  √  √  √   √    √ 
33   √ √  √  √    √  
40  √   √ √  √      
41  √ √   √     √   
44   √   √ √ √  √    
45   √   √ √ √  √    
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The impurities that were found to co-occur in the same chemical profile included 
piperonal  and  3,4-MDP2P  (31.8 %,  n = 7);  and isosafrole,  piperonal  and  3,4-MDP2P 
(27.3%, n = 6).  Table 5.8 shows the impurities from precursor chemicals and reaction 
by-products found in MDMA from the analysed tablets.  Other groups of impurities from 
precursor chemicals found together in the same chemical profiles included: safrole, 
piperonal and 3,4-MDP2P; isosafrole and 3,4-MDP2P; and safrole, isosafrole and 
piperonal.  Moreover, the impurity from the precursor chemical 3,4-MDP2P was found 
alone in only one chemical profile.  The key intermediate seemed to be 3,4-MDP2P for 
all the chemically profiled MDMA tablets.  The compound 3,4-MDP2P was detected in 
most of the (86.4%, n = 22) tablets.   
 
5.3.4 Experiment D: Determination of major excipients of ‘ecstasy’ tablets 
 
A single tablet was used from each of the 35 batches (batches 4-18, 21-23, 25, 26, 29, 31-
41, 44 and 45, 35 out of the 45 batches were used as tablets from the other batches were 
all used) to determine major excipients. The detected excipients were (% number of 
tablets) were lactose (34.3%, n = 12, Figure 5.10), sorbitol (25.7%, n = 9), dibasic 
calcium phosphate (DCP) (22.9%, n = 8) and starch (17.1%, n = 6) (Table 5.9).  Nearly 
all of the tablets contained the lubricant magnesium stearate (94.1%, n = 32).   
 
Table 5.9 Characteristic FTIR spectral peaks of reference substances that are used 
as major excipients in tablets (scan range 4000 cm-1 - 500 cm-1). 
 
 
Major Excipients FTIR – Transmittance – peaks (wavenumber, cm-1) 
Lactose 3522 3381 2900 1657 1427 
Sorbitol  3390 2933 2105 1632 1414 
Starch  3536 - 3215 2926 1644 1142 1005 










Figure 5.10 FTIR transmittance spectra of: (A) a standard MDMA-HCl [212] 
(peaks at 2710 cm-1 correspond to the N-H stretching of amine salt, that at 2458 cm-1 
to the C-H stretching of CH3 group, that at 1488 cm-1 to the C-H band, those at 1244 
and 1030 cm-1 to the C-O-C stretching of methoxy group and the 930 cm-1 to the C-
O stretching), (B) a sample of lactose (peaks from 3600 to 3200 cm-1 correspond to 
the C-O-H stretching of lactose alchol groups and the peaks standing within 1049 to 
1160 cm-1 correspond the C-O-C stretching of ether unit bonds), (C) an ‘ecstasy’ 
tablet containing MDMA-HCl and lactose (batch 18, additional lactose peaks at 
1140 cm-1, 1114 cm-1, 1070 cm-1 and 1018 cm-1). 
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Table 5.10 The detected major excipients in MDMA tablets.  
 
Batch 







































kangaroo DCP 41 
 
Route 66 starch 
22 
 






shaped starch 45  
lacoste lactose 
 
Table 5.11 The detected major excipients in ‘ecstasy’ tablets that contained mCPP 
and caffeine as their active ingredient.  
 
Batch 





lacoste mCPP lactose 
31 
 
tulip mCPP DCP 
32 
 








mark caffeine DCP 
36 
 
heart caffeine starch 
37 
 













Figure 5.11 FTIR transmittance spectra of three tablets, white with euro logo, taken 
from three different batches (batches 11-13).  
 
Less than half of the MDMA tablets were found to contain lactose as the main excipient 
(42.3 %, n = 11), followed by sorbitol (34.6%, n = 9), starch (19.2%, n = 5) and one 
tablet containing DCP as the major excipient (Table 5.10).  The detected major excipients 
in the ‘ecstasy’ tablets containing the active ingredients mCPP and caffeine were DCP, 
lactose and starch.  The predominant excipient detected in the ‘ecstasy’ tablets containing 
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the active ingredients mCPP and caffeine was DCP (7 tablets out of 9), while the 
excipients lactose and starch were detected in one tablet each (Table 5.11).  The presence 
of both DCP and magnesium stearate were confirmed by SEM/EDX analyses.    
 
The FTIR transmittance spectra of the MDMA-only tablets were fairly similar but 
differed in the fingerprint region (1500 – 900 cm-1).  Tablets with similar physical 
features (shape, colour and logo) had very similar FTIR transmittance spectra (Figure 
5.11).  
 
5.3.5 Experiment E: Elemental profiling of ‘ecstasy’ tablets 
 
A total of 37 ‘ecstasy’ tablets from batches 2, 4-18, 21, 23, 24, 26-41, 44 and 45 were 
analysed (37 not 45 batches were used as tablets from the other batches were all used).  
Almost three quarters of the tablets (70.3%, n = 26) contained MDMA as the only active 
ingredient.  The other tablets contained other active ingredients which included BZP 
batch 2, mCPP batches 4, 31 and 32, an anabolic steroid, batch 30, and caffeine, batches 
34-39.  The tablets used for analyses were each mounted on a SEM sample stub using 
double-sided carbon adhesive tape.  The tablets were then coated with a thin carbon layer 
and then each analysed by SEM/EDX (Section 2.2.3.5).  A total of ten  ions  were  
detected  in  the  analysed  tablets,  which  were:  sodium  (Na), magnesium (Mg), 
aluminium (Al), silicone (Si), phosphorus (P), sulphur (S), chlorine (Cl), potassium (K), 
calcium (Ca) and titanium (Ti).  Because the sensitivity of energy dispersive X-ray 
analysis is relatively low (≥ 0.1%), trace elements could not be detected. 
 
The chloride ion was the most commonly detected ion (97.3%, n = 36) followed by the 
magnesium ion (91.9%, n = 34) and the silicon ion (83.8%, n = 31).  The presence of the 
detected elemental ions was mainly due to the excipients used in the analysed ‘ecstasy’ 
tablets.  More than half (51.4%, n = 19) of the analysed tablets could be differentiated by 
the detected elemental ions.  The most common group of ions found together with no 
other ions on the tablets, containing MDMA as the only active ingredient, were the Mg, 
Si and Cl, ions which were found on 21.6% (n = 8) of the tablets (Table 5.12). 
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Table 5.12 Percentage weights of elemental ions Mg, Si and Cl detected on the 






No. Tablet Logo 
 
MDMA Tablets Characterised by 
their Elemental Ions - Weight % 
 




19.65 17.37 62.98 
12 22.65 18.13 59.22 
13 17.37 25.24 57.39 
17 
 
euro 24.50 34.01 41.48 
26 
 




mark 29.05 46.21 24.74 
28 
 
heart 23.90 31.16 44.94 
33 
 
versace 19.35 21.87 58.78 
 
Six MDMA tablets with a mixture of colour and logos but which all contained the same 
ions, which were Mg, Si and Cl, were investigated for difference in % weight (Table 
5.12) of the detected elements in their profile (Figure 5.12).  The inorganic profile for 
tablet from batch 11, white tablet with euro logo (tablet 1 in Figure 5.12), was very 
similar to the profile of tablet from batch 33, white tablet with versace logo (tablet 6 in 
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Figure 5.12).  The inorganic profiles of tablets 2, 3 and 5 shown in Figure 5.12 were very 
similar.  The tablets with reference to Figure 5.12 were: tablet 2, white with euro logo 
from batch 17, tablet 3, pink with smiley logo from batch 26, and tablet 5, white with 
heart logo from batch 28.  The elemental profile of tablet 4, blue with question mark logo 




Figure 5.12 Similar inorganic profiles (Weight % of the elemental ions Mg, Si and 
Cl) of six MDMA tablets, shown in Table 5.12, with a mixture of colour and logos 
seized on different occasions. 
 
From surface analyses conducted on MDMA tablets from batches 5-10, 14-16, 23, 29, 40, 
and 41 (Table 5.13) six elemental ions were detected which included Na, Mg, Al, Si, S 
and Cl.  The elemental ion Cl was detected on all the tablets, while Mg was on 12 tablets 
(Table 5.13).  Moreover,  from  the  surface analyses of another group of  MDMA  tablets  
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Table 5.13 Percentage weights of the elemental ions Na, Mg, Al, Si P, S and Cl 




No. Tablet Logo 
 
MDMA Tablets Characterised by their 
Elemental Ions  - Weight % 
 




3.47 10.32 3.57 21.24 3.62 57.78 
6 4.32 7.53 4.68 22.47 4.76 56.24 




1.37 23.06 / 28.27 4.75 42.55 
9 2.24 20.48 0.84 29.37 3.80 43.27 




1.84 3.64 / 2.55 / 91.98 
15 2.83 3.89 / 3.37 / 89.91 




shaped 7.79 12.44 3.68 18.61 1.96 55.51 
29 
 
D&G / 21.01 6.95 21.06 / 50.98 
40 
 
E = mc2 / / / / 0.23 99.77 
41 
 





from batches 18, 21, 24, 44 and 45 seven elemental ions were detected which were Na, 
Mg, Al, Si, P, Cl, and Ca (Table 5.14).  The elemental ions Mg, Si, Cl and Ca were 
detected on all five tablets (Table 5.14). 
 
Table 5.14 Percentage weights of elemental ions Na, Mg, Al, Si P, S, Cl and Ca 
detected on the surface of MDMA tablets by SEM/EDX analyses. 
 
Batch 
No. Tablet Logo 
 
MDMA Tablets Characterised by their  
Elemental Ions (Weight %) 
 
Na Mg Al Si P Cl  Ca 
18  D&G 3.23 21.78 2.53 26.05 / 44.52 1.89 
21  kangaroo / 17.55 / 16.49 22.80 25.02 18.14 
24  
letter X 




/ 18.75 / 25.92 / 51.12 4.21 
45 / 19.36 / 22.32 / 55.54 2.78 
 
 
  A comparison of tablets with different active ingredients 
 
Surface analyses were conducted on five tablets containing BZP,  mCPP and an anabolic 
steroid (batches 2, 4, 30-32) seven elemental ions were detected which were Na, Mg, Al, 
Si, P, Cl and Ca (Table 5.15).  The elemental ions Cl was detected on four tablets, Mg on 
three tablets and the ions P and Ca were detected on two tablets respectively (Table 5.15).  
No elemental ions were detected on the anabolic steroid tablet (batch 30) (Table 5.15). 
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Table 5.15 Percentage weights of elemental ions Na, Mg, Al, Si P, S, Cl and Ca 









‘Ecstasy’ Tablets Characterised 
by their Elemental Ions (Weight %) 
 
Na Mg Al Si P Cl Ca 
2  diamond shaped BZP / 1.41 / 0.84 / 95.86 / 






steroid no ions 
31  tulip mCPP 1.43 / 0.43 / 28.93 29.49 39.72 
32  mercedes mCPP / 2.59 / / 37.04 21.25 39.12 
 
 
From the surface analyses carried out on six tablets from batches 34-39, containing 
caffeine as the only active ingredient, ten elemental ions were detected which were Na, 
Mg, Al, Si, P, S, Cl, K, Ca and Ti (Table 5.16).  While the Mg, Si, P and Cl ions were 
detected on the surface of all six tablets the Al and Ca ions were detected on five tablets 
(Table 5.16).   
  
The weight % of the detected 10 elemental ions together with the active ingredient of the 
tablets was used as variable in a multivariate analysis to link (similarity in the number of  
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Table 5.16  Percentage weights of elemental ions Na, Mg, Al, Si P, S, Cl, K, Ca and 
Ti detected on the surface of ‘ecstasy’ tablets, containing caffeine as the only active 




No. Tablet Logo 
 
‘Ecstasy’ Tablets Characterised 
by their Elemental Ions (Weight %) 
 




/ 16.40 3.70 25.64 20.67 2.59 13.34 / 14.98 2.59 
35 
 




7.33 39.75 4.61 7.67 5.51 19.26 15.87 / / / 
37 
 




/ 11.14 4.18 5.03 29.11 / 10.55 / 26.80 13.09 
39 
 
/ 38.84 3.73 10.36 8.99 13.42 13.14 3.06 8.46 / 
 
attributes of tablets from different batches) or differentiate between the tablets from the 
batches.  The data matrix obtained was examined by hierarchical cluster analysis using a 
dendrogram (Figure 5.13).  The dendrogram (cut-off < 2) shows the following linkage: a) 
tablets from batches 5-7, b) tablets from batches 8-10, c) tablets from batches 11-13, 24, 
33, 44 and 45, d) tablets from batches 14-16, e) tablets from batches 17, 26 and 28 and f) 
tablets from batches 40 and 41.  The tablets from the other batches (2, 4, 18, 21, 23, 27, 
29-32, 34-39) were differentiated (Figure 5.13).  
 
5.3.6 Linkage between batches 
From  chemical  characterisation  it  transpired that there was a high possibility of linkage  
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                      Rescaled Distance Cluster Combine 
 
   C A S E    0         5        10        15        20        25 
   Batch No.  +---------+---------+---------+---------+---------+ 
 
          40   ─┬─────┐ 
          41   ─┘     ├───┐ 
          14   ─┬─┐   │   │ 
          15   ─┘ ├───┘   ├───────┐ 
          16   ───┘       │       ├───────────────────┐ 
           2   ───────────┘       │                   │ 
           4   ───────────────────┘                   │ 
          26   ─┐                                     │ 
          28   ─┼───┐                                 │ 
          17   ─┘   │                                 │ 
           9   ─┐   ├───┐                             │ 
          10   ─┼───┤   │                             │ 
           8   ─┘   │   │                             │ 
          18   ─────┘   │                             ├─┐ 
          13   ─┬─┐     │                             │ │ 
          24   ─┘ │     │                             │ │ 
          33   ───┤     │                             │ │ 
          45   ───┼─┐   │                             │ │ 
          11   ───┤ ├─┐ │                             │ │ 
          12   ───┘ │ │ │                             │ │ 
          44   ─────┘ ├─┼─────────────┐               │ │ 
           5   ───┐   │ │             │               │ │ 
           6   ───┼─┐ │ │             │               │ ├───────┐ 
           7   ───┘ ├─┘ │             ├───────────────┘ │       │ 
          23   ─────┘   │             │                 │       │ 
          29   ─────────┘             │                 │       │ 
          27   ───────────────────────┘                 │       │ 
          36   ───────────────┬─────────────────────┐   │       │ 
          39   ───────────────┘                     ├─┐ │       │ 
          31   ─────────────┬─────────────────┐     │ │ │       │ 
          32   ─────────────┘                 ├─────┘ │ │       │ 
          35   ─────────────┬─────────┐       │       ├─┘       │ 
          38   ─────────────┘         ├───────┘       │         │ 
          34   ───────────────────┬───┘               │         │ 
          37   ───────────────────┘                   │         │ 
          21   ───────────────────────────────────────┘         │ 
          30   ─────────────────────────────────────────────────┘ 
 
 
Figure 5.13 Dendrogram resulting from hierarchical cluster analysis of ‘ecstasy’ 
tablets for weight % of the detected elemental ions and active ingredients. 
 
between batches 5 to 7, blue tablets with omega logo, batches 8 to 10, green tablets with 
omega logo, batches 11 to 13, white tablets with euro logo, batches 14 to 16, orange 
tablets with pisces logo and batches 44 and 45 pink tablets with lacoste logo (Table 5.17). 
The batches from 5 to 16 were all from the same seizure while batches 44 and 45 were 
from different seizures. 
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Table 5.17 Batches of ‘ecstasy’ tablets with similar mass and chemical characteristics indicative of a possible linkage between the 
respective batches (batches 5 – 16 from same seizure and batches 44 and 45 from two different seizures). 
 
 
 Key: The numbers in columns mass and main active ingredient are the means and the numbers in parenthesis are the RSD 
 
Batch 














Elemental Profile - % Weight 





240 (4.65)  57.8 (3.69) 49.69 / 50.13 
profiles 
similar 
(tablets from  
batches  
5 and 8,  
Table 5.8) 
sorbitol 
3.47 10.32 3.57 21.24 3.62 57.78 / 
6 239 (3.32) 57.1 (3.15)   4.32 7.53 4.68 22.47 4.76 56.24 / 





239 (4.02) 49.8 (4.64) 51.77 / 48.23 
sorbitol 
1.37 23.56 / 28.27 4.75 42.55 / 
9 236 (4.21) 48.8 (4.32)  2.24 20.48 0.84 29.37 3.80 43.27 / 




201 (3.22) 43.6 (3.22)  52.04 / 47.96 
Profiles for 
tablets from 




/ 19.65 / 17.37 / 62.98 / 
12 202 (4.51) 43.6 (4.66)  / 22.65 / 18.13 / 59.22 / 




154 (3.41) 57.4 (3.66) 49.49 / 50.51 
sorbitol 
1.84 3.64 / 2.55 / 91.98 / 
15 154 (3.47) 57.7 (4.35)  2.83 3.89 / 3.37 / 89.91 / 








/ 18.75 / 25.92 / 51.12 4.21 
45 248 (8.27) 65.3 (10.9) 47.19 / 52.81 / 19.36 / 22.32 / 55.54 2.78 
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 5.4 Discussion 
 
This part of the study, which focused on the chemical characterisation of batches of 
tablets seized in Malta over a five year period from 2006 - 2011, showed that most of the 
seized batches were ‘ecstasy’ tablets containing a racemic mixture of MDMA. The 
organic impurity profiling of MDMA tablets using GC-MS analyses helped detect 
impurities which served to infer two plausible synthetic pathways which included the 
Leuckart and reductive amination reactions, while the TIC profiles were used as 
fingerprints to differentiate or link batches of MDMA tablets seized on different 
occasions.  The major excipients most commonly used in the seized batches, which were 
lactose and sorbitol, were also determined using FTIR transmittance spectroscopy.  
Elemental profiling of ‘ecstasy’ tablets from the different batches using SEM/EDX, 
which was used to further link or differentiate between the  batches, also helped 
determine other excipients used in the production of ‘ecstasy’ tablets.  The conjoint use 
of organic and elemental profiling, which provided a more definite profile of the analysed 
‘ecstasy’ tablets, demonstrated their potential for use in a forensic ‘ecstasy’ tablets 
intelligence perspective.  Using the above methods it was possible to link a total of 14 
batches of ‘ecstasy’ tablets from three seizures and differentiate between the other 
batches.  
 
In experiment (A) ‘ecstasy’ tablets were analysed to determine and quantisise the 
psychoactive substances if present. The majority of the ‘ecstasy’ tablets seized in Malta 
over the 5 year period (2006 - 2011) were MDMA-only tablets (n = 30 batches, 66.7%).  
However, ‘ecstasy’ tablets containing other psychoactive substances, as the only active 
ingredient, such as caffeine, mCPP, BZP and DPIA (n = 12 batches, n = 26.7%), or no 
active ingredients (2 batches) or unrelated chemicals such as the anabolic steroid 
methandrostenolone, found in one batch of tablets, were also seized during the study 
period.  The finding of ‘ecstasy’ tablets containing other psychoactive substances instead 




 The mean content of the batches of MDMA-only tablets was 52.6 mg (SD 14.75, range 
12.9 – 81.3 mg), which was fairly similar to that reported in England and Wales which 
ranged between 33.1 mg and 71.0 mg (base) / tablet [39, 275], for the same period, 2006 - 
2011. The range of the mean content of MDMA in the analysed tablets fell nearly in the 
centre of the range for the mean content of MDMA in ecstasy tablets seized in Europe 
which ranged between 3 and 113 mg (base) / tablet during the period of study (56, 311-
313].   The mean MDMA (base) content of tablets (weight to weight) was 19.5%, which 
was determined from a sample from a population of 33,158  MDMA-only tablets 
obtained in 19 seizures (30.96% of all seized ‘ecstasy’ tablets, 107,098 tablets, in Malta 
during the period of study)  during the years 2006 - 2011.  According to the EMCDDA 
2010 Annual Report “there were no clear trends in the MDMA content” in the tablets 
found in Europe [54], thus batches of MDMA tablets in Europe had different dosage as 
was determined in this study.   
 
Six batches (batches 34-39) of round shaped tablets coloured blue and green with 
question mark, heart and rolex crown logos were found to contain the psychoactive 
compound caffeine only.  It is not uncommon to find ‘ecstasy’ tablets containing caffeine 
as an adulterant or as the only psychostimulant substance [276].  The mean purity of 
these tablets for the compound caffeine was 32.42 mg (base) / tablet.  Although caffeine 
in low doses is less harmful than MDMA [276] repeat users of ‘ecstasy’ tablets with high 
doses of caffeine may be putting themselves at risk for health problems.  While low or 
intermediate doses of caffeine (< 100 – 250 mg / day) have a positive effect, such as 
increased mental performance and alertness, high doses of caffeine (300 - 800 mg / day) 
could cause serious health problems such as substance-induced anxiety, nervousness and 
insomnia mood [277]. Thus the use of ≥ 8 tablets of tablets from batches 34-36 or ≥ 15 
tablets from batches 37-39 could have caused serious health problems. A caffeine tablet 
can promote acute toxicity if taken with ‘ecstasy’ containing MDMA, which is a serious 
drug interaction [278]. Although it is not known why this happens, it was suggested that 
caffeine might blocks the adenosine A2 receptors and by so doing potentiate the DA 




 Two other batches of tablets which were seized in Malta were found to contain the 
psychoactive compound BZP (batches 2 and 3) had a mean dosage of 211.5 mg (base) / 
tablet.  These two batches consisted of diamond and round shaped white tablets with no 
logos. The substance BZP, which can be synthesised from piperazine monohydrochloride 
and benzyl chloride [280], is a central nervous system stimulant and has about 10% 
relative potency that of amphetamine [281].  Little is known about the toxicity of BZP, 
however in New Zealand where this substance was used as a recreational drug since 2000 
there were some incidents which resulted in medical emergencies [280] 
 
Three other batches of ‘ecstasy’ tablets which were seized in Malta were found to contain 
the psychoactive substance mCPP (batches, 4, 31 and 32) at a mean dosage of 53.7 mg 
(base) / tablet.  These three batches consisted of round shaped white tablets with lacoste, 
tulip and mercedes logos.  The compound mCPP can be synthesised by many routes but it 
is commonly manufactured by diethanolamine with m-chloroaniline [282].  The 
compound mCPP is ingested by clubbers for its stimulant-like effects which to some 
extent are similar to those MDMA [283]. Although little is known about the toxicity of 
mCPP no fatal cases involving this ubstance has been reported in Europe [282]. 
 
Another batch of round shaped tablets, blue coloured with thumbs-up logo (batch 1), 
which was analysed in this study, was found to contain DPIA.  This compound was not 
found in any of the analysed batches of tablets.  The compound DPIA has two chiral 
centers, and therefore both a diastereomeric pair and a meso stereoisomer are usually 
present in illicit amphetamines prepared via the Leuckart method [284].   Illicit 
amphetamine samples frequently contain this substance as the main impurity which is 
formed during the Leuckart synthesis [285] or as a reaction intermediate following 
reductive amination of phenylacetone [286] but in lesser amounts than when produced 
during the Leuckart synthesis (Andersson K, 2008, personal communication, Scientist, 
Swedish National Laboratory of Forensic Science, email, 23 April).  The Leuckart 
synthesis is known to produce a higher production of DPIA than the reductive amination 
process (Andersson K, 2008, personal communication, Scientist, Swedish National 
Laboratory of Forensic Science, email, 14 March).   
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 The possibility that amphetamine, not DPIA, was the intended constituent cannot be 
excluded because the producers may not have realized that their synthesis produced 
DPIA and not amphetamine. Thus it could be speculated that the presence of the DPIA 
molecule as the main active ingredient in the tablets could indicate incomplete synthesis 
of amphetamine via the Leuckart route where the formamide – formic acid mixture has 
been used [287].  The tablets would not have provided the clubbers with the effects of 
amphetamine because DPIA is less potent [288].  
 
One batch of tablets, blue coloured and heart shaped (batch 30), were found to contain 
the anabolic steroid methandrostenolone, was seized by the Maltese police during an 
EDM party. These were being sold as ‘ecstasy’ tablets on the basis of their appearance.  
The phenomenon of selling ‘fake’ ‘ecstasy’ is not new and has been reported in the 
literature [289].  Two other batches (batches 42 and 43) which were analysed in this 
study, consisted of blue coloured and round shaped tablets with euro and armani logos, 
very similar to ‘ecstasy’ tablets.  These two batches, which were seized in 2011, 
contained tablets with excipients only and no active ingredients. 
 
In this study no correlation was found between the means of the tablets mass and the 
means of the psychoactive substances contents of the analysed tablets. However, when 
the analysed ‘ecstasy’ tablets were evaluated for the uniformity of content of the active 
ingredient using as bench mark the European Pharmacopeia criterion 42 batches (95.5%) 
were found to have a uniform active ingredient in the tablets (tolerance of + 15%) [221], 
indicating that most of the tablets in the batches were well made  
 
Overall it was found that most of the ‘ecstasy’ tablets seized in Malta contained MDMA 
as the only active ingredient but other ‘ecstasy’ tablets containing other psychocative 
substances, such as caffeine, mCPP, BZP and DPIA were also found. Thus the 
hypothesis (2) which stated that: 
 





 was not verified.  
 
In experiment (B) the separation of MDMA enantiomers from ‘ecstasy’ tablets was 
important to determine if illegal chemists were producing chiral-specific MDMA tablets.  
In this experiment an achiral derivatising agent (TFAA) together with a chiral capillary 
column were used to separate the enantiomers. As far as is known this is a novel 
approach to determine the enantiomeric composition of MDMA.  The results from the 
analysed single MDMA-only tablets from each of the 22 batches, using paired t-test, 
demonstrated that there was no difference in the percentage of S(+)-MDMA (M = 50.36, 
SD = 1.90) when compared to R(-)-MDMA (M = 49.64, SD = 1.90), t(21) = 0.895, p = 
0.381, isomers in the tablets.  This indicated that the MDMA present in ‘ecstasy’ tablets 
seized in Malta between the years 2006 – 2011 were racemates.  The results obtained in 
this study were similar to those obtained by the CHAMP group where MDMA samples 
were also found to be racemates [179]. Hence the hypothesis (3) that: 
 




The two MDMA enantiomers have different pharmacological effects.  The S(+)-MDMA, 
which has a stimulant effect [290], inhibit serotonin (SERT) and DA transporters, while 
the R(-) MDMA, which has a “hallucinogen-like” effect [290], is selective for 5-HT(2A) 
[291].  Moreover, while the carbon responsible for the MDMA chirality is maintained 
during the drug metabolism, the more active S(+)-MDMA enantiomer is metabolized 
faster than the R(-)-MDMA enantiomer [88, 292].  The subjective net effect of the 
racemic MDMA as reported by recreational users includes euphoria, emotional openness 
and empathy, among other [27].     
 
The two isomers of MDMA could be separately synthesised for their different 
psychoactive effects. One such method described in the literature involves the ring 
opening of enantiopure aziridines and derivatisation from S(+)- and R(-)- alanine, 
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 respectively, by the Grignard reagent, by methylation and detosylation to produce the 
S(+)- and R(-)-MDMA, which can then be converted to their hydrochlorides [291]. 
However, the illicit synthesis of the single MDMA enantiomers does not seem to happen 
and that clandestine chemists prefer to produce racemic MDMA using Leuckart reaction 
or reductive amination.  
 
In experiment (C) 22 MDMA-only tablets from different batches (5, 8, 11, 14, 17-29, 33, 
40, 41, 44-45) were analysed to determine some of the impurities from basic extracts 
after analyses by GC-MS.  It has been reported that ‘ecstasy’ tablets from different 
seizures containing MDMA as their main active ingredient could be linked using their 
chemical profile by the similarity and correlation of two or more impurities found in the 
synthesized MDMA [212, 273].   
 
In the present study the detected impurities were identified, using the EI mass spectra 
published in the literature was not high.  The number of detected impurities depended on 
such factors as the purification of MDMA prior to tabletting of the tablets at the 
clandestine laboratories and the storage conditions of the tablets which might have altered 
some minor chemicals to new impurities [266] that were not reported in the literature.  If 
MDMA is thoroughly purified after synthesis this decreases the number of available 
markers in the tablets making it sometimes difficult to determine the synthetic route for 
MDMA production [272].   
 
There are four main chemical precursors that are normally used to synthesise MDMA.  
These are: safrole, isosafrole piperonal and 3,4-MDP2P [121, 273].  The precursors, 
especially isosafrole, piperonal and 3,4-MDP2P, were detected in all 22 tablets that were 
chemically profiled.  All the four precursors, which are available commercially, are 
controlled by the UN (the 1988 UN Convention Against Illicit Traffic in Narcotic Drugs 
and Psychotropic Substances), the European Union [121] including the UK and Malta as 




 The precursors chemicals that were most often found together in the same chemical 
profile from the 22 MDMA tablets were: the two precursors chemicals piperonal and 3,4-
MDP2P (31.8%, n = 7), and the three precursor chemicals isosafrole, piperonal and 3,4-
MDP2P (27.3%, n = 6, possibly because both piperonal and 3,4-MDP2P can both be 
synthesised from isosafrole [128, 293].  However, it seems that 3,4-MDP2P was the 
precursor that was mostly used to synthesise the MDMA because it was found in 19 
tablets (86.43%).  Two other impurities, 3,4-(methylenedioxy)-phenylpropane and 
piperonyl alcohol, were detected in 5 tablets (22.7%).  The former is formed by the 
chemical reduction of safrole or isosafrole [121], and the latter by the chemical reduction 
of piperonal [121].  Other impurities indicated the possibility that MDMA in the 22 
tablets was synthesised by either the Leuckart or the reductive amination reactions.   
 
The Leuckart reaction, which is the most usual route for the production of amphetamine 
type drugs, can also be used for the production of the methylenedioxy-substituted 
analogues [200].  Two impurities DMMDA and N-formyl which could be formed during 
the synthesis of MDMA by the Leuckart reaction were detected in 50% (n = 11) of the 
profiled tablets.  Renton et al. [200] claimed that the presence of the impurity DMMDA 
in MDMA prepared by N-methylformamide / formic acid reaction was possibly caused as 
a result of N,N-dimethylformamide impurity in the N-methylformamide [200].  The other 
impurity, N-formyl-MDMA, which is considered as a Leuckart reaction marker, is 
formed during the reaction between 3,4-MDP2P, N-methylformamide and formic acid 
[123, 212].  The resulting N-formyl-MDMA is then converted to MDMA by refluxing 
using either a strong acid or base [294].  Thus the presence of DMMDA and N-formyl-
MDMA in six batches indicates that the MDMA in these tablets was possibly synthesised 
by the Leuckart reaction. [200, 240, 273].    
 
Another impurity N-acetyl MDMA was found in two of the analysed tablets (batches 18 
and 28, white tablets with D&G and heart logo respectively), together with N-formyl-
MDMA.  The presence of the N-acetyl MDMA impurity was reported in two studies that 
were conducted in France between the years 1999 - 2000 [273] and in Australia on tablets 
seized in Macedonia between the years 2006 - 2007 [295].  The tablet samples from 
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 Macedonia contained both N-acetyl-MDMA and N-formyl-MDMA [295].  It could thus 
be speculated that N-acetyl MDMA, which was found together with N-formyl-MDMA, is 
another impurity formed during the Leuckart synthesis of MDMA.   
 
The synthesis of MDMA by reductive amination involves the use of 3,4-MDP2P and an 
amine under reducing conditions as described in Chapter 1, Section 1.5..2.  The presence 
of the alcohol 3,4-methylenedioxyphenyl-2-propanol detected in half of the profiled 
MDMA tablets (n = 11, batches 17-19, 22-24, 27, 33, 40, 44-45) together with 3,4-
MDP2P could be an indication that the reductive amination route was used [212, 273].  
The alcohol could have been formed by the reduction of 3,4-MDP2P with excess 
reductant during the synthesis of MDMA as reported by Cheng et al. [212].  However, 
3,4-methylenedioxyphenyl-2-propanol could have also be formed during the synthesis of 
MDMA by the bromopropane route [273].  Since no brominated impurity compounds 
were detected in the profiles where the compound 3,4-methylenedioxyphenyl-2-propanol 
was present, the probability was that the alcohol was produced during the synthesis of 
MDMA by reductive amination.  Both N-formyl-MDMA, which is normally considered 
as Leuckart route marker for MDMA [200, 296]  synthesis and DMMDA were also 
found as impurities in MDMA synthesised by reductive amination [272, 273].  The 
presence of DMMDA in MDMA impurity profile synthesised by reductive amination 
was detected in 5 chemically profiled tablets (22.7%).  The presence of MDA as an 
impurity in the chemical profile of some (n = 5, 22.7%) of the tablets further confirmed 
the possibility that the MDMA in these tablets was synthesized by reductive amination.  
Both MDA and DMMDA impurities detected in some of the profiles of the tablets are 
normally produced by the ammonia impurity present in the methylamine during the 
reductive amination of 3,4-MDP2P [296].  Another impurity which was detected in the 
tablets (n = 5, 22.7%), which is normally also attributed to reductive amination, was N--
methyl-(1,2-(methylenedioxy)-4-(1-ethyl-2-aminopropyl)benzene [297].  Thus from the 
chemical impurity profiling of the MDMA-only tablets from the 22 batches it was 
concluded that 13 tablets (59.1%) were probably synthesized using the reductive 
amination reaction, while 9 tablets were probably synthesized using the Leuckart 
reaction.   
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 Two other compounds which were also detected in some of the tablets (n = 7, 31.8%) 
included palmitic and stearic acid, compounds which are normally used as lubricants 
[273] during tablet manufacture.  The presence of cocaine in the chemical profile of two 
tablets (blue coloured with omega logo, batch number 6 and white coloured with heart 
logo, batch number 28 respectively) was found to be contact contamination.  This was 
confirmed by analyzing two other tablets from the same batches where no traces of 
cocaine were detected.            
 
In this study (Section 5.3.3, Experiment C) the comparison of the TIC profiles of the of 
the blue and green MDMA-only tablets with omega logo from batches 5 and 8 and the 
comparison of the TIC profiles of the two pink MDMA-only tablets with lacoste logo 
from batches 44 and 45 showed similarity between the impurities.  The correlation 
between the impurities of the two pink tablets, shown in Figure 5.10 above, such as 
piperonal, 3,4-MDP2P, MDA, 3,4-methylenedioxy-phenyl-2-propanol and 3-methyl-6,7-
methylenedioxy-3,4-dihydroisoquinolin-1(2H)-one, indicated that the method used to 
synthesise MDMA was the same, possibly reductive amination.  The presence of the 
impurity 3-methyl-6,7-methylenedioxy-3,4-dihydroisoquinolin-1(2H)-one, detected in 
the same TIC profile (Figure 5.10) could be indicative that the used precursor 3,4-
MDP2P was synthesised from piperonal via β-nitroisosafrole [272] (MDP-2-
nitropropene).  Other two detected peaks on the TIC profiles of the two tablets from 
batches 44 and 45, which were not synthetic impurities, were palmitic and stearic acids 
used as lubricants during tablets manufacture.  Although there was some variability 
between the TIC profiles of the tablets from batches 44 and 45 respectively, this could 
have been caused by intra and inter-batches variability, of tablets.  The similarity between 
the chemical profiles of these four tablets (blue and green tablets with omega logo and 2 
pink tablets with lacoste logo) was indicative that the batches were possibly linked.   
 
The overall results indicated that the difference in the precursor chemicals and the 
synthesis methods used to produce MDMA found in the analysed tablets provided 
different chromatographic profiles.  It was also concluded that the MDMA in the tablets 
seized in Malta during the period of study (2006 – 2011) was predominately synthesised 
251 
 
 by one of the different reductive amination reactions using the intermediate 3,4-MDP2P 
which was prepared from piperonal.  This finding was consistent with the literature [209, 
273].  
 
In experiment (D) the use of FTIR transmittance spectroscopy was applied to determine  
the major excipients in the seized ‘ecstasy’ tablets.  This approach which was novel, as 
far as it is known, have never been used to identify major excipients in ‘ecstasy’ tablets.   
 
By FTIR transmittance analyses of ‘ecstasy’ tablets from 35 batches it was possible to 
identify four major excipients, which included the excipients lactose, sorbitol, DCP and 
starch and one minor excipient the lubricant magnesium stearate, which was present in 
most tablets (97.1%, n = 33).  The presence of DCP and / or magnesium stearate in some 
of the tablets was confirmed by SEM/EDX analyses.  The most commonly encountered 
excipient in the analysed ‘ecstasy’ tablets was lactose (34.3%, n =12), followed by 
sorbitol (25.7%, n = 9), DCP was found in 8 tablets and starch in 6 tablets.  The finding 
of lactose and sorbitol as the most common excipients in the anlysed ‘ecstasy’ tablets was 
concurrent with results of another study [126].  It was noted that the excipient DCP was 
present in most of the tablets (7 out of 9 tablets containing other active ingredient instead 
of MDMA, batches 31, 32, 34, 35, 37-39) containing mCPP or caffeine as their main and 
only psychoactive substance.   
 
The possibility of using FTIR transmittance spectroscopy method to distinguish between 
tablets from different batches was also investigated. The FTIR transmittance analyses of 
‘ecstasy’ tablets produces spectra that represent the particular tablet composition as a 
whole.  Therfore, it seemed possible that FTIR transmittance spectroscopy could be used 
to link or differentiate ‘ecstasy’ tablet from different batches by comparing FTIR peaks 
characteristics.  This was partially confirmed from the comparison of the FTIR spectra of 
‘ecstasy’ tablets containing MDMA. The FTIR spectra of MDMA-only tablets was fairly 
similar, the only noted difference was in the FTIR ‘fingerprint’ region when the 
composition of the tablets was different.  It was also noted that when MDMA-only tablets  
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 had similar physical features, such as colour, shape and logo, such as batches 5-7, 8-10, 
11-13, 14-16, and 44-45, the FTIR ‘fingerprint’ region was similar.  The similarity in the 
spectra of tablets with similar physical features could be attributed to the powdering of 
the tablets, thus overcoming any difference that might have been in the homogenity, prior 
to the FTIR transmittance analyses.   
 
The FTIR transmittance spectra of the blue and green tablets with the omega logo, 
batches 5-10, and the pink tablets with the lacoste logo, batches 44-45, taken from 
different batches and seized on different occassions, were found to be very similar.  
Hence it was speculated that the blue and green tablets with the omega logo like the pink 
tablets with lacoste logo had a common origin. It was also speculated that the two batches 
of pink tablets with the lacoste logo might have been a single batch which was divided 
for distribution.  This was concluded from FTIR spectra and the results from the physical 
and chemical characterisation.  
 
Overall it was found that the FTIR transmittance spectroscopy method could be used to 
determine major illicit tablet excipients.  Moreover, the results obtained from comparing 
the FTIR peaks characteristics indicated that this method could be used with other 
physical and characterisation methods, to link or differentiate between ‘ecstasy’ tablets 
from different batches.     
 
In experiment (E) the use SEM/EDX analyses of ‘ecstasy’ tablets was to determine the 
elements present in the tablets and to use the detected elements to inorganically profile 
the tablets.  This was a new approach of elemental profiling of ‘ecstasy’ tablets.  Ten ions 
of elements (which were Na, Mg, Al, Si, P, S, Cl, K, Ca and Ti) were detected.  The most 
common elements that were detected on the 37 ‘ecstasy’ tablets from the batches were 
the Cl (97.3%, n = 36), followed by Mg (91.9% n = 34) and Si (83.8%, n = 31).  
However, there was variation in the presence of excipients in different ‘ecstasy’ tablets, 
which together with the elements present and their concentration provided the possibility 
of linking or discriminating between tablets.  When a sufficient number of elements were  
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 detected, as was the case for the tablets from batches 34-39, where 10 elements where 
detected (Na, Mg, Al, Si, P, S, Cl K, Ca, and Ti) or the percentage weight of the 
respective elements was different it was possible to establish an elemental profile and 
differentiate between samples.  It has also been shown that the inorganic profile and the 
percentage weight alone in some instances was not enough to discriminate between 
samples.  This has been shown above were tablets from batches 11, 17, 26-28 and 33 had 
similar elemental profile (Mg, Si and Cl) and percentage weight.   This could be an 
indication that if inorganic profiling, using SEM/EDX analyses, is taken alone a false 
positive link could occur between two samples.  Thus it could be that elemental analysis 
would not be enough to discriminate or link ‘ecstasy’ tablets from different seizures and 
that additional information, such as physical and chemical profiling, would be necessary 
to interpret the results.  
 
The elemental ions detected by SEM/EDX analyses on the surface of the tablets could 
most be explained by the fact that these elements could be found in excipients used in the 
manufacture of ‘ecstasy’ tablets [144].  However, no elemental ions were detected on one 
of the tablets, blue coloured with a heart shape containing an anabolic steroid (batch 30), 
indicating that the excipients used in this tablet were all organic.  Although excipients 
make a big part of the ‘ecstasy’ tablets there is very little information about these in the 
literature.  This was the first study that has investigated the use of elemental ions from 
excipients for ‘ecstasy’ tablet profiling. 
 
The presence of the elements Mg, Ca, Si, which were found in most of the tablets 
(83.8%, n = 31) was probably from glidants used in the tablets such as magnesium 
carbonate [298], talc (hydrated magnesium silicate) and silicone dioxide (fumed silica) 
[299, 300].  Glidants are used in tablets to improve the flow property of the formulation 
by reducing friction and cohesion [298, 299].  Some of the detected elemental ions 
included the elements Na, Ca, the presence of S for the sulphate and the presence of P for 
the phosphates [144] which have been due to the presence of excipients, used to increase 
the bulk content of the tablet (e.g. both magnesium and calcium carbonate [301], calcium  
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 sulphate and dibasic calcium phosphate [302], (dibasic calcium phosphate was detected 
by FTIR was confirmed by SEM/EDX).  Other detected elements included the Na, Mg, 
Al, Ca which have originated from the lubricants Mg, Al and Ca stearates (Mg stearate 
confirmed by FTIR) and Na benzoate [144, 299, 300].  The lubricants are used in tablets 
to reduce the friction between the tablet and the die during the tablet ejection from the die 
[299].  The elemental ions detected on the surface of most (94.6%, n =35) of the ‘ecstasy’ 
tablets were from the excipients (glidants, diluents and lubricants) which are concurrently 
used during tablet manufacture.  Organic excipients (i.e. glidants, diluents and lubricants) 
were used in the tablets where no elemental ions were detected (e.g. batch 30 and batch 
40).    
 
The detection of the element Ti (batches 34, 35, 37 and 38) was probably due to the use 
of a ‘whitener’ in the tablets [300].  The detected elemental ion Cl was mainly due to 
hydrochloride salt of the active ingredients present.  It is claimed that in large scale 
production of MDMA-HCl high yields are obtained by the use of gaseous HCl instead of 
the acid and that crytallisation is performed in closed vessels at low temperatures [179].  
 
Overall the number of detected elemental ions, a total of ten ions, mainly from the 
excipients of the analysed ‘ecstasy’ tablets was rather low when the SEM/EDX profiling 
method was used.  This method, which is semi-quantitative, could sometimes not be 
enough to link or discriminate between samples of ‘ecstasy’ tablets; however, some 
batches of tablets could still be differentiated by SEM/EDX profiling.   
 
Finally, this study has demonstrated that by using chemical characterisation it was 
possible to determine if ‘ecstasy’ tablets from different police seizures could be linked or 
differentiated.  This was achieved by five experiments and examining the results for 
similarities or differences in the psychoactive substances and their amounts in the tablets, 
the synthetic impurities and the enantiomer ratio for  MDMA-only tablets, the major 
excipients and the elemental profile of the tablets, irrespective of their physical features.  
While most (80.0%, n = 36) of tablets could be differentiated by chemical 
characterisation, 14 batches were found to be linked (batches 5-7, 8-10, 11-13, 14-16, 44- 
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 45). This study also evaluated hypothesis (4) that: 
  
The chemical composition of different batches of ‘ecstasy’ tablets seized 
on different occasions in Malta during 2006 – 2011 will be significantly 
different from each other. 
 
























 Chapter 6 
 
ELECTRONIC DANCE MUSIC EVENTS: 
ILLICIT SUBSTANCES AND BEHAVIOUR 
OF PARTICIPANTS 
 
This chapter consists of two studies which deal with: (a) seizures of illicit substances 
from electronic dance music (EDM) events in Malta over a six year (2006 - 2011) period 
by Malta Police Drug Squad and (b) a study which investigated the behaviour of 
participants at an EDM event in Malta during the summer of 2010.   
 
6a Seizures of illicit tablets and substances at major electronic dance 
music (EDM) events in Malta. 
 
The extent of drug use at electronic dance music (EDM) events in Malta tends to be 
anecdotal accounts of use and little formal investigation has been made.  This research 
was to investigate substances being consumed at a party.  Young people attend these 
dance venues to socialise and dance, and the use of both legal and illicit substances 
during this time become necessary [41].  In Malta plain clothes policemen are normally 
present during EDM events. They aim to stop and search young people, while entering 
and during the party, for illicit substances.  This section will describe the results of 




Modern late-night EDM parties, together with drug use, were imported to major 
European cities mainly from Ibiza [303].  As already discussed in Chapter 1, Section 
1.1.2, these parties were originally rave parties and where held in secret warehouses, and 
then began to be highly promoted and organized in popular venues such as bars and 
dance clubs [304].  One of the factors that caused this shift was legislative control, which 
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 mainly forbade raves from being organised in clandestine spaces. This pushed raves 
towards partnership with legal clubs and consequently raves became commercialised 
EDM parties and part of the leisure industry.  The change in raves to commercialised 
EDM parties brought with it a change in substance use [305], where alcohol became part 
of the drug mix [304].  The same happened in Malta where illegal rave parties were 
pushed to legal main stream night club and dance setting, where alcohol, ‘ecstasy’ and 
cocaine were used [48].     
 
A study was conducted to investigate the illicit substances confiscated by the police, from 
partygoers at EDM events.  The information gathered from the analyses of the illicit 
tablets and substances would provide more accurate information on the exact contents of 
these substances to healthcare professionals, since this information would not depend on 
what users thought these substances contain.  The study also examined the visual and 
measurable features together with the dose of the seized ‘ecstasy’ tablets from EDM 
events and compared the data with the data from the 45 batches and also attempted to test 
the hypothesis (5) that: 
 
Those ‘ecstasy’ tablets seized by the police at EDM events in Malta will 
match batches seized on different occasions in Malta. 
 
6a.2 Methodology      
 
6a.2.1 Drugs seized at EDM parties 
 
Ramsey et al. [306] developed a method to monitor illicit substance use at EDM parties 
in the UK, which involved the analyses of substances discarded in amnesty bins by 
clubbers before entering the party [306].  In this study substances were confiscated by the 
police from partygoers during major EDM parties and not freely volunteered by the 
clubbers themselves.  These were seizures confiscated by the police during eighteen large 





 In Malta, during major EDM parties, the police stop and search approximately sixty 
people (range from 50 to 80 persons) and always detain a number (average 10 persons, 
range from 5 to 13) of partygoers (N. Harrison, 2006, personal communication, Assistant 
Commissioner, Malta Police, telephone conversation, 10 January) who are found in 
possession of substance/s suspected to be illegal drugs.  Seized drugs found in possession 
of each party attendee would be individually packed (considered as one seizure) by the 
Drug Squad Police at the party, and sent for examination and analysis at the Forensic 
Laboratory by order of the Inquiring Magistrate.  The contents of each seizure, contained 
in separate plastic bags, were individually examined and analysed by the researcher.   
 
 6a.2.3.1 Tablet and substance examinations 
 
The visual characteristics of the ‘ecstasy’ tablets were noted and the physical 
characteristics, mass, diameter and thickness, were measured as described in Sections 
2.2.1.1 and 2.2.1.3 and analysed using colour tests, TLC and GC-MS analyses as 
described in Sections 2.2.3.1 and 2.2.4.1.  The identification of MDMA tablets were 
specified by TFAA derivatisation and quantified as described in Sections 2.2.3.1.  For the 
powders and plants and cannabis-like material, a methanoic extract was prepared with a 
final concentration of approximately 1mg mL-1.  The powders were assumed to be 50% 
pure, while the plants and cannabis-like material was assumed to be 10% pure.  For liquid 
suspected to be gamma-butyrolactone (GBL), a 0.1% solution in chloroform was 
prepared.   
 
6a.3 Results  
 
6a.3.1 Monitoring of seized tablets and substances 
 
A total of 172 seizures were investigated, which contained 238 separate items: 75 tablets 
(31.5%), 83 powders (34.9%) (white and brown), 79 plants and cannabis-like material 
(33.2%)  and  1 (0.4%) small amount of transparent liquid.  The drug seizures over the 6 
year period from 18 large open air “commercial” EDM parties are shown in Table 6a.1. 
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 Most of the seizures (80.2%, n = 138) contained one substance, while the rest contained 
two or more drugs.   
 




A total of 75 tablets were found in nearly one third of the seizures (29.7%, n = 51).  Most, 
(94.7%, n = 71) of the tablets had logos and white (74.7%, n = 56), a much smaller 
number were blue (10.7%, n = 8) or pink (9.3%, n = 7) and 2 tablets were coloured green 
and yellow respectively. Table 6a.2 shows the substances detected in the 172 seizures. 
 
From the GC-MS analyses it was found that nearly a quarter, (23.8%, n = 41), of the 
seizures (n = 172) contained MDMA tablets and that 61 (85.9%) out of the 71 ‘ecstasy’ 
tablets contained MDMA (Table   6a.3 below).  In most (95.1%, n = 39) of the seizures 
where MDMA was the only psychoactive substance found in the tablets, one to two 
tablets were involved.   
 
The MDMA tablets (n = 61) were all round with most, (77.1%, n = 47), having a flat 
side,  more  than  half  of  the  tablets had a breakline, (54.1%, n = 33), and were coloured  
 
Year EDM Party Seizures Year 
EDM 









2 9 8 6 14 9 
3 11 9 9 15 11 
Total 32 10 6 Total 30 
2007 





11 10 17 11 
6 7 12 11 18 9 
Total 25 Total 21 Total 33 
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 Table 6a.2  A total of 238 substance items were detected in the 172 seizures, which 
were confiscated during 18 major EDM parties (% represents the percentage of the 
specific item with respect to the total number of items found, 238 items, and N is 









MDMA  25.6  (61) 
BZP   02.5  (06) 
Caffeine   00.8  (02) 
mCPP   00.8  (02) 
Dihydrocodeine   00.8  (02) 
Promethazine  00.4  (01) 




Cocaine  18.9  (45) 
Unidentified  05.5  (13) 
Mephedrone  03.4  (08) 
Heroin  02.1  (05) 
Caffeine (range 0.2-0.4 g)  01.7  (04) 
Paracetamol (range 0.3–0.5 g)  01.7  (04) 
Lignocaine (mean 0.2 g)  00.8 (02) 
Amphetamine (0.4 g)  00.4  (01) 
Ketamine (0.2 g)  00.4  (01) 
 
Plants and cannabis-like material 
 
Cannabis items  31.9  (76) 
1-pentyl-3-(1-naphthoyl)indole (JWH-018)  01.3  (03) 




Gamma-butyrolactone (GBL) (3 mL)  00.4  (01) 
_______________________________________________________ 
  
white (68%, n = 42, the 14 other tablets had other active ingredients).  The MDMA 
tablets had logos, the most common logo on the tablets was the euro symbol with (9.8%, 
n = 6), followed by smiley, (8.2%, n = 5), heart, D&G and rolex, with (6.6%, n = 4 each) 




 The means of the measurable features including the dose of the seized 61 MDMA tablets 
were: mean mass 228 mg (SD 25.56, range 184 – 276 mg), mean diameter was 8.00 mm 
(SD 0.77, range 7.01 – 9.67 mm), mean thickness was 3.89 mm (SD 0.72, range 2.75 – 
5.39  mm)  and  mean  dose  was  54.4 mg  (SD  14.10,  range  12.9  –  75.2 mg).   Nearly  
 
Table 6a.3 ‘Ecstasy’ tablets containing MDMA found in 13 seizures in 2006. 
  
 
three quarters of the tablets, (72.1%, n = 44), had a mass which ranged between 200 – 
250 mg (typically ≈ 240 mg, 16.4%, n = 10).  The majority (95.1%, n = 58) of MDMA 







 yes heart 266 8.71 4.62 75.2 









 yes euro 249 7.13 4.74 73.7 















 no shell 217 7.06 4.82 53.4 
 yes mitsubischi 249 7.06 4.45 68.1 
 yes euro 230 7.11 4.69 50.4 









 yes yin-yang 184 8.02 3.34 59.8 
 no cherries 247 7.21 5.22 68.6 









 no armani 187 7.12 3.51 40.3 











 tablets had diameter which could be grouped in three classes, 7, 8, and 9 mm (typically 8 
mm, 39.3%, n = 24), thickness which could be grouped in three classes of 3, 4, and 5 
mm, (98.4%, n = 60, typically 4 mm, 39.3%, n = 24).   
 
The mean MDMA content in the ecstasy tablets over the 6 year period ranged between a 
maximum of 63.5 mg in 2006 and a minimum of 38.8 mg in 2008.  There was a 
significant decrease (p < 0.05, one-way ANOVA) in the mean MDMA content when the 
year 2008 (mean 38.8 mg) was compared with years 2006 (mean 63.5 mg), 2007 (mean 
56.6 mg), 2010 (mean 57.9 mg) and 2011 (mean 64.2 mg) and when the year 2009 (mean 
46.9 mg) was compared with years 2006 and 2011 respectively (Tables from 6a.3 to 
6a.8).   
 
In 2006 there were thirteen seizures which contained 18 MDMA tablets (Table 6a.3).  
The tablets in four of the seizures, which contained more than one tablet in  each  seizure,     
 





















 yes shark 283 9.04 3.75 68.1 
 yes diamond 265 8.54 4.03 63.7 


















 no kangaroo 240 8.09 3.57 47.9 
 yes twins 193 7.11 3.62 44.2 











 had tablets which were very similar in both  their  physical measurable feature and the 
dose (white with tulip logo, 2 tablets, white with smiley logo, 3 tablets, white with star 
logo, 2 tablets, and white with mitsubishi logo, 2 tablets,  Table 6a.3).   
 
In 2007 there were seven seizures which contained ten MDMA tablets.  The tablets in 
three of the seizures, which contained more than one tablet in the seizure, had tablets 
which were very similar in both the physical measurable features and the dose (white 
with D&G logo, 2 tablets, white with heart logo, 2 tablets and white with euro logo, 2 
tablets,  Table 6a.4).  The two tablets with euro logo seized in 2007 were not found to be 
related with the euro tablet seized in 2006 because both the measurable features and the 
dose of MDMA were different.    
 
In 2008 there were eight seizures which contained twelve MDMA tablets (Table 6a.5).  
The  tablets  in  four  of  the  seizures,  which  contained  more than one tablet, had tablets  
 
Table 6a.5 ‘Ecstasy’ tablets containing MDMA found in 8 seizures in 2008. 
 
 
















 yes fish 221 7.86 4.34 54.7 
 yes heart 236 8.39 4.94 61.6 











mark 242 7.12 5.39 40.3 


















 yes star 193 8.10 3.44 42.6 











 which were very similar in both the physical measurable features and the dose (white 
with D&G logo, 2 tablets, white with heart logo, 2 tablets, violet with butterfly logo, 2 
tablets and pink with lacoste logo, 2 tablets,  Table 6a.5).  The two tablets with the D&G 
logo seized in 2008 were found to have similar measurable features and dose with two 
other D&G tablets that were seized in 2007 (Tables 6a.4 and 6a.5).  However, the 
measurable features and the dose of the two tablets with the euro logo seized in 2008 
(Table 6a.5) were not found to be related with the euro tablets seized in 2006 (Table 6a.3) 
and 2007 (Table 6a.4).    
 
In 2009 there were six seizures which contained ten MDMA tablets (Table 6a.6).  Two of 
the seizures, which contained more than one tablet in each seizures, had tablets which 
were very similar in both the physical measurable features and the dose (white with rolex 
crown logo, 4 tablets, and white with versace logo, 2 tablets, Table 6a.6).  The other 
tablets had different physical features and dose.     
 































- VM 234 8.51 3.34 38.9 
 yes smurf 224 7.93 4.47 60.3 
 yes crown 237 8.69 3.01 45.7 









 no cross 191 7.89 3.43 43.4 











 In 2010 there were three seizures which contained five MDMA tablets (Table 6a.7).  The  
tablets in two of the seizures, which contained more than one tablet in the seizure, had 
tablets which were very similar in both the physical measurable features and the dose 
(white with dollar logo and white with E=mc2 logo, 2 tablets, Table 6a.7).  The other 
tablet (logo motorala) had different physical features and dose.   
 
Table 6a.7 ‘Ecstasy’ tablets containing MDMA found in 3 seizures in 2010. 
 
 
In 2011 there were four seizures which contained six MDMA tablets (Table 6a.8).  The 
tablets in two of the seizures, which contained more than one tablet in each seizure, had 
tablets which  were  very  similar  in  both  the  physical measurable features and the dose  
 
Table 6a.8 ‘Ecstasy’ tablets containing MDMA found in 4 seizures in 2011. 
 
















 no motorola 226 7.81 4.87 67.8 
 no E=mc
























2 237 9.09 3.06 58.1 









 yes superman 272 7.64 4.89 71.2 




















 (white with route 66 logo  and pink with lacoste logo, 2 tablets,  Table 6a.8).  It was 
noted that the tablet with the E=mc2 logo seized in 2011 had fairly similar measurable 
features and dosage to two tablets with the same logo seized in 2010 (Table 6a.7).  
 
 ‘Ecstasy’ containing other stimulants and other tablets 
 
The GC-MS analyses of 10 ‘ecstasy’ tablets from 8 seizures (4.7% of the total seizures, n 
= 172) were found to contain a psychoactive substances other than MDMA (Table 6a.9 
below).  In six of the tablets, having a diamond shape, BZP was detected.  The means of 
the measurable features and dose of the BZP tablets were: mean mass was 438 mg (SD 
14.19,  range 417 – 450 mg), mean width was 8.18 mm (SD 0.13, range 8.00 – 8.40 mm),  
 
Table 6a.9  ‘Ecstasy’ tablets containing other psychoactive substances.   
 
 
mean length was 11.27 mm (SD 0.10, range 11.1 – 11.40 mm), the mean thickness was  
6.10 mm (SD 0.013, range 5.93 – 6.25 mm) and the mean dose was 207.3 mg (SD 6.16,  
































   BZP 
214 
447 l – 11.3 w – 8.1 6.14 211 
448 l – 11.3 w – 8.2 6.25 212 
423 l – 11.1 w – 8.2 5.98 201 
417 l – 11.3 w – 8.2 6.08 199 
2007 442 l – 11.4 w – 8.4 5.93 207 
 2008 no tulip 209 7.12 3.23 mCPP 60.3 









 2011 no bird 221 6.89 4.04 mCPP 63.6 
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 range 199 – 214 mg).  Two other tablets, one with the tulip and another with bird logos, 
contained mCPP and another two tablets, with the apple logo, contained caffeine.  Three 
of the four types of ‘ecstasy’ tablets found had logos and only one type, tablet with apple 
logo, had a breakline.  The tablets were all white coloured and had a round shape with the 
exception of six tablets which had a diamond shape.  The means of the measurable 
features of the 4 round tablets were: mean mass was 220.5 mg (SD 8.19, range 209 – 228 
mg), mean diameter was 7.43 mm (SD 0.50, range 6.89 – 7.89 mm) and the mean 
thickness was 3.74 mm (SD 0.36, range 3.23 – 4.04 mm).    Moreover, the mean dosage 
of the mCPP tablets was 62.0 mg and the mean dosage for the caffeine tablets was 19.1 
mg.  
 
Some of the ‘ecstasy’ tablets that were seized at the EDM events during 2006 – 2011, 
shown in bold in Tables 6a.4 to 6a.9 were found to have very similar physical measurable 
features and dosage with seizures containing ≥ 100 MDMA tablets which were 
examined, analysed and described in Chapters 3 and 5 respectively (Table 6a.10).  
Moreover, the tablet seizures also included three tablets usually obtained by prescription 




Of the 83 doses of powder, found in 77 seizures, more than one third (37.3%, n = 31) 
were individually wrapped in paper sachets while the rest, 53 doses, were individually 
sealed in small plastic bags.  Cocaine was the substance most commonly found in 
powders, (54.2%, n = 45, typical mass – 0.5 g, range 0.4 - 1.2 g), followed by 
mephedrone (9.6%, n = 8, typical mass 0.2 g, range – 0.1 - 0.4 g) and heroin (6.0%, n = 5 
and mass range – 0.06 - 0.1 g).  Other substances found in the powders included 
amphetamine powder (n = 1, 0.1 g), and caffeine (n = 4), paracetamol (n = 4), lignocaine, 
n = 1)   and ketamine (n = 1 scheduled under Maltese drug laws).  Cocaine powder was 
also found to contain lignocaine (6.7%, n = 3) and phenacetin (68.9%, n = 31).  In 13 
powders (15.6%, typical mass – 0.5 g, range – 0.8 -2.1 g), which were white in colour  
(76.9%, n = 10), no illegal or pharmaceutical substances were detected.  
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 Table 6a.10 MDMA tablets seized at EDM parties which had similar physical 
features (visual and measurable) and dose to the batches of tablets. 
 
Key: For the batches the numbers given are the means. 
 
Tablet / 









 2006 / 












Batch 2 2006 no no 432 / 6.10 BZP 206.4 
 







Batch 17 2007 no euro 211 8.09 4.37 MDMA 57.1 
 







Batch  18 2007 no D&G 200 7.02 4.13 MDMA 57.2 
 







Batch 19 2007 no heart 202 7.10 4.38 MDMA 60.6 
 
2007 no kangaroo 240 8.09 3.57 MDMA 47.9 
Batch 21 2007 no kangaroo 241 8.09 3.58 MDMA 48.8 
 







Batch 24 2008 no euro 202 7.13 3.59 MDMA 12.9 
 
2008 yes star 193 8.10 3.44 MDMA 42.6 
Batch 25 2008 yes star 194 8.10 3.45 MDMA 43.5 
 







Batch 26 2008 no smiley 209 8.20 3.28 MDMA 19.6 
 
2008 yes question mark 242 7.12 5.39 MDMA 40.3 
Batch 27 2008 yes question mark 258 7.11 5.34 MDMA 43.8 
 
2008 yes heart 236 8.39 4.94 MDMA 61.6 
Batch 28 2008 yes heart 236 8.40 5.08 MDMA 62.8 
 
2008 no tulip 209 7.12 3.23 mCPP 60.3 
Batch 31 2008 no tulip 206 7.10 3.20 mCPP 58.5 
 




























Batch 40 2010 no E=mc2 237 9.09 3.01 MDMA 60.2 
 







Batch 41 2010 cross route 66 246 9.08 3.36 MDMA 69.3 
 



















  6a.3.1.3 Plants and cannabis-like material 
 
From the 76 cannabis items 24 (31.6%) were cannabis joints, while 28 (36.8%) small 
packets of tobacco were found to be mixed with herbal cannabis (marijuana – 7.1%, n = 
13) or cannabis resin (hashish – 19.7%, n = 15). Other cannabis material found was 
crushed marijuana, (14.5%, n = 11, typical mass of 1 g, range 0.89 – 2 g), which were 
normally found in small plastic bags, and small pieces of hashish, (17.1%, n =13, typical 
mass of 1 g, range 0.76 - 1.5 g), where some were wrapped in aluminum foil.  
Furthermore, three samples of plant-like material, similar to marijuana from three 
different seizures, contained the substance naphthalen-1-yl-(1-pentylindol-3-
yl)methanone (JWH-018), a ‘synthetic cannabinoid’. 
 
 6a.3.1.4 Liquids 
 
One of the seizures contained one small plastic bottle, in the form of a fish, which 
contained 3 mL of transparent liquid.  The liquid was found to contain the substance 
GBL. 
 
6a.3.2 Illegal drug seizures and drug combinations 
 
The three major illicit drugs found in the seizures were the cannabis items, found in 76 
(44.2%) seizures, ‘ecstasy’ tablets, 48 (27.9%) and cocaine, 45 (26.2%).  The graph 
below (Figure 6a.1) gives an overview of the trends in the seizures of the major illegal 
drugs during major EDM events in Malta over the 6 year period.   
 
There  was  a significant decrease (p < 0.05, one-way ANOVA) in the seizures of 
‘ecstasy’ tablets by the police from EDM parties during 2010 and 2011, as compared to 
2006, from 48.5% to 16.7% in 2010 and 15.2% in 2011 respectively.  Conversely, there 
was a significant increase (p < 0.05, one-way ANOVA) in the seizure of cocaine from 













































Figure 6a.1  Percentage seizures of cannabis items, cocaine and ‘ecstasy’ tablets 
containing MDMA over a 6 year period (2006 – 2011).  
 
Confiscated ‘ecstasy’ tablets, containing MDMA and other psychoactive substances, 
were mostly found alone in the seizures (23.2%, n = 23).  However, when ‘ecstasy’ 
tablets were found with other substances in the seizures, the most common were cannabis 
items (37.0%, n = 10) and to a lesser extent cocaine (11.1%, n = 3).  When cocaine was 
found together with another substance in the seizure, the most common were the cannabis 
items (40.7%, n = 11).  There was a significant difference (p < 0.01, one-way ANOVA) 
between the combinations of ‘ecstasy’ with cocaine or cannabis (54.2%, n = 13) and 
cannabis with cocaine or ‘ecstasy’ (87.5%, n = 21).  Thus the combination of cannabis 
with either cocaine or ‘ecstasy ‘was significantly more likely than the use of ‘ecstasy’ 




The  aim  of  this  study  was  to  investigate  illicit  substance,  with  special  attention   to  
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 ‘ecstasy’ tablets confiscated by the police from major open air “commercial” EDM 
parties in Malta over a 6 year period from 2006 to 2011.  The ‘ecstasy’ tablets found in 
the seizures were compared with the batches seized during 2006 – 2011.  A total of 172 
seizures containing 238 separate items, were examined.  The items consisted of 75 
(31.5%) tablets, 83 (34.9%) powders, 79 (33.2%) crushed plants and cannabis like 
material and 1 (0.4%) small amount of transparent liquid.  The indications from these 
seizures were that the cannabis items were the most confiscated from major EDM events 
(44.2%, n = 76 seizures), followed by ‘ecstasy’ tablets (27.9%, n = 48 seizures) and 
cocaine (26.2%, n = 45 seizures).   
 
Most (85.9%, 61 out of 71 tablets) of the ‘ecstasy’ tablets confiscated from the EDM 
parties contained MDMA.  The MDMA tablets confiscated at EDM events had a mass 
which ranged between 200 - 250 mg (72.1%, n = 44).  The majority, (95.1%, n = 58), of 
the tablets had  diameters which could be grouped in three classes, 7, 8, and 9 mm, and 
thickness which could be grouped in three classes of 3, 4, and 5 mm, (98.4%, n = 60 
tablets).  The physical features, both visual and measurable, of the confiscated MDMA 
tablets were very similar to the physical features of ‘ecstasy’ tablets described in Chapter 
3 and were similar to ‘ecstasy’ tablets seized in other countries, such as Israel [139], 
Finland, Netherlands, Czech Republic, France, Germany, Switzerland and USA [181] 
and Switzerland [214].  A total 30 tablets (42.3% of the total ‘ecstasy’ tablets) 
confiscated at EDM parties over the six years period had similar visual and measurable 
features (mass, diameter and thickness) and dosage to tablets from 16 out of the 45 
batches (batches 2, 17-19, 21, 24-28, 31, 33, 40, 41, 44 and 45) described in Chapter 3.  
The 16 batches of tablets were seized during the same year when the ‘ecstasy’ tablets 
were confiscated from the EDM parties.  Moreover, 41 (57.7% of the total tablets) 
‘ecstasy’ tablets, with 29 different logos and colours, confiscated at the EDM parties 
during the six year period, did not match any of the tablets from the 45 batches.  Thus 
hypothesis (5) that: 
 
Those ‘ecstasy’ tablets seized by the police at EDM events in Malta will 




 was not verified. 
 
The mean MDMA content of the analysed ‘ecstasy’ tablets was found to have decreased 
from 63.5 mg in 2006 to 38.8 mg in 2008 and started to increase again in 2009 from 46.9 
mg to 64.6 mg in 2011.  The same happened in the UK where the mean MDMA base 
content of the ‘ecstasy’ tablets decreased from 64.5 mg in 2003  to 33.1 mg in 2008 and 
started to increase again in 2009 to 43.5 mg and continued to increase to 49.0 mg in 2010 
[307, 308].  These results from Malta and UK are consistent with what was reported in 
the UN 2012 World Drug Report that “during the second half of the 2000s the decline in 
the availability of the main precursor of “ecstasy” 3,4-MDP2P led to a shortage of 
MDMA” [309]. 
  
According to the same report, producers had to reduce the MDMA content in “ecstasy” 
tablets and “use various other substances to compensate” [309] for the decrease in 
MDMA. These substances included the use of piperazines and caffeine and in fact these 
were also found in ‘ecstasy’ tablets seized in Malta from partygoers during the period 
2006-2011.  However, as the piperazines, BZP, mCPP and its isomers, were scheduled in 
Maltese drug legislation in 2006 and 2007 respectively [310, 311], the use of these 
substances appears to have declined since then.  Moreover, the increase in the mean 
MDMA content of ecstasy tablets seized in Malta in 2011 (64.6 mg in 2011 from 57.9 mg 
in 2010) and in the UK in 2010 (43.5 mg in 2009 to 49.0 mg in 2010 [339]) could be an 
indication that the MDMA is recovering both in Malta and the UK as have been 
suggested by the UN 2012 World Drug Report [309]. 
 
A few cocaine powders contained the adulterant lignocaine, a local 
anesthetic and antiarrhythmic drug.  However, more than half of the powders contained 
the adulterant phenacetin, an analgesic which was banned in 1983 in the US by the Food 
and Drug Administration because of its carcinogenicity and because it could cause kidney 
failure [41, 312].  Other psychoactive substances found in the powders included 
mephedrone and amphetamine (both stimulants), lignocaine and ketamine, a substance 
which is used as an anesthetic both in human and veterinary medicine.  Ketamine, which 
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 has spread in many parts of the world for its recreational use [313], has a stimulant effect 
at low doses and a psychedelic effect at higher doses [314].  Some powders contained no 
illegal or pharmaceutical substances, while others contained caffeine or paracetamol.  
The use of unidentified powders and the occurrence of powders containing paracetamol 
and caffeine in wraps could possibly have been done in order to mimic illicit drugs [306].  
The presence of heroin (opioid analgesic), found in some brown powder, was not 
expected because these dance events are not usually associated with depressants; 
however, similar findings have been reported in the literature [41].   
 
The finding in these seizures of a small amount (3 mL) of transparent liquid containing 
GBL was also important.  The substance GBL, which is a prodrug to gamma-
hydroxybutyric acid (liquid ecstasy), could be used in committing drug-facilitated sexual 
assaults, [315, 316].  Prescription tablets (1.6%) which included dihydrocodeine (a semi-
synthetic opioid analgesic); counterfeit Viagra ® (used to treat erectile dysfunction) and 
promethazine (an antihistamine) were also detected in these seizures.  
 
It was also noted from the seizures the subtle change in the drug use at major dance 
events where new substances such as ‘legal highs’ or ‘herbal highs’ started to emerge.  
These included mephedrone, a synthetic stimulant detected in Malta in 2010, and the 
cannabinoid antagonist JWH-018, detected for the first time in Malta in 2011.  
 
The different types of illegal drugs found in these seizures, also reflected the occasional 
polydrug use by partygoers at major EDM events in Malta.  It has been reported that 
polydrug use (use of two or more drugs at the same time or the active use of more than 
one drug by users [317]), frequently occur during recreational activities [318].  Although 
users tend to prefer certain psychoactive substances in combinations, it does not solely 
depend on personal preferences, but also on the availability, the price, the perceived 
quality, legality and fashion of the drugs [242, 318].  Moreover, drug users frequently 




 tablets and cocaine replaced MDMA tablets when the availability of this substance was 
low [309, 318].   
 
Recreational polydrug users could also use a combination of drugs to get targeted effects 
such as the use of ‘ecstasy’ tablets or cocaine to increase endurance during dancing, and 
cannabis to relieve the unpleasant come-down effects, such as dysphoria and depression 
[65, 309, 319].  These combinations were noticed in the examined seizures where 
cannabis items were found together with ‘ecstasy’ tablets, or cocaine.  The UN World 
Drug Report, 2012 claimed that during polydrug use the sequential use of drugs is most 
common [309].  However, sometimes MDMA tablets are also taken with cocaine and 
although there is evidence that the pleasurable effects of MDMA is increased when taken 
with cocaine, the mixture is claimed to be mostly dangerous because of the neurotoxic 
action of MDMA [320].  For this reason, while polydrug use could enhance the intended 
effects for the user, it could also cause serious health consequences due to the possible 
risk of increasing the adverse health effects of the drugs used [309]. 
 
6b Assessing the behaviour of participants at a major EDM event in 
Malta  
 
In the last decade, clandestinely organised rave events have become more main stream, 
and well organised commercialised party culture [321].  ‘Ecstasy’ users began to 
consume other substances such as alcohol, cannabis, cocaine and amphetamines [112].  
 
6b.1 Introduction  
 
In Malta, as with many other countries, the organization and participation at major EDM 
events have always been influenced by changes happening on the European continent, 
especially in the UK [49].  England, which is considered to be a key city for EDM and 
rave culture [50], was and still is one of the main holiday destinations for many Maltese 




 are being organized around Europe, even in Malta, and which have also been linked with 
illegal drug use, especially ‘ecstasy’.  While it is generally acknowledged that illicit 
substance use, such as the use of MDMA, is common at EDM parties [41] this is largely 
hidden  making  it  difficult  to obtain objective data on the type of illicit substances being 
consumed by the interviewees. Previous research conducted at EDM events, have 
focused primarily on demographic information of drug users, their method of drug use 
and the supply and availability of drugs at such events. Yet there are still important gaps 
on the understanding of the attendee behaviour at these events [323].   
 
The commercial nature of major EDM events is a key limiting factor, making the events 
largely impenetrable for research studies to obtain this type of data because of the fear of 
bad publicity by the organisers [324].  However, the differences between the late 1990s 
raves and the new commercial outdoor major EDM events require a better understanding 
of the behaviour of attendees before, during and after the event. Young people like to 
socialize and going out had become an important part of their lives [218].  Thousands of 
young Maltese (66.9%, n = 59,254) had attended to nightlife venues during 2007, with 
nearly one fifth of these (16.2%, n = 14,362) claiming to like EDM [325].  It is claimed 
that illicit drugs are normally found at these venues and that the prevalence use of these 
drugs at these nightlife setting is much higher [218].  Thus a study was conducted to 
investigate the behaviour at a major EDM event in Malta and the use of both licit and 
illicit substances.   
 
This research, which was self-report based, sought to investigate details about: 
- the way participants prepared for the party;  
- their activity during the party;  
- their activities in the after party phase;  
- the use of licit substances, such as alcohol and nicotine;  
- the possible use of EOCD;  





 6b.2 Methodology      
 
The study was approved by the Foundation for Social Welfare Services, Sedqa Ethical 
Committee  on  the  11th  of  August  2010  (see  Appendix  3).  Sedqa is Malta’s National  
Agency Against Dependencies.  Permission was also granted to use the Sedqa logo on the 
questionnaire. 
 
6b.2.1 Research setting 
    
The study was conducted during Malta’s peak tourism season in August 2010. The 
“commercial” mainstream EDM event was organised by partnership between event 
promoters and leisure companies.  It was held at an outdoor club located in the centre of 
the island, in large open space around 5 km from the closest inhabited areas.  The club, 
which is surrounded by trees, has one of Malta’s largest dance floors and has a capacity 
of over four thousand people.  The club owners granted the authors permission for the 
study and facilitated the access for the researchers to attend the event.   
 
6b.2.2 Procedure for data collection and analyses 
 
The questionnaires were administered by ten interviewers, who had previously undergone 
training regarding the recruitment and data collection (Appendices 4 and 5).  The 
questionnaire was semi-structured and available in Maltese and English. The 
questionnaire (see Appendix 6) was composed of five sections which sought information 
on:  
 
• demographic information; 
• in-party behaviour; 
• EOCD drug consumption; 
• use of ecstasy;  




 1. The demographic section, which sought information on the age, nationality, 
education status and employment, helped to determine and describe the 
interviewed population. 
 
2. Interviewees were asked about their behaviour during the event itself in order to 
determine if their actions during the event were predetermined from the illegal 
drug they intended to or had consumed.  In addition the questions were set such 
that the answers also tried to discriminate between those interviewees who used 
only ‘ecstasy’ and those who used ‘ecstasy’ and / or other illegal drugs.   
 
3. The section on drug consumption provided information about patterns of drug 
use in the interviewee.  This section also includes the Alcohol Use Disorder 
Identification Test (Audit-C) [326]. 
 
4. The section on the use of ecstasy contained questions which dealt with the 
possible use or otherwise of ‘ecstasy’ by interviewees at the EDM event.  
 
The information obtained from Sections 3 and 4 assisted in determining the quantity and 
type of illegal drugs consumed at these events and also provide some information on the 
dimensions in the local Maltese context.   
 
5. The section on post-party behaviour provided information on the way 
interviewees sought to minimise the negative effects of any drugs they may 
have consumed.  They were asked about what they did if they became unwell at 
the event, whether they took fruit or vitamins after the event and if they did 
anything to help them sleep after the event.  In addition this section sought to 
determine if there were any similarities and differences between those who used 
only ‘ecstasy’ and those who used ‘ecstasy’ and / or other illegal drugs.   
 
The coded and fully anonymised questionnaires were analysed as described in Chapter 2, 
Section 2.4.2.    
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A total of 58 subjects took part.  There were more male interviewees (70.7%, n = 41) than 
females (29.3%, n = 17).  Their mean age was 24.98 years (SD 6.11, modes 19, 20, 22 
and 24, range 16 - 43 years).  Nearly all the interviewees (96.6%, n = 56) were Caucasian 
(white), with a large majority (60.3%, n = 35) being Maltese.  About a third (36.2%, n = 
21) of those interviewed were tourists coming mainly from European countries.  Almost 
all of the interviewees (94.8%, n = 55) listed upper secondary and tertiary level as their 
highest level of completed education. The majority of the interviewees (67.2%, n = 39) 
were fully employed and most (63.8%, n = 37) still lived with their parents.  
 
Party behaviour  
 
While over half (59.7%, n = 37) of the partygoers attended these parties with friends, in 
groups of 4 to 10 people, 27 of the interviewees (46.6%) stated that they informed their 
friends that they were going to the event.  Moreover, 26 interviewees (44.8%) reported 
that they go to a party every week.  Before attending the event, two thirds of the 
interviewees (67.2%, n = 39) stated that they usually had a good meal or vitamins or 
minerals.  Most (81.1%, n = 47) of those interviewed attended the event for between 4 to 
6 hours, with the majority 82.8%, (n = 48) of those attending spending between 40-80% 
of the time dancing.  The mean money spent during such an event, according to 
interviewees, was € 59.5 euros (SD 51.5, range € 0 - 200).   
 
Alcohol and tobacco use 
 
All but one (98.3%, n = 57) of the interviewees were found to have consumed alcohol at 
least once, during the year and in the month before the interview took place. Most 
(96.55%, n = 56) of the interviewees stated that they had consumed alcohol during the 
event itself.  The mean age for the first time consumption of alcohol among interviewees 
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 was 15.44 years (SD 2.5, range 11 – 24 years).  The interviewees were found to consume 
alcohol on a mean of 11 days during a month (SD 7.62).  
 
More than half (62.1%, n = 36) stated that they drank ≥ 8 units of alcohol.  The mean 
number of units drank at a typical party was 11.05 (SD 35.37, range 0 – 30 units).   The 
Alcohol Use Disorder Identification Test (Audit-C) was used as a diagnostic tool to 
screen for  alcohol  use disorders in the subjects Table 6b.1).  The majority (87.7%) of the  
 
Table 6b.1 Results from “Alcohol Use Disorder Identification Test” (Audit-C).  The 
table shows the percentage results of the frequency alcohol consumption of the 
interviewed participants at the EDM event. 
 
Audit-C 
Scoring system  
0 1 2 3 4 
 
Frequency of drinking 
 
 
Number of subjects responded 









1 4 20 15 17 
Quantity of  units of alcohol 
consumed on a typical day 
 
 
Number of subjects responded 
1-2 3-4 5-6 7-9 10+ 
 4  5 18 11 19 
Alcohol consumption on single 
occasion during the  
last year: Female ≥ 6 units and 
Male  ≥ 8 units  
 
Number of subjects responded 




7 9 8 29 4 
Scores 0-7 8 (cutoff) 9-12 
%  37.5, n = 21 16.1, n = 9 46.4, n = 26 
 
 
interviewees confirmed consumption ≥ 6 units or ≥ 8 units on a single occasion during 
the  last year.   While the majority (84.2%, n = 48) reported that they would consume 5 or  
more  units  of  alcohol  when  they  were  drinking, more than half (56.1%, n = 32) of the  
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 interviewees stated that they drank ≥ 2 to 4 alcoholic drinks per week (Table 6b.1).  The 
Audit-C showed that nine (16.1%) of the interviewees were a score of 8, an indication of 
hazardous and harmful alcohol use [327].  As shown in Figure 6b.1 it can be seen that 
most subjects (62.5%) scored between 8-12 on the scale, while 16.1%  (n  =  9,  males 
scored 4  to  5  points,  and  females scored 3 to 5 points) consumed alcohol with 
moderation (Figure 6b.1).  More than one third (39.7%, n = 23) of the interviewees stated 




Figure 6b.1 Graph showing the percentage results of the Audit-C Score.  Men who 
score 4 or women who score 3 or higher, drink above recommended limits and are 
at increased risk of harm (56 replies). 
 
Most of the interviewees (75.9%, n = 44) were found to have ever used tobacco, in the 
form of cigarettes.  The mean age for first use of tobacco for those who answered (58.8%, 
n = 20/34) was 15.62 years (SD 2.15, range 12 - 21 years).  More than half stated that 
they had smoked on the day of study (60.3%).   
 
 Illicit substance use 
 
Just  over  half  of  the  subjects  (55.2%,  n =  2)  reported  ‘ever-use’   of   illicit   drugs.   





















Cannabis (such as resin, grass, oil and skunk) were found to be the most popular drugs 
(87.5%, n = 28) among those who claimed to have ‘ever-used’ illicit drugs (Figure 6b.2).  
The use of cannabis was also the most common illicit drug used among EOCD users 
during the year and month of the study (46.9%, n = 15 and 37.5%, n = 12 respectively).  
Half of the subjects (50%, n = 16) who stated ‘ever-used’ of illicit substances had used 
‘ecstasy’ (tablet and / or powder) and 15 (46.9%) interviewees had used cocaine (powder 
and / or crack) (Figure 6b.2).  The use of these two illicit drugs by the EOCD users 
during the year and month of the study was: for the ‘ecstasy’ items 37.5% for the tablets 
(n =12) and 21.9% for the powder (n = 7) respectively and for the cocaine items 15.6% 
























Figure 6b.2 Percentage of illicit drugs that were consumed by interviewees some 
time in their lives.  
 
‘ever used’ EOCD (Figure 6b.2) by the interviewees included amphetamine (28.1%, n = 
9), alkyl nitrate (25.0%, n = 8) magic mushrooms (18.8%, n = 6) and nitrous oxide 
0 10 20 30 40 50 60 70 80 90 100 
Cannabis (resin, grass, 
skunk, oil) 
Cocaine (powder / crack) 














Ever consumed (%) 
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 (12.5%, n = 4).  Additionally ketamine, LSD, salvia devanorum, MDA, MA, 
mephedrone, and gamma-hydroxybutyric acid were reported as ‘ever-used’ as were 
heroin and opium. 
 
The mean age of ‘first-time’ use of illicit drugs among subjects was 19.69 years (SD 
4.03, range 13 – 24 years).  The mean age for the ‘first-time’ of ‘ecstasy’ (tablets and / or 
powder) was 20.95 (SD 4.09, range 14 – 33 years), for cannabis mean 17.24 years (SD 
2.73, range 13 – 25 years) and for cocaine (powder and / or crack) mean 20.58 years, (SD 
2.71, range 17 – 25 years).   
 
Among the interviewees who ‘ever-used’ illicit drugs, 40.6% (n = 13/32) reported using 
them in the month prior to the study.  The majority of the interviewees who attended the 
EDM event did not report any use of EOCD.  Only four interviewees stated that they had 
smoked cannabis on the day of the event.  No significant difference (p > 0.05, one-way 
ANOVA) in the party behavior (i.e preparing, informing friends, before party, etc. see 
Appendix 6)  of the interviewees was detected between those who claimed to have never 
used (43.1%, n = 25) and those who ever used illicit drugs (55.2%, n = 32).  Moreover, 
there was no significant difference (p > 0.05, one-way ANOVA) between those 
interviewees who claimed to have never used and ‘ever-used’ EOCD, irrespective of 
gender, for alcohol consumption. 
 
Use of ‘ecstasy’ 
 
Nine subjects who had ‘ever-used’ ‘ecstasy’ tablets (24.1%, n = 14), reported that on 
average they consumed between one to four tablets for each event and four of these 
interviewees added that they took ‘ecstasy’ for only one day.   Eight of the interviewees 
felt that it was important that ‘ecstasy’ tablets contained MDMA and a further eight 
would test their tablets if they could for curiosity and / or for health concerns.  Only 




 Although on the night of study none had used ‘ecstasy’ according to self-reports the 
prices quoted for ‘ecstasy’ tablets and powder, ranged between € 2.5 to 10 per tablet, and 
between € 20 to 80 per gram of MDMA powder.  Out of the sixteen interviewees who 
declared ever used ‘ecstasy’ (tablets and powder), twelve stated that they did not prefer 
the powder.  Those that did prefer the powder did so because of its supposedly better 
quality.  Interviewees (n = 4) took other drugs with ‘ecstasy’ tablets such as Viagra®, 
LSD, ketamine and mushrooms.  Alcohol was found to be the most common licit 
substance (93.8%, n = 15), followed by tobacco (81.3%, n = 13) and the illicit cannabis-
items (75%, n = 12) that were mostly taken by the ever used ‘ecstasy’ partygoers. 
 
Of the 16 subjects who had previously used ecstasy the most common side-effects 
reported was excessive sweating (13/16), thirst / dehydration (10/16), numbness / tingling 
(6/16), feeling dizzy (6/16) and on occasion unable to pass urine (5/16).  Others stated 
that on occasion they vomited or felt nauseated (3/16) and had sexual problems (2/16).   
 
Post-party behaviour  
  
Asked to record how they felt at the EDM event nearly a third (34.5% n = 20) declared 
sometimes feeling unwell.  There were significance differences between interviewees 
who ‘ever-used’ illicit drugs and those who did not report drugs.  Those who ‘ever-used’ 
slept longer (8 h vs 5 h, p < 0.05, one-way ANOVA). However, there was no difference  
(p > 0.05, one-way ANOVA)  in alcohol drinking. 
  
 6b.4 Discussion  
 
This study provided some insight and understanding into the context of attendee’s 
behaviour at a major EDM event in Malta.  The average event-goer was found to be 
about 25 years old, well educated, most probably employed and still living with parents 





 6b.4.1 Alcohol and tobacco 
 
Alcohol was found to be the most commonly used licit substance at this EDM event. 
More than half (52.6%, n = 30) of those that reported alcohol use on a typical day would 
consume more than half of the national average weekly units of alcohol for those aged 
between 18-34 years (12.7 units for those aged 18-24 years and 13.3 units for those aged 
25-34 years [325].  Of those interviewed 75.9% were found to be high to severe risk 
alcohol drinkers (scored 6-12, Audit C).  These results were found to be similar to results 
obtained in the Scotland study [324].  Most of the interviewees were found to be smokers 
and more than half (60.3%) were current smokers.  
 
6b.4.2 Illicit substances used 
 
The majority of the interviewees did not report any use of illicit drugs on the night at the 
EDM event. However, respondents in this study who once used or were using illicit 
substances were more likely to use psychedelic drugs.  Cannabis items were the most 
preferred illicit drugs that were used by users in this study.  Also, a fair number (36.21%, 
n = 21) of interviewees in this study stated that they had experimented with stimulants, 
such as ‘ecstasy’, cocaine and amphetamine, among others. ‘Ecstasy’ tablets were 
preferred to the powder; however, those that did prefer the powder did so because of the 
perceived better quality.  However, although most of the users of ‘ecstasy’ tablets were 
concerned about the contents of tablets they did not bother to test them.   
 
Other drugs reported to be ‘ever-used’ included the psychedelics magic mushroom and 
LSD, and the stimulants amphetamine, MA, mephedrone and herbal ecstasy.  The use of 
anesthetic drugs, such as gamma-hydroxybutyric acid and ketamine, did not seem 
popular with the drug users at such events because only a very small number of 
participants stated that they had at some time used these substances.  Illegal depressants, 
such as heroin and opium which are not normally found at EDM events, were also 
reported to have been used at least once in a life-time by a very small number of 
participants.  However, this is not surprising because the very nature of the effect of these 
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 substances would impair dancing ability.  It is also worth noting that most of the licit and 
illicit substances mentioned by respondents of this study were similar to the drugs seized 
by the Malta Police Drug Squad over a six year period, 2006 - 2011, (Chapter 6, Section 
6a.3.1) from 18 large open-air EDM events in Malta.   
 
6b.4.3 Party behaviour of attendees 
 
The  party  behaviour  of  interviewees  attending  this  open-air  EDM   event   was   also  
examined.  The interviewees were asked about how often they attend such events, with 
whom they went to the party, what they did before a party, the length of time they partied 
in one go, the time spent dancing, the money spent on a typical night and the type of  
drinks they consumed at the event.     
 
Going through the behaviour results a typical attendee to this major EDM Malta event 
would have taken a good night sleep and would have informed his friends before going to 
the event.  The young adult would normally have attended the event with 4 or more 
friends and partied for 4 to 6 hours with half of the time spent dancing.  Becoming unwell 
at EDM event is not uncommon even if illicit drugs are not used.  While the hot and 
crowded atmosphere could be one of the reasons for this, the most probable cause would 
have been the high alcohol consumption which was not uncommon at the studied event.  
After the event, if not going to an after party, the event-goer would normally sleep for 
less than 8 hours, without taking anything to sleep.   
 
6b.4.4 Overall findings 
 
The rate for lifetime use of alcohol (98.3%) followed by cannabis (48.3%), ‘ecstasy’ 
(27.6%) and cocaine (25.9%), which were found to be relatively high in this study when 
compared to the general population, were found to be similar to a study conducted among 
Swiss partygoers [305].  
 
The  high  use  of  alcohol  at this specific Malta EDM event was found to be similar with  
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 findings from other studies that were conducted on EDM event-goers in other countries 
including Belgium, UK and Australia [218, 242, 329].  In these studies interviewees 
claimed that at these events alcohol can be used as a substitute for the most commonly 
used EOCD, such as cannabis, ecstasy and cocaine, but no substance was able to replace 
alcohol [242].  
  
This further supported the idea that those who are poly EOCD users are primarily alcohol 
users [218, 242, 329].  Similar findings were reported by Riley et al. [219] and then by 
Measham [330, 331] who found that there was a decline in the use of cocaine and 
‘ecstasy’ tablets and increase in alcohol consumption in EDM events [219, 330, 331].   
 
Measham, in 2006, claimed that the increase in alcohol consumption and the decrease in 
illicit EOCD use were caused by the merger of the “legal and illicit psychoactive 
markets, with normalization of recreational drug use” [331].  Similarly Martinus et al. 
[324] again maintained that alcohol was the main substance used, whilst illicit drug use 
was minority behaviour [324]. Whereas in the late 1990s, the EDM scene was associated 
with club drugs (‘ecstasy’, LSD, amphetamine and cannabis) and alcohol popularity was 
then low; in the last decade the use of alcohol had greatly increased in the EDM event 
scene [324].  In addition, similar to other studies, interviewees in the Malta study were 
also found to be predominantly current tobacco smokers [329, 332]. 
 
It was also evident that the three most common illicit drugs ‘ever-used’ were (in order 
most frequently mentioned): cannabis, ‘ecstasy’ and cocaine.  This could be an indication 
that cannabis, ‘ecstasy’ and cocaine are the most popular EDM drugs among Maltese 
partygoers similar to their counterparts in the UK [2, 333].  The drug types did not differ 
significantly between ‘ever-used’, used this year and last month.  Although on the day of 
the Malta event very few attendees stated to have used an illicit drug, probably due to the 
presence of plain-clothes policemen at the party, most of the subjects did not avoid from 
alcohol consumption, being legal. This could have caused problems if the partygoer was 
a  polydrug  user.   The  use  of  illicit  drugs  together  with  alcohol  consumption  is  not  
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 uncommon in these types of events [363, 334].  Polydrug use may be due to a need by the 
user for drugs serving different purposes such as stimulants being used in the early part of 
the event in order to increase energy levels to dance, whilst the use of alcohol and 
cannabis later on in the event would serve to decrease agitation and sleeplessness [333].   
 
This study also provided a distinct sequence for the age of first use for the most popular 
EOCD.  Most users began to use alcohol and tobacco at a mean age of about 15 years, 
followed by cannabis, for those who used illicit drugs, at a mean age of about 19 years.   
‘Ecstasy’ and cocaine products, when consumed, were first taken at a mean age of 20 
years.     Although the pattern of first use of these substances was comparable to a similar 
study conducted in 2001 in three European cities, Amsterdam, Hanover and Vienna (14 
years for alcohol and tobacco, 15 years for cannabis, 17 and 18 years for ‘ecstasy’ and 
cocaine respectively)  the ages of onset were found to be higher in the Malta [332]. 
 
Of the 16 people that reported ever using ecstasy it was also established that one to four 
‘ecstasy’ tablets were taken by users at a party whenever they used this drug.  This 
finding was similar to other previously published studies [2, 335, 336].  Presumably the 
number of ‘ecstasy’ tablets taken during a night out would be dependent on the duration 
of the party, personal preferences and the quality of the ‘ecstasy’ tablets with regards to 
the amount and the type of active ingredient present. 
 
As already stated in the introduction to this part of the chapter, the use of stimulants in 
EDM events, are seldom the centre of recreational activities [337].  In effect the majority 
of the interviewees who attended the Malta EDM event did not report any use of EOCD. 
However, the few that did use EOCD did so to enhance some other activities such as 
social interaction [337].  Contrary to what was expected the behaviour at the event and 
the post-party period of those who ever used or continued to use EOCD was not different 
from those who never used these illicit drugs.  However, the most important finding of 





 6b.4.5 Limitations of the study 
 
This study, as with most research studies, has some methodological limitations which 
need to be acknowledged.  The questionnaire which had to be kept short, since it is 
difficult to keep the interviewees attention for a long time during an EDM event, did not 
delve deep enough into the behavior and substance use of the clubbers.  The findings 
should be interpreted with some caution since the information given by the interviewees 
could have been subject to errors in recollection.   
 
In addition, the presence of plain-clothes policemen during the event might have affected 
the interviewees’ responses, causing them to under-report their EOCD use. As with all 
studies involving questionnaires to possible EOCD users, the use of the mentioned drugs 
cannot be taken confirmed since the ‘ecstasy’ available may not have contained MDMA 
but other substances.    
 
This study however, as far as can be found, was the first Maltese study which sought to 
investigate the behaviour of EDM event attendees and use of EOCD at major EDM 
events and a  number of interviewees were willing to talk while at the event.  The results 
from this study could be used to formulate strategies and education campaigns as part of 












As discussed in Chapter 1, this thesis had tried to address of how physical 
characterisation of ecstasy tablets could be used to establish links and contrast and 
compare tablets found in specific batches for use for forensic drug intelligence purposes.  
Similarity in the physical features of tablets normally indicates that the tablets were from 
the same batch and that the same tabletting machines and punches were used [136], 
whilst difference in the physical features of tablets is usually indicative that these were 
from different batches.  It was for this purpose that the physical characterisation of 
batches of ‘ecstasy’ tablets, which included both the visual features (shape, colour, logo 
and colour) and the measurable features (mass, diameter, thickness, hardness, friability 
and disintegration rates) were investigated. However, the physical features of tablets are 
dependent on the storage conditions of the batches after manufacture.  Thus stability 
studies focusing on the photostability, temperature and RH, were conducted to investigate 
possible changes in the physical features of tablets and to propose an ideal storage 
conditions for the ‘ecstasy’ tablets while held at the forensic laboratory.  This was to 
ensure that the physical characteristics of the tablets in the batches remain stable 
throughout an investigation.         
 
It is sometimes argued that the physical features of tablets are not sufficient enough to 
link or differentiate between batches of ‘ecstasy’ tablets [212] and chemical 
characterisation is recommended.  Thus chemical characterisation of ‘ecstasy’ tablets 
from seized different batches was undertaken using in the process experiments to 
determine the psychoactive substances both qualitatively and quantitatively of the tablets, 
determining the isomeric content ratio and impurity profiles of MDMA-only tablets, 
determining the major excipients and elemental profiles of the tablets from the batches.  
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 The chemical characterisation, which complemented the physical characterisation, further 
helped link or differentiate between the examined seized batches of ‘ecstasy’ tablets.  
 
This research has also tried to investigate the use of ‘ecstasy’ tablets at EDM parties, for 
this purpose two studies were conducted.  The first study involved the analyses of 
substances and tablets which were confiscated by the police during 18 “commercial” 
EDM parties in Malta over a six year period from 2006 - 2011.  The second study, which 
was called the “Malta study”, investigated the behavior of participants and their use of 
both licit and illicit substance at a “commercial” EDM event held during the summer of 
2010.  
 
The present research utilised a unique national collection of ‘ecstasy’ tablets which were 
seized from traffickers by legal authorities and ‘ecstasy’ tablets and substances which 
were confiscated by the police during EDM parties, in Malta.  The ‘ecstasy’ tablets from 
traffickers consisted of 45 batches (total 98,653 tablets) which were seized over a five 
year period (2006 - 2011).  From the EDM parties a total of 172 seizures, suspected to be 
drugs of abuse and containing a total of 75 tablets mostly ‘ecstasy’ tablets ( 94.7%, n = 
71), were confiscated by the police during the commercial” EDM parties, over a six year 
period (2006 - 2011).   
 
During the period of study the European ‘ecstasy’ market has changed and this might 
have affected the small illicit drug market in Malta.  Hence, it will be demonstrated 
whether the Maltese batches of ‘ecstasy’ tablets that were used in this study also reflected 
the changes that occurred in the European ‘ecstasy’ market during the five year period 
(2006 – 2011).  It will also be discussed whether the data and results from this thesis can 
be extrapolated to the European-wide scenario and be used in the forensic analyses of 
ecstasy found across Europe.   
 
7.1 The ‘Ecstasy’ Drug Market in Malta and Europe, 2005 - 2011 
 
In  2005  in  Europe  ‘ecstasy’  tablets  that  were  supposed  to  contain MDMA started to  
291 
 
 contain other psychoactive substances creating instability in the ‘ecstasy’ market [309].  
Part of the reason for the use of other psychotropic drugs in ‘ecstasy’ tablets was 
attributed to the lack in the availability of the precursor chemical 3,4-MDP2P which 
caused a decrease in the production of MDMA [309, 338].  The decrease in the 
availability of the chemical 3,4-MDP2P was credited to the successful investigations by 
the Dutch and Belgian into Chinese organized crime [309, 338].   The decline in the 
production of MDMA also caused a reduction in the content of MDMA in ‘ecstasy’ 
tablets [309].  Moreover, by 2006, the number of ‘ecstasy’ tablets seized in Europe 
started to decline, even  more in 2008 [1, 213] until the drastic decline  in 2009 (12.7 
million tablets in 2008 to 1.9 million in 2009 seized tablets, EU and Norway) [339, 340].  
Nevertheless, by mid-2010 Europol reported a resurgence of ‘ecstasy’ tablets in Europe 
[309].  The revival of the ‘ecstasy’ tablets was confirmed when three million tablets were 
seized in Europe in 2010 [341].  However, the resurgence in ‘ecstasy’ tablets seems to 
have occurred without the re-emergence of the primary MDMA precursor 3,4-MDP2P, 
indicating that clandestine chemists were using new precursors, or pre-precursors, to 
manufacture MDMA [309].  
 
The European ‘ecstasy’ market also affected the UK illicit drug market.  During the same 
period, 2006 - 2009, the number of ‘ecstasy’ tablets that were seized in the UK had 
decreased drastically (from ~ 6.7 million in 2006 to 171 thousand ‘ecstasy’ tablets in 
2009 [342]). Similar to what had happened in Europe in the UK by the mid-2008 
‘ecstasy’ tablets containing piperazines outnumbered ‘ecstasy’ tablets containing 
MDMA, implying that other psychoactive substances were being used instead of 
MDMA.  However, when in 2009 the piperazines became controlled substances in the 
UK, the number of tablets containing piperazines fell sharply [308].  Moreover, the 
resurgence of ‘ecstasy’ tablets that was noticed in Europe in 2010, was also witnessed in 
the UK (357 thousand ‘ecstasy’ tablets seized in 2010 [308]).  By 2010, the purity of 
‘ecstasy’ tablets for the substance MDMA had increased, further confirming the revival 




 In Malta, no ‘ecstasy’ laboratories have ever been found, and police investigations have 
determined that most of the ‘ecstasy’ tablets imported to the Island, come from European 
mainland, especially from the Netherlands (N. Harrison, 2012, personal communication, 
Assistant Commissioner, Malta Police, interview, 12 June).  Thus any changes which 
occurred in the European ‘ecstasy’ market during the study period 2006 - 2011 would 
have been expected to affect the Maltese illicit drug market.   
 
However the study came up with some key differences.  Unlike the situation in Europe, 
where there was a decrease in the number of ‘ecstasy’ tablets seized, in Malta between 
2006 and 2010 the number of ‘ecstasy’ tablets seized, which contained MDMA, was 
fairly stable averaging 20,376 tablets annually (N. Harrison, 2012, personal 
communication, Assistant Commissioner, Malta Police, interview, 12 June).  However, as 
happened in the European market, ‘ecstasy’ tablets containing other psychoactive 
substances, also started to be seen in Malta during the period of the research study.  The 
highest number of ‘ecstasy’ tablets, a total of 67,182, was seized in Malta in 2006.  One 
of the 2006 seizures, which contained 50,703 ‘ecstasy’ looking tablets, contained the 
piperazine substance mCPP instead of MDMA.  Moreover, in that period mCPP was not 
a scheduled substance in Europe including Malta and this may have accounted for this 
unusually large seizure.  In 2006, small amounts (< 150 tablets) of ‘ecstasy’ tablets 
containing another piperazine substance, BZP, were also seized.   
 
Contrary to what was happening in Europe in 2010 with regards to the resurgence of 
‘ecstasy’ tablets, in Malta the opposite occurred.  In 2011 and 2012 there was a drastic 
decrease in the numbers of ‘ecstasy’ tablets seized (2,143 and 1080 tablets respectively, 
N. Harrison, 2012, personal communication, Assistant Commissioner, Malta Police, 
interview, 12 June]).  The decrease in the seized number of ‘ecstasy’ tablets was probably 
due to a new psychoactive drug, 4-methylmethcathinone (mephedrone) in powder form, 
which had appeared by the mid-2010 on the Maltese illegal market.  By the end of 2010, 
this new psychoactive substance, 4-methylmethcathinone, was the most common drug 
seized at EDM parties and was probably the cause for the displacement of ‘ecstasy’ 
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 tablets from these parties.  So overall there were some differences between the European 
and the small Maltese ‘ecstasy’ drug markets.  
   
7.2 ‘Ecstasy’ Tablets: Physical Characterisation, Stability and Chemical 
Profiling 
 
As already described the prime objectives of this thesis was to establish methods for 
physical and chemical characterisation of ‘ecstasy’ tablets which could be used to 
establish links between batches of tablets in a forensic drug intelligence perspective.  This 
study has demonstrated that the methods used and developed in Chapter 2, “Materials and 
Methods”, have a potential in developing forensic science intelligence for the supply and 
manufacture of ‘ecstasy’ tablets.  Another prime objective of this research was the study 
which examined the effects of light, temperature and humidity on the physical 
measurable features of the tablets.  This study might influence the conclusions that could 
be drawn from using physical characteristics to link or discriminate between batches.  
The forensic scientists might need to take into account the possible changes in physical 
characteristics of tablets that might have taken place before seizure such that two batches 
from the same origin but which have been subjected to different environmental 
conditions during transport / handling may not give a match through physical 
characterisation. 
 
7.2.1 ‘Ecstasy’ tablets: Physical characteristics 
 
The batches of ‘ecstasy’ tablets that were examined in this study were mainly imported 
from the Netherlands, the country mostly associated with large ‘ecstasy’ production (N. 
Harrison, personal communication, Assistant Commissioner, Malta Police, interview, 12 
June).  In the Netherlands, ‘ecstasy’ tablets are normally manufactured by high capacity 
tabletting machines, producing between 15,000 to 60,000 tablets per hour [338].   
 
The results from the physical characterisation concluded that similar tablets from the 
same  and  different  batches  having  similar  logo,  shape  and  colour  had  very   similar  
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 measurable physical features, such as mass, diameter and thickness, thus indicating the 
possibility that the tablets were produced by the same tabletting machine and punches 
[139]. This part of the study showed that the visual features logo, shape, breakline and 
friability were found to be very reliable features to be used to characterise and 
discriminate between batches of ‘ecstasy’ tablet, however the measurable features mass, 
diameter, thickness were found to be the most discriminating features.  It was also 
determined from this study that the ‘ecstasy’ tablets that were seized on different 
occasions did not always have different physical features thus the set hypothesis (1) that:  
 
The physical state of different batches of ‘ecstasy’ tablets seized on 
different occasions in Malta during 2006 – 2011 was significantly 
different from each other. 
 
was partially satisfied because 14 batches confiscated during 3 out of the 30 seizures 
were found to have similar features. 
 
It was also concluded from this part of this study that there was good compliance for the 
pharmacopeial and pharmaceutical criteria for the individual physical measurable 
features of the examined batches of ‘ecstasy’ tablets.  This indicated the good expertise 
available to the illicit chemists producing these tablets and to the use of more professional 
tabletting machines found in the illicit ‘ecstasy’ market [338].  
 
7.2.2 ‘Ecstasy tablets’: Stability of colour and measurable physical features     
 
If the physical features of ‘ecstasy’ tablets are to be used for intelligence purposes these 
characteristics should be protected during the storage of tablets at the laboratory.  A study 
was conducted to try and determine how the light, both visible and UV, would affect the 
colour of tablets.  Two other studies were conducted to determine how different 
temperatures and RH would effects the measurable features (mass, diameter, thickness, 
friability, hardness and disintegration) of the tablets.  The stress tests used to determine 
changes in the colour and the measurable features of ‘ecstasy’ tablets were adopted from 




In the literature the general consensus is that colour and colour variation of ‘ecstasy’ 
tablets are not reliable characteristics for discrimination because interpretation is “highly 
operator dependent” [181].  No studies have been published which characterise ‘ecstasy’ 
tablets by their colour and colour variation using instrumental evaluation.  However, 
instrumental evaluation methods using reflectance spectrometry have been used to 
evaluate the stability of dyes in pharmaceutical tablets [230].  In this research study 
‘ecstasy’ tablets were subjected to photostability stress conditions to investigate change 
in the colour of the tablets, including white tablets, using reflectance spectrometry based 
on the CIE colour system.  
 
This study confirmed that if the colour of ‘ecstasy’ tablets is evaluated by reflectance 
spectrometry it could be one of the physical features that could be used to characterise 
‘ecstasy’ tablets.  Portable spectrcolorimeters with data storage capacity, similar to the 
instrument used in this study, makes colour evaluation of seized batches of ‘ecstasy’ 
tablets easy and quick.   The results indicated that the colour of the tablets changed under 
both visible and UV light. After 38 days obvious colour change was noted in the colour 
of orange tablets with the pisces logo (batch 14) but only slight to very slight changes in 
the colour was recorded for the blue and green tablets with the omega logo (batches 5 and 
8) and white tablets with the euro logo (batch 11).  
 
The two other stability studies, which involved the storage of ‘ecstasy’ tablets under 
different temperatures and RH, confirmed that changes do occur to the measurable 
features of tablets if stored at high 75% RH, and mostly when kept at a temperature of 
40°C.  The changes in the measurable physical features of ‘ecstasy’ tablets, such as the 
diameter, thickness and volume, which were caused by swelling of the tablets due to 
major excipients such as lactose, were found to be in accordance with results from 
experiments conducted on pharmaceutical tablets [253, 254].  The use of major excipients 
such as lactose permits the manufacture of tablets by direct compression, which is 
probably the method used for the manufacture for ‘ecstasy’ tablets [134], has the 
advantage of lower costs and tablet stability [253].  However, when tablets are produced 
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 by direct compression using lactose as the major excipient the tablets tend to swell [253] 
when stored at high RH (≈ 75%), thus making  it difficult to link batches of tablets if 
these have common origin.   The hardness was also found to decrease more markedly 
when tablets were stored at 75% RH and 40ºC making it difficult and sometimes 
impossible to measure the tablets physical features.  It was also determined from the 
stability study that the least change in the measurable features had occurred when tablets 
were stored at 33% RH and at temperatures between 15 and 35°C. Thus it is 
recommended that batches of ‘ecstasy’ should be stored at low RH (≈ 25%) and 
temperature (≈ 25 °C) and away from sunlight if the measurable features are to be used 
for intelligence purposes.  
 
7.2.3 ‘Ecstasy’ tablets: Organic and inorganic chemical profiling 
 
All ‘ecstasy’ tablets taken from batches of major seizures were subjected to a general 
organic chemical profile to determine the major psychoactive substances present.  More 
than half (66.7%, n = 30) of the analysed tablets were found to contain MDMA as their 
active ingredient.  ‘Ecstasy’ tablets would not always contain MDMA as their major 
active ingredient and thus the tablets seized in Malta were found to contain other 
psychoactive substances such as DPIA, a psychoactive substance first detected in 
‘ecstasy’ tablets in Malta in 2006 and reported to EMCDDA, mCPP, BZP, caffeine, the 
anabolic steroid methandrostenolone and tablets with no psychoactive substances.  Thus 
hypothesis (2) which stated that: 
   
 Seized ‘ecstasy’ tablets will contain MDMA as the predominant 
psychoactive substance. 
 
was not verified. 
 
Although not much have been written about the use of the general organic chemical 
profiling of ‘ecstasy’ tablets for evidential and intelligence purposes [126], this should be 
used because it adds another discriminating factor that together with other features, such 
as physical characteristics, could help link or differentiate between batches of tablets. 
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 Clearly there is no set recipe for the production of ‘ecstasy’ tablets and the drug content 
tends to vary between different batches of tablets.  Hence, the drug content was another 
discriminator that was used to link or differentiate between batches of ‘ecstasy’ tablets.  
The European pharmacopeial method was used to determine the mean content of the 
psychoactive substance present in ten similar ‘ecstasy’ tablets that were taken from the 
same batch [221].  The results from these analyses have shown that in general the dose of 
the psychoactive substances between ‘ecstasy’ tablets from the same batch did not vary 
much (< 5% RSD).  However, there was variation in the mean dose between different 
batches of tablets, normally having different physical features.    
 
The batches containing MDMA tablets that were seized in Malta over the five year period 
(2006 – 2011) were also analysed to determine their enantiomeric composition.  From the 
analyses it was determined that the batches contained tablets with a racemic mixtures of 
MDMA.  Thus hypothesis (3) which stated that:  
 




Impurity profiling of seized MDMA tablets was another discriminator that was used to 
try and classify tablets into related batches.  Impurities in the tablets are mainly generated 
by the precursors chemicals used in the synthesis of MDMA, impurities present in the 
starting materials, and by-products from side reactions produced during MDMA 
synthesis.  Other generated impurities are caused by inadequate purification of MDMA 
after synthesis and by contaminants [190] that are carried over unchanged to the final 
synthesised product.  The impurity profiling of MDMA tablets in this study focused 
mainly on identification of the precursors and the synthetic routes used.  From the 
chemical profiling results it was determined that 3,4-MDP2P was the precursor mostly 
used and that two synthetic routes, the Leuckart or reductive amination reactions, were 




 The excipients of ‘ecstasy’ tablets were also investigated for their discriminating power.  
Major excipients were identified by means of FTIR transmittance spectroscopy, while the 
elemental profiling of some of the excipients present in ‘ecstasy’ tablets was done by 
SEM/EDX analyses.  The compounds lactose and sorbitol were found to be the most 
common major excipients used in ‘ecstasy’ tablets, while elemental profiles of the 
excipients indicated the presence of magnesium stearate as the common lubricant, 
together with other possible glidants used in tablet production.  Although the 
identification of the major excipients and the inorganic profiling methods used for the 
tablets were not found to be highly discriminating it could still be used with other 
characterisation and profiling methods to further help differentiate or link batches of 
‘ecstasy’ tablets.  From the chemical characterisation it was possible to link 14 batches of 
‘ecstasy’ tablets containing MDMA as the major and only psychoactive substance.  Thus 
hypothesis (4) which stated that: 
 
The chemical composition of different batches of ‘ecstasy’ tablets seized 
on different occasions in Malta during 2006 – 2011 will be significantly 
different from each other. 
 
was not verified. 
 
In conclusion the two step process in the production of ‘ecstasy’ tablets, that of synthesis 
of the active ingredient/s and the production of tablets, provides many characteristics that 
could be used for linking or discriminating between batches of tablets.  This study which 
mainly focused on the physical and chemical characteristics of ‘ecstasy’ tablets tried to 
provide methods and examples as to how these characteristics could be used for 
intelligence purposes.  The measurable physical features mass, diameter and thickness 
together with the determination of the psychoactive substances and excipients, inorganic 
impurity profiling in the case of MDMA-only tablets and elemental profiling were found 
to provide enough data to link or discriminate batches of ‘ecstasy.   
 
In the future data exchange on ‘ecstasy’ tablets between European forensic laboratories 
intelligence must be further developed, if possible with the support from EMCDDA.  The 
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 continuous monitoring of the national ‘ecstasy’ markets and the sharing of data on these 
tablets will provide a better ‘picture’ of this dynamic European illicit drug market.  
 
7.3. Seizures of Drugs from EDM Parties and the Malta EDM Party 
 
In Malta the data about illicit substance is dominated by heroin and cannabis and there is 
no data about ‘ecstasy’ tablets characterisation.  This is because the majority of ‘ecstasy’ 
users do not normally come into contact with drug and health agencies and thus there is 
lack of data on the use of this drug.  It is claimed that contrary to heroin, ‘ecstasy’ tablets 
are mainly used by young adults as a “club drug” due its popularity and use at parties and 
clubs [334].   
 
To try and better understand the illicit drug market at EDM parties, especially the 
‘ecstasy’ use, two studies were conducted as described in Chapter 6 of thesis.  One of the 
studies involved the analyses of suspected illicit substances and the characterisation of 
‘ecstasy’ tablets confiscated from eighteen EDM parties in Malta during a six year period 
(2006 - 2011).  The second study, named the “Malta Study”, concerned the interviewing 
of partygoers during an EDM party, in 2010.   
 
The analyses conducted on the seized substances provided information on the drugs used 
at the EDM parties.  This type of drug monitoring, which did not rely on what users 
thought about their substances, gave an indication of the subtle changes in drug use 
which was occurring during the period at dance venues in Malta.  The most common 
confiscated drugs from these parties were cannabis, ‘ecstasy’ tablets and cocaine.  
 
Most of the ‘ecstasy’ tablets seized at these parties contained MDMA.  All the MDMA 
tablets had a round shape, had a logo and most (78.7%, n = 48 out of 61) were white.  
The measurable physical features (mass, diameter and thickness) of the MDMA tablets 
were similar to ‘ecstasy’ tablets described in Chapter 3 and similar to ‘ecstasy’ tablets 
seized in Europe.  Thirty of the tablets which were confiscated from the EDM parties had 
very similar visual and measurable features and dosage to 16 batches (batches 2, 17-19, 
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 21, 24-28, 31, 33, 40, 41, 44 and 45) described in Chapter 3.  The rest of the tablets (n = 
41) did not match any of the batches.  Thus hypothesis (5) that:  
 
Those ‘ecstasy’ tablets seized by the police at EDM events in Malta will 
match batches seized on different occasions in Malta. 
 
was not verified.  
 
The study on illicit substances confiscated at EDM parties has underlined the importance 
of on-going monitoring of illicit drug use because of the dynamic nature of this drug 
market.  The changes detected from illicit drug use and drugs habits during monitoring at 
EDM parties would provide accurate information which could be used by health care 
professionals to better plan drug prevention intervention.  Also, the information gathered 
about demand side for illicit drugs at EDM parties together with the supply side could 
provide better data for the market profiling of these drugs. 
 
The results from the “Malta Study”, conducted in 2010,  indicated  no ‘ecstasy’ use at the 
EDM event but demonstrated that on the night of the party clubbers were mainly using 
alcohol, in excessive amounts. The high use of alcohol at this EDM Malta party was 
found to be similar to alcohol use at similar parties in other countries including Belgium, 
UK and Australia [218, 242, 329].  From the Malta study it was evident that the three 
most common illicit drugs ‘ever-used’ were cannabis, ‘ecstasy’ and cocaine.  From the 
study of the seizures of illicit tablets from EDM events, it was noted that by 2010 the 
seizures of ‘ecstasy’ tablets from parties had decreased.  This could have been an 
indication that either the users of ‘ecstasy’ were declining at parties, or that the ‘ecstasy’ 
use was moving out of parties due to police surveillance, or else new psychoactive 
substances, like mephedrone, were replacing ‘ecstasy’ use.   
 
7.4 Future Work 
 
More research work should be carried out on the colour aspect of ‘ecstasy’ tablets to 
further confirm that the colour of these tablets could be evaluated by reflectance 
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 spectrometry and to determine the discrimination potential of colour to link or 
differentiate between batches of tablets.  Further work should also be carried out on the 
stability of organic impurities from MDMA tablets. This would help to determine how 
MDMA tablets should be stored prior to organic impurity profiling.  Another possible 
future study could focus on the setting up of European computerised database for both 
physical and chemical characteristics of ‘ecstasy’ tablets that could be used by European 
forensic drug laboratories to possibly establish origin of tablets and distribution routes.  
 
Since the number of EDM parties held in Malta has grown and it is accepted that some 
illicit substance use will continue during these parties, it is contemplated that for the next 
study the Police Drug Squad section would act as a catchment area to carry out voluntary 
and confidential interviews with police released partygoers.  A pilot study, which was 
approved by King’s College Ethics Committee (PNM/10-11-125, see Appendix 7), to 
gain information on drug use from low-level offenders has already been conducted.  It is 
hoped that this future study would provide information on changes in patterns of illicit 
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Appendix 1 – Figures of 2-D and 3-D Scatter Plots of Physical Characteristics of ‘Ecstasy’ Tablets (Chapter 3) 
 
 
Figure 1.1 2-D scatter plot of the means of mass versus thickness of 45 batches of ‘ecstasy’ tablets (the numbers near the coloured 





Figure 1.2 2-D scatter plot of the means of diameter versus thickness of 41 batches of round ‘ecstasy’ tablets (the numbers near 





Figure 1.3  3-D  scatter plot of the means of mass, diameter and thickness of 28 batches of round ‘ecstasy’ tablets which appeared 
touching, overlapping or superimposed in Figure 3.6 (the numbers near the coloured spots indicate the batch number as in Table 





Figure 1.4 2-D scatter plot of the friability versus mean hardness of 45 batches of ‘ecstasy’ tablets (the numbers near the spots in 





Figure 1.5 2-D scatter plot of the means of disintegration versus hardness of 45 batches of ‘ecstasy’ tablets (the numbers near the 





Figure 1.6 2-D scatter plot of the friability versus mean mass of 45 batches of ‘ecstasy’ tablets (the numbers near the spots in the 





Figure 1.7 3-D scatter plot of the means of disintegration and hardness, plus friability of 45 batches of ‘ecstasy’ tablets (the 





Figure 1.8 3-D scatter plot of the means of diameter, mass and hardness of 41 batches of round ‘ecstasy’ tablets (the numbers 





Figure 1.9 3-D scatter plot of the friability and the means of diameter and mass of 41 batches of round ‘ecstasy’ tablets (the 
numbers near the spots in the scatter plot indicate the batch number as in Table 3.2, batch 0 is the control batch, bumetanide). 
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 Appendix 2 – Tables of Temperatures and Relative Humidity  
of Stability Study (Chapter 4) 
 
Table 2.1  Mean mass (mg) of ‘ecstasy’ tablets when stored at 33 and at 75% RH 
during the 16 weeks. 
 
 
Key: Tablets from batch 33 stored at different conditions (33% RH and temperatures of 5, 15, 25 and 
35°C; 75% RH and temperatures of 5, 15, 25 and 40°C); the numbers in parenthesis are the SDs; the 






5 15 25 35 
0 270.5 (6.62) 275.1 (7.16) 275.9 (7.02) 277.6 (6.79) 0.141 
1 269.6 (6.50) 276.0 (7.45) 273.4 (6.65) 270.3 (6.48) 0.148 
2 269.1 (6.52) 277.2 (7.63) 273.2 (6.76) 269.8 (6.32) 0.045 
3 268.8 (6.58) 277.0 (7.85) 273.1 (6.82) 269.2 (6.55) 0.041 
4 268.5 (6.52) 276.6 (7.90) 272.5 (6.70) 268.9 (6.44) 0.044 
5 268.2 (6.76) 276.3 (8.21) 272.1 (6.82) 268.7 (6.48) 0.055 
8 268.1 (6.81) 276.3 (8.21) 272.1 (6.82) 268.5 (6.67) 0.051 
10 267.7 (6.41) 276.3 (7.96) 271.5 (6.92) 268.6 (6.60) 0.040 
12 267.6 (6.67) 275.9 (8.05) 271.2 (7.02) 268.2 (6.83) 0.054 
14 267.2 (6.73) 275.7 (7.78) 271.0 (6.83) 268.0 (6.91) 0.045 





5 15 25 40 
0 275.2 (6.18) 274.5 (5.68) 273.5 (7.44) 274.0 (5.33) 0.938 
1 278.5 (6.50) 278.7 (5.85) 275.1 (7.78) 274.6 (5.56) 0.351 
2 277.8 (6.46) 278.4 (5.85) 274.8 (7.64) 273.7 (5.40) 0.298 
3 278.1 (6.61) 278.6 (5.85 275.0 (7.66) 274.1 (5.17) 0.316 
4 277.6 (6.54) 278.2 (5.98) 274.4 (7.79) 273.3 (5.17) 0.264 
5 277.3 (6.57) 277.8 (6.11) 273.9 (8.05) 272.4 (5.06) 0.204 
8 277.4 (6.70) 277.9 (6.03) 273.8 (7.91) 271.5 (4.99) 0.106 
10 276.7 (6.31) 277.5 (6.02) 273.0 (7.99 271.5 (5.28) 0.134 
12 276.5 (6.77) 277.4 (6.04) 272.7 (8.04) 271.3 (4.97) 0.130 
14 276.5 (6.06) 276.9 (5.93) 272.4 (8.40) 271.3 (4.97) 0.142 




Table 2.2  Mean mass (mg) of the total ‘ecstasy’ tablets (n = 40) when stored at 33 
and 75% RH during the 16 weeks. 
 
 
Key: Tablets from batch 33 stored at different conditions (33% RH and temperatures of 5, 15, 25 and 
35°C; 75% RH and temperatures of 5, 15, 25 and 40°C); the numbers in parenthesis are the SDs; the 
numbers in bold text indicate statistical significance. 
 
Week 
RH of 33% RH of 75% 



























00 274.8  (7.14) 272.5 277.1 
274.3 
(6.00) 272.4 276.2 0.748 
01 272.3 (7.01) 270.1 274.6 
276.7 
(6.51) 274.6 278.1 0.005 
02 272.3 (7.32) 270.0 274.7 
276.2 
(6.46) 274.1 278.2 0.015 
03 272.0 (7.50) 269.6 274.4 
276.5 
(6.44) 274.4 278.5 0.006 
04 271.6 (7.42) 269.3 274.0 
275.9 
(6.53) 273.8 278.0 0.008 
05 271.3 (7.57) 268.9 273.7 
275.4 
(6.69) 273.2 277.5 0.014 
08 271.3 (7.65) 268.8 273.7 
275.2 
(6.79) 273.0 277.3 0.018 
10 271.0 (7.53) 268..6 273.4 
274.7 
(6.72) 272.5 276.8 0.025 
12 270.7 (7.64) 268.3 273.2 
274.5 
(6.80) 272.3 276.7 0.023 
14 270.5 (7.59) 268.0 272.9 
274.3 
(6.69) 272.1 276.4 0.020 
16 270.3 (7.36) 267.9 272.6 
274.3 
(6.90) 272.0 276.5 0.015 
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 Table 2.3  Mean diameter (mm) of ‘ecstasy’ tablets when stored at 33 and 75% RH 
during the 16 weeks. 
 
 
Key: Tablets from batch 33 stored at different conditions (33% RH and temperatures of 5, 15, 25 and 
35°C; 75% RH and temperatures of 5, 15, 25 and 40°C); the numbers in parenthesis are the SDs; the 






5 15 25 35 
0 8.20 (0.02) 8.21 (0.04) 8.20 (0.02) 8.20 (0.02) 0.743 
1 8.20 (0.02) 8.21 (0.03) 8.20 (0.02) 8.14 (0.01) 0.000 
2 8.22 (0.02) 8.22 (0.04) 8.23 (0.01) 8.18 (0.03) 0.002 
3 8.21 (0.02)  8.21 (0.04) 8.21 (0.03) 8.20 (0.02) 0.718 
4 8.22 (0.01) 8.21 (0.03) 8.22 (0.02) 8.20 (0.02) 0.131 
5 8.22 (0.02) 8.21 (0.03) 8.21 (0.01) 8.20 (0.02) 0.327 
8 8.22 (0.01) 8.22 (0.03) 8.22 (0.02) 8.19 (0.02) 0.003 
10 8.22 (0.01) 8.22 (0.03) 8.22 (0.02) 8.19 (0.02) 0.008 
12 8.22 (0.01) 8.22 (0.02) 8.21 (0.02) 8.20 (0.02) 0.071 
14 8.22 (0.02) 8.21 (0.02) 8.21 (0.01) 8.20 (0.02) 0.061 
16 8.22 (0.02) 8.21 (0.02) 8.21 (0.01) 8.21 (0.03) 0.335 




5 15 25 40 
0 8.19 (0.02) 8.20 (0.03) 8.19 (0.02) 8.20 (0.04) 0.752 
1 8.24 (0.02) 8.28 (0.02) 8.27 (0.06) 8.22 (0.02) 0.001 
2 8.23 (0.01) 8.27 (0.02) 8.24 (0.03) 8.24 (0.02) 0.005 
3 8.28 (0.03) 8.30 (0.02) 8.25 (0.02) 8.28 (0.03) 0.007 
4 8.28 (0.03) 8.30 (0.03) 8.25 (0.03) 8.29 (0.03) 0.003 
5 8.28 (0.02) 8.30 (0.02) 8.24 (0.02) 8.28 (0.02) 0.000 
8 8.28 (0.03) 8.31 (0.02) 8.27 (0.03) 8.29 (0.02) 0.007 
10 8.29 (0.02) 8.31 (0.02) 8.25 (0.02) 8.29 (0.04) 0.000 
12 8.26 (0.02) 8.30 (0.03) 8.25 (0.03) 8.29 (0.03) 0.000 
14 8.26 (0.02) 8.30 (0.02) 8.25 (0.02) 8.29 (0.04) 0.000 
16 8.26 (0.01) 8.30 (0.03) 8.24 (0.02) 8.29 (0.04) 0.000 
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 Table 2.4  Mean diameter (mm) of the total ‘ecstasy’ tablets (n = 40) when stored at 
33 and 75% RH during the 16 weeks. 
 
 
Key: Tablets from batch 33 stored at different conditions (33% RH and temperatures of 5, 15, 25 and 
35°C; 75% RH and temperatures of 5, 15, 25 and 40°C); the numbers in parenthesis are the SDs; the 
bold numbers indicate statistical significance. 
 
Week 
RH of 33% RH of 75% 



























00 8.20 (0.03) 8.19 8.21 
8.19 
(0.03) 8.18 8.20 0.175 
01 8.19 (0.04 8.18 8.20 
8.25 
(0.04) 8.24 8.26 0.000 
02 8.21 (0.03) 8.20 8.22 
8.24 
(0.02) 8.24 8.25 0.000 
03 8.21 (0.03) 8.20 8.22 
8.28 
(0.03) 8.27 8.29 0.000 
04 8.21 (0.02) 8.20 8.22 
8.28 
(0.03) 8.27 8.29 0.000 
05 8.21 (0.02) 8.20 8.22 
8.28 
(0.03) 8.27 8.29 0.000 
08 8.21 (0.02) 8.21 8.22 
8.29 
(0.03) 8.28 8.30 0.000 
10 8.21 (0.02) 8.21 8.22 
8.28 
(0.03) 8.27 8.29 0.000 
12 8.21 (0.02) 8.21 8.22 
8.27 
(0.03) 8.26 8.29 0.000 
14 8.21 (0.02) 8.21 8.22 
8.27 
(0.03) 8.26 8.28 0.000 
16 8.21 (0.02) 8.21 8.22 
8.27 
(0.04) 8.26 8.28 0.000 
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 Table 2.5  Mean thickness (mm) of ‘ecstasy’ tablets when stored at 33 and 75% RH 
during the 16 weeks. 
 
 
Key: Tablets from batch 33 stored at different conditions (33% RH and temperatures of 5, 15, 25 and 
35°C; 75% RH and temperatures of 5, 15, 25 and 40°C); the numbers in parenthesis are the SDs; the 






5 15 25 35 
0 4.38 (0.07) 4.39 (0.08) 4.43 (0.08) 4.42 (0.05) 0.477 
1 4.36 (0.05) 4.42 (0.08) 4.42 (0.08) 4.40 (0.07) 0.367 
2 4.38 (0.04) 4.48 (0.10) 4.41 (0.07) 4.39 (0.07) 0.033 
3 4.39 (0.05) 4.48 (0.10) 4.42 (0.07) 4.42 (0.07) 0.058 
4 4.39 (0.04) 4.48 (0.10) 4.41 (0.06) 4.42 (0.07) 0.030 
5 4.38 (0.04) 4.47 (0.10) 4.39 (0.07) 4.41 (0.07) 0.038 
8 4.39 (0.03) 4.48 (0.10) 4.41 (0.05) 4.41 (0.07) 0.023 
10 4.38 (0.04) 4.48 (0.10) 4.40 (0.05) 4.42 (0.06) 0.021 
12 4.37 (0.04) 4.47 (0.10) 4.40 (0.06) 4.41 (0.06) 0.021 
14 4.38 (0.04)) 4.47 (0.10) 4.39 (0.06) 4.41 (0.06) 0.026 
16 4.38 (0.04) 4.46 (0.10) 4.39 (0.06) 4.42 (0.06) 0.045 




5 15 25 40 
0 4.37 (0.05) 4.40 (0.09) 4.40 (0.06) 4.38 (0.06) 0.707 
1 4.46 (0.08) 4.51 (0.09) 4.46 (0.06) 4.42 (0.06) 0.104 
2 4.49 (0.06) 4.54 (0.08) 4.50 (0.05) 4.48 (0.06) 0.118 
3 4.48 (0.06) 4.52 (0.09) 4.47 (0.05) 4.48 (0.06) 0.320 
4 4.48 (0.07) 4.52 (0.09) 4.47 (0.05) 4.49 (0.06) 0.368 
5 4.47 (0.06) 4.51 (0.09) 4.44 (0.04) 4.49 (0.05) 0.165 
8 4.48 (0.07) 4.52 (0.09) 4.48 (0.07) 4.51 (0.06) 0.471 
10 4.48 (0.07) 4.52 (0.09) 4.48 (0.05) 4.52 (0.06 0.346 
12 4.47 (0.07) 4.52 (0.09) 4.48 (0.05) 4.53 (0.06) 0.175 
14 4.47 (0.05) 4.52 (0.09) 4.48 (0.05) 4.52 (0.05) 0.239 
16 4.48 (0.04) 4.52 (0.09) 4.48 (0.05) 4.52 (0.06) 0.257 
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 Table 2.6  Mean thickness (mm) of the total ‘ecstasy’ tablets (n = 40) when stored at 
33 and  75% RH during the 16 weeks (Number in bracket is the SD). 
 
 
Key: Tablets from batch 33 stored at different conditions (33% RH and temperatures of 5, 15, 25 and 
35°C; 75% RH and temperatures of 5, 15, 25 and 40°C); the numbers in parenthesis are the SDs; the 
numbers in bold text indicate statistical significance. 
 
Week 
RH of 33% RH of 75% 





























00 4.41 (0.07) 4.38 4.43 
4.39 
(0.07) 4.37 4.41 0.267 
01 4.40 (0.07) 4.38 4.42 
4.46 
(0.08) 4.44 4.49 0.000 
02 4.42 (0.08) 4.39 4.44 
4.50 
(0.07) 4.48 4.52 0.000 
03 4.43 (0.08) 4.40 4.45 
4.49 
(0.07) 4.46 4.51 0.001 
04 4.42 (0.07) 4.40 4.45 
4.49 
(0.07) 4.47 4.51 0.000 
05 4.41 (0.08) 4.39 4.44 
4.48 
(0.07) 4.46 4.50 0.000 
08 4.42 (0.07) 4.40 4.44 
4.50 
(0.07) 4.48 4.52 0.000 
10 4.42 (0.07) 4.40 4.44 
4.50 
(0.07) 4.48 4.53 0.000 
12 4.41 (0.07) 4.39 4.44 
4.50 
(0.07) 4.47 4.52 0.000 
14 4.41 (0.07) 4.39 4.43 
4.50 
(0.07) 4.48 4.52 0.000 
16 4.41 (0.07) 4.39 4.43 
4.50 
(0.07) 4.48 4.52 0.000 
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 Table 2.7  Mean volume (mm3) of ‘ecstasy’ tablets when stored at 33 and 75% RH 
during the 16 weeks. 
 
 
Key: Tablets from batch 33 stored at different conditions (33% RH and temperatures of 5, 15, 25 and 
35°C; 75% RH and temperatures of 5, 15, 25 and 40°C); the numbers in parenthesis are the SDs; the 






5 15 25 35 
0 231.5 (4.9) 232.5 (6.2) 233.9 (5.4) 233.3 (3.9) 0.762 
1 230.5 (4.1) 234.0 (6.0) 233.2 (5.2) 228.9 (4.2) 0.102 
2 232.3 (3.3) 237.6 (7.1) 234.4 (4.7) 230.9 (5.3) 0.123 
3 232.6 (3.4) 237.5 (7.4) 234.2 (5.5) 233.4 (4.6) 0.339 
4 232.5 (2.7) 237.3 (6.6) 233.6 (4.0) 233.2 (4.5) 0.261 
5 232.2 (3.2) 236.8 (7.0) 232.8 (4.1) 232.8 (4.9) 0.367 
8 232.6 (2.4) 237.7 (6.6) 234.0 (3.6) 232.5 (4.6) 0.170 
10 232.7 (2.8) 237.5 (6.7) 233.4 (3.8) 232.7 (4.4) 0.261 
12 232.2 (2.6) 236.9 (6.4) 233.0 (3.9) 233.0 (4.3) 0.248 
14 232.3 (2.7) 236.6 (6.2) 232.5 (3.9) 232.7 (4.3) 0.311 
16 232.4 (2.9) 236.1 (6.1) 232.1 (3.8) 233.8 (4.8) 0.332 




5 15 25 40 
0 230.4 (3.6) 232.5 (6.6) 231.7 (4.3) 231.1 (5.6) 0.835 
1 237.6 (5.3) 242.6 (6.1) 239.8 (6.3) 234.7 (4.5) 0.024 
2 238.8 (3.9) 243.5 (5.3) 239.5 (4.0) 239.0 (4.5) 0.080 
3 241.3 (5.0) 244.5 (6.0) 239.1 (4.2) 240.8 (5.3) 0.148 
4 241.0 (5.0) 244.4 (6.1) 238.9 (4.4) 242.0 (4.9) 0.134 
5 240.8 (4.6) 243.8 (5.9) 237.0 (3.7) 242.0 (4.2) 0.019 
8 241.3 (4.7) 245.3 (6.1) 240.9 (5.0) 243.5 (4.2) 0.203 
10 241.9 (4.7) 245.0 (5.9) 239.7 (4.3) 244.0 (5.2) 0.106 
12 239.4 ( 4.9) 244.5 (6.2) 239.3 (4.4) 244.2 (5.0) 0.040 
14 239.6 (3.9) 244.3 (6.2) 239.4 (4.1) 244.0 (5.1) 0.043 
16 240.0 (2.8) 244.4 (6.4) 239.1 (4.1) 244.2 (5.6) 0.040 
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 Table  2.8  Mean volume (mm3) of the total ‘ecstasy’ tablets (n = 40) when stored at 
33 and 75% RH during the 16 weeks. 
 
 
Key: Tablets from batch 33 stored at different conditions (33% RH and temperatures of 5, 15, 25 and 
35°C; 75% RH and temperatures of 5, 15, 25 and 40°C); the numbers in parenthesis are the SDs; the 


































00 232.8 (5.04) 231.2 234.4 
231.4 
(5.02) 229.8 233.0 0.219 
01 231.7 (5.19) 230.0 233.3 
238.7 
(6.12) 236.7 240.6 0.000 
02 233.8 (5.66) 232.0 235.6 
240.2 
(4.72) 238.7 241.7 0.000 
03 234.4 (5.53) 232.7 236.2 
241.4 
(5.36) 239.7 243.1 0.000 
04 234.1 (4.86) 232.6 235.7 
241.6 
(5.33) 239.9 243.3 0.000 
05 233.7 (5.17) 232.0 235.3 
240.9 
(5.13) 239.2 242.5 0.000 
08 234.2 (4.88) 232.6 235.8 
242.7 
(5.18) 241.0 244.4 0.000 
10 234.1 (4.91) 232.5 235.6 
242.7 
(5.28) 241.0 244.4 0.000 
12 233.8 (4.73) 232.3 235.3 
241.9 
(5.56) 240.1 243.6 0.000 
14 233.5 (4.65) 232.1 235.0 
241.8 
(5.26) 240.1 243.5 0.000 
16 233.6 (4.69) 232.1 235.1 
241.9 




Table  2.9  Hardness (H) of tablets (in Newtons – N) at week 0 and week 16 stored at 
RHs of 33 and 75% respectively temperatures of 5, 15, 25, 35 and 40°C. 
 
 














75% RH 33% RH 
T (oC) – Hardness (N) T (oC) – Hardness (N) 
05 15 25 40 05 15 25 35 
01 50.49 36.34 34.33 32.59 20 > 52.82 46.12 49.05 49.28 
02 48.81 36.16 35.81 33.32 20 > 48.33 47.54 47.63 53.35 
03 49.05 38.10 36.46 35.17 20 > 46.92 47.83 56.03 57.47 
04 46.55 38.25 35.21 31.57 20 > 43.14 48.89 49.41 51.20 
05 47.52 37.68 35.78 32.47 20 > 46.63 49.47 48.32 49.32 
06 45.51 35.26 33.92 36.63 20 > 47.12 48.59 48.43 48.47 
07 44.76 39.74 36.17 33.13 20 > 45.37 46.35 47.56 45.61 
08 45.84 38.45 35.83 32.56 20 > 45.46 43.46 49.26 46.58 
09 45.11 38.69 36.67 33.12 20 > 43.11 45.81 48.52 46.11 
10 46.35 35.92 34.38 34.83 20 > 46.95 48.53 47.84 48.92 
Mean H. 47.00 37.46 35.46 33.54 / 46.59 47.26 49.21 49.63 
Min. H. 44.76 35.26 33.92 31.57 / 43.11 43.46 47.56 45.61 
Max. H. 50.49 39.74 36.67 36.63 / 52.82 49.47 56.03 57.47 
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 Table 2.10 Changes in mean mass (mg) of ‘ecstasy’ tablets from batches 5, 8, 11, 
after 90 and 180 days when stored at 75% RH and 40°C and tablets from batch 33 
after 13 and 16 weeks when stored at 75% RH and at 35 and 40°C. 
 
Tablets 
Mean Mass  
(mg) 
Decrease after 
90 days / 





180 days / 
16 weeks  
(%) 
Day 1 / 
Week 0 
Day 90 / 
Week 13 
Day 180 / 
Week 16 















Batch 33   





















Key: The numbers in parenthesis are the RSDs 
 
Table 2.11 Changes in mean diameter (mm) of ‘ecstasy’ tablets from batches 5, 8, 
11, after 90 and 180 days when stored at 75% RH and 40°C and tablets from batch 
33 after 13 and 16 weeks when stored at 75% RH and at 35 and 40°C. 
 
Tablets 
Mean Diameter  
(mm) 
Increase after 
90 days / 





180 days / 
16 weeks  
(%) 
Day 1 / 
Week 0 
Day 90 / 
Week 13 
Day 180 /  
Week 16 















Batch 33   















Control 8.16 8.16 0 8.17 0.12 
 






 Table 2.12 Changes in mean thickness (mm) of ‘ecstasy’ tablets from batches 5, 8, 
11, after 90 and 180 days when stored at 75% RH and 40°C and tablets from batch 
33 after 13 and 16 weeks when stored at 75% RH and at 35 and 40°C. 
 
Tablets 
Mean Thickness  
(mm) 
Increase after 
90 days / 





180 days / 
16 weeks  
(%) 
Day 1 / 
Week 0 
Day 90 / 
Week 13 
Day 180 /  
Week 16 















Batch 33   
(33% RH, 35°C) 4.42 4.41 
0.23 
decrease 4.42 0 
Batch 33 
(75% RH, 40°C) 4.38 4.53 3.43 4.52 3.20 
Control 2.77 2.78 0.36 2.78 0.36 
 
Key: The numbers in parenthesis are the RSDs 
 
Table 2.13 Changes in mean volume of ‘ecstasy’ tablets from batches 5, 8, 11, after 
90 and 180 days when stored at 75% RH and 40°C and tablets from batch 33 after 
13 and 16 weeks when stored at 75% RH and at 35 and 40°C. 
 
Tablets 
Mean Volume  
(mm3) 
Increase after 
90 days / 





180 days / 
16 weeks  
(%) 
Day 1 / 
Week 0 
Day 90 / 
Week 13 
Day 180 /  
Week 16 















Batch 33   

















Control 145.1 145.3 0.14 145.5 0.28 
 










 Appendix 4 – Consent Form for the Malta Study 
 
 





   
 
CONSENT FORM FOR PARTICIPANTS IN RESEARCH STUDIES 
 
Please complete this form after you have read the Information Sheet and/or listened to an 
explanation about the research. 
 
Title of Study:  Malta’s party (rave) scene: a field study on the behaviour of attendees. 
 
King’s College Research Ethics Committee Ref:  
 
• Thank you for considering taking part in this research. The person organizing the 
research must explain the project to you before you agree to take part. 
 
• If you have any questions arising from the Information Sheet or explanation already given 
to you, please ask the researcher before you decide whether to join in. You will be given a 
copy of this Consent Form to keep and refer to at any time. 
 
• I understand that I can decide to withdraw from the study at any time while I am being 
interviewed. 
 
• I consent to the processing of my personal information for the purposes explained to me.  
I understand that such information will be handled in accordance with the terms of the 






agree that the research project named above has been explained to me to my satisfaction and I 
agree to take part in the study. I have read both the notes written above and the Information Sheet 
about the project, and understand what the research study involves. 
 






confirm that I have carefully explained the nature, demands and any foreseeable risks (where 
applicable) of the proposed research to the volunteer. 
 









The information supplied above is to the best of my knowledge accurate.  I have read the 
Application Guidelines and clearly understand my obligations and the rights of participants, 
particularly in so far as to obtaining valid consent.  I understand that I must not commence 
research with human participants until I have received full approval from the ethics committee. 
 
Signature …………………………………………………                                     Date…………………………. 
____________________________________________________________________________________ 
STUDENT PROJECTS (including PhD) – SUPERVISOR AUTHORISATION 
____________________________________________________________________________________ 
I confirm that I have read this application and will be acting as the student researcher’s supervisor 
for this project.  The proposal is viable and the student has appropriate skills to undertake the 
research.  The Information Sheet and recruitment procedures for obtaining informed consent are 
appropriate and the ethical issues arising from the project have been addressed in the application.  
I understand that research with human participants must not commence without full approval 
from the ethics committee. 
Name of Supervisor:       
 
Signature ………………………………………………….                                     Date………………………… 
____________________________________________________________________________________ 
MEDICAL SUPERVISION (if appropriate) 
____________________________________________________________________________________ 
 
Name of Medical Supervisor:        




Signature of Medical Supervisor: 
 
………………………………………………………………                                    Date………………………….. 
____________________________________________________________________________________ 
 
CONTACT DETAILS Give the details of the individual who should receive all correspondence concerning 
the application.  Correspondence will normally be sent for the attention of the researcher.  It is the 
responsibility of the researcher (and contact if different) to forward all copies of correspondence to the 




Name:                                       Mario Mifsud 
Full postal address:                70, Mifriz House, Kittien Street, Zabbar, ZBR 1582. 
Telephone number:                 21 691917 





 Appendix 5 – Information Sheet for the Malta Study 
 
INFORMATION SHEET FOR PARTICIPANTS 
REC Reference Number: [INSERT ONCE PROVIDED BY REVIEW BODY] 
YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET 
Malta’ party (rave) scene: a field study on the behaviour of attendees 
 
We would like to invite you to participate in this postgraduate research project, which is entirely your 
choice; choosing not to take part will not disadvantage you in any way. Before you decide whether you 
want to take part, it is important for you to understand why the research is being done and what your 
participation will involve.  Please take time to read the following information carefully and discuss it with 
others if you wish. Ask us if there is anything that is not clear or if you would like more information. 
 
Aims of the study: The aim of the study is to compare the behaviour of attendees at parties (raves) as 
a function of their choice of substances used in consenting male or female attendees over the age of 18 
years. The study will look at information such as age, gender and ethnic group; this is done to 
understand better who attends raves. It will investigate the party habits of rave attendees. The study will 
look at participants’ choice of access to health care and as well collect information on the 
consequences of drug use behaviour and on physical and psychological health. 
 
Possible benefits from the study: The potential benefit of this study is that a better understanding will 
be gained about rave attendees and who goes to these events. Gathering information on drug use 
behaviour and the effects on general health are very important to be able to create better help for rave 
attendees. This study will look at what kind of help is sought by raves attendees in case of problems 
and may help facilitate engagement and access to this population. In general a better understanding of 
behaviour at rave events will help the development of prevention and harm reduction messages for 
those who need this information. 
 
If you are happy to participate you will be briefly screened against our exclusion criteria before you 
enter into the study. We will need to be sure that you are not intoxicated and fully understand the 









 purpose of the study.  The researcher needs to be reassured that you are able answer a number of 
questions in a competent way.  Anyone under the influence of alcohol or drugs and unable to 
comprehend the information sheet, and, those under the age of 18 years will be excluded. 
 
If you do decide to take part in the study you will be given this information sheet to keep after having completed 
the interview. It is estimated that completing the interview will take between 10 and 15 minutes. 
 
All subjects who chose to participate in the study will help provide an understanding of the party (raving) 
environment in Malta by providing crucial data on party (raving) behaviour. On request, all participants can obtain 
a copy of the completed study for further information. 
 
You may decide to withdraw from the study at any time while you are completing this questionnaire. As 
there is no identification mark on it, it will not be possible to identify your questionnaire once put with the 
others. A decision not to take part, will not affect your rights in any way. Anonymity throughout the study 
is insured. All data will be stored securely and in compliance with the Data Protection Act, Chapter 440 
of the Laws of Malta. 
 
You may find that some of the questions are exploring topics or issues that might be sensitive, 
embarrassing or upsetting, if so do not hesitate to contact us. For any information about drug or alcohol 
abuse you can Talk to SEDQA on Supportline 179. 
 
Supportline 179 
Supportline 179 is a 24 hour free telephone service run by a team of professionally trained volunteers 
offered by Agenzija Appogg. It provides immediate, confidential support to callers of any age, who 
require assistance both in day-to-day and crisis situations. It also provides information on social welfare 
services and referral systems to those callers who require further assistance. Supportline 179 receives 
calls on situations such as child abuse, domestic violence, drug/alcohol/gambling problems amongst 
others. 
It is up to you to decide whether to take part or not. If this study has harmed you in any way you can 
contact King's College London using the details below for further advice and information:  
 
Principal investigator: Mario Mifsud 
Email: mario.mifsud @kcl.ac.uk 







 Appendix 6 – Research Questionnaire for the Malta Study 
 
 
RESEARCH QUESTIONNAIRE NUMBER:     TIME NOW:         
 
 
The researcher confirms that the following observable signs have been considered 
 
Speech: slurring, difficulty-forming words, repetitive, loses train of thought, nonsensical, loud 
unintelligible?   Yes □  No □     
 
Coordination: sways, staggers, stumbles, trips, weaves, walks into objects?  Yes □  No □     
 
Appearance: bloodshot-eyes, eyes-glazed, inability to focus, tired, asleep?      Yes □  No □     
 
Behaviour: inappropriate actions/ language, rude, aggressive, argumentative?  Yes □  No □     
 
Interviewer judged that attendee was able to complete the questionnaire:   Y □     N □ 
 
 
I. Demographic information 
 
1. Sex?            Male □      Female □               
 
2.  Age? ______________________ 
 
3. Ethnic group?  White □   Black □   Asian □   Chinese □   mixed □  other___________ 
 
4. Nationality? ___________________________________________________ 
 
5. Tourist?     Yes □             No □     
 
6. English Language School Student?      Yes □             No □ 
 
7. Current University Student?                   Yes □             No □ 
 







10. Do you live with you parents?      Yes □    No □     





   
 
primary level lower secondary upper secondary tertiary level 
 11+ 16+ 18+ 




II.  Party Behaviour 
 
1. How often do you party?     
 
2. With whom do you usually go to a party?        
 
3. Typically before a party do you do any of the following?         Take the day off work □  
 
Not drink any alcohol □            Have a good night sleep □                  Not use any drugs □   
 
Have a good meal □     Let friends know you’re going out □     Take vitamins or minerals □ 
 
4. Typically how long do you party for in one go? __________________________hours 
 
5. At a party how much of the time is spent dancing? 
 
 
6. Do you go to after parties?  
 
 
7. How much money do you spend on a typical night out? ___________________EUR 
 
8. Do you drink any non alcoholic drinks at a typical party?  
 










Scoring system Your 
score 0 1 2 3 4 

















How many units of alcohol do you drink 
on a typical day when you are 
drinking? 
1 -2 3 - 4 5 - 6 7 --9 10+  
How often have you had 6 or more units if 
female, or 8 or more if male, on a single 











every week 2 to 3 times/month once monthly or less 
alone with partner with friend group of friends n=_____________ 
almost none 20% 40% 60% 80% most of the time 
never seldom sometimes often always 
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  III.  Drug Consumption 
 
Substances ever used age first used used this year days used last month used today 
Alcohol      
Tobacco      
Cannabis resin (hasish)      
Cannabis – oil      
Cannabis – grass      
Cannabis – skunk      
LSD/acid      
Magic mushrooms      
Cocaine (powder)      
Crack cocaine      
Amphetamine Powder (speed)       
Methamphetamine (crystal meth)      
Ritalin      
Opium      
Heroin      
Methadone      
Benzodiazepines (eg. Vlalium/diazepam, Librium)      
Ketamine      
alkyl nitrate (poppers)      
GHB (Gamma-Hydroxybutyric acid)      
GBL (gamma-Butyrolactone)      
Anabolic steroids      
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 Substances ever used used this year age first used days used last month Used today 
Nitrous Oxide (laughing gas)      
spice / magic / warrior      
BZP (Benzylpiperazine - Party Pills)      
Mephedrone (meow)      
MDAI (woof woof)      
Methylone      
Salvia Divinorum      
Viagra (Cialis)      
herbal ecstasy / ephedra      
Ecstasy tablets      
MDMA (ecstasy powder)      
Other..      
      
 
1. Do you take any prescribed medication? What? 
____________________________________________________________________________________________________________ 
 
2. Do you always use drugs at a party? 
 
3. What drugs do you most commonly use together during a party (incl route)? a.  alcohol  b.  cannabis  c. nicotine  
d._____________________________e.____________________________f.____________________________g__.________________________ 
4. PILLS:  Please describe what you have taken today: Name?____________________How many? ___________________Shape?___________   
Colour?_____________________  Logo_________________________How much did it cost?____________________________________________ 
5. POWDER:  Please describe what you have taken today:  Name?___________________________How much?__________________________ 
Texture?____________________Colour?____________________How much did it cost? ____________________Route?_____________________









1. What is the average number of tablets you take during a party?____________      
       
       
2. What is the greatest number of tablets you have ever taken during a party? ______    
 
 




4. What is the most number of consecutive days you have used ecstasy? _________  
 
 












7. If you could, would you like to test your ‘ecstasy’ tablets?     Yes □    No □    
 
7a. Why?  Health concern □    Curiosity □   Check dealer □   Other?_________________ 
 
8. How many tablets do you usually buy and how much do they cost? 
_________________________________________________________________________ 
9. Do you ever take MDMA (powder)?     Yes □    No  □     
 
 
10. Do you prefer tablets, or MDMA (powder)?  tablets □    powder  □   no preference  □ 
 
 
10a. Why? easier to dose □    better quality □     easier to get hold of □   other__________ 
 
 
11. How much MDMA do you buy and how much does it cost?_________g_______EUR 
 
 
IV. Use of Ecstasy  
gone up gone down stayed the same don’t know 
never seldom sometimes often always 
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 12. Typically do you take any of the following drugs with Ecstasy? 
 
12a. Antidepressants? SSRIs eg Prozac, Seroxat, Sertraline, Lustral, Sertralin, Sertral  
 
Yes □   No  □   What?____________________  
 
 
Is this prescribed?   Yes □  No  □   
 
12b. Vicks inhalants    Yes □   No  □    
 
12c. Viagra (sextasy)     Yes □  No  □  
 
12d. LSD (candy-flipping)  Yes □ No □   
 
12e. Ketamine (kitty-flipping) Yes □ No □   
 
12d. Mushrooms (hippy-flipping)  Yes □ No □ 
 
12. How often do you take the following substances when you use Ecstasy?  
 
 
13a. Alcohol never seldom sometimes often always 
 
 
13b. Cannabis never seldom sometimes often always 
 
 
13c. Cocaine never seldom sometimes often always 
 
 




14. After taking ecstasy or MDMA do you typically experience any of the following? 
 
excessive sweating □  thirst/dehydration □  numbness/ tingling □ vomiting or nausea □ 
 
feeling dizzy □  sexual problems □ unable to urinate □ 
 












before after at the same time 
before after at the same time 
before after at the same time 
before after at the same time 
before after at the same time 
before after at the same time 
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 V. Post Party Behaviour 
 
1. At a typical party do you become unwell? 
 
never seldom sometimes often always 
 
1a. Why might this be?__________________________________________________________ 
_____________________________________________________________________________ 
 
2. How long do you usually sleep after a party? 
 
 
3. Do you take extra fruit or vitamins the day after a party? 
never seldom sometimes often always 
 
3a. What?__________ ____________________________________________________ 
 
4. Do you take anything to help you sleep after a party? 
 
never seldom sometimes often always 
 
4a. What? ______________________________________________________________ 
PLEASE GIVE CARD TO THOSE WHO WANT FURTHER INFORMATION OR WOULD LIKE 




















less than 6 hours 6 to 8 hours 8 to 12 hours more than 12 hours 
Thanks for your collaboration 
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 Appendix 7 – King’s College Ethics Committee Approval 
for Pilot Study for Police Released Partygoers 
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